CN101845438A - Sensitive diagnosis and relative treatment for cancers through 20 tumor specific related genes and products - Google Patents

Abstract

The invention relates to a method for diagnosing cancers by quantitively detecting 20 tumor specific related genes and products thereof in a tumor product such as mRNA or protein as well as application of 20 tumor specific related genes and products thereof to preparing a diagnosis kit and a vaccine for treating the tumor. In the invention, an identification method and a kit of 20 tumor specific related genes and products thereof can be effectively applied to the sensitive diagnosis and relative treatment for the cancers including colon cancer, breast cancer, gastric cancer, lung cancer and liver cancer.

Description

The sensitive diagnosis and the associated treatment of the gene that 20 kinds of tomour specifics are relevant and the cancer of product

Technical field

The present invention mainly is centered around the novel Clinics and Practices of people's tumour.With the specific target gene of new diagnosing tumor, the discovery of target protein, with and purposes and usage in novel tumor diagnosis, in tumor vaccine, be applied as core with target protein.

Background technology

Cancer, the disease of suffering from altogether for the universe, at present, radiotherapy is only arranged, the main method that non-special oncotherapy means such as chemotherapy are present clinical diagnosis and treatment, its 5 years surviving rates are also very low in most of tumour patient. and special diagnosing tumor also be confined to alpha-fetoglobulin in liver cancer or PSA in the application of minority tumor types such as prostate cancer. the discovery of new tumour target antigen is made slow progress in the past 20 years, because common technology is at the specific target gene of new diagnosing tumor at present, difficult in the discovery procedure of target protein. and the clinical diagnosis and treatment of cancer has the urgent need new technology in using, the specific target gene of new diagnosing tumor provides new tool for treatment.

Cancer, at present still for being only second to lethal second the lethal killer of clinical disease of myocardial infarction. every year is died from the patient of cancer still with millions of notes in the whole world. in China, the number of the infected of annual kinds of tumor is more than 1,200,000, the patient who dies from cancer also has more than 500,000 people. and various countries' kinds of tumor type is basic identical in general, with lung cancer, mammary cancer, cancer of the stomach, liver cancer, prostate gland, colorectal cancer, cerebral tumor, carcinoma of the pancreas, in case ovarian cancers etc. are multiple case. mortality ratio is also roughly suitable. and also metastases, its clinical prognosis extreme difference. at present, radiotherapy is only arranged, non-special oncotherapy means such as chemotherapy, and its side effect is also very big.

At present, early stage special diagnosing tumor also only is confined to alpha-fetoglobulin in the liver cancer (AFP) or PSA in minority tumours such as prostate cancer. and most of clinical kinds of tumor does not still have good diagnostic method. the X-ray that uses in now clinical, rectoscope, Deng expense height not only, patient is the utmost point misery of being operated also. be late period because of the patient has the clinical symptom Shi Zeyi that is admitted to hospital often. in treating because of lacking special diagnosing tumor index, often result of treatment also has blindness. so in the clinical diagnosis and treatment of cancer, be badly in need of new technology, the discovery and the development of the specific target gene of new diagnosing tumor at present. and the present technique invention is innovated just for this reason.

Summary of the invention

The invention provides isolating polynucleotide, it is selected from: (1) sequence is the polynucleotide of one of SEQ ID NO:1-20; (2) sequence is the complementary sequence of the polynucleotide of one of SEQID NO:1-20; (3) sequence is the antisense sequences of the polynucleotide of one of SEQ ID NO:1-20.

The invention provides the polypeptide of described polynucleotide encoding.In optimized technical scheme, amino acid sequence of polypeptide is one of SEQ ID NO:21-40.

The invention provides the expression vector that carries described isolating polynucleotide.

The present invention also provides host cell, its conversion or transfection described isolating polynucleotide or described expression vector.The invention provides antibody or its fragment of specificity in conjunction with described polypeptide.

The invention provides described isolating polynucleotide or polypeptide in the purposes of preparation in the preparation, said preparation is used to stimulate or the T cell of the energy specific recognition oncoprotein that increase.

The invention provides the preparation that is used to stimulate or increases T cell that can the specific recognition oncoprotein, it contains described isolating polynucleotide or described polypeptide; And the T cell mass of described formulation preparation.

The present invention also provides described isolating polynucleotide, described polypeptide or described T cell mass to prevent and/or treat purposes in the vaccine of tumour and/or cancer in preparation.

The present invention also provides the vaccine that prevents and/or treats tumour and/or cancer, and it contains described isolating polynucleotide, polypeptide or T cell mass and pharmaceutically acceptable adjuvant.

The present invention also provides described isolating polynucleotide, polypeptide or the T cell mass purposes in the test kit of preparation diagnosing tumour and/or cancer.

The present invention also provides the test kit of diagnosing tumour and/or cancer, and it contains described isolating polynucleotide, polypeptide or T cell mass.

In the technical scheme of tumor vaccine of the present invention, we provide how to use target protein antibody, or target protein antigen itself is in conjunction with the technological method of carrier proteins. furthermore, in the technical scheme of tumor vaccine of the present invention, we describe in detail has: 1) how target protein being expressed as the immunocyte surface stimulates patient's immunity system as target protein antigen, described immunocyte comprises: dendritic cell, .2 such as T and bone-marrow-derived lymphocyte) technology contents that develops as the adjuvant carrier proteins. this class technology includes fusion protein technology, wherein contain to have how partly to stimulate patient's immunity system by carrier proteins in the fusion rotein, albumen how to select high immunogenicity for use is carrier proteins. the characteristics of how to use carrier proteins part are simplified the purifying process of recombinant protein etc.

Early diagnosis application facet at clinical tumor, the invention provides and specifically how to use target protein and all kinds of routine clinical inspection technologies of polypeptide binding antibody technological development: the antibody ELISA method, the tissue staining method is analyzed technology application specific details such as mass spectrum polypeptide identification method. and the present invention simultaneously also provides the technological system of checking as core with D N A hybridization that specifically how to use the special D N of target gene A sequence and carry out: as P C R technology and GeXP technological system etc.

At last, in the overall diagnosis of clinical application, the treatment aspect the invention provides concrete case: 1) how to detect 2 from the patient tumors tissue

0 kind of target gene expression spectrum, 2) according to detected 20 kinds of target gene expression spectrum in the patient tumors tissue, the recombinant protein that 20 kinds of target genes that utilize the high expression level target gene to instruct the clinician to select for use production in advance to get well immediately manufacture is treated the concrete treatment plan of killing tumour cell and prevention of postoperative tumor recurrence as patient's exceptional function tumor vaccine and to patient.

Description of drawings

Fig. 1 is the human brain source DNA CHIP_DSL people's gene promoter DNA experimental result scintigram that methylates. and the as a result exploded view of this figure after for the MA correction, the F532 coordinate is a logarithmic value. and to be that the fluorescent signal of 2 o'clock its target genes is actual strengthened 4 times to reading.

Fig. 2 is DNALI1 target gene mRNA specific expressed figure in various tissues in GNF chip storehouse. and this result comes from the U.S. U133A DNA of Affymetrix company chip acrobatics 61 kinds of normal human tissues, result's displaying after the analysis-by-synthesis behind 16 kinds of clones and a kind of tumor sample. and the horizontal .DNALI1 that figure top reading is represented its relative genetic expression is at people's testis sexual cell expression level 3500 times for its hetero-organization. and simultaneously visible this target gene is expression hardly in other regular tissues.

Fig. 3 is the title of 20 kinds of target genes and gene order number

Fig. 4 is the polypeptide composition sequence of 14 kinds of target genes

Fig. 5 is title and the gene order number of 20 kinds of target genes and its corresponding full length cDNA clone number

Fig. 6 is the dna primer composition sequence at 6 kinds of target genes of expression in escherichia coli.For cloning 6 target genes so that obtain the total length recombinant protein at expression in escherichia coli, the target gene specific dna primer is synthetic as follows: 5 ' end primer is added with EcoRI enzyme point of contact, and 3 ' end primer is added with XhoI enzyme point of contact.

Fig. 7 is that two kinds of target protein SSCPDH and GSTM3 expression bacterium induce the back target gene to scheme at expression in escherichia coli SDS-PAGE at 2mM IPTG.

Fig. 8 carries out the various tumour cells of immune protein trace (Western Blot) screening and health adult tissue's lysate figure as a result for the target protein specific antibody.

Fig. 9 identifies with target gene dna primer composition sequence for REALTIME-PCR

Figure 10 is human colon carcinoma sample REALTIME-PCR interpretation of result figure.The CSNK2A2 expression of target gene expression level of analyst's colon tumor tissue is with purchasing the Origene company in the U.S., (catalog number #H C R T 101﹠amp; H C R T 501), it includes the cDNA sample of 5 routine normal people colons (C1 to C5) and 19 routine human colon tumor tissues. and target gene D NA primer is synthetic through American I D T company, its sequence is seen Fig. 9: real-time PCR reactions detects with U.S. Bio-Rad iQ5 detector, use simultaneously iQ SYBR Green Supermix (catalog number: 170-8884) carry out example reaction .CSNK2A2 expression of target gene expression level with the matter of multiple mark and brief summary in Figure 10.

Figure 11 has listed whole target genes and 4 kinds of dna primers that the House-Keeping gene is used in the GeXP experiment for the GEXP system identifies with target gene dna primer composition sequence.

Figure 12 is GeXP result's brief summary.Because this group target gene is expressed in respectively in different types of tumour, be test GeXP result, we are with the initial test of several tumour blended high quality RNA. the Universal human Reference RNA of U.S. Stratagene company (catalog number 740000), be human adenocarcinoma, liver cancer, cervical cancer, tumor of testis, cerebral glioma, melanoma, lipoma, leukemia cells etc. organize the purified RNA mixture. in this experiment, 20 kinds of target genes are in being detected .C17ORF39 clearly in 2 kinds of house-keeping genes (TBP, ATP50, ACTB and GAPDH) in tumor sample and CPD expression of target gene level obviously increases.

Figure 13 is the application of target protein C17ORF39 specific antibody in people's tumor of kidney tissue tissue chemical staining (IHC). the immunohistochemical methods working concentration of the anti-C17ORF39 recombinant protein specific antibody of albumin A column purification is 1ug/ml.Tissue sample is fixed in the formalin solution fixing earlier, and paraffin embedding then is cut into the slice, thin piece of 4 (μ m) thickness then.Tissue microwave heating treatment method is carried out histochemical stain with U.S. Ventana company active immunity histochemical stain instrument after the tissue sample sheet is handled routinely. and dyeing is used AEC to detect the immunohistochemical methods that closes (U.S. Covance company product) .C17ORF39 and be the results are shown in figure below. the as seen nucleus of high expression level dyeing in people's tumor of kidney tissue of part. and almost detect less than any dyeing signal in normal people's nephridial tissue of contrast.

The sequence that relates among the present invention is described as follows:

Sequence number be the target gene of 1 (SEQ ID NO:1) in N C B I gene pool for gene order number for NM_001464, name is called the gene of ADAM2.

Sequence number be the target gene of 2 (SEQ ID NO:2) in N C B I gene pool for gene order number for NM_024052, name is called the gene of C17ORF39.

Sequence number be the target gene of 3 (SEQ ID NO:3) in N C B I gene pool for gene order number for NM_145036, name is called the gene of CCDC46.

Sequence number be the target gene of 4 (SEQ ID NO:4) in N C B I gene pool for gene order number for NM_001304, name is called the gene of C P D.

Sequence number be the target gene of 5 (SEQ ID NO:5) in N C B I gene pool for gene order number for NM_144782, name is called the gene of CRAT.

Sequence number be the target gene of 6 (SEQ ID NO:6) in N C B I gene pool for gene order number for NM_001896, name is called the gene of CSNK2A.

Sequence number be the target gene of 7 (SEQ ID NO:7) in N C B I gene pool for gene order number for NM_003462, name is called the gene of DNALI1.

Sequence number be the target gene of 8 (SEQ ID NO:8) in N C B I gene pool for gene order number for NM_033214, name is called the gene of G K 2.

Sequence number be the target gene of 9 (SEQ ID NO:9) in N C B I gene pool for gene order number for NM_153823, name is called the gene of GSG1.

Sequence number be the target gene of 10 (SEQ ID NO:10) in N C B I gene pool for gene order number for NM_000849, name is called the gene of GSTM3.

Sequence number be the target gene of 11 (SEQ ID NO:11) in N C B I gene pool for gene order number for NM_000640, name is called the gene of IL13RA2.

Sequence number be the target gene of 12 (SEQ ID NO:12) in N C B I gene pool for gene order number for NM_016368, name is called the gene of ISYNA1.

Sequence number be the target gene of 13 (SEQ ID NO:13) in N C B I gene pool for gene order number for NM_004923, name is called the gene of MTL5.

Sequence number be the target gene of 14 (SEQ ID NO:14) in N C B I gene pool for gene order number for NM_153485, name is called the gene of NUP155

Sequence number be the target gene of 15 (SEQ ID NO:15) in N C B I gene pool for gene order number for NM_015589, name is called the gene of SAMD4A

Sequence number be the target gene of 16 (SEQ ID NO:16) in N C B I gene pool for gene order number for NM_016002, name is called the gene of SCCPDH

Sequence number be the target gene of 17 (SEQ ID NO:17) in N C B I gene pool for gene order number for NM_019073, name is called the gene of SPATA6

Sequence number be the target gene of 18 (SEQ ID NO:18) in N C B I gene pool for gene order number for NM_003284, name is called the gene of TNP1

Sequence number be the target gene of 19 (SEQ ID NO:19) in N C B I gene pool for gene order number for NM_021733, name is called the gene of TSKS

Sequence number be the target gene of 20 (SEQ ID NO:20) in N C B I gene pool for gene order number for NM_017481, name is called the gene of UBQLN3

Sequence number be the target protein of 21 (SEQ ID NO:21) in N C B I gene pool for protein sequence number for NP_001455, name is called the albumen of ADAM2.

Sequence number be the target protein of 22 (SEQ ID NO:22) in N C B I gene pool for protein sequence number for NP 076957, name is called the albumen of C17ORF39

Sequence number be the target protein of 23 (SEQ ID NO:23) in N C B I gene pool for protein sequence number for NP_659473, name is called the albumen of CCDC46.

Sequence number be the target protein of 24 (SEQ ID NO:24) in N C B I gene pool for protein sequence number for NP_001295, name is called the albumen of CPD.

Sequence number be the target protein of 25 (SEQ ID NO:25) in N C B I gene pool for protein sequence number for NP_000746, name is called the albumen of CRAT.

Sequence number be the target protein of 26 (SEQ ID NO:26) in N C B I gene pool for protein sequence number for NP_001887, name is called the albumen of CSNK2A2.

Sequence number be the target protein of 27 (SEQ ID NO:27) in N C B I gene pool for protein sequence number for NP_003453, name is called the albumen of DNALI1.

Sequence number be the target protein of 28 (SEQ ID NO:28) in N C B I gene pool for protein sequence number for NP_149991, name is called the albumen of G K 2.

Sequence number be the target protein of 29 (SEQ ID NO:29) in N C B I gene pool for protein sequence number for NP_722545, name is called the albumen of GSG1.

Sequence number be the target protein of 30 (SEQ ID NO:30) in N C B I gene pool for protein sequence number for NP_000840, name is called the albumen of GSTM3

Sequence number be the target protein of 31 (SEQ ID NO:31) in N C B I gene pool for protein sequence number for NP_000631, name is called the albumen of IL13RA2

Sequence number be the target protein of 32 (SEQ ID NO:32) in N C B I gene pool for protein sequence number for NP_057452, name is called the albumen of ISYNA1

Sequence number be the target protein of 33 (SEQ ID NO:33) in N C B I gene pool for protein sequence number for NP_004914, name is called the albumen of MTL5

Sequence number be the target protein of 34 (SEQ ID NO:34) in N C B I gene pool for protein sequence number for NP_004289, name is called the albumen of NUP155

Sequence number be the target protein of 35 (SEQ ID NO:35) in N C B I gene pool for protein sequence number for NP_056404, name is called the albumen of SAMD4A

Sequence number be the target protein of 36 (SEQ ID NO:36) in N C B I gene pool for protein sequence number for NP_057086, name is called the albumen of SCCPDH

Sequence number be the target protein of 37 (SEQ ID NO:37) in N C B I gene pool for protein sequence number for NP_061946, name is called the albumen of SPATA6

Sequence number be the target protein of 38 (SEQ ID NO:38) in N C B I gene pool for protein sequence number for NP_003275, name is called the albumen of TNP1

Sequence number be the target protein of 39 (SEQ ID NO:39) in N C B I gene pool for protein sequence number for NP_068379, name is called the albumen of TSKS

Sequence number be the target protein of 40 (SEQ ID NO:40) in N C B I gene pool for protein sequence number for NP_059509, name is called the albumen of UBQLN3

Embodiment

Any bibliography of quoting such as patent, the document of delivering etc. is all used as document.

Core part of the present invention is to find target gene and its encoded protein of specifically expressing in the new kinds of tumors. the target gene that provides explanation of detailed technological step and experiment case to instruct simultaneously how to use specifically expressing in this group tumour and its encoded protein at clinical diagnosis and recombinant protein in the developing application of tumor vaccine.

Among detailed description of the present invention, can quote out many common virusology, immunology, microbiology, molecular biology, the routine techniques of DNA recombinant technology and academic term can be inquired about in following books and quote: Sambrook, et al.Molecular Cloning:A LaboratoryManual (2nd Edition, 1989); Maniatis et al.Molecular Cloning:A Laboratory Manual (1982); Oligonucleotide Synthesis (N.Gait, ed., 1984); Nucleic Acid Hybridization (B.Hames﹠amp; S.Higgins, eds., 1985); Transcription and Translation (B.Hames﹠amp; S.Higgins, eds., 1984); Animal CellCulture (R.Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984).

20 kinds of technological lines that refer in particular to tumor associated antigen (TAA) that isolation identification is come out from people's tumor tissues among the present invention are the new technique thinking, it at first utilizes business-like technology such as CHIP-DSL system looks to go out the gene promoter target gene of healthy tissues camber dna methylation, from the array of DNA chip, find its corresponding target gene easily then and obtain the gene order number of target gene simultaneously. with this gene order number and obtain target-gene sequence and target protein sequence very soon. simultaneously, according to gene order number, from the NCBI storehouse, can surf the Net and search complete homologous full length cDNA clone (IMAGE clone number), inferior exploitation and buy the target gene full length cDNA clone from ATCC or OPEN BIOSYSTEMS company. this technological line has avoided traditional tumor tissues cDNA storehouse to make up, the gene recombination screening, full length cDNA clone, technology consuming time during sequencing.

After tumor associated antigen (TAA) is refered in particular in 20 kinds of acquisitions, utilize its target gene to develop the diagnosis of relative dna sequence dependent, the gene clone of expression of recombinant proteins, the application in specific antibody of polypeptide or recombinant protein, and antibody is used in early diagnosis of tumor etc. and to be conventional Development Technology route. last the present invention goes back emphasis and describes this group tumor associated antigen in the developing use of tumor vaccine.

Protein polypeptide herein comprises any continuously at 8 peptide sequences more than the amino acid of target protein. also comprise common multiple modification acidic amino acid simultaneously and the peptide sequence formed: as glycosylation; acetylize; phosphorylation; methylating etc. this patent is because of relating to clinical diagnosis and recombinant protein in the developing application of tumor vaccine simultaneously; use immune notion always as some: the immunogenicity of protein polypeptide; polypeptide epitopes etc. are the description emphasis of this patent especially. and target protein herein is referred to as tumor associated antigen (TAA sometimes; Tumor associated Antigen), because of its have special in tumor tissues the characteristics of high expression level.

In finding new kinds of tumors behind this group target gene and its encoded protein of specifically expressing, the immunological method of many routines naturally can be organized target gene and its encoded protein in view of the above and develop and various clinical diagnosis system: as select the target protein polypeptide for use and prepare specific antibody, set up ELISA then, Radioactive colloidal gold, traditional diagnostic reagent such as radioimmunity closes. or with this group target gene dna sequence dna and develop with PCR, diagnostic kits such as DNA chip. there is detailed teachings in this class routine techniques system in following document: Harlow and Lane, Antibodies:A LaboratoryManual, Cold Spring Harbor Laboratory, 1988.Fundamental Immunology, 3rd ed., 243-247 (RavenPress, 1993).

Though the immunogenicity of protein polypeptide is not easy to grasp sometimes, have in the detailed description of the present invention and contain the technological line that uses the target protein full length sequence to prepare recombinant protein. if membrane-spanning protein is at expression in escherichia coli in the cell, we also illustrate the high expression level that technological lines such as the signal peptide of how to dispel albumen n end and membrane-spanning protein functional domain ensure recombinant protein. in addition, the e. coli protein that DNA synthetic technology has now been used synthesizes precedence code (codon optimization) becomes routine techniques, further guarantee the success ratio of recombinant protein technological line of high expression level in intestinal bacteria. the technological line as for recombinant protein high expression level in other cells of mamma animals comprises the use expression vector, with stronger promotor, carrier carries selection markers gene etc. is all having concrete leading case in the leading case example down.

In chemiluminescent polypeptide synthetic technological line, utilize similar amino acid come part replace the partial amino-acid in the target protein sequence and produce function class like but the different polypeptide of sequence is unusual proven technique in fact: as Kyte and Doolittle, 1982) promptly go out to terminate out amino acid whose hydrophilic, hydrophobic branch and come the considered amino acid displacement to amino acid correlation in each at its document: as: Isoleucine (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine/cystine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (0.4); Threonine (0.7); Serine (0.8); Tryptophan (0.9); Tyrosine (1.3); Proline (1.6); Histidine (3.2); Glutamate (3.5); Glutamine (3.5); Aspartate (3.5); Asparagine (3.5); Lysine (3.9); And arginine (4.5). at U.S.Pat.No.4, also specify in 554,101 patents.

When polypeptide is used as the tumor vaccine development in selecting target protein sequence for use, the selection of the uniqueness of its peptide sequence also is one of successful key factor of treatment. select the polypeptide of sequence uniqueness, can reduce with other body in proteic homology and produce the side effect of cross reaction, thereby make the tumor vaccine result of treatment more special. it is very convenient to utilize in the U.S. NCBI protein pool BLAST function to carry out this work. and concrete operation method is at Altschulet al. (1977) Nucl.Acids Res.25:3389-3402and Altschul et al. (1990) J.Mol.Biol.215:403-410, detailed description is arranged in the document. and following document provides many-side to the selection of the uniqueness of peptide sequence, more detailed description (DNASTAR, Inc., Dayhoff, M.O. (1978) A model of evolutionary change in proteins--Matrices for detectingdistant relationships.In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, NationalBiomedical Research Foundation, Washington D.C.Vol.5, Suppl.3, pp.345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp.626-645Methods in Enzymology vol.183, AcademicPress, Inc., San Diego, Calif.; Higgins, D.G.and Sharp, P.M. (1989) CABIOS 5:151-153; Myers, E.W.and Muller W. (1988) CABIOS 4:11-17; Robinson, E.D. (1971) Comb.Theor 11:105; Santou, N.Nes, M. (1987) Mol.Biol.Evol.4:406-425; Sneath, P.H.A.and Sokal, R.R. (1973) NumericalTaxonomy--the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W.J.and Lipman, D.J. (1983) Proc.Natl.Acad., Sci.USA 80:726-730.

Sometimes, when the selection of the uniqueness of peptide sequence has been picked out some zone and need be through step refining the time, have been provided many concrete guides in the following document: Smith and Waterman (1981) Add.APL.Math 2:482.Needleman and Wunsch (1970) J.Mol.Biol.48:443.Pearson and Lipman (1988) Proc.Natl.Acad.Sci.USA 85:2444.

Utilize fusion protein technology to increase the production of polypeptide in the target protein sequence, make things convenient for purifying, the immunogenicity of raising target protein polypeptide etc. can be operated by the method in the following document of part. as His-Tag, HA-Tag, albumen such as the warm carrier of GST can merge through special proteolytic enzyme point of contact peptide section such as TEV etc., obtaining the pure product of target protein polypeptide behind the affinity column purifying, removing the fusion vector protein part with the TEV proteolytic cleavage. (Lucast et al.Biotechniques 30:544-550,2001) other fusion vector albumen commonly used also comprise FC section in the antibody and human albumin etc. this also has detailed description (WO/2003/035105) in following document.

The immunogenicity of utilizing fusion protein technology to improve the target protein polypeptide is a first-selection to select those that human T-cell, dendritic cell etc. is had the carrier proteins than strong and stimulating often. the IgG Fc end of some subclass is because of having stronger pungency by specific combination immunocyte surface receptor, this is at document Stoute et al.New Engl.J.Med., 336:86-91 has a detailed description in 1997.

Sometimes the three-dimensional structure of carrier proteins and immunogenic target protein polypeptide is also most important in fusion protein technology, need to place the little peptide of link field in the two junction, immunogenicities such as 3 are low as GGGGS with (GGGGS), and the structure little peptide of link field flexibly. this class technology has a detailed description in following document: Maratea et al., Gene 40:39-46,1985; Murphy et al., Proc.Natl.Acad.Sci.USA 83:8258-8262,1986; U.S.Pat.No.4,935,233and U.S.Pat.No.4,751,180.

And, also comprise the DNA-albumen integration technology that newly-developed goes out in the fusion protein technology. at present, one class RNA is arranged in the immunocyte surface receptor, DNA bind receptor such as TLR3, TLR9 can greatly transfer immune response when it is activated. so but TLR9 also twists the curative effect that connects the target protein immune peptide and strengthen its tumor vaccine in conjunction with non-methylated DNA chemosynthesis. and following document has more detailed description (Stefan et al Vaccine.2003 to this class DNA-albumen integration technology, vol.21, pp.990-995).

Polypeptide is also most important the biological half-life in blood. and in chemiluminescent polypeptide synthetic technological line, use alpha-non-natural amino acid, use modifying acidic amino acid waits and increases polypeptide stability also have a detailed description (FH Arnold.The FASEB Journal in following document, Vol 7,744-749,1993.). as for come the technology of while stabilized DNA nucleotide chain then more ripe through chemical synthesis process. as using phosphorothioate or 2 ' O-methyl rather than phosphodiesterase linkages, with the non-natural base as inosine, queosine and wybutosine, and acetyl-, methyl-, thio-etc. modify adenine, cytidine, guanine, technology such as thymineand uridine can both increase the biological half-life of DNA nucleotide chain in blood.

U.S.Patent Application 7270821 describes in patent, the core protein of hepatitis B virus (HBcAg) is one of structural protein of virus, molecular weight is only about 18KD. but often occur with nucleoid bodily form formula. it is 27nm that each core body is formed diameter with about 180 monomer-polymer, have extremely strong immunogenicity. simultaneously, years of researches are found in the past, this nucleoid body has special density buoyancy, can be purified into through simple sucrose density gradient centrifugation. the immunogenic target protein polypeptide is merged at the proteic C-terminal of HBcAg, high expression level recombinant protein in intestinal bacteria then, steps such as warp breaks bacterium, and is centrifugal can obtain the high fusion recombinant protein of immunogenicity. and this technology is having detailed description (WO/9940934) in the routine document down.

Because of 16 types, the infection of the human papillomavirus of hypotypes such as 18 types can be brought out woman uterus cancer and it be had more deep research at scientific research field. in the several years in past, the vaccine that utilizes the reorganization membranin L1 of human papillomavirus and develop the human papillomavirus that is by drugs approved by FDA and in wide clinical application. and reorganization membranin L1 has high immunogenicity, its production simultaneously, purifying process maturation ((US patent 6908613). even 194 high immunogenicity of tool of the proteic polypeptide 53 of the L1 of HPV18 type itself.

Other is used always, the carrier proteins of high immunogenicity also comprises the LYTA albumen of streptococcus pneumoniae (Streptococcus pneumoniae). its function be responsible for synthetic N-acetyl-L-alanine amidase. this at Gene 43:265-292, so there is detailed explanation .LYTA albumen that phosphorylcholine and DEAE are all had higher avidity in 1986 documents. the fusion rotein of its reorganization can come purifying with the DEAE post. (Biotechnology10:795-798,1992). when the proteic C-terminal of LYTA, after 178 amino acid, (may be better with the 188-305 district) fragment is that carrier proteins and the fusion of immunogenic target protein polypeptide can obtain the development that recombinant protein is used for tumor vaccine.

When carrier proteins and the fusion of immunogenic target protein polypeptide, have functional peptide section as: increase albumen and enter Cytolysosome, or increase fusogenic peptide and all can consider to add among the fusion rotein showing in conjunction with MHC class II on the immune target cell etc. concrete ins and outs U.S.Pat.No.5 in patent, 633,234. have more detailed explanation.

The present invention's protein polypeptide production technology that hits is one of proven technique very, existing Peptide synthesizer can be bought also has commercial company to provide the fine polypeptide synthetic service. in the document as Merrifield, J.Am.Chem.Soc.85:2149-2146,1963 pairs of polypeptide composition principles have detailed explanation, and Peptide synthesizer can be bought U.S. Perkin Elmer/Applied BioSystems Division (Foster City, or product such as ACT company Calif.). the biochemical company limited of Chinese Shanghai gill etc. provides polypeptide synthetic service. and 20 kinds that indication target protein polypeptide is meant us isolation identification is come out from people's tumor tissues among the present invention are refered in particular to tumor associated antigen (TAA).

As for the relevant called after sequence number of one group of tumor diagnosis and treatment of coming out of isolation identification among the present invention is 1 to 20 target gene, can refer to and this group gene-correlation at this, gene fragment, dna probe, the inverted defined gene sequence, RNAi etc. also comprise its expression vector simultaneously, plasmid etc. certainly, this group gene also comprises those and synthesizes through DNA, coding has been optimized but still has been produced similar proteic DNA product. after understanding the relevant target gene particular sequence of this group tumor diagnosis and treatment, the mutant that derives with this, homologous sequences etc. are the ordinary skill in the art. as sequence number among DNA product and the present invention is that 1 to 20 target gene has any homologous sequence more than 75% all to be considered as similar gene. and the length of dna fragmentation also has any homologous sequence more than 75% also to be considered as being similar gene with target gene when above when reaching the length of 15bp. the conventional genetically engineered experimental implementation of this class can have more detailed explanation .Maloy et al., 1994 in following this class document; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; And Maniatis et al., 1982.U.S.Pat.No.4,683,202.

According to sequence number is that 1 to 20 target gene derives the inverted defined gene sequence, the application of RNAi in suppressing target gene expression is conspicuous technology, this is at patent document such as U.S.Pat.No.5,739, in 119 and U.S.Pat.No.5,759,829 detailed explanation is arranged. with the tumour target gene as the inverted defined gene sequence suppress growth of tumour cell at U.S.Pat.No.5,747,470; And U.S.Pat.No.5,591,317 and U.S.Pat.No.5,783, the introduction of technical scheme is all arranged in the patents such as 683. so, in the present invention in the application of the relevant target gene of this group tumor diagnosis and treatment of coming out of institute's isolation identification, derive its inverted defined gene sequence with target gene, RNAi treats tumour just to be become treatment and one of uses. more correlation technique document as follows: Int.Pat.Appl.Publ.No.WO 93/23569 and Int.Pat.Appl.Publ.No.WO 94/02595. can be from below with reference to obtaining the data as for the technology of stablizing the small segment dna molecular: Int.Pat.Appl.Publ.No.WO 92/07065; Iht.Pat.Appl.Publ.No.WO 93/15187; Int.Pat.Appl.Publ.No.WO 91/03162; Eur.Pat.Appl.Publ.No.92110298.4; U.S.Pat.No.5,334,711; And Iht.Pat.Appl.Publ.No.WO 94/13688. relative dna-polypeptide heterozygosis technology such as PNA (peptide nucleic acids) have detailed explanation also at document Good and Nielsen among Antisense Nucleic Acid Drug Dev.19977 (4) 431-37. and specifically being applied in of this technology has further description in the following technology summary document: Corey et al (Trends Biotechnol 1997 June; 15 (6): 224-9).

According to sequence number among the present invention is that the polymerized nucleoside acid fragment will become important applying portion in the DNA dependency clinical diagnosis that derives of 1 to 20 target gene. its purity is identified, quality test, expression level etc. are the important techniques composition. so will briefly be described at this:

One, the segmental purity of polynucleotide is identified, quality test, expression level mensuration etc. is conventional Protocols in Molecular Biology, at Sambrooket al., Molecular Cloning:A Laboratory Manual, Cold Spring Harbor Laboratories, Cold SpringHarbor, N.Y., 1989, have a detailed description in the book. simultaneously, synthetic service company of commercial at present DNA such as American I DT company are to the synthetic quality test that strictness is arranged of its dna primer. the design of various PCR primers, the PCR operation, the use of enforcement PCR etc. all has producer that standard reagent is provided, and process specifications. see document as DNA interconnection technique deutero-Ligation PCR: Eur.Pat.Appl.Publ.No.320,308 and U.S.Pat.No.4,883,750. PCT Intl.Pat.Appl.Publ.No.PCT/US87/00880 patent is seen in the application of unique Qbeta Replicase enzyme. strand displacement type DNA cloning technology (Strand Displacement Amplification) is seen Great Britain Pat.Appl.No.2202328, with other technology of PCT Intl.Pat.Appl.Publ.No.PCT/US89/01025. as transcribe dependent form DNA cloning technology (transcription-based amplification systems (TAS) sees document PCT Intl.Pat.Appl.Publ.No.WO88/10315 etc. that also appears in the newspapers in the literature also has: cyclically synthesizing single-stranded RNA (" ssRNA "), ssDNA, and double-stranded DNA (dsDNA). technology, see that PCT Intl.Pat.Appl.Publ.No.WO 89/06700. is in " RACE " technology of nineteen ninety Frohman report etc.

In the genetically engineered as for target gene, use various expression vectors, bacterial strain or clone also are conventional Protocols in Molecular Biology, its expression system can be intestinal bacteria, yeast, silkworm Zhong virus, the mammalian cell system, transgenosis is moving, to carry out in the systems such as plant. expression promotor commonly used comprises CMV, and strong promoter systems such as T7 obtain high expression level. express strain for obtaining stable mammalian cell, comprise the use of various screening-genes, the application of enhanser (enhancer) etc. all has commercial system: as the pET carrier system of U.S. EMD company, and the pSPORT1 carrier system of American I nvitrogen company etc.

As for the expression of target gene in the intestinal bacteria system, the pET carrier system of U.S. EMD company just can be used as first-selected system. and this expression system is a core with the promotor of phage t7, be equipped with various screening-genes such as blue or green enzyme element, block that enzyme element etc. still be so that the IPTG abduction delivering is the expression level height simultaneously. simultaneously, the pET carrier system also is furnished with various fusion roteins such as GST, HIS polypeptide etc., if make simple relatively that the recombinant protein purification of expression becomes. in conjunction with protease cutting site such as TEV, the pure product of recombinant protein can be controlled at easily and merge recombinant protein or non-fusion recombinant protein state. other expression systems, as the pIN carrier system, the document Van Heeke that is everlasting, G.and S.M.Schuster (1989) J.Biol.Chem.264:5503-5509) in detailed description being arranged. the pGEX carrier system of U.S. Promega company also is one of optional system.

If use Yeast system, with the methanol yeast expression system commercial system being arranged all in the cereuisiae fermentum system. the methanol yeast expression system accessory and the industrial amplifying technique of American I nvitrogen company are perfect, and there is detailed description in the cereuisiae fermentum system in document Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol.153:516-544.

When the expression amount of the target protein that has reaches feather weight, perhaps select for use the transgenic plant system to express target protein for reducing the long-term production cost. promotor commonly used in this system is 35S and the 19S gene promoter of CaMV. be equipped with the secreting signal peptide of tobacco mosaic virus (TMV) (TMV) omega simultaneously. this technological system is at document Takamatsu, N. (1987) EMBO has detailed description in J.6:307-311. other promoter systems, as the RUBISCO promotor, heat shock protein(HSP) promotors etc. are at document Coruzzi, and G.et al. (1984) EMBO J.3:1671-1680; Broglie, R.et al. (1984) Science 224:838-843; And Winter, J.et al. (1991) Results Probl.Cell Differ.17:85-105) in detailed description is arranged. and the working specification of concrete protein expression is at Hobbs, S.or Murry, L.E.in McGraw HillYearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; In the pp.191-196 document detailed description is arranged.

Silkworm Zhong virus (baculovirus) protein expression system also is one of religion engineering bacteria system commonly used. its expression vector, cell strain all can be purchased from American I nvitrogen company.

As for the mammalian cell protein expression system, its technology maturation has many commercial systems can select to use simultaneously. as promotor commonly used CMV is arranged, B-ACTIN etc., the screening-gene that has commonly used has G418, ZEOSIN etc., carrier commonly used has SV40, adenovirus carrier, retroviral vector etc. this type systematic is applied in document Dachs et al.Oncology Research, Vol.9 in expression of recombinant proteins, pp:313-325 has detailed description in 1997.

No matter at which kind of system expression, relevant technologies details in the genetically engineered recombinant technology commonly used should be noted that: the Kozak sequence of translating yard ATG upstream as target gene helps the high expression level of gene in cell, some albumen selects for use the secreting signal peptide of antibody protein IgG to help to obtain high yield when secreting, expressing. and in expression vector, to use suitable enhanser to have and can effectively improve the expression of recombinant proteins amount. this class technology has detailed description at document Scharf among D.et al. (1994) the Results Probl.Cell Differ.20:125-162.

And the selection of express cell system has many documents that the special report of this respect is arranged at present. as clone CHO commonly used, COS, HeLa, MDCK, HEK293, and W138, row etc. have sophisticated commercial system, it covers the selection from cell culture fluid, the screening of stable clone. cell fermentation jar technology etc. all has monograph. certainly, because glycosylation modified its immunogenicity that often influences of target protein, when expression host cell is selected, its glycosylation ability is one of Consideration. the target protein selected because of this patent is the usefulness of tumor vaccine development, and selecting strong immunogenic protein form for use is one of important selection factor.

The transfection of stable high-expression clone, triage techniques has special report in following document: as the use of TK gene: Wigler, M.et al. (1977) Cell 11:223-32. such as adenine phosphoribosyltransferase gene select (Lowy for use, I.et al. (1990) Cell 22:817-23). the use routine of screening-gene DHFR commonly used: Wigler, M.et al. (1980) Proc.Natl.Acad.Sci.77:3567-70); Xin Meisu and G-418 select for use: (Colbere-Garapin, F.et al (1981) J.Mol.Biol.150:1-14) etc. the applying marking gene co-transfection also is one of common technique simultaneously, as beta-glucuronidase and luciferase etc. at Rhodes, in C.A.et al. (1995) the Methods Mol.Biol.55:121-131. document detailed description is arranged. the rotaring dyeing technology of stable high-expression clone can use the lipofectamin of American I NVITROGEN company, (Cat#18324-111) and the calcium phosphate precipitation method test kit of Promega company (

Mammalian Transfection System, Cat#E1200)

The authenticate technology of relevant stable high-expression clone is also more ripe. and the probe of common available target gene measures that expression vector inserts chromosomal number gene in the high-expression clone, also can directly measure the cell conditioned medium proteinic amount that hits. this class is measured the immune enzyme-linked method enzyme-linked immunosorbent assay (ELISA) of the special antibody construction of available target protein, emission exempts to send out radioimmunoassay (RIA), with fluorescent marker method fluorescence activated cell sorting (FACS) etc. this class routine techniques has detailed description .Hampton in following document, R.et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul.Minn.) and Maddox, D.E.et al. (1983; J.Exp.Med.158:1211-1216).

Third part emphasis of the present invention is set forth the technological line and the application of the specific antibody of producing according to target protein. and the specialized vocabulary that relates to that has among the present invention waits the specially specific combination albumen of finger energy specific combination target protein as " conjugated protein body; antibody; binding substances ", or the protein polypeptide fragment etc. this combination all refers to non-covalent high-affinity combination, how waiting and describe (Davies et al. (1990) Ann.Rev.Biochem.59:439-473) with " binding constant; separation constant ". this class technology also has detailed description in documents such as Davies et al. (1990) Annual Rev.Biochem.59:439-473. and the antigen joint portion of antibody often refers to Fab part in the antibody, have light, the branch of heavy chain. and this class " conjugated protein body; antibody; binding substances " that we describe specially refers to can detect on the function binding substances of tumor associated antigen, at least can in certain type tumour, detect in its clinical use＞patient more than 20%, its false positive rate in normal population is in the certain use value of ability tool below 10%. and its sample to be checked can be a blood sample, urine, tumor tissues etc. in the nearest document, the RNA molecule also can develop into protein conjugates, the knowledge of the basic relevant usage of antibody is at Harlow and Lane, Antibodies:A Laboratory Manual, Cold Spring HarborLaboratory has a detailed description in 1988.

Have as for its technological line of the specific antibody producing of target protein multiple, as the polyclonal antibody that the polypeptide immune of rabbit produces, the monoclonal antibody technique of mouse and rabbit, phage antibody display technique etc. the monoclonal antibody technique of mouse

As far back as 1976 by Kohler and Milstein, Eur.J.Immunol.6:511-519,1976 deliver. and the monoclonal antibody technique of rabbit was just progressively growing up in recent years, and U.S. Epitomic company provides the client technical service. and the monoclonal antibody technique of mouse has further report in following document: Inbar et al. (1972) Proc.Nat.Acad.Sci.USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; And Ehrlich et al. (1980) Biochem 19:4091-4096.

Relevant to the proteic stable mouse monoclonal antibody cell strain of acquisition specific target, or from the phage antibody display technique, be cloned into antibody gene, all available single-chain antibody technology is made single-chain antibody product (single chain Fv: " sFv "), it is light that it connects antibody, the strand commonly used of heavy chain connects polypeptide at document Huston et al. (1988) Proc.Nat.Acad.Sci.USA 85 (16): have a detailed description among the 5879-5883. and how to improve single-chain antibody to the affinity technological line of target antigen at U.S.Pat.Nos.5,091,513 and 5,132,405, and U.S.Pat.No.4,946,778, waiting has detailed guidance in the patent documentation.

After obtaining special antibody gene, use clinically as needs, it can reduce its immunogenicity (Kettleborough through the Humanization of murine monoclonal antibody technology ¹Et al.Protein Engineering vol.4 no.7pp.773-783,1991). antibody protein amino acid Kabat database important in this technology is at Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S.Dept.of Health and Human Services, U.S.Government Printing Office, 1987) have a detailed description in the document.

As target protein is the membranin of tumor cell surface, and the high affinity antibody of its specificity just might be developed to therapeutic antibodies. therefore, but on the therapeutic anti body protein mark radio isotope as: ⁹⁰I, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi, or all kinds of toxic protein and reach its treatment tumour curative effect (U.S.Pat.No.4,735,792. and U.S.Pat.No.4,673,562). common toxin protein subunit comprises: ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigellatoxin, the micromolecular antitumor drug of and pokeweed antiviral protein. also can hang on the antibody and increase the curative effect that tame anti-tumour antibody kills knurl. and getting as Rodwell has the description of experimental procedure U.S.Pat.No.4,671 in the patent, 958. further illustrate the technology that new antibody and other molecules are twisted together: U.S.Pat.No.4 below with reference to patent, 489,710, to Spitler.U.S.Pat.No.4,625,014, to Senter et al.U.S.Pat.No.4,638,045, to Kohn et al..U.S.Pat.No.4,671,958, to Rodwellet al..U.S.Pat.No.4,569,789, to Blattler et al.

In antineoplastic immunotherapy, activated T cell is an important link wherein. both also external immuno-stimulating .T cell can be from marrow in the body for this class step, obtain in the peripheral blood. the Isolex.TM. system of many commercial systems such as California Nexell Therapeutics company. other experiment correlation technique details is at U.S.Pat.No.5,240,856; U.S.Pat.No.5,215,926; WO89/06280; In the patents such as WO 91/16116and WO 92/07243 explanation being arranged also. new iPS stem cells technology has also been opened up new technological line (Ariff et al.Journal of Cellular Biochemistry.Jan 2009 for inducing differentiation to obtain the T cell, Vol.105, No.6:1352-1360).

This group cancer-related target antigen can carry out from a few class technical schemes the activation of immunocyte: 1) with the target antigen or the direct activated T cell of its polypeptide of total length. and also available expression plasmid carries target antigen cDNA and is transformed into antigen and shows cell (antigen presenting cell:APC), express target antigen and activated T cell among dendritic cell (dentritic Cells) myocyte. the immunological technique of this genoid mediation is proven technique (Diebold et al comparatively in the clinical trial, Human Gene Therapy.March 20,1999,10 (5): 775-786.). certainly, also can use particulate carrier to wait during with the target antigen of total length or the direct activated T cell of its polypeptide and strengthen its immunocompetence.

Whether measuring immunocyte is that target antigen or its polypeptide are when directly activating, can measure the secreted cytokine level of T cell in many ways and judge its function. measure cell chromium release assay or cell value-added approach (proliferation assay) is that base value is judged with the control cells as the cracking target cell. this type of technology is at document Chen et al., Cancer Res.54:1065-1070, have a detailed description in 1994. measuring the cell proliferation of T cell with the radiolabeled H3-thymidine method of mixing when target antigen or its polypeptide directly activate also is the technology Coligan et al. that uses always, Current Protocols in Immunology, vol.1, Wiley Interscience (1998). this class T cell is also cd8 cell of CD4 both.

During clinical application, immunocyte is after target antigen or its polypeptide directly activate, and (often also adding cytokine such as IL2, GMCSF, IL12 etc.) has in the body or the process of in-vitro multiplication, uses to tumour patient then.

The important acceptor (TCR) of T cell roughly divides two classes: alpha and beta chain, through disulfide linkage and covalency links to each other. its structure is at document Janeway, Travers, Walport.Immunobiology.Fourth Ed., 148-159.Elsevier having a detailed description .Alpha and beta chain among the ScienceLtd/Garland Publishing.1999. forms mixture with CD3 albumen together and comes specific recognition to be incorporated into target antigen polypeptide .T cell receptor on the MHC to form numerous molecule types through the same gene recombination of similar antibody gene and open up and show the affinity different to the target antigen polypeptide under the stimulation of immune molecule. this class rudimentary knowledge is at document Janeway, Travers, Walport.Immunobiology.Fourth Ed., have a detailed description among the 98and 150.Elsevier Science Ltd/Garland Publishing.1999. after utilizing this group tumor associated antigen to stimulate the T cell, can screen, clone and obtain the tcr gene of high-affinity. then can V-J orV-D-J etc. gene recombination form and changing in the T cell of tumour patient. after the group tumor associated antigen stimulates, this class T cell can efficiently produce very strong immuno-stimulating in conjunction with MHC. and there is report to show that the analogue that utilizes TCR also can produce identical effect (A Sette et al.AnnualReview of Immunology.Vol.12:413-431.1994). in the cell of target gene changes over to, expression vector can be taked many forms: add IRES (internal ribosome entry site) sequence between TAA protein gene and direct amalgamation and expression of specific TCR or the two gene and separate and .Rolland such as express, Crit.Rev.Therap.Drug Carrier Systems 15:143-198,1998. relevant expression vector system has: the naked DNA direct injection, the particle gun injection, adenovirus carrier, retrovirus, adeno-associated virus (AAV) carrier A AV (adeno-associated virus), vaccinia virus, deutero-expression vectors such as fowlpox virus. the characteristics of each system have detailed description in following document: Ulmer et al., Science 259:1745-1749, (1993. Rich et al. (1993) Human Gene Therapy4:461-476). and Carter, B.J. (1992) Current Opinion in Biotechnology 3:533-539.Elroy-Stein andMoss, Proc.Natl.Acad.Sci.USA (1990) 87:6743-6747; Fuerst et al.Proc.Natl.Acad.Sci.USA (1986) 83:8122-8126.U.S.Pat.Nos.5,843,723; 6,015,686; 6,008,035 and 6,015,694.U.S.Pat.Nos.5,846,796; 6,010,478; 5,865,796; 5,584,807; With EP Patent No.0500799.

In sum, developing " special tumor vaccine " with the tumor correlated albumen of finding among the present invention is set forth in above-mentioned each brief summary. through gene clone, gene imports, the T cytositimulation, the amplification of activating cells, the explanation of technological lines such as the use of TCR, made the conventional medical science of tool, the personage of biology can develop, use present technique. the concrete technological operation of relevant more detailed tumor vaccine, gene transfer the summary document such as is used and is seen in tumor vaccine: M.F.Powell and M.J.Newman, eds., " Vaccine Design (the subunit and adjuvantapproach); " Plenum Press (NY, 1995) .U.S.Pat.No.5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990.

The use of adjuvant is most important in the tumor vaccine development, also describe one of emphasis in detail for the present invention. immunostimulant is to make a general reference all can increase immunoreactive any reagent. the function of many adjuvants is to allow antigen molecule slowly-releasing such as aluminium hydroxide aluminum hydroxide and mineral oil (mineral oil), or non-specific increase immunostimulation, as phosphatide A (lipid A), Bao Te bacillus albumen (Bortadella pertussis) and tubercule bacillus albumen (Mycobacterium tuberculosis derived proteins). there is medical adjuvant supply in many manufacturers: as Freund ' the s Incomplete Adjuvant and Complete Adjuvant (DifcoLaboratories of U.S. Difco Laboratories company, Detroit, Mich.); Other products of AS-2. of Adjuvant 65. U.S. SmithKline Beecham companies of U.S. Merck company as: aluminium hydroxide gel (aluminum hydroxide gel) is or aluminum phosphate (aluminum phosphate) (alum); Calcium salt (salts of calcium), iron or zinc (iron or zinc); Insoluble acetylizad Tyrosine (an insoluble suspension ofacylated tyrosine); Acetylize sugar (acylated sugars); The polysaccharide of cationization or anionization (cationically oranionically derivatized polysaccharides); Polyphosphonitrile (polyphosphazenes); Biodegradable microparticles (biodegradable microspheres); Monophosphoryl lipid A (monophosphoryl lipid A) and quil A also is immunostimulant commonly used. cytokine, and as GM-CSF, interleukin-22, interleukin 7, interleukin 12 waits also in clinical use.

Because of emphasis of the present invention is using tumor associated antigen to stimulate patient's autoimmunization system to reach prevention and result of treatment, priority activation Th1 cell response when we select immunostimulation for use. high-caliber Th1 cell response will produce cytokine such as Interferon, rabbit gamma., tumour necrosis factor alpha (TNF.alpha)., interleukin-22, interleukin 12, it has the immune response of the body fluid of enhancing mediation property. certainly, stimulate in the process for the treatment of at tumor associated antigen for tumor vaccine, Th1 and Th2 cell response all can strengthen. and read documents is asked in the plain use of cells involved Jie: Mosmann and Coffman, Ann.Rev.Immunol.7:145-173,1989.

The adjuvant that has is preferably to stimulate the Th1 cell response, is added with monophosphoryl lipid A and aluminum salt uses with as adjuvant. in document U.S.Pat.Nos.4,436,727; 4,877,611; 4,866,034 and 4,912, detailed description is arranged in 094. it also is preferably to stimulate the Th1 cell response that non-methylated CpG polynucleotide use as adjuvant. this in patent documentation as WO 96/02555, WO 99/33488and U.S.Pat.Nos.6,008,200and 5,856, also having in 462 and elaborate. the Quil A derivative QS21and QS7 that U.S. Aquila Biopharmaceuticals company sells also has the effect that stimulates the Th1 cell response. in adjuvant mixture, add various particulates such as chitosan, Fructus Tribulus total saponins and other polymer, polycation type macromolecular material polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides orchemically modified polysaccharides, liposomes and lipid-based particles, particles composedof glycerol monoesters, also can mix and use Deng. Fructus Tribulus total saponins (saponins) with liposome such as ISCOMs. also can add the degree of adhesion (viscosity) that Carbopol.RTM increases adjuvant. so the first-selected adjuvant of the tumor vaccine of this patent is imitative is: monophosphoryl lipid A, the QS21 of Fructus Tribulus total saponins class and 3D-MPL.RTM mixture are core reagent. the method in this and the document WO 94/00153 is similar.

It is available at this that more adjuvant reagent is example: the French Seppic Montanide ISA of company 720 products. the SAF of U.S. Chiron company, ISCOMS, products such as MF-59, the products such as SBAS-2or SBAS-4 of U.S. SmithKline Beecham company. the RC-529 product of U.S. Corixa company. in patent documentation, also have the elaboration of more relevant novel adjuvant reagent: U.S.patent application Ser.Nos.08/853,826and 09/074,720 and WO 99/52549A1.

Cell type selects that (stimulation of antigen presenting cells (APCs) serves as preferential with antigen presenting cell for use in the special tumor vaccine development of the present invention, this comprises: dendritic cell (dendritic cells), scavenger cell, the B cell, monocyte etc. the cell of other types also might be treated and be possessed the antigen presentation ability, as import tcr gene, allow HLA join the production that technology such as type is suitable all can be used for antigen presenting cell. as for the source of antigen presenting cell, promptly from body, also available allosome material. the approach of drawing materials comprises various body fluid, organ-tissue etc.

In all kinds of available antigen presenting cells, dendritic cell is optimal cell type. this is at document (Banchereau andSteinman, Nature 392:245-251, comparatively detailed elaboration is arranged 1998). and cooperate above selected TH1 adjuvant prescription that good immunostimulating effect is arranged. (Timmerman and Levy, Ann.Rev.Med.50:507-529,1999). in general, dendritic cell can be identified from morphology, also can its (take up) ability of engulfing separate particulate matter. its function is often to measure the stimulation ability of special T cell mass. and utilizing technology such as transgenosis TCR to make the tumour patient dendritic cell possess irritant reaction ability to special tumour antigen also is one of technological line of pointing out of this patent. and the details of this class technology is at Zitvogel et al., Nature Med.4:594-600 has more detailed elaboration in 1998 articles.

The peripheral blood that the source of dendritic cell is desirable, marrow, the immunocyte of invasion tumor tissues, immunocyte in the tumour peripheral tissues, lymphoglandula, spleen. skin histology, or Cord blood etc. from peripheral blood isolating monocyte in the cell in vitro culture system through cytokine GM-CSF, IL-4, IL-13 or TNF.alpha handle to induce and are divided into dendritic cell. and from Cord blood, isolating CD34 positive cell also can be through GM-CSF in the marrow, IL-3, TNF.alpha., CD40l igand, LPS, flt3 substrate (ligand) and extracorporeal treatment are induced and are divided into dendritic cell. in general, dendritic cell roughly is divided into " adult form and non-adult form " two kinds: non-adult form often refers to that its cell still has very strong engulfing (take up) ability, and on cytolemma, still have higher Fc.gamma expression of receptor. and the adult form dendritic cell is meant MHC I and the high CD54 of II type developed by molecule, CD11 and CD40, CD80, CD86 and 4-1BB receptor protein are than the cell mass of high expression level.

Separating, after being purified into dendritic cell, to use conventional molecular biotechnology 20 kinds of tumor-related genes described in this patent are imported dendritic cell just for feasible. this class technology has comparatively detailed elaboration in following document: patent WO 97/24447.Mahvi et al., Immunology and cell Biology 75:456-460,1997. technology commonly used is liposome (Liposomes) transformation technology. liposome cell with T, liver cell, specifically be applied in Renneisen et al., J Biol.Chem.1990Sep.25 among the cell strain PC 12; 265 (27): 16337-42; Muller et al., DNA Cell Biol.1990 April; 9 (3): 221-9) in the article such as grade more detailed elaboration is arranged.

As for the dendritic cell behind immuno-stimulating treatment use by way of, but both intramuscular injection, intravenous injection, but also intracutaneous, subcutaneous, wait by way of medication in the big net. this class technology has comparatively detailed elaboration: U.S.Pat.No.5 in following document, 543,158; U.S.Pat.No.5,641,515and U.S.Pat.No.5,399,363

Partial immunity in the medication preparation stimulates particulate composition biological degradation class often material. and this class component has conventional formulation in immune class medicine: as microparticles of poly (lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran etc. the use of this class preparation in patent documentation as: U.S.Pat.Nos.4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344,5,407,609 and 5,942, carefully state again in 252. also in preparation, add the polysaccharide material of super large molecule thing for reaching slow release effect sometimes, or use different phosphate lipid material (phospholipid) as being twisted together. following document elaborates U.S.Pat.No.5 to this class technology, and 151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). use in the relevant tumor vaccine preparation or use different phosphate lipid material also is conventional knowledge, and this class technological system has play-by-play: Lasic in following document, Trends Biotechnol 1998 July; 16 (7): 307-21.Takakura, Nippon Rinsho 1998March; 56 (3): 691-5; Chandran et al., Indian J Exp Biol.1997 August; 35 (8): 801-9; Margalit, Crit RevTher Drug Carrier Syst.1995; 12 (2-3): 233-61; U.S.Pat.No.5,567,434; U.S.Pat.No.5,552,157; U.S.Pat.No.5,565,213; U.S.Pat.No.5,738,868and U.S.Pat.No.5,795,587.

Other composition in the relevant tumor vaccine preparation such as all kinds of damping fluids etc., both available physiological saline, also available PBS (phosphate bufferedsaline) liquid. additive commonly used such as glucose, seminose, sucrose, dextran, N.F,USP MANNITOL, glycine, antioxidant (antioxidants), fungistat (bacteriostats), sequestrant (chelating agents) EDTA or gsh (glutathione) etc. preparation type is also freeze-dried preparation of the aqueous solution both. and the packing controlled amount contains multiple injection dosage in one bottle of shot dosage or one bottle.

Growth of tumor is often due to the intravital immune surveillance function deficiency of patient, and the immunotherapy of tumour is based on and transfers immunologic function own in patient's body and come the target antigen on the tumor cell and suppress its growth. this class rudimentary knowledge is at Jager, et al., Oncology 2001; 60 (1): 1-7; Renner, et al., Ann Hematol 2000December; 79 (12): in the documents such as 651-9 play-by-play is arranged. have at least four class functioning cells relevant in the present known body: 1) bone-marrow-derived lymphocyte with the antitumor activity of human body, secretory antibody comes specially recognizing tumor cells .2) monocyte, generation complement etc. directly kills target cell .3) neutrophil leucocyte (natural killer lymphocytes), can utilize specific antibody to attack target cell afterwards or discharge lethal gene and directly produce complement etc. and directly kill target cell (natural killing) in conjunction with tumour cell, 4) T cell, processing tumour specific antigen then submission kills and wounds oncocyte for other immune attack cell, or have an oncocyte of complement in conjunction with those surfaces. (Schreiber, H., 1989, in Fundamental Immunology (ed) .W.E.Paul, pp.923-955) though. humoral immunization and cell-mediated immunity are all most important to tumor suppression, so but the activation that experimental result shows cd4 t cell has crucial regulating effect to the antibody of inducing body to produce high specificity anti-tumor. and the protein tumor associated antigen is a utmost point ideal tumour target antigen and being used for the treatment of. the 20 kinds of tomour specific associated protein (TAA) described in this patent provide particular content for oncotherapy. and this group TAA mainly uses and uses in people's oncotherapy, it promptly provides preventative-therapeutic possibility, also, the tumor resection postoperative is used for stoping tumor recurrence that means are provided for making as tumor vaccine. the use of TAA, both the albumen form as antigen, also can the next usefulness that plays tumor vaccine through gene transfer of dna form. when treatment, the course of treatment is 8 several months such as every month of a several weeks pin tumor vaccine often, continuous 6 pins are a course of treatment. and comparatively the ideal treatment plan is to have the patient greater than 10% that good antitumor reaction is arranged in the similar tumour patient, can reach to be idealized system more than 50%. the immune using dosage of target recombinant protein can from patient's per kilogram of body weight inject 25 nanogram(ng)s (25ug) to 5 micrograms ((5mg) albumen does not wait. volumes of formulation does not also wait from 0.1 milliliter to 5 milliliters.

Stimulate the method for patient's autoimmunization system in example five to example seven parts narration to be arranged with the TAA that obtains. as one of technology of passive immunization as the use of antitumor idiotype antibody (anti-idiotypic antibodies) at patent documentation U.S.Pat.No.4,918,164) play-by-play is arranged. carry out diagnosing tumor with antitumor specific antibody, the successful experience of treatment can be found everywhere in the literature, U.S.Pat.Nos.6,090,365; 6,015,542; 5,843,398; 5,595,721; And 4,708,930. anti-tumour antibodies or be marked with lethal isotropic substance, or the toxic protein part of amalgamation and expression. and the explanation of following patent documentation is both around this part: Ong etal, Cancer Immunol Immunother.Nov; 39 (5): 325-31,1994.Kreitman R.J.Immunotoxins. Expert Opinion on Pharmacotherapy, Vol 1, and Num 6,, pp.1117-1129.2000.

Finding tumour antigen in tumour patient is one of typical early diagnosis of tumor method, being proteantigen as AFP albumen in the liver cancer and the PSA in the prostate cancer etc. this class oncoprotein antigen can be from blood, urine is measured in the neoplasmic tissue sample. so some TAA of quantitative analysis provides technological possibility for the early diagnosis tumour.

Measure the mRNA level of target gene: the TAA in most of clinical trial becomes so-called tumour antigen because of its expression amount in normal and tumor tissues is different, so quantitatively be higher than 2 times and become " high expression level " to control tissue to express in the tumor tissues in the process. the tumour antigen of finding to some extent in this patent is only to express in the embryonic tissue in early days and obtain according to it, it is not generally expressed in healthy tissues fully, for the mRNA level of measuring target gene provides accuracy.

Being reported in the document in the recent period in the peripheral blood of tumour patient has the round-robin tumour cell to exist. singly often be difficult to be found in quantitatively this class circulating tumor cell with morphological indexes. and this group tumour-specific gene and proteic be found to be quantitative, qualitative this class circulating tumor cell provides may. (Muller et al.Breast Cancer Res.8 (5): 110.2006.) quantitative to the mRNA level of target gene to be measured with round pcr, with the ELISA method tumour antigen mensuration etc. there is description in this article. and the sequence of the dna primer that in this paper test case PCR is used, the target protein peptide sequence for preparing specific antibody and use etc. all has a detailed description. and Sackett et al., Clinical Epidemiology:ABasic Science for Clinical Medicine, Little Brown and Co., 1985, p.106-107, wait monograph that the analysis of monitoring result is also described.

PCR in real time (real-time PCR) also is one of the technological system of the mRNA level of monitoring target gene commonly used in the clinical trial, in the test case of this paper, provide the sequence of the dna primer that the PCR in real time of all 20 kinds of target genes uses and result in the quantitative analysis of people's colorectal cancer tumor sample. (Figure 11). real time pcr binding antibody-magnetic bead is arrested the target cell technology and is provided conveniently method for many neoplastic hematologic disorders. and it is available in following company that this class magnetic bead is arrested the target cell technology: the Dynal magnetic bead, U.S. Dynal Biotech company, the StemSep magnetic bead. (Canadian StemCell Technologies, company), with RosetteSep magnetic bead (U.S. StemCell Technologies company). this class target antibody-magnetic bead system usually hangs with CD antibody, antibody all has commercial product: CD2 in the following example, CD3, CD4, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD24, CD25, CD29, CD33, CD34, CD36, CD38, CD41, CD45, CD45RA, CD45RO, CD56, CD66B, CD66e, HLA-DR, IgE, and TCR.alpha..beta.. arrests from target cell, lysis, the fast purifying of RNA, RT reaction and PCR can buy from QIAGEN company and be with commercial test kit. and this class reagent also approved is used clinical trial. (QIAamp DNABlood Maxi Kit 50, Cat#51194).

Though PCR in real time (real-time PCR) can accurately be measured the expression of target gene level, but because of operation is that PCR sample of a kind of gene carries out, reading error between the sample is arranged sometimes. for overcoming this difficult problem, this patent further shows new technology GeXP quantitative assay technology. in this technological system, special (Housekeeping) genes of the DNA special primer of 20 kinds of target genes and 4 kinds react in single PCR test tube, make the quantitative assay target gene normally in tumor tissues expression level more accurate. provide correct information for the tumor vaccine that instructs next step. specifically being applied in the test examples (six) of this GeXP quantitative assay technology has detailed description.

The narration of this test examples part is only for providing the part test means as using model, according to conventional genetically engineered, cytology, immunology, technological methods such as oncology can be obtained similar test-results through the different technologies system. so 20 kinds of human tumor-specific related antigens are at diagnosing tumor among the present invention, the application of treatment is not limited in the example of this test.

The target gene of gene promoter dna methylation in embodiment 1, the identifier's healthy tissues:

The gene promoter dna methylation is one of important function of gene expression regulation step in the tissue differentiation process in the people's gene group, early stage at tumor invasion, many important relevant genes of tissue differentiation, the regulation and control imbalance that methylates because of tumour cell, reach and become active list by former silent status, people AFP (alpha-fetoglobulin in the liver) is exactly good example. this experiment be intended to obtain in those people's gene groups gene promoter its in normal circumstances by high methylation, and might be the demethylation state in tumour cell. the gene demethylation provides the foundation this information in the tumour cell in order to seek. this experiment use U.S. AVIVA SYSTEMS BIOLOGY (ASB) CHIP_DSL of company technological system. and the present technique system delivers among the PNAS in 2006 that (March 20, Vol.104.2007, PNAS pp:4852-4857), the commercial test kit of the ASB company of available purchase carries out.

This experiment is carried out group leader people in conjunction with special anti-cytosine methylation monoclonal antibody, and purifying after stain colour solid dna antibody immunoprecipitation technology combines with the gene promoter chip technology and carry out.

1A: chromosomal DNA antibody mediated immunity precipitation (ChIP Assays) is prepared with the amplification of DNA product:

Below experiment is the guidance of basic experiment step with the U.S. CHIP_DSL of ASB company technological system process specifications.

Reagent: special anti-cytosine methylation monoclonal antibody (5-Methylcytosine Antibody) is an Eurogentec company product, (catalog number (Cat.No.): BI-MECY-0100) .20K people's gene promotor chip be the AVIVA product (catalog number (Cat.No.): AK0504). normal various human body tissue genomic dna derives from brain, liver, kidney, placenta, lung, stomach, small intestine, the rectum colon, pancreas, fetal thymus, muscle, mononuclearcell will be put into digestion damping fluid (100mM sodium-chlor, 10mM TrisCl after these homogeneous microstructure grindings, the pH value is 8.0, the 25mM tetraacethyl, pH value 8.0,0.5%SDS) and 0.1 mg/ml Proteinase K in, placed 12-18 hour for 50 ℃, ethanol-isopropanol method is purified.The DNA that extracts becomes length behind ultrasonic degradation be that the segment .10 microgram genomic dna of 500-800bp is earlier 95 ℃ of sex change 10 minutes, rapidly in cooled on ice, add 1ug monoclonal antibody IgG then and add simultaneously behind 20 microlitre albumin A-magnetic beads and the 50 microlitre PBS solution 37 ℃ of insulations 60 minutes. wash 4 times through centrifuging with 1 milliliter of PBS solution at last. resuspended magnetic bead sample is in 50 microlitre TE solution. through the sedimentary sample methylate DNA of antibody sample 95 ℃ of sex change 3 minutes, through centrifugal removal magnetic bead, keep DNA sample in the supernatant.

The DSL reaction is finished in the DNA ligation that sedimentary DNA sample (about 200-300ng DNA) instructs by primer in the CHIP_DSL test kit, final step is with fluorescently-labeled T7 primer (Cy3 and Cy5) mark amplification, and the DNA sample dissolution that is purified into through QIAquick pcr amplification purification kit (Qiagen company product) is in the water of 50 μ L.Be added to 20K people's promotor chip (seeing detailed preparation specification sheets) after 5 minutes in 50 ℃ of incubated overnight through 95 ℃ of sex change.Chip after the hybridization by the preparation specification sheets after centrifugal developing a film again through centrifugal drying, with GenePix 4000B scanner (Axon equipment) scanning.Extract software with Axon and from the oligonucleotide arrays scanning image, obtain fluorescence intensity numerical value; for each locational array, the log2 ratio of Cy5 mark test sample and the reference sample of Cy3 mark compare, then; the log2 ratio deducts each point, corrects and carry out each passage normalizing.The chip sample of Cy5 mark is the sedimentary sample methylate DNA of antibody, and the Cy3 mark is the crt gene group DNA. that derives from without antibody treatment

1B: data analysis

Use GenePix 5000 scanners and GenePixPro 5.1 software analysis Cy5 and Cy3 fluorescence intensity.Remove the abnormity point (for example, those pollute speckle, the assorted band that produces in fragment or the hybridization) of mark in the analysis

The chip results analysis software package R. that this experiment use is used always ( Http:// www.R-project.org) divides with the Erroe model for the basis Analyse. present method be published in ( Nature, 2005.Aug 11; 436 (7052): 876-80.Epub 2005Jun 29.) the .Erroe model analysis can be summarized as follows: to all scan-datas.According to the detected result of P value, earlier with normalizing as a result. (result who calculates with negative control is a parameter).Detection P value calculation formula is 1 R/n, and wherein R is meant the relative value of gene signal and negative control, and N is the quantity of negative control.Detect the P value and can be interpreted as detected certain signal level when not having the hybridization of specificity target-probe.We the threshold value of having set the P value have several retainings low signal (LEGs) of expressing: 0.05 (0.05≤P value＜1), medium expression (MEGs) we to set P value threshold value be greater than 0, but " the P value less than 0.05 (0＜P value＜0.05) high expression level (HEGs) equals 0.Fig. 1 is a human brain source DNA CHIP_DSL experimental result scintigram.

The array design of having used each gene promoter area to represent in the promotor chip array of AVIVA people 20K with the unique DNA primer. it is included in whole 18560 specific genes in the U.S. NCBI RefSeq database, and wherein 2912 genes select to design 2 promoter DNA primers are arranged because of it possesses the double startup subarea.The definite design of each chip dot matrix sees the ASB chip for details and prepares specification sheets.The chip results analytical data is returned to the promoter region of each gene by point, and learns its degree that methylates. this experiment obtain altogether common in multiple healthy tissues about 721 of the target gene of the promoter region hyper-methylation of its gene.

The experiment of embodiment 2, evaluation tumor specific expression gene.

Because of the present invention aims at obtaining the tumour-specific target gene, second step that historical facts or anecdotes is tested concentrate on that searching is not expressed substantially in healthy tissues and in tumor tissues the gene of high expression level.

Introduce in the proved recipe case one factually, the phenomenon that imbalance is arranged because of its regulation and control that methylate in many tumor tissue cells, many body early embryo stage specific genes are unusual high expression level in adult tumor tissue cell but. and this genoid is often closed in healthy tissues well and not at all and is expressed. and theoretical in view of the above, second step of experiment concentrates on the evaluation of the early stage specific expression gene of embryo. because of sexual cell in the human body near the early stage state of embryo, so use the specific expressed chip mensuration storehouse result of the mRNA of various human tissue and people's sexual cell to carry out to recently analyzing and researching.

This experimental technique is that the target gene with 721 gene promoter area hyper-methylations of being found in experimental program one is a starting point, the specific expressed chip that each gene is put into the many tissue mRNA of GNF symAtlas measure the storehouse ( Http:// symatlas.gnf.org/SymAtlas/), only seek gene in the expression of people's testis sexual cell. with these 172 target genes that obtain. this group gene is only expressed at people's testis sexual cell, its mRNA expresses and almost can not survey in healthy tissues. and for proving these 172 target genes may be tumor associated antigen, we further continue to identify the expression of these 172 target genes in 60 kinds of tumour cells of NCI by the symAtlas database. and through this step screening, these 172 target genes all have expression in various degree in kinds of tumor cells. and Fig. 2 is the specific expressed representative diagram of DNALI1 target gene mRNA in GNF chip storehouse.

The production of embodiment 3, tumor specific expression gene protein target antibody:

For these 172 target genes in the further proof tumour cell have the expression of relevant albumen really in different tumour cells, we further select 20 kinds of target gene albumen and carry out rabbit polyclonal antibody production. and (show among Fig. 3 20 kinds of target gene titles and NCBI gene pool gene order number). wherein 14 target proteins are with synthetic its specific polypeptides antigen that obtains of polypeptide, and each target protein design has two specific polypeptides antigens. and 6 target proteins obtain proteantigen and carry out the production of target protein specific antibody with the full-length gene reorganization in addition.

3A: the polypeptide of target protein is synthetic:

The polypeptide of 14 target proteins synthesizes the Guide Book routine of closing the behaviour that ACT company provides in the instrument at the Apex of ACT company polypeptide to carry out: with the Wang resin is solid phase carrier, improves Fmoc (fluorenylmethyloxycarbonyl)/tBu method and carries out .Fmoc and activate through HPTU.Specific peptide sequence is that solid phase carrier begins reaction by sequence with the Wang resin, and entire reaction is carried out on a fixed surface.The full-length polypeptide warp of shearing from the fixed upholder: trifluoroacetic acid: dehydrated alcohol: thioanisole: water: phenol (40: 1: 2: 2: 3).After 2 hours, last polypeptide is deposited in the cold methyl tertiary butyl ether after the cracking.The peptide particles dissolving contains in the water of 0.1% trifluoroacetic acid, with C18 post reversed-phased high performace liquid chromatographic purifying and freeze-drying.14 target protein polypeptid acid sequences are seen Fig. 4 (each target protein design has two specific polypeptides antigens).

The strand of 3B:KLH carrier proteins connects:

Keyhole relative blood Blue albumen (KLH) is U.S. EMD company product (catalog number #374805), and sulfo-SMCC is a U.S. SOLTEVentures company product (catalog number #C L 207).

This project synthetic polypeptide all is added with cys at its C-terminal will provide S H group, water-soluble S M C C act on N H 2 groups of K L H protein surface through the maleimide reaction and produce the covalency strand and connect. concrete operation is as follows: get equivalent (3mg) K L H and wait the target gene protein polypeptide (3mg) of the company of strand, add in 50 ml beakers, slowly add then through the good sulfo-SMCC of water dissolution (1.8mg) approximately. stirring at room 30 minutes and finish strand and connect reaction. strand connects albumen through Sephadex G25 post separated and collected. measure the usefulness of protein concentration in order to animal immune.

3C: antiserum(antisera) production process:

For these 14 TAA albumen of Fig. 4, from the zone of each target antigen uniqueness, selected two polypeptide and synthesized, frozen after being connected to KLH, when needing, immunization uses.

The polyclonal antiserum production process: with 400 microgram target antigen polypeptide-K LH binding substancess (0.5 milli is given birth to), add the mixing of the complete Freund's adjuvant (CFA) of equivalent, ((S.C.) becomes rabbit in subcutaneous injection.After 4 weeks, the incomplete Freund's adjuvant (IFA) of 400 micrograms antigenic peptide-KLH binding substances and equivalent mix the subcutaneous injection rabbit 2 times, each 4 weeks at interval.Last intravenous rabbit is injected the pure antigen KLH of 100 micrograms binding substances.Last immunity was got rabbit blood after 7 days, blood is placed 4 degree hatched 12-24 hour, obtained serum after centrifugal.Obtain rabbit igg antibody through the albumin A column purification.

The mensuration that specific antibody is tired: in 96 orifice plates, spent night by 4 with 50ul polypeptide bag. peptide concentration normally 1ug/50ul. to seal non-specific reflection be to add under the 250ul BSA room temperature in every hole to hatch 2 hours. polyclonal antiserum 50ul (normally 2ug/ul) is through 1: 20 ten thousand (with PBS/0.1%Tween/0.1% bovine serum albumin dilution rabbit antibody) of doubling dilution, add in the hand-hole and combine, be used in 96 orifice plates under the 4 degree conditions and hatched 2 hours with antigen-specific.Plate is washed by following condition and undertaken: the PBS that contains 0.1% tween washs 6 times.Every then hole added 50ul 1: 10, goat antirabbit horseradish peroxidase (HRP) incubated at room 30 minutes of 000 dilution and developing the color.The H.sub.2SO.sub.4 termination reaction that adds the 1N of 100ul, and reading under the 450nm wavelength around immediately.Tiring of each antibody is many＞1: more than 10000.

3D: target gene full length cDNA clone preparation:

After the CHIP_DSL chip results is analyzed, data are returned to the promoter region of each gene by the dot matrix on the chip and obtain the gene pool code name (accession#) of target gene. and search for through the state-run biotechnology of U.S. NCBI information center cdr database according to the gene pool code name of target gene then and obtain the target gene full length cDNA sequence. target gene full length cDNA sequence according to this, obtain the IMAGE clone of target gene through a step search U.S. M G C cdr database, homology with 100% is as the criterion. buy target specificity IMAGE clone from U.S. Open Biosystems company then, according to different carriers, at the D of ABI N A sequenator each being cloned in the exactness that purifying is further verified its D N A sequence with different D N A primers. corresponding target gene IMAGE clone brief summary is in Fig. 5.

3E: the expression of target recombinant protein in intestinal bacteria

6 target protein: C17ORF39 are selected in this experiment for use, CSNK2A2, and DNALI1, GSG1, GSTM3, IL13RA2. carries out its Recombinant Protein Expression and purifying, is used for antibody producing:

6 target protein genes through P C R routinely technology carry out total length encoding gene people's amplification, concrete D N A primer is seen Fig. 6. the IMAGE clone of target protein gene is all from U.S. Open Biosystems company purchase substrate DNA for the PCR reaction behind plasmid vector DNA purifying, PC R fragment with inserting in the expression vector of pET41a transformation behind the restriction endonuclease NdeI-XhoI double digestion, has MASMTGGQQMGRHHHHHH to merge at the N-of target protein end behind glue purification in pET41 carrier recombinant expression system T7 promotor lower end.

Transform expression vector at colibacillus high expression with BL21star bacterium (Invitrogen company product), add LB liquid and serve as that screening is in 37 degree shaking table overnight growth with the kanamycin microbiotic.The next morning, the bacterium liquid of 10 milliliters of incubated overnight joins in the 500ml LB nutrient solution, the kanamycin microbiotic.Shake bacterium to the optical density(OD) of cultivating when 560 nanometers reach 0.4-0.6, add IPTG (1mM) and induced four hours, last centrifugal results reorganization bacterium.Thalline is through PBS liquid centrifuge washing cell.Abandon supernatant.Add the 10ml lysate and shake resuspended (lysozyme).Bacillus coli cells is 16, cracking under the 000psi pressure, and eccentric cell is intestinal bacteria reorganization inclusion body protein at the bottom of the centrifuge tube again.

Inclusion body protein is resuspended in 10mM Tris pH 8.0, centrifuge washing inclusion body again in the 1%CHAPS liquid.Repeat this process 2 times.In sample protein liquid, slowly add final concentration 8M solid urea then, dissolve fully through being stirred to inclusion body.The soluble proteins sample was hatched the room temperature continuously stirring 45 minutes to 1 hour in 5 milliliters of nickel resins (the His Tag column of Qiagen company).Resin and protein mixture are collected by the disposable post that waters.Buffered soln washing pillar (2M urea P B S liquid) with 12-20 times of volume. collect 3 milliliters of components through the Tris of 10mM pH value 8.0 and 300mM imidazoles.Run the SDS-PAGE gel, to determine the purity of purifying protein.As the not enough purifying of albumen, last purification step is used anionite-exchange resin, and Hi-Prep Q (Biorad) packs in the pillar with damping fluid and mixed solution.Utilize the every kind of antigen of salt concn wash-out that increases.Collect each component, run the SDS-PAGE gel, obtain purification of recombinant proteins to determine each component.The recombinant protein component is dialysed again with 10mM Tris pH 8.0.Pack into to pacify with 0.22 micron strainer filtration albumen at last and cut open immunization or directly frozen standby in the bottle antigen.

Embodiment 4, usefulness immunoblotting (Western blot) detect the cancer sample.

Reagent: each tumor cell line is all purchased the ATCC in the U.S., and carry out cell cultures by its cell strain culture condition. human hepatoma cell strain HepG2, (catalog number: HB-8065), human T-cell's tumor line Jurkat, (catalog number: TIB-152). human breast cancer cell strain MCF7:(catalog number: HTB-22): human B cell strain 721B, present for professor Feitelson of U.S. THOMAS JEFFERSON medical college. people's teratocarcinoma cell NTERA2, (catalog number CRL-1973), human cervical carcinoma cell strain Hela, (catalog number: CCL-2). people's healthy tissues is as brain, the heart, lung, liver, voluntary muscle and placenta tissue all are extracted from the fetus sample of 22 all induction of labor with water bag.

Protein sample preparation: 5 * 10 ⁷(150mMNaCl in the resuspended lysate with 1 milliliter of fresh configuration of the tissue homogenate of culturing cell or 0.4 gram, 50mM Tris-HCl, pH7.4,1mM EDTA, 1%NP-40,0.5% Septochol, 0.1%SDS, 1mM PMSF, 1ug/ml Leupeptin, Aprotinin, Pepstatin). add S D S-P A G E sample solution (2 * SDS Loading Buffer:0.2M DTT, the 4%SDS of equal-volume 2X behind the mixing, 0.2%Bromophenol blue, 20%Sucrose or glycerol, 0.1M Tris-HCl, pH6.8). and further put behind the mixing to the 95C water-bath and handled 5 minutes. get that sample carries out protein electrophoresis on the 30ul sample after centrifugal.

Protein electrophoresis carries out in 8% polyacrylamide gel electrophoresis routinely, with electrotransfer system of Bio-RAd company albumen is transferred on the PVDF Hybond membrane behind the protein isolate, after 1% dried milk/4 ℃ of sealings of P B S liquid are spent the night, then by an anti-(dilution (final concentration is 1ug/ml) in 1: 4000, be incubated 37 ℃, 2 hours. wash film 5 times through 0.1%NP-40/P B S liquid, added then 1: 50, goat-anti rabbit two anti-antibodys of the H R P mark of 00 dilution, be incubated 37 ℃, 1 hour, after 0.1%NP-40/P B S liquid is washed film 5 times with film through E C L solution (PIERCE company product, catalog number #32160) sandwich after handling in the X-ray sheet through developing, the detection of immunoblotting is finished in photographic fixing. and Fig. 8 is target protein UBQLN3 and the DNALI1 situation at tumour and normal tissue expression.

Embodiment 5, PCR in real time method are analyzed the expression of specific target gene in kinds of tumors.

PCR in real time (Real-time PCR) is analyzed tumor sample: with PCR in real time detection prostate cancer and the expression technology of breast tumor sample in various tumours and healthy tissues is general routine techniques.In brief, the logarithmic value that is higher than background with the DNA of the several all after dates of pcr amplification is come quantitatively.Utilize the continuous fluorescence monitoring, each PCR reaction is easy to determine the threshold value of the DNA cloning multiple under the cycle index.At present, some commercial fluorescence detecting systems are available.A specificity binding fluorescent dyes dyeing that is based on double-stranded DNA.Use in addition contain the fluorescent quantitation probe dye be marked at 5 ' end (FAM) simultaneously the Quencher dyestuff in mark 3 ' end (TAMRA) (Perkin Elmer/ Applied Biosystems, Inc., Foster city, California).The pcr amplification product of target is from cracking of Quencher dyestuff and the release of the nucleic acid probe AmpliTaq Gold.TM. (Perkin Elmer/ Applied Biosystems, Inc., Foster city, California) that contains.Therefore, determine the fluorescent signal that the PCR product produces from the labeling dye ratio that discharges.These two kinds of detection methods have been found identical result.The level relatively of genetic expression in the more multiple tissue sample adopts the RNA of tissue to generate cDNA through reverse transcription, with the target gene specific primer each identical cDNA amount is carried out PCR in real time then.Each cdna sample is normally repeating.The PCR in real time result of last each gene generally is the genic value of average copy number.The quantitative result of real-time PCR reactions can detect with the painted GeneAmp 5700 of SYBR Green I or with TaqMan probe (Perkin Elmer//department of Applied Biosystems, Inc., Foster city, California) ABI PRISM company 7700 detectors detect.

Reagent: the cDNA sample of human colon tumor tissue is all purchased the Origene company in the U.S., (catalog number #H C R T 101﹠amp; HC R T 501, it includes the cDNA sample of 5 routine normal people colons and 19 routine human colon tumor tissues. and target gene D N A primer is synthetic through American I D T company, its sequence is seen Fig. 9: real-time PCR reactions detects with U.S. Bio-Rad iQ5 detector, use simultaneously iQ SYBRGreen Supermix (catalog number: 170-8884) carry out example reaction.

The CSNK2A2 expression of target gene level of PCR in real time analyst's colon tumor tissue is undertaken by following schedule of operation in the 0.2ml centrifuge tube: add in the 0.2ml centrifuge tube: 12.5ul iQ SYBR Green Supermix liquid, 2ul human colon tumor tissue cDNA sample, 2ul (20pM/ul) has adopted primer and 2ul (20pM/ul) antisense primer, 6.5ul deionized water. the vibration sample hose, of short duration then centrifugal.The Bio-Rad iQ5 detector that pipe is put into preheating detects and to begin P C R reaction. begin circulation by follow procedure: 94 ℃ of pre-sex change 4 minutes 1 time, 94 ℃ of sex change 1 minute, anneal 55 ℃ 1 minute, extend 72 ℃ 1 minute, circulating 38 times. this reaction uses house-keeping gene (house-keeping geneas control) GAPDH (glyceraldehyde dehydrogenase) transcriptional level to proofread and correct the horizontal .CSNK2A target gene of expression of target gene to be measured in the relative expression level of PCR in real time acquisition in each human colon tumor tissue, the results are summarized in Figure 10.

Embodiment 6, use GeXP system detect the human cancer tissue.

GeXP is a kind of new, the multiple target D N A sample of improvement carries out the reaction and the quantitative analysis of RT-PCR method (reverse transcriptase polymerase chain reaction) in same test tube. and it can change two primers of multiple RT-PCR with universal primer, and final product can detect by the GenomeLab GeXP genetic analysis systems of existing BeckmanCoulter company.Sample manual operation error when this detection method is eliminated and connected single target gene carry out the PCR in real time method in single tube. for the quantitative assay of the multiple expression of target gene level of clinical detection provides may. this experiment is intended to proof and uses the monitoring effect of GeXP technology in conjunction with 20 kinds of novel tumor target genes.

Reagent: the mRNA sample of the many tumor tissues of people is all purchased the strategene company in the U.S. respectively, (catalog number 740000, it includes the mRNA sample that several tumour cells extract. and target gene D N A primer is synthetic through U.S. Allele Bioscience company, and its sequence is seen Figure 11: real-time PCR reactions carries out with the American AB I Verit of company 96 orifice plate P C R machines. and the response sample reaction detects with the GenomeLabGeXP genetic analysis systems of Beckman Coulter company. ( Http:// www.beckman.com/products/instrument/geneticanalysis/gexp instdcr.asp)

According to GenomeLab GeXP analytical system working instructions, the primer of 20 kinds of target genes is that reference gene combines design with 4 kinds of house-keeping genes. as T B P (TATA box binding protein), ATP50 (ATP synthetic enzyme, the transhipment of H+, mitochondrial F1 complex body, the O subunit), ACTB (beta Actin), GAPD (glycerine triphosphoric acid desaturase).The design of primers principle of gene has detailed introduction in GenomeLab GeXP analytical system working instructions, Beckman Coulter company also provides the design of primers service of gene for the client simultaneously.

The GeXP specimen preparation is all undertaken by GenomeLab GeXP analytical system working instructions with detection: in brief, the tumor tissues mRNA of purifying (U.S. stratagene company product), the first round becomes the specific target gene of cDNA to adopt reverse primer to see Table X the mRNA reverse transcription, and wherein reversed transcriptive enzyme and test kit are available from Invitrogen company.According to working instructions, preceding 3 circulations adopt the primer of universal/gene specific to carry out the PCR reaction, mix the back and add F and 30 circulations of R PCR primer amplification.5 ' end (The forward) primer mark the D4 dyestuff, it derives from GenomeLab GeXP and prepares in the test kit.GenomeLab GeXP system reads the fluorescence X degree qualitative, quantitative of P C R product with the surge of capillary pipet gel because of the difference that 2-5bp is arranged between each gene P C R product length by means of the synthetic target gene. and obtain the prostate cancer of some amount and the result of breast tumor sample according to the GeXP systems analysis, see Figure 12.

The immunohistochemistry of embodiment 7, target gene C17ORF39 is to the human cancer fabric analysis

Target gene C17ORF39 is not for completely newly still there being the gene of any bibliographical information. and find C17ORF39 high expression level phenomenon in groups of people's tumor sample when analyzing tumor sample according to PCR in real time in early stage (Real-time PCR), this experiment is carried out elementary immunohistochemistry screening to the tumor sample of clinical acquisition behind its specific antibody of preparation.

Step obtains purification of recombinant proteins and antibody purification to the inclusion body protein purifying after the renaturation in experimental technique three.In order to determine of the expression of C17ORF39 albumen, carry out immunohistochemical analysis with the C17ORF polyclonal antibody of affinity purification at various normal and various cancerous tissues.Specifically, tissue sample was fixed in the formalin solution 12-24 hour, and paraffin embedding is cut into the slice, thin piece of 4 (μ m) thickness then.Tissue microwave heating treatment method is carried out histochemical stain with U.S. Ventana company active immunity histochemical stain instrument (model Ventana320-202) after the tissue sample sheet is handled routinely. and dyeing uses AEC to detect box (U.S. Covance company product), and C17ORF polyclonal antibody working concentration the results are shown in Figure the 13. as seen nucleus of high expression level dyeing in people's tumor of kidney tissue of part for the immunohistochemical methods of (1ug/ml) .C17ORF39. almost detect less than any dyeing signal in the normal people's nephridial tissue that contrasts.

SEQUENCE?LISTING1

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_001464

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2657

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(130)

<220>

<221>exon

<222>(131)..(207)

<220>

<221>exon

<222>(208)..(263)

<220>

<221>exon

<222>(264)..(342)

<220>

<221>exon

<222>(343)..(419)

<220>

<221>exon

<222>(420)..(588)

<220>

<221>exon

<222>(589)..(645)

<220>

<221>exon

<222>(646)..(717)

<220>

<221>exon

<222>(718)..(884)

<220>

<221>exon

<222>(885)..(966)

<220>

<221>exon

<222>(967)..(1103)

<220>

<221>exon

<222>(1104)..(1287)

<220>

<221>exon

<222>(1288)..(1386)

<220>

<221>exon

<222>(1387)..(1582)

<220>

<221>exon

<222>(1583)..(1688)

<220>

<221>exon

<222>(1689)..(1872)

<220>

<221>exon

<222>(1873)..(1950)

<220>

<221>exon

<222>(1951)..(2089)

<220>

<221>exon

<222>(2090)..(2249)

<220>

<221>exon

<222>(2250)..(2313)

<220>

<221>exon

<222>(2314)..(2643)

<220>

<221>STS

<222>(2386)..(2555)

<220>

<221>polyA_signal

<222>(2618)..(2623)

<220>

<221>polyA?site

<222>(2640)..(2640)

<400>1

gcg?tca?tct?cgc?gct?tcc?aac?tgc?cct?gta?acc?acc?aac?tgc?cat?tat 48

Ala?Ser?Ser?Arg?Ala?Ser?Asn?Cys?Pro?Val?Thr?Thr?Asn?Cys?His?Tyr

1 5 10 15

tcc?ggc?tgg?gac?cca?gga?ctt?caa?gcc?atg?tgg?cgc?gtc?ttg?ttt?ctg 96

Ser?Gly?Trp?Asp?Pro?Gly?Leu?Gln?Ala?Met?Trp?Arg?Val?Leu?Phe?Leu

20 25 30

ctc?agc?ggg?ctc?ggc?ggg?ctg?cgg?atg?gac?agt?a?at ttt?gat?agt?tta 144

Leu?Ser?Gly?Leu?Gly?Gly?Leu?Arg?Met?Asp?Ser Asn?Phe?Asp?Ser?Leu

35 40 45

cct?gtg?caa?att?aca?gtt?ccg?gag?aaa?ata?cgg?tca?ata?ata?aag?gaa 192

Pro?Val?Gln?Ile?Thr?Val?Pro?Glu?Lys?Ile?Arg?Ser?Ile?Ile?Lys?Glu

50 55 60

gga?att?gaa?tcg?cag?gca?tcc?tac?aaa?att?gta?att?gaa?ggg?aaa?cca 240

Gly?Ile?Glu?Ser?Gln?Ala?Ser?Tyr?Lys?Ile?Val?Ile?Glu?Gly?Lys?Pro

65 70 75 80

tat?act?gtg?aat?tta?atg?caa?aa a?aac?ttt?tta?ccc?cat?aat?ttt?aga 288

Tyr?Thr?Val?Asn?Leu?Met?Gln?Lys Asn?Phe?Leu?Pro?His?Asn?Phe?Arg

85 90 95

gtt?tac?agt?tat?agt?ggc?aca?gga?att?atg?aaa?cca?ctt?gac?caa?gat 336

Val?Tyr?Ser?Tyr?Ser?Gly?Thr?Gly?Ile?Met?Lys?Pro?Leu?Asp?Gln?Asp

100 105 110

ttt?cag?aat?ttc?tgc?cac?tac?caa?ggg?tat?att?gaa?ggt?tat?cca?aaa 384

Phe?Gln?Asn?Phe?Cys?His?Tyr?Gln?Gly?Tyr?Ile?Glu?Gly?Tyr?Pro?Lys

115 120 125

tct?gtg?gtg?atg?gtt?agc?aca?tgt?act?gga?ctc?ag g?ggc?gta?cta?cag 432

Ser?Val?Val?Met?Val?Ser?Thr?Cys?Thr?Gly?Leu?Arg Gly?Val?Leu?Gln

130 135

ttt?gaa?aat?gtt?agt?tat?gga?ata?gaa?ccc?ctg?gag?tct?tca?gtt?ggc 480

Phe?Glu?Asn?Val?Ser?Tyr?Gly?Ile?Glu?Pro?Leu?Glu?Ser?Ser?Val?Gly

145 150 155 160

ttt?gaa?cat?gta?att?tac?caa?gta?aaa?cat?aag?aaa?gca?gat?gtt?tcc 528

Phe?Glu?His?Val?Ile?Tyr?Gln?Val?Lys?His?Lys?Lys?Ala?Asp?Val?Ser

165 170 175

tta?tat?aat?gag?aag?gat?att?gaa?tca?aga?gat?ctg?tcc?ttt?aaa?tta 576

Leu?Tyr?Asn?Glu?Lys?Asp?Ile?Glu?Ser?Arg?Asp?Leu?Ser?Phe?Lys?Leu

180 185 190

caa?agc?gta?gag?cca?cag?caa?gat?ttt?gca?aag?tat?ata?gaa?atg?cat 624

Gln?Ser?Val?Glu?Pro?Gln?Gln?Asp?Phe?Ala?Lys?Tyr?Ile?Glu?Met?His

195 200 205

gtt?ata?gtt?gaa?aaa?caa?ttg?tat?aat?cat?atg?ggg?tct?gat?aca?act 672

Val?Ile?Val?Glu?Lys?Gln?Leu?Tyr?Asn?His?Met?Gly?Ser?Asp?Thr?Thr

210 215 220

gtt?gtc?gct?caa?aaa?gtt?ttc?cag?ttg?att?gga?ttg?acg?aat?gct?att 720

Val?Val?Ala?Gln?Lys?Val?Phe?Gln?Leu?Ile?Gly?Leu?Thr?Asn?Ala?Ile

225 230 235 240

ttt?gtt?tca?ttt?aat?att?aca?att?att?ctg?tct?tca?ttg?gag?ctt?tgg 768

Phe?Val?Ser?Phe?Asn?Ile?Thr?Ile?Ile?Leu?Ser?Ser?Leu?Glu?Leu?Trp

245 250 255

ata?gat?gaa?aat?aaa?att?gca?acc?act?gga?gaa?gct?aat?gag?tta?tta 816

Ile?Asp?Glu?Asn?Lys?Ile?Ala?Thr?Thr?Gly?Glu?Ala?Asn?Glu?Leu?Leu

260 265 270

cac?aca?ttt?tta?aga?tgg?aaa?aca?tct?tat?ctt?gtt?tta?cgt?cct?cat 864

His?Thr?Phe?Leu?Arg?Trp?Lys?Thr?Ser?Tyr?Leu?Val?Leu?Arg?Pro?His

275 280 285

gat?gtg?gca?ttt?tta?ctt?gt?t?tac?aga?gaa?aag?tca?aat?tat?gtt?ggt 912

Asp?Val?Ala?Phe?Leu?Leu?Val Tyr?Arg?Glu?Lys?Ser?Asn?Tyr?Val?Gly

290 300

gca?acc?ttt?caa?ggg?aag?atg?tgt?gat?gca?aac?tat?gca?gga?ggt?gtt 960

Ala?Thr?Phe?Gln?Gly?Lys?Met?Cys?Asp?Ala?Asn?Tyr?Ala?Gly?Gly?Val

305 310 315 320

gtt?ctg?cac?ccc?aga?acc?ata?agt?ctg?gaa?tca?ctt?gca?gtt?att?tta 1008

Val?Leu?His?Pro?Arg?Thr?Ile?Ser?Leu?Glu?Ser?Leu?Ala?Val?Ile?Leu

325 330 335

gct?caa?tta?ttg?agc?ctt?agt?atg?ggg?atc?act?tat?gat?gac?att?aac 1056

Ala?Gln?Leu?Leu?Ser?Leu?Ser?Met?Gly?Ile?Thr?Tyr?Asp?Asp?Ile?Asn

340 345 350

aaa?tgc?cag?tgc?tca?gga?gct?gtc?tgc?att?atg?aat?cca?gaa?gca?at?t 1104

Lys?Cys?Gln?Cys?Ser?Gly?Ala?Val?Cys?Ile?Met?Asn?Pro?Glu?Ala?Ile

355 360 365

cat?ttc?agt?ggt?gtg?aag?atc?ttt?agt?aac?tgc?agc?ttc?gaa?gac?ttt 1152

His?Phe?Ser?Gly?Val?Lys?Ile?Phe?Ser?Asn?Cys?Ser?Phe?Glu?Asp?Phe

370 375 380

gca?cat?ttt?att?tca?aag?cag?aag?tcc?cag?tgt?ctt?cac?aat?cag?cct 1200

Ala?His?Phe?Ile?Ser?Lys?Gln?Lys?Ser?Gln?Cys?Leu?His?Asn?Gln?Pro

385 390 395 400

cgc?tta?gat?cct?ttt?ttc?aaa?cag?caa?gca?gtg?tgt?ggt?aat?gca?aag 1248

Arg?Leu?Asp?Pro?Phe?Phe?Lys?Gln?Gln?Ala?Val?Cys?Gly?Asn?Ala?Lys

405 410 415

ctg?gaa?gca?gga?gag?gag?tgt?gac?tgt?ggg?act?gaa?cag?gat?tgt?gcc 1296

Leu?Glu?Ala?Gly?Glu?Glu?Cys?Asp?Cys?Gly?Thr?Glu?Gln?Asp?Cys?Ala

420 425 430

ctt?att?gga?gaa?aca?tgc?tgt?gat?att?gcc?aca?tgt?aga?ttt?aaa?gcc 1344

Leu?Ile?Gly?Glu?Thr?Cys?Cys?Asp?Ile?Ala?Thr?Cys?Arg?Phe?Lys?Ala

435 440 445

ggt?tca?aac?tgt?gct?gaa?gga?cca?tgc?tgc?gaa?aac?tgt?cta?ttt?atg 1392

Gly?Ser?Asn?Cys?Ala?Glu?Gly?Pro?Cys?Cys?Glu?Asn?Cys?Leu?Phe?Met

450 455 460

tca?aaa?gaa?aga?atg?tgt?agg?cct?tcc?ttt?gaa?gaa?tgc?gac?ctc?cct 1440

Ser?Lys?Glu?Arg?Met?Cys?Arg?Pro?Ser?Phe?Glu?Glu?Cys?Asp?Leu?Pro

465 470 475 480

gaa?tat?tgc?aat?gga?tca?tct?gca?tca?tgc?cca?gaa?aac?cac?tat?gtt 1488

Glu?Tyr?Cys?Asn?Gly?Ser?Ser?Ala?Ser?Cys?Pro?Glu?Asn?His?Tyr?Val

485 490 495

cag?act?ggg?cat?ccg?tgt?gga?ctg?aat?caa?tgg?atc?tgt?ata?gat?gga 1536

Gln?Thr?Gly?His?Pro?Cys?Gly?Leu?Asn?Gln?Trp?Ile?Cys?Ile?Asp?Gly

500 505 510

gtt?tgt?atg?agt?ggg?gat?aaa?caa?tgt?aca?gac?aca?ttt?ggc?aaa?g?aa 1584

Val?Cys?Met?Ser?Gly?Asp?Lys?Gln?Cys?Thr?Asp?Thr?Phe?Gly?Lys Glu

515 520 525

gta?gag?ttt?ggc?cct?tca?gaa?tgt?tat?tct?cac?ctt?aat?tca?aag?act 1632

Val?Glu?Phe?Gly?Pro?Ser?Glu?Cys?Tyr?Ser?His?Leu?Asn?Ser?Lys?Thr

530 535 540

gat?gta?tct?gga?aac?tgt?ggt?ata?agt?gat?tca?gga?tac?aca?cag?tgt 1680

Asp?Val?Ser?Gly?Asn?Cys?Gly?Ile?Ser?Asp?Ser?Gly?Tyr?Thr?Gln?Cys

545 550 555 560

gaa?gct?ga?c?aat?ctg?cag?tgc?gga?aaa?tta?ata?tgt?aaa?tat?gta?ggt 1728

Glu?Ala?Asp Asn?Leu?Gln?Cys?Gly?Lys?Leu?Ile?Cys?Lys?Tyr?Val?Gly

565 570 575

aaa?ttt?tta?tta?caa?att?cca?aga?gcc?act?att?att?tat?gcc?aac?ata 1776

Lys?Phe?Leu?Leu?Gln?Ile?Pro?Arg?Ala?Thr?Ile?Ile?Tyr?Ala?Asn?Ile

580 585 590

agt?gga?cat?ctc?tgc?att?gct?gtg?gaa?ttt?gcc?agt?gat?cat?gca?gac 1824

Ser?Gly?His?Leu?Cys?Ile?Ala?Val?Glu?Phe?Ala?Ser?Asp?His?Ala?Asp

595 600 605

agc?caa?aag?atg?tgg?ata?aaa?gat?gga?act?tct?tgt?ggt?tca?aat?aag 1872

Ser?Gln?Lys?Met?Trp?Ile?Lys?Asp?Gly?Thr?Ser?Cys?Gly?Ser?Asn?Lys

610 615 620

gtt?tgc?agg?aat?caa?aga?tgt?gtg?agt?tct?tca?tac?ttg?ggt?tat?gat 1920

Val?Cys?Arg?Asn?Gln?Arg?Cys?Val?Ser?Ser?Ser?Tyr?Leu?Gly?Tyr?Asp

625 630 635 640

tgt?act?act?gac?aaa?tgc?aat?gat?aga?ggt?gta?tgc?aat?aac?aaa?aag 1968

Cys?Thr?Thr?Asp?Lys?Cys?Asn?Asp?Arg?Gly?Val?Cys?Asn?Asn?Lys?Lys

645 650 655

cac?tgt?cac?tgt?agt?gct?tca?tat?tta?cct?cca?gat?tgc?tca?gtt?caa 2016

His?Cys?His?Cys?Ser?Ala?Ser?Tyr?Leu?Pro?Pro?Asp?Cys?Ser?Val?Gln

660 665 670

tca?gat?cta?tgg?cct?ggt?ggg?agt?att?gac?agt?ggc?aat?ttt?cca?cct 2064

Ser?Asp?Leu?Trp?Pro?Gly?Gly?Ser?Ile?Asp?Ser?Gly?Asn?Phe?Pro?Pro

675 680 685

gta?gct?ata?cca?gcc?aga?ctc?cct?g?aa agg?cgc?tac?att?gag?aac?att 2112

Val?Ala?Ile?Pro?Ala?Arg?Leu?Pro Glu?Arg?Arg?Tyr?Ile?Glu?Asn?Ile

690 695 700

tac?cat?tcc?aaa?cca?atg?aga?tgg?cca?ttt?ttc?tta?ttc?att?cct?ttc 2160

Tyr?His?Ser?Lys?Pro?Met?Arg?Trp?Pro?Phe?Phe?Leu?Phe?Ile?Pro?Phe

705 710 715 720

ttt?att?att?ttc?tgt?gta?ctg?att?gct?ata?atg?gtg?aaa?gtt?aat?ttc 2208

Phe?Ile?Ile?Phe?Cys?Val?Leu?Ile?Ala?Ile?Met?Val?Lys?Val?Asn?Phe

725 730 735

caa?agg?aaa?aaa?tgg?aga?act?gag?gac?tat?tca?agc?gat?ga?g?caa?cct 2256

Gln?Arg?Lys?Lys?Trp?Arg?Thr?Glu?Asp?Tyr?Ser?Ser?Asp?Glu Gln?Pro

740 745

gaa?agt?gag?agt?gaa?cct?aaa?ggg?tag?tct?gga?caa?cag?aga?tgc?cat 2304

Glu?Ser?Glu?Ser?Glu?Pro?Lys?Gly Ser?Gly?Gln?Gl?nArg?Cys?His

755 760 765

gat?atc?act?tct?tct?aga?gta?att?atc?tgt?gat?gga?tgg?aca?caa?aaa 2352

Asp?Ile?Thr?Ser?Ser?Arg?Val?Ile?Ile?Cys?Asp?Gly?Trp?Thr?Gln?Lys

770 775 780

aat?gga?aag?aaa?aga?atg?tac?att?acc?tgg?ttt?cct?ggg?att?caa?acc 2400

Asn?Gly?Lys?Lys?Arg?Met?Tyr?Ile?Thr?Trp?Phe?Pro?Gly?Ile?Gln?Thr

785 790 795

tgc?ata?ttg?tga?ttt?taa?ttt?gac?cag?aaa?ata?tga?tat?ata?tgt?ata 2448

Cys?Ile?Leu Phe Phe?Asp?Gln?Lys?Ile Tyr?Ile?Cys?Ile

800 805 810

att?tca?cag?ata?att?tac?tta?ttt?aaa?aat?gca?tga?taa?tga?gtt?tta 2496

Ilc?Ser?Gln?Ile?Ile?Tyr?Leu?Phe?Lys?Asn?Ala Val?Leu

815 820 825

cat?tac?aaa?ttt?ctg?ttt?ttt?taa?agt?tat?ctt?acg?cta?ttt?ctg?ttg 2544

His?Tyr?Lys?Phe?Leu?Phe?Phe Ser?Tyr?Leu?Thr?Leu?Phe?Leu?Leu

830 835 840

gtt?agt?aga?cac?taa?ttc?tgt?cag?tag?ggg?cat?ggt?ata?agg?aaa?tat 2592

Val?Ser?Arg?His Phe?Cys?Gln Gly?His?Gly?Ile?Arg?Lys?Tyr

845 850

cat?aat?gta?atg?agg?tgg?tac?tat?gat?taa?aag?cca?ctg?tta?cat?ttc 2640

His?Asn?Val?Met?Arg?Trp?Tyr?Tyr?Asp Lys?Pro?Leu?Leu?His?Phe

855 860 865

aaa?aaaaaaaaaa?aaaa 2657

Lxs

870

SEQUENCE?LISTING2

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_024052

<160>1

<170>PatentIn?version?3.5

<210>1

<211>4232

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(606)

<220>

<221>exon

<222>(607)..(666)

<220>

<221>exon

<222>(667)..(774)

<220>

<221>exon

<222>(775)..(876)

<220>

<221>exon

<222>(877)..(1007)

<220>

<221>exon

<222>(1008)..(4232)

<220>

<221>polyA_signal

<222>(1094)..(1099)

<220>

<221>polyA_site

<222>(1117)..(1117)

<220>

<221>polyA_site

<222>(1151)..(1151)

<220>

<221>STS

<222>(3822)..(3950)

<400>1

gcc?gct?cgc?gca?ccg?cgc?cac?gtg?ttt?tct?cct?ccc?gcc?aat?ggg?cgg 48

Ala?Ala?Arg?Ala?Pro?Arg?His?Val?Phe?Ser?Pro?Pro?Ala?Asn?Gly?Arg

1 5 10 15

aag?cgc?cgc?ctg?agc?ctg?ctc?ccg?ccc?ccc?agg?ctc?gcc?tga?gcc?aat 96

Lys?Arg?Arg?Leu?Ser?Leu?Leu?Pro?Pro?Pro?Arg?Leu?Ala Ala?Asn

20 25 30

cgg?aag?ggg?cgg?ggt?gtg?tgt?gtg?tct?gtg?tgt?gtt?tgt?gtg?ttg?tgt 144

Arg?Lys?Gly?Arg?Gly?Val?Cys?Val?Ser?Val?Cys?Val?Cys?Val?Leu?Cys

35 40 45

gtc?tgt?gag?tgt?ctg?tgt?gtg?tgt?atg?tgt?gcg?cga?ggg?caa?gtc?ggg 192

Val?Cys?Glu?Cys?Leu?Cys?Val?Cys?Met?Cys?Ala?Arg?Gly?Gln?Val?Gly

50 55 60

agg?ggg?acc?cag?ctc?agg?act?ggg?agg?ccc?tgc?tcg?cag?gtc?cct?ggg 240

Arg?Gly?Thr?Gln?Leu?Arg?Thr?Gly?Arg?Pro?Cys?Ser?Gln?Val?Pro?Gly

65 70 75

tcc?cgg?tgg?cgg?ccg?gag?cgc?ttg?ctc?cgc?agg?cag?cgg?gcg?ggt?ggt 288

Ser?Arg?Trp?Arg?Pro?Glu?Arg?Leu?Leu?Arg?Arg?Gln?Arg?Ala?Gly?Gly

80 85 90 95

cgc?ccc?tcc?cgc?ccc?cac?ccc?gcg?cgt?gcg?cgc?ccc?ggc?ctc?tcc?ctc 336

Arg?Pro?Ser?Arg?Pro?His?Pro?Ala?Arg?Ala?Arg?Pro?Gly?Leu?Ser?Leu

100 105 110

ccc?gcc?acc?ctc?ctc?ggc?tcc?cgc?gcg?gcg?gcg?gcg?gtt?cct?ctc?cca 384

Pro?Ala?Thr?Leu?Leu?Gly?Ser?Arg?Ala?Ala?Ala?Ala?Val?Pro?Leu?Pro

115 120 125

ctc?ccc?cca?gcc?ctg?gct?ccg?ggg?gac?ccc?gcg?atg?ccg?gtc?cgc?acc 432

Leu?Pro?Pro?Ala?Leu?Ala?Pro?Gly?Asp?Pro?Ala?Met?Pro?Val?Arg?Thr

130 135 140

gag?tgt?ccc?ccg?ccg?gcc?ggt?gcc?tcc?gct?gcc?tcc?gcg?gcc?tca?ctc 480

Glu?Cys?Pro?Pro?Pro?Ala?Gly?Ala?Ser?Ala?Ala?Ser?Ala?Ala?Ser?Leu

145 150 155

atc?ccg?ccg?ccg?ccc?atc?aac?acc?cag?cag?ccc?ggc?gtg?gcc?acc?agc 528

Ile?Pro?Pro?Pro?Pro?Ile?Asn?Thr?Gln?Gln?Pro?Gly?Val?Ala?Thr?Ser

160 165 170 175

ctg?ctc?tac?agc?ggc?tcc?aag?ttc?cgc?ggc?cac?cag?aag?agc?aag?ggg 576

Leu?Leu?Tyr?Ser?Gly?Ser?Lys?Phe?Arg?Gly?His?Gln?Lys?Ser?Lys?Gly

180 185 190

aac?tcg?tac?gac?gta?gag?gtg?gtg?ctg?cag?cac?gtg?gac?acg?ggg?aac 624

Asn?Ser?Tyr?Asp?Val?Glu?Val?Val?Leu?Gln?His?Val?Asp?Thr?Gly?Asn

195 200 205

tct?tac?ctt?tgt?ggg?tac?ttg?aag?att?aaa?ggc?ctt?act?gag?gag?tat 672

Ser?Tyr?Leu?Cys?Gly?Tyr?Leu?Lys?Ile?Lys?Gly?Leu?Thr?Glu?Glu?Tyr

210 215 220

cca?acc?ctt?aca?acc?ttc?ttc?gaa?gga?gaa?ata?atc?agc?aaa?aaa?cac 720

Pro?Thr?Leu?Thr?Thr?Phe?Phe?Glu?Gly?Glu?Ile?Ile?Ser?Lys?Lys?His

225 230 235

cct?ttc?tta?act?cgc?aag?tgg?gat?gca?gat?gaa?gat?gtt?gat?cgg?aaa 768

Pro?Phe?Leu?Thr?Arg?Lys?Trp?Asp?Ala?Asp?Glu?Asp?Val?Asp?Arg?Lys

240 245 250 255

cac?tgg?ggc?aag?ttt?ctg?gct?ttt?tat?cag?tat?gca?aaa?tca?ttt?aac 816

His?Trp?Gly?Lys?Phe?Leu?Ala?Phe?Tyr?Gln?Tyr?Ala?Lys?Ser?Phe?Asn

260 265 270

tca?gat?gac?ttt?gat?tat?gaa?gag?ctg?aag?aat?gga?gac?tac?gtc?ttc 864

Ser?Asp?Asp?Phe?Asp?Tyr?Glu?Glu?Leu?Lys?Asn?Gly?Asp?Tyr?Val?Phe

275 280 285

atg?agg?tgg?aag?gaa?cag?ttt?ctg?gtc?cca?gat?cac?acg?atc?aaa?gac 912

Met?Arg?Trp?Lys?Glu?Gln?Phe?Leu?Val?Pro?Asp?His?Thr?Ile?Lys?Asp

290 295 300

atc?agt?ggt?gct?tct?ttt?gcc?ggg?ttc?tac?tac?atc?tgc?ttt?cag?aag 960

Ile?Ser?Gly?Ala?Ser?Phe?Ala?Gly?Phe?Tyr?Tyr?Ile?Cys?Phe?Gln?Lys

305 310 315

tca?gca?gcc?tcc?ata?gag?ggc?tac?tac?tac?cat?agg?agt?tca?gaa?tg g 1008

Ser?Ala?Ala?Ser?Ile?Glu?Gly?Tyr?Tyr?Tyr?His?Arg?Ser?Ser?Glu?Trp

320 325 330

tat?cag?tcc?ctc?aat?cta?acc?cat?gtt?cct?gaa?cac?agt?gca?ccc?atc 1056

Tyr?Gln?Ser?Leu?Asn?Leu?Thr?His?Val?Pro?Glu?His?Ser?Ala?Pro?Ile

340 345 350

tat?gaa?ttc?cgg?tga?caa?cgg?ttc?aga?aca?gca?acc?aaa?taa?aac?tga 1104

Tyr?Glu?Phe?Arg Gln?Arg?Phe?Arg?Thr?Ala?Thr?Lys Asn

355 360

act?tgg?caa?aaa?aga?act?ttg?ccg?aga?aaa?ttg?tgt?acc?tgc?cag?aac 1152

Thr?Trp?Gln?Lys?Arg?Thr?Leu?Pro?Arg?Lys?Leu?Cys?Thr?Cys?Gln?Asn

365 370 375 380

cag?gag?aag?tgt?gtt?cct?gtt?tct?tca?cga?gca?gac?tcg?cat?cac?aaa 1200

Gln?Glu?Lys?Cys?Val?Pro?Val?Ser?Ser?Arg?Ala?Asp?Ser?His?His?Lys

385 390 395

gca?tga?atg?tta?acc?cac?aga?atc?caa?gga?gca?tgg?ctg?gcc?cgt?ggg 1248

Ala Met?Leu?Thr?His?Arg?Ile?Gln?Gly?Ala?Trp?Leu?Ala?Arg?Gly

400 405 410

gca?ggt?gga?ggg?agc?agt?ctt?cgt?tct?tcc?tcc?cct?cag?tgg?cag?ttt 1296

Ala?Gly?Gly?Gly?Ser?Ser?Leu?Arg?Ser?Ser?Ser?Pro?Gln?Trp?Gln?Phe

415 420 425

ggt?ctt?cac?ctg?ttt?tta?agc?tac?ctt?aaa?cgc?act?ttt?cct?tcc?tgc 1344

Gly?Leu?His?Leu?Phe?Leu?Ser?Tyr?Leu?Lys?Arg?Thr?Phe?Pro?Ser?Cys

430 435 440

aca?gct?aac?ttc?tac?atc?act?gaa?atg?ccc?att?cct?tcc?tcc?gtc?cca 1392

Thr?Ala?Asn?Phe?Tyr?Ile?Thr?Glu?Met?Pro?Ile?Pro?Ser?Ser?Val?Pro

445 450 455

cct?cca?gcc?gaa?tag?aag?gtc?tgc?tcc?cgg?atc?acc?ctc?agc?ctt?ggt 1440

Pro?Pro?Ala?Glu Lys?Val?Cys?Ser?Arg?Ile?Thr?Leu?Ser?Leu?Gly

460 465 470

gct?cag?tgg?tcc?cga?ggc?cct?aga?ccc?cca?ccc?ccc?gcc?agt?tgc?ttt 1488

Ala?Gln?Trp?Ser?Arg?Gly?Pro?Arg?Pro?Pro?Pro?Pro?Ala?Ser?Cys?Phe

475 480 485 490

gtc?tgg?tag?ctc?aag?aga?agg?cag?agc?ccc?agc?acc?tct?gtg?ccc?ccc 1536

Val?Trp Leu?Lys?Arg?Arg?Gln?Ser?Pro?Ser?Thr?Ser?Val?Pro?Pro

495 500 505

aga?gct?ctg?tgc?agg?gag?ttg?gcc?agc?tgc?cgc?atc?atc?ggc?cac?caa 1584

Arg?Ala?Leu?Cys?Arg?Glu?Leu?Ala?Ser?Cys?Arg?Ile?Ile?Gly?His?Gln

510 515 520

ggg?cac?aag?agg?cgg?agg?ctc?cag?tcc?ctg?ctg?ggc?tgc?ctc?agt?ctt 1632

Gly?His?Lys?Arg?Arg?Arg?Leu?Gln?Ser?Leu?Leu?Gly?Cys?Leu?Ser?Leu

525 530 535

cag?tgc?tga?ttg?tgt?cac?ggg?tca?gcg?tgc?gct?gct?gag?ccc?tgt?act 1680

Gln?Cys Leu?Cys?His?Gly?Ser?Ala?Cys?Ala?Ala?Glu?Pro?Cys?Thr

540 545 550

gtt?aac?agt?gca?aag?cta?gtg?agt?agc?tgt?cag?gtt?ccc?tgg?gcc?tgc 1728

Val?Asn?Ser?Ala?Lys?Leu?Val?Ser?Ser?Cys?Gln?Val?Pro?Trp?Ala?Cys

555 560 565

cat?cag?gga?tca?cta?aat?tta?agg?ctt?cca?gat?ccc?tgg?cag?gaa?cag 1776

His?Gln?Gly?Ser?Leu?Asn?Leu?Arg?Leu?Pro?Asp?Pro?Trp?Gln?Glu?Gln

570 575 580

att?cca?gtc?ctg?ctt?act?cag?tac?att?tgc?tcc?aaa?ctt?ttc?aac?ttg 1824

Ile?Pro?Val?Leu?Leu?Thr?Gln?Tyr?Ile?Cys?Ser?Lys?Leu?Phe?Asn?Leu

585 590 595 600

agg?gca?ata?cta?aac?tta?aaa?ata?aga?gtt?ttt?tta?tta?caa?aat?tat 1872

Arg?Ala?Ile?Leu?Asn?Leu?Lys?Ile?Arg?Val?Phe?Leu?Leu?Gln?Asn?Tyr

605 610 615

ttt?tat?ggt?ccc?ttt?aac?gag?gac?cct?atg?gca?aat?gca?caa?tta?ttc 1920

Phe?Tyr?Gly?Pro?Phe?Asn?Glu?Asp?Pro?Met?Ala?Asn?Ala?Gln?Leu?Phe

620 625 630

aga?att?aca?ttt?tat?cgt?ttt?cac?att?gaa?aac?agc?aaa?tgt?tga?ctt 1968

Arg?Ile?Thr?Phe?Tyr?Arg?Phe?His?Ile?Glu?Asn?Ser?Lys?Cys Leu

635 640 645

agt?aat?ttt?tat?atc?gat?atc?tat?atg?tat?atg?tat?att?taa?tca?acc 2016

Ser?Asn?Phe?Tyr?Ile?Asp?Ile?Tyr?Met?Tyr?Met?Tyr?Ile Ser?Thr

650 655 660

agc?agt?ttt?gaa?act?agt?cat?cct?ggt?aca?aaa?gtt?ttg?cag?cat?tgc 2064

Ser?Ser?Phe?Glu?Thr?Ser?His?Pro?Gly?Thr?Lys?Val?Leu?Gln?His?Cys

665 670 675

cta?aat?tat?agt?gct?caa?cac?aag?aac?tgt?ttt?tgg?ggc?cag?ttt?agc 2112

Leu?Asn?Tyr?Ser?Ala?Gln?His?Lys?Asn?Cys?Phe?Trp?Gly?Gln?Phe?Ser

680 685 690

att?tgt?gcc?gcc?tcc?ttt?tgc?tac?tca?aaa?cag?caa?tgc?ttg?gcg?gca 2160

Ile?Cys?Ala?Ala?Ser?Phe?Cys?Tyr?Ser?Lys?Gln?Gln?Cys?Leu?Ala?Ala

695 700 705 710

gcc?ttc?cat?gag?gca?gaa?ggg?gtc?gtc?gtt?ctc?tga?aaa?cag?tga?ctc 2208

Ala?Phe?His?Glu?Ala?Glu?Gly?Val?Val?Val?Leu Lys?Gln Leu

715 720

tga?aat?gtt?ggg?aca?ggg?gaa?ggg?gtg?gga?aac?atg?aac?atg?ctc?aaa 2256

Asn?Val?Gly?Thr?Gly?Glu?Gly?Val?Gly?Asn?Met?Asn?Met?Leu?Lys

725 730 735

taa?ctc?gag?gct?cac?gtg?cca?aag?tgt?gtg?tgt?gtg?tgt?gtg?tgt?gtg 2304

Leu?Glu?Ala?His?Val?Pro?Lys?Cys?Val?Cys?Val?Cys?Val?Cys?Val

740 745 750

tgt?gtg?tgt?atg?atg?ttt?tgt?ttt?ttt?aaa?tgt?ttt?aaa?agc?tta?ata 2352

Cys?Val?Cys?Met?Met?Phe?Cys?Phe?Phe?Lys?Cys?Phe?Lys?Ser?Leu?Ile

755 760 765 770

ggt?tgg?cat?cag?ttg?tag?ccc?aca?aac?atg?gct?agg?gct?ttg?ggg?att 2400

Gly?Trp?His?Gln?Leu Pro?Thr?Asn?Met?Ala?Arg?Ala?Leu?Gly?Ile

775 780 785

tgg?cat?ttt?tct?ggt?ggt?tta?caa?gac?tta?ctc?cga?ata?caa?gag?gaa 2448

Trp?His?Phe?Ser?Gly?Gly?Leu?Gln?Asp?Leu?Leu?Arg?Ile?Gln?Glu?Glu

790 795 800

aag?ctt?taa?aaa?caa?gat?tgc?atc?ata?acc?ccc?agg?agc?aaa?gca?acc 2496

Lys?Leu Lys?Gln?Asp?Cys?Ile?Ile?Thr?Pro?Arg?Ser?Lys?Ala?Thr

805 810 815

tgg?agg?ctg?cat?atc?cat?ggg?cgg?gca?gca?taagag?aat?gtg?aag?ccc 2544

Trp?Arg?Leu?His?Ile?His?Gly?Arg?Ala?Ala Glu?Asn?Val?Lys?Pro

820 825 830

ttc?agt?gag?acg?aga?cga?gca?atg?gga?aac?ctt?ttc?tgt?tct?taa?gaa 2592

Phe?Ser?Glu?Thr?Arg?Arg?Ala?Met?Gly?Asn?Leu?Phe?Cys?Ser Glu

835 840 845

gtg?act?tta?att?tta?ttg?aca?tat?gta?ctg?tat?gtt?act?gag?att?gaa 2640

Val?Thr?Leu?Ile?Leu?Leu?Thr?Tyr?Val?Leu?Tyr?Val?Thr?Glu?Ile?Glu

850 855 860

tgt?tag?ggg?aag?cct?taa?ggt?aga?ggt?att?tgg?gaa?agt?agc?cag?tgg 2688

Cys Gly?Lys?Pro Gly?Arg?Gly?Ile?Trp?Glu?Ser?Ser?Gln?Trp

865 870 875

gca?ctt?gtg?ata?tct?aaa?atc?tgt?tat?ccc?agg?act?gtg?tac?aga?ggg 2736

Ala?Leu?Val?Ile?Ser?Lys?Ile?Cys?Tyr?Pro?Arg?Thr?Val?Tyr?Arg?Gly

880 885 890

gca?acc?tac?cca?ttc?agg?aag?gtc?agg?gct?ttg?gaa?ccc?taa?aaa?gtt 2784

Ala?Thr?Tyr?Pro?Phe?Arg?Lys?Val?Arg?Ala?Leu?Glu?Pro Lys?Val

895 900 905

ggc?ccg?atg?act?taa?agg?gaa?aaa?taa?ttc?att?ccc?aga?gat?gag?tca 2832

Gly?Pro?Met?Thr Arg?Glu?Lys Phe?Ile?Pro?Arg?Asp?Glu?Ser

910 915 920

gaa?cag?tct?cct?caa?tcc?tga?aat?tca?aca?agg?cat?cag?aag?ggc?tgg 2880

Glu?Gln?Ser?Pro?Gln?Ser Asn?Ser?Thr?Arg?His?Gln?Lys?Gly?Trp

925 930 935

ctg?tgg?tca?agc?cca?gct?gct?gtc?atg?tga?gga?gat?gct?cac?tgt?ggt 2928

Leu?Trp?Ser?Ser?Pro?Ala?Ala?Val?Met Gly?Asp?Ala?His?Cys?Gly

940 945 950

ctt?gtt?gag?ctg?atg?gcc?ttg?gtt?gag?ctg?atg?gac?aag?tga?agg?agg 2976

Leu?Val?Glu?Leu?Met?Ala?Leu?Val?Glu?Leu?Met?Asp?Lys Arg?Arg

955 960 965

cca?tgg?ggc?tgt?gct?gtc?ctt?cct?gcc?gta?cgt?gcc?att?cca?ctc?tct 3024

Pro?Trp?Gly?Cys?Ala?Val?Leu?Pro?Ala?Val?Arg?Ala?Ile?Pro?Leu?Ser

970 975 980

tca?gct?ctc?ccc?tca?aca?gca?tgc?gag?ccc?ata?cct?tct?gca?ttt?ttc 3072

Ser?Ala?Leu?Pro?Ser?Thr?Ala?Cys?Glu?Pro?Ile?Pro?Ser?Ala?Phe?Phe

985 990 995

cag?gcc tgt?gag?gga?tat?agg?cct?ccc?ctt?gga?gca ctg?agt?ccg 3117

Gln?Ala Cys?Glu?Gly?Tyr?Arg?Pro?Pro?Leu?Gly?Ala Leu?Ser?Pro

1000 1005 1010

gag?gtc atc?cct?gag?ctc?atc cac?ggc?tca?tgc?tgt ggc?tcc?gag 3162

Glu?Val Ile?Pro?Glu?Leu?Ile His?Gly?Ser?Cys?Cys Gly?Ser?Glu

1015 1020 1025

tag?tgg?ttt gag?tgg?gca?gga?agg gcc?att?tgc?aaa?cac tgc?tgt 3207

Trp?Phe Glu?Trp?Ala?Gly?Arg Ala?Ile?Cys?Lys?His Cys?Cys

1030 1035 1040

gtt?cta?gac aaa?caa?ccc?aag?tcc tat?ggc?agg?att?tct tcc?ttc 3252

Val?Leu?Asp Lys?Gln?Pro?Lys?Ser Tyr?Gly?Arg?Ile?Ser Ser?Phe

1045 1050 1055

ctt?cct?ttt tta?ccc?agg?tga?tga?agt?gca ccc?att?gta?ctg?gga 3297

Leu?Pro?Phe Leu?Pro?Arg Ser?Ala Pro?Ile?Val?Leu?Gly

1060 1065 1070

aga?atg?aag?agg?tga?tac ctt?tac?tag?atc?ctt?cag aca?cat?cta?tga?3345

Arg?Met?Lys?Arg Tyr Leu?Tyr Ile?Leu?Gln Thr?His?Leu

1075 1080

gaa?gat ttg?ttc?att?taa?aag?tct gcc?cac?tga?gga?tag?gga?aag 3390

Glu?Asp Leu?Phe?Ile Lys?Ser Ala?His Gly Gly?Lys

1085 1090 1095

gat?taa?gga?ttt?ttc?cac ctc?ctc?tta?gta?act cct?gaa?tta?cca 3435

Asp Gly?Phe?Phe?His Leu?Leu?Leu?Val?Thr Pro?Glu?Leu?Pro

1100 1105

aca tca?act?tct?ttc?tct ccg?ttc?ctg?aag?gaa ctt?tgg?gga?atc 3480

Thr Ser?Thr?Ser?Phe?Ser?Pro?Phe?Leu?Lys?Glu Leu?Trp?Gly?Ile

1110 1115 1120

atc ttc?atc?cgt?agt?tac gct?ttc?ctg?aac?ctt ctc?agt?ggt?tta 3525

Ile Phe?Ile?Arg?Ser?Tyr Ala?Phe?Leu?Asn?Leu Leu?Ser?Gly?Leu

1125 1130 1135

cat gcc?tct?gaa?act?atg tgc?aat?att?ttt?ggt tga?cac?ttg?tat 3570

His Ala?Ser?Glu?Thr?Met Cys?Asn?Ile?Phe?Gly His?Leu?Tyr

1140 1145 1150

cca?tcc tta?aga?aat?tag?tgc?aga ttg?cag?atg?ttc?tgt ctt?cca 3615

Pro?Ser Leu?Arg?Asn Cys?Arg?Leu?Gln?Met?Phe?Cys Leu?Pro

1155 1160 1165

tcc?caa?aca agc?ctg?cca?tga?ggt?agg atc?cta?ggg?gtt?tgg ctg 3660

Ser?Gln?Thr Ser?Leu?Pro Gly?Arg Ile?Leu?Gly?Val?Trp Leu

1170 1175 1180

ttc?tta?ctc?cac tgc?tca?gaa?agc?ttc cat?tct?gct?gtc?ctc agc 3705

Phe?Leu?Leu?His Cys?Ser?Glu?Ser?Phe His?Ser?Ala?Val?Leu Ser

1185 1190 1195

ctc?gac?cct?ctt ctg?tgc?tgg?act?tcc acc?cac?cca?ccc?ttt tca 3750

Leu?Asp?Pro?Leu Leu?Cys?Trp?Thr?Ser Thr?His?Pro?Pro?Phe Ser

1200 1205 1210

agt tta?gat?agt gtt?tca?gct?gct?gtc cca?aag?taa?caa?aac?aat 3795

Ser?Leu?Asp?Ser Val?Ser?Ala?Ala?Val Pro?Lys Gln?Asn?Asn

1215 1220 1225

acc?tac?tgt?taa?gta?gga agt?caa?tct?gtg?tgc tgg?ttt?tgt?tgg 3840

Thr?Tyr?Cys Val?Gly Ser?Gln?Ser?Val?Cys Trp?Phe?Cys?Trp

1230 1235

tta tgt?gga?aat?cac?aaa ctc?cag?agg?agc?aaa ggg?gtt?ttt?caa 3885

Leu Cys?Gly?Asn?His?Lys Leu?Gln?Arg?Ser?Lys Gly?Val?Phe?Gln

1240 1245 1250

tgt ctt?ttg?ctt?tca?gaa aca?gag?aat?ata?ata ttc?tca?cta?agg 3930

Cys Leu?Leu?Leu?Ser?Glu Thr?Glu?Asn?Ile?Ile Phe?Ser?Leu?Arg

1255 1260 1265

cct tga?att?gat?ttt?ttt?ctc ata?aaa?tag?tct?gat?aag cta?att 3975

Pro Ile?Asp?Phe?Phe?Leu Ile?Lys Ser?Asp?Lys Leu?Ile

1270 1275 1280

ttt?aaa?aag?aaa?tgc?cat?taa?ctg?tgt?tgt?atc?gtg?gtt?taa?aat 4020

Phe?Lys?Lys?Lys?Cys?His Leu?Cys?Cys?Ile?Val?Val Asn

1285 1290 1295

tac?taa?caa?gtt?gtg?gga aag?aaa?aat?aat?att?tga?ttt?tga?atc?tta 4068

Tyr Gln?Val?Val?Gly Lys?Lys?Asn?Asn?Ile Phe Ile?Leu

1300 1305

aat?gtt?ttt?aaa?aat?tag?act?tga?atg?ggc?aca?aag?tat?aaa tat 4113

Asn?Val?Phe?Lys?Asn Thr Met?Gly?Thr?Lys?Tyr?Lys Tyr

1310 1315 1320

ttt?gtt?tct?tta tgg?agg?aca?tgt?gga?agg?agt?ttg?agg?gtt?tgg 4158

Phe?Val?Ser?Leu Trp?Arg?Thr?Cys?Gly?Arg?Ser?Leu?Arg?Val?Trp

1325 1330 1335

gat?ggg?aga?agt att?ttg?cag?agc?tat?caa?tgt?cca?aat?aat?tta 4203

Asp?Gly?Arg?Ser Ile?Leu?Gln?Ser?Tyr?Gln?Cys?Pro?Asn?Asn?Leu

1340 1345 1350

aaa?aaa?aaa?ata aag?gta?ttt?aag?cag?tg 4232

Lys?Lys?Lys?Ile Lys?Val?Phe?Lys?Gln

1355 1360

SEQUENCE?LISTING3

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_145036

<160>1

<170>PatentIn?version?3.5

<210>1

<211>3525

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(211)

<220>

<221>exon

<222>(212)..(325)

<220>

<221>exon

<222>(326)..(516)

<220>

<221>exon

<222>(517)..(689)

<220>

<221>exon

<222>(690)..(783)

<220>

<221>exon

<222>(784)..(861)

<220>

<221>exon

<222>(862)..(909)

<220>

<221>exon

<222>(910)..(987)

<220>

<221>exon

<222>(988)..(1074)

<220>

<221>exon

<222>(1075)..(1174)

<220>

<221>exon

<222>(1175)..(1293)

<220>

<221>exon

<222>(1294)..(1437)

<220>

<221>exon

<222>(1438)..(1592)

<220>

<221>exon

<222>(1593)..(1722)

<220>

<221>exon

<222>(1723)..(1815)

<220>

<221>exon

<222>(1816)..(1875)

<220>

<221>exon

<222>(1876)..(1955)

<220>

<221>exon

<222>(1956)..(2091)

<220>

<221>exon

<222>(2092)..(2199)

<220>

<221>exon

<222>(2200)..(2382)

<220>

<221>exon

<222>(2383)..(2613)

<220>

<221>exon

<222>(2614)..(2676)

<220>

<221>exon

<222>(2677)..(2826)

<220>

<221>exon

<222>(2827)..(2916)

<220>

<221>exon

<222>(2917)..(3018)

<220>

<221>exon

<222>(3019)..(3083)

<220>

<221>STS

<222>(3024)..(3150)

<220>

<221>exon

<222>(3084)..(3518)

<400>1

ggg?ccc?gtt?ctc?cgg?gcc?tgg?ggg?gcg?cgc?gcc?cct?ggg?gtc?ccg?gcg 48

Gly?Pro?Val?Leu?Arg?Ala?Trp?Gly?Ala?Arg?Ala?Pro?Gly?Val?Pro?Ala

1 5 10 15

ctg?ccc?gct?gtg?gtg?tcc?ccg?gca?ggc?aga?gcg?cga?tcc?agg?ccg?gga 96

Leu?Pro?Ala?Val?Val?Ser?Pro?Ala?Gly?Arg?Ala?Arg?Ser?Arg?Pro?Gly

20 25 30

cga?ctt?ggg?aaa?gtt?cta?agt?aaa?gtt?tga?tca?gcc?ggt?ttg?atc?ggt 144

Arg?Leu?Gly?Lys?Val?Leu?Ser?Lys?Val Ser?Ala?Gly?Leu?Ile?Gly

35 40 45

ctg?acg?tgg?tcc?aag?agt?ctg?acc?caa?ggg?ttt?gcg?act?ggg?aga?gga 192

Leu?Thr?Trp?Ser?Lys?Ser?Leu?Thr?Gln?Gly?Phe?Ala?Thr?Gly?Arg?Gly

50 55 60

aat?ctg?tgt?cct?gga?caa?g?at tgg?att?atg?gaa?gtg?gga?agt?gaa?gaa 240

Asn?Leu?Cys?Pro?Gly?Gln Asp?Trp?Ile?Met?Glu?Val?Gly?Ser?Glu?Glu

65 75

gaa?aaa?tgg?gag?aag?ctg?gat?gca?gaa?ttt?gat?cac?ttt?gtg?gtt?gat 288

Glu?Lys?Trp?Glu?Lys?Leu?Asp?Ala?Glu?Phe?Asp?His?Phe?Val?Val?Asp

80 85 90 95

atg?aag?ccc?ttt?gtt?cta?aaa?tta?cct?cat?agg?aca?g?aa cgg?cag?agg 336

Met?Lys?Pro?Phe?Val?Leu?Lys?Leu?Pro?His?Arg?Thr Glu?Arg?Gln?Arg

100 105 110

tgt?gct?ctt?tgg?att?aga?aag?ctg?tgc?gaa?cct?tca?gga?aca?ggt?gca 384

Cys?Ala?Leu?Trp?Ile?Arg?Lys?Leu?Cys?Glu?Pro?Ser?Gly?Thr?Gly?Ala

115 120 125

gga?ata?atg?ggg?agg?aag?aat?cgg?aac?ctg?tat?gca?aaa?ttg?tta?ttg 432

Gly?Ile?Met?Gly?Arg?Lys?Asn?Arg?Asn?Leu?Tyr?Ala?Lys?Leu?Leu?Leu

130 135 140

cat?atg?ctt?aaa?cga?ggt?gcg?ctt?gaa?ggc?cct?ttt?aca?cac?cga?cct 480

His?Met?Leu?Lys?Arg?Gly?Ala?Leu?Glu?Gly?Pro?Phe?Thr?His?Arg?Pro

145 150 155

gaa?ccc?ggg?aca?cta?aaa?att?cta?cct?tca?tac?atg?tcc?atc?tat?ttt 528

Glu?Pro?Gly?Thr?Leu?Lys?Ile?Leu?Pro?Ser?Tyr?Met?Ser?Ile?Tyr?Phe

160 165 170 175

gat?gaa?cca?aat?cca?gca?cga?gca?aaa?ggt?tca?agc?cca?gag?gga?tta 576

Asp?Glu?Pro?Asn?Pro?Ala?Arg?Ala?Lys?Gly?Ser?Ser?Pro?Glu?Gly?Leu

180 185 190

cca?gcc?tgg?gta?ctg?ggt?gag?ctg?gag?aca?agt?gaa?cac?aaa?tta?aat 624

Pro?Ala?Trp?Val?Leu?Gly?Glu?Leu?Glu?Thr?Ser?Glu?His?Lys?Leu?Asn

195 200 205

gaa?tca?tgg?aaa?ctc?tct?tct?gga?gaa?gat?aac?act?tta?gta?cag?tcg 672

Glu?Ser?Trp?Lys?Leu?Ser?Ser?Gly?Glu?Asp?Asn?Thr?Leu?Val?Gln?Ser

210 215 220

cca?act?gat?gtc?tac?ag c?agg?gaa?cag?tac?act?ggg?aag?ctc?cga?gtg 720

Pro?Thr?Asp?Val?Tyr?Ser Arg?Glu?Gln?Tyr?Thr?Gly?Lys?Leu?Arg?Val

225 230 235

aga?tca?cac?tcc?ttg?agt?cca?act?cac?aga?gaa?gat?gga?caa?aat?att 768

Arg?Ser?His?Ser?Leu?Ser?Pro?Thr?His?Arg?Glu?Asp?Gly?Gln?Asn?Ile

240 245 250 255

acc?cca?aag?att?tgt?gaa?gtt?tat?tcg?aaa?aaa?tct?cct?gtt?tct?ttg 816

Thr?Pro?Lys?Ile?Cys?Glu?Val?Tyr?Ser?Lys?Lys?Ser?Pro?Val?Ser?Leu

260 265 270

gat?gat?agt?gac?att?gaa?gct?cgc?ctt?aat?agt?tgg?aat?ctt?ggg?ata 864

Asp?Asp?Ser?Asp?Ile?Glu?Ala?Arg?Leu?Asn?Ser?Trp?Asn?Leu?Gly?Ile

275 280 285

gaa?aat?cct?cga?tac?ctg?aga?cag?aag?cct?atc?cca?gtt?tct?ctg?atg 912

Glu?Asn?Pro?Arg?Tyr?Leu?Arg?Gln?Lys?Pro?Ile?Pro?Val?Ser?Leu?Met

290 295 300

aca?ccg?aaa?ttc?agc?ctg?aga?aaa?tcc?agc?agt?ttc?cat?gat?gat?cat 960

Thr?Pro?Lys?Phe?Ser?Leu?Arg?Lys?Ser?Ser?Ser?Phe?His?Asp?Asp?His

305 310 315

ttt?ctc?tct?cga?ata?cgt?gag?aaa?gag?ctg?gac?atg?aaa?aca?aaa?atg 1008

Phe?Leu?Ser?Arg?Ile?Arg?Glu?Lys?Glu?Leu?Asp?Met?Lys?Thr?Lys?Met

320 325 330 335

atg?gaa?gct?aaa?ttt?cat?gaa?gaa?aag?ctt?aaa?ctg?caa?cag?aaa?cat 1056

Met?Glu?Ala?Lys?Phe?His?Glu?Glu?Lys?Leu?Lys?Leu?Gln?Gln?Lys?His

340 345 350

gat?gct?gat?gtt?cag?aag?att?tta?gaa?aga?aag?aat?aat?gaa?ata?gaa 1104

Asp?Ala?Asp?Val?Gln?Lys?Ile?Leu?Glu?Arg?Lys?Asn?Asn?Glu?Ile?Glu

355 360 365

gaa?ctg?aaa?act?tta?tac?agg?agt?aaa?caa?cat?gaa?act?gaa?gag?act 1152

Glu?Leu?Lys?Thr?Leu?Tyr?Arg?Ser?Lys?Gln?His?Glu?Thr?Glu?Glu?Thr

370 375 380

att?aga?aag?ctt?gaa?aag?aaa?g?tt cag?aca?ctg?ata?cgt?gac?tgt?caa 1200

Ile?Arg?Lys?Leu?Glu?Lys?Lys Val?Gln?Thr?Leu?Ile?Arg?Asp?Cys?Gln

385 390 395

gtt?atc?aga?gag?act?aaa?gaa?gac?cag?att?gca?gag?ctg?aaa?aag?ata 1248

Val?Ile?Arg?Glu?Thr?Lys?Glu?Asp?Gln?Ile?Ala?Glu?Leu?Lys?Lys?Ile

400 405 410 415

tgt?gaa?caa?agt?acg?gaa?tct?cta?aat?aat?gac?tgg?gaa?aaa?aag?ctt 1296

Cys?Glu?Gln?Ser?Thr?Glu?Ser?Leu?Asn?Asn?Asp?Trp?Glu?Lys?Lys?Leu

420 425 430

cac?aat?gct?gta?gca?gaa?atg?gaa?cag?gaa?aag?ttt?gat?ctt?caa?aag 1344

His?Asn?Ala?Val?Ala?Glu?Met?Glu?Gln?Glu?Lys?Phe?Asp?Leu?Gln?Lys

435 440 445

caa?cac?act?gaa?aac?att?caa?gaa?ttg?ctt?gag?gat?aca?aat?gtg?cgt 1392

Gln?His?Thr?Glu?Asn?Ile?Gln?Glu?Leu?Leu?Glu?Asp?Thr?Asn?Val?Arg

450 455 460

ctg?aat?aaa?atg?gag?agt?gaa?tac?atg?gcg?caa?aca?cag?tcc?aca?aac 1440

Leu?Asn?Lys?Met?Glu?Ser?Glu?Tyr?Met?Ala?Gln?Thr?Gln?Ser?Thr?Asn

465 470 475

cac?atg?atc?aaa?gaa?ctg?gag?gcc?cgt?gtc?cag?cag?ctg?act?gga?gaa 1488

His?Met?Ile?Lys?Glu?Leu?Glu?Ala?Arg?Val?Gln?Gln?Leu?Thr?Gly?Glu

480 485 490 495

gca?gag?aac?agt?aat?tta?cag?agg?cag?aaa?tta?att?caa?gaa?aaa?gca 1536

Ala?Glu?Asn?Ser?Asn?Leu?Gln?Arg?Gln?Lys?Leu?Ile?Gln?Glu?Lys?Ala

500 505 510

gaa?ctt?gaa?aga?tgt?tac?cag?ata?acg?tgt?agt?gaa?tta?caa?gaa?gta 1584

Glu?Leu?Glu?Arg?Cys?Tyr?Gln?Ile?Thr?Cys?Ser?Glu?Leu?Gln?Glu?Val

515 520 525

aag?gca?ag g?cgt?aac?aca?ctg?cat?aaa?gag?aag?gac?cat?ctt?gta?aat 1632

Lys?Ala?Arg Arg?Asn?Thr?Leu?His?Lys?Glu?Lys?Asp?His?Leu?Val?Asn

535 540

gat?tat?gag?caa?aac?atg?aaa?ctg?tta?caa?acc?aaa?tat?gat?gct?gat 1680

Asp?Tyr?Glu?Gln?Asn?Met?Lys?Leu?Leu?Gln?Thr?Lys?Tyr?Asp?Ala?Asp

545 550 555

ata?aac?ctt?cta?aaa?caa?gaa?cat?gct?ctt?tca?gct?tct?aag?gca?tct 1728

Ile?Asn?Leu?Leu?Lys?Gln?Glu?His?Ala?Leu?Ser?Ala?Ser?Lys?Ala?Ser

560 565 570 575

agt?atg?att?gaa?gaa?tta?gag?cag?aat?gtc?tgt?caa?tta?aaa?cag?cag 1776

Ser?Met?Ile?Glu?Glu?Leu?Glu?Gln?Asn?Val?Cys?Gln?Leu?Lys?Gln?Gln

580 585 590

tta?cag?gaa?tca?gaa?ctt?caa?aga?aag?caa?caa?cta?agg?gat?caa?gaa 1824

Leu?Gln?Glu?Ser?Glu?Leu?Gln?Arg?Lys?Gln?Gln?Leu?Arg?Asp?Gln?Glu

595 600 605

aat?aag?ttt?cag?atg?gag?aaa?agt?cat?tta?aaa?cac?atc?tat?gaa?aaa 1872

Asn?Lys?Phe?Gln?Met?Glu?Lys?Ser?His?Leu?Lys?His?Ile?Tyr?Glu?Lys

610 615 620

aag?gct?cat?gac?ttg?cag?agt?gaa?ctt?gat?aaa?gga?aaa?gaa?gat?act 1920

Lys?Ala?His?Asp?Leu?Gln?Ser?Glu?Leu?Asp?Lys?Gly?Lys?Glu?Asp?Thr

625 630 635

caa?aag?aaa?att?cat?aaa?ttt?gag?gaa?gct?ttg?aa g?gaa?aaa?gag?gag 1968

Gln?Lys?Lys?Ile?His?Lys?Phe?Glu?Glu?Ala?Leu?Lys Glu?Lys?Glu?Glu

640 645 650 655

cag?cta?act?cgt?gtg?act?gaa?gtt?cag?agg?ttg?cag?gcc?cag?cag?gca 2016

Gln?Leu?Thr?Arg?Val?Thr?Glu?Val?Gln?Arg?Leu?Gln?Ala?Gln?Gln?Ala

660 665 670

gat?gcc?gct?ctg?gaa?gag?ttt?aag?cgg?cag?gtg?gaa?ctg?aac?tca?gag 2064

Asp?Ala?Ala?Leu?Glu?Glu?Phe?Lys?Arg?Gln?Val?Glu?Leu?Asn?Ser?Glu

675 680 685

aaa?gtc?tat?gct?gaa?atg?aaa?gag?cag?atg?gaa?aaa?gtg?gag?gca?gat 2112

Lys?Val?Tyr?Ala?Glu?Met?Lys?Glu?Gln?Met?Glu?Lys?Val?Glu?Ala?Asp

690 695 700

cta?act?aga?tcc?aaa?tct?ctt?cgt?gag?aaa?caa?tca?aag?gag?ttt?tta 2160

Leu?Thr?Arg?Ser?Lys?Ser?Leu?Arg?Glu?Lys?Gln?Ser?Lys?Glu?Phe?Leu

705 710 715

tgg?caa?ctg?gag?gac?atc?aga?cag?cgg?tat?gaa?caa?cag?ata?gta?gag 2208

Trp?Gln?Leu?Glu?Asp?Ile?Arg?Gln?Arg?Tyr?Glu?Gln?Gln?Ile?Val?Glu

720 725 730 735

ctg?aag?ctg?gag?cat?gaa?cag?gag?aag?acg?cac?cta?tta?cag?cag?cat 2256

Leu?Lys?Leu?Glu?His?Glu?Gln?Glu?Lys?Thr?His?Leu?Leu?Gln?Gln?His

740 745 750

aac?gca?gag?aag?gat?agc?cta?gtc?cga?gac?cat?gaa?cgg?gaa?att?gaa 2304

Asn?Ala?Glu?Lys?Asp?Ser?Leu?Val?Arg?Asp?His?Glu?Arg?Glu?Ile?Glu

755 760 765

aac?ctg?gaa?aaa?cag?ctt?cgc?gct?gcc?aat?atg?gag?cac?gaa?aat?caa 2352

Asn?Leu?Glu?Lys?Gln?Leu?Arg?Ala?Ala?Asn?Met?Glu?His?Glu?Asn?Gln

770 775 780

att?cag?gag?ttc?aag?aaa?cga?gat?gca?cag?gtt?att?gcc?gac?atg?gag 2400

Ile?Gln?Glu?Phe?Lys?Lys?Arg?Asp?Ala?Gln?Val?Ile?Ala?Asp?Met?Glu

785 790 795

gcc?cag?gtt?cac?aag?ttg?aga?gaa?gaa?ttg?atc?aat?gtg?aac?tca?cag 2448

Ala?Gln?Val?His?Lys?Leu?Arg?Glu?Glu?Leu?Ile?Asn?Val?Asn?Ser?Gln

800 805 810 815

cgg?aaa?cag?cag?ctg?gta?gag?ctt?ggt?ctt?ctt?cgt?gaa?gag?gaa?aag 2496

Arg?Lys?Gln?Gln?Leu?Val?Glu?Leu?Gly?Leu?Leu?Arg?Glu?Glu?Glu?Lys

820 825 830

caa?agg?gct?aca?agg?gaa?cat?gag?att?gtc?gtc?aat?aaa?ctg?aag?gct 2544

Gln?Arg?Ala?Thr?Arg?Glu?His?Glu?Ile?Val?Val?Asn?Lys?Leu?Lys?Ala

835 840 845

gaa?tca?gaa?aag?atg?aaa?ata?gag?ctg?aaa?aag?act?cat?gct?gct?gag 2592

Glu?Ser?Glu?Lys?Met?Lys?Ile?Glu?Leu?Lys?Lys?Thr?His?Ala?Ala?Glu

850 855 860

aca?gag?atg?aca?ctg?gaa?aag?gcc?aac?agc?aag?ctg?aag?cag?att?gag 2640

Thr?Glu?Met?Thr?Leu?Glu?Lys?Ala?Asn?Ser?Lys?Leu?Lys?Gln?Ile?Glu

865 870 875

aag?gaa?tac?act?cag?aag?ctt?gcc?aaa?tct?tca?cag?atc?ata?gca?gaa 2688

Lys?Glu?Tyr?Thr?Gln?Lys?Leu?Ala?Lys?Ser?Ser?Gln?Ile?Ile?Ala?Glu

880 885 890 895

ctt?cag?aca?acc?att?tcc?tct?ctg?aaa?gaa?gag?aac?agc?cag?cag?cag 2736

Leu?Gln?Thr?Thr?Ile?Ser?Ser?Leu?Lys?Glu?Glu?Asn?Ser?Gln?Gln?Gln

900 905 910

ctt?gct?gca?gaa?agg?cgg?ctc?cag?gat?gtt?aga?caa?aag?ttt?gaa?gat 2784

Leu?Ala?Ala?Glu?Arg?Arg?Leu?Gln?Asp?Val?Arg?Gln?Lys?Phe?Glu?Asp

915 920 925

gag?aag?aag?cag?ctg?att?aga?gat?aat?gac?caa?gca?atc?aag?gtt?tta 2832

Glu?Lys?Lys?Gln?Leu?Ile?Arg?Asp?Asn?Asp?Gln?Ala?Ile?Lys?Val?Leu

930 935 940

caa?gat?gaa?tta?gaa?aac?cgt?tct?aat?cag?gtg?cga?tgt?gca?gag?aaa 2880

Gln?Asp?Glu?Leu?Glu?Asn?Arg?Ser?Asn?Gln?Val?Arg?Cys?Ala?Glu?Lys

945 950 955

aaa?tta?caa?cac?aaa?gaa?ttg?gag?tca?cag?gaa?cag?ata?act?tac?ata 2928

Lys?Leu?Gln?His?Lys?Glu?Leu?Glu?Ser?Gln?Glu?Gln?Ile?Thr?Tyr?Ile

960 965 970 975

cga?caa?gaa?tat?gaa?aca?aaa?ttg?aaa?gga?ttg?atg?cca?gca?tcc?cta 2976

Arg?Gln?Glu?Tyr?Glu?Thr?Lys?Leu?Lys?Gly?Leu?Met?Pro?Ala?Ser?Leu

980 985 990

aga?caa?gaa?ctt?gaa?gac?acc?att?tcc?tcc?cta?aaa?tca?cag?gtt?aat 3024

Arg?Gln?Glu?Leu?Glu?Asp?Thr?Ile?Ser?Ser?Leu?Lys?Ser?Gln?Val?Asn

995 1000 1005

ttt?ctg?caa aag?aga?gct?tcc?atc ctt?cag?gaa?gaa?ctg act?aca 3069

Phe?Leu?Gln Lys?Arg?Ala?Ser?Ile Leu?Gln?Glu?Glu?Leu Thr?Thr

1010 1015 1020

tat?caa?ggc aga?ag g?taa?ctg?cac?gag aga?atg?caa?cgg?atg caa 3114

Tyr?Gln?Gly Arg?Arg Leu?His?Glu Arg?Met?Gln?Arg?Met Gln

1025 1030 1035

ttt?cca?ggc?tgt gct?gtg?gac?ttc?ttc cag?cag?gtt?tga?aga?ttt 3159

Phe?Pro?Gly?Cys Ala?Val?Asp?Phe?Phe Gln?Gln?Val Arg?Phe

1040 1045 1050

gga?tat?tgt?aaa?ctg?tga?gat?cag?tgg?cat?ttt?tta?aat?cct?taa?atg 3207

Gly?Tyr?Cys?Lys?Leu Asp?Gln?Trp?His?Phe?Leu?Asn?Pro Met

1055 1060

taa?tta?aga?tca?taa?aaa?cat?gca?tca?ttc?ata?cac?tag?tgg?ggt 3252

Leu?Arg?Ser Lys?His?Ala?Ser?Phe?Ile?His Trp?Gly

1065 1070 1075

ggt?ttt?att?tgt?gtc?tgc?cta?agt?tat?ttt?ttt?aac?att?cct?tta 3297

Gly?Phe?Ile?Cys?Val?Cys?Leu?Ser?Tyr?Phe?Phe?Asn?Ile?Pro?Leu

1080 1085 1090

ttt?ccg?att?ttc atg?ttt?gtg?tgc?att?tga?gta?tgt?gct?gag?aac 3342

Phe?Pro?Ile?Phe Met?Phe?Val?Cys?Ile Val?Cys?Ala?Glu?Asn

1095 1100 1105

tgc?tta?tat?tgg?gca?aag?tga?ttt?cct?atg?ata?tgc?ctt?gtt?aat 3387

Cys?Leu?Tyr?Trp?Ala?Lys Phe?Pro?Met?Ile?Cys?Leu?Val?Asn

1110 1115

cct?ttt?gca?tag?aat?ttt?acc?agt?tgc?gta?cga?tca aaa?tca?cgt 3432

Pro?Phe?Ala Asn?Phe?Thr?Ser?Cys?Val?Arg?Ser Lys?Ser?Arg

1120 1125 1130

ttg?tag?tat?cat?atc?aaa?aat?tct?aac?ctg?ttt?aca?ttg?ttt?tca 3477

Leu Tyr?His?Ile?Lys?Asn?Ser?Asn?Leu?Phe?Thr?Leu?Phe?Ser

1135 1140 1145

tgt?tca?tgt tcc?tat?gtt?att?aaa ata?tta?ttt?tgt?act?ta?aaaaaaa 3525

Cys?Ser?Cys Ser?Tyr?Val?Ile?Lys Ile?Leu?Phe?Cys?Thr

1150 1155 1160 SEQUENCE?LISTING4

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_001304

<160>1

<170>PatentIn?version?3.5

<210>1

<211>8025

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(761)

<220>

<221>sig_peptide

<222>(16)..(105)

<220>

<221>misc_feature

<222>(106)..(1395)

<220>

<221>exon

<222>(762)..(1009)

<220>

<221>exon

<222>(1010)..(1152)

<220>

<221>exon

<222>(1153)..(1322)

<220>

<221>exon

<222>(1323)..(1672)

<220>

<221>misc_feature

<222>(1396)..(1497)

<220>

<221>misc_feature

<222>(1498)..(2616)

<220>

<221>exon

<222>(1673)..(1864)

<220>

<221>exon

<222>(1865)..(2032)

<220>

<221>exon

<222>(2033)..(2142)

<220>

<221>exon

<222>(2143)..(2245)

<220>

<221>exon

<222>(2246)..(2388)

<220>

<221>exon

<222>(2389)..(2558)

<220>

<221>exon

<222>(2559)..(2888)

<220>

<221>misc_feature

<222>(2617)..(2703)

<220>

<221>misc_feature

<222>(2704)..(3912)

<220>

<221>exon

<222>(2889)..(3084)

<220>

<221>exon

<222>(3085)..(3220)

<220>

<221>exon

<222>(3221)..(3352)

<220>

<221>exon

<222>(3353)..(3448)

<220>

<221>exon

<222>(3449)..(3513)

<220>

<221>exon

<222>(3524)..(3645)

<220>

<221>exon

<222>(3646)..(3831)

<220>

<221>exon

<222>(3832)..(3931)

<220>

<221>misc_feature

<222>(3904)..(3981)

<220>

<221>misc_feature

<222>(3904)..(3981)

<220>

<221>exon

<222>(3932)..(8025)

<220>

<221>STS

<222>(4493)..(4622)

<220>

<221>STS

<222>(5585)..(5734)

<220>

<221>polyA_site

<222>(5764)..(5764)

<220>

<221>STS

<222>(6399)..(6505)

<220>

<221>STS

<222>(6820)..(6939)

<220>

<221>STS

<222>(6830)..(6978)

<220>

<221>polyA_signal

<222>(7014)..(7019)

<220>

<221>polyA_signal

<222>(7018)..(7023)

<220>

<221>polyA_site

<222>(7042)..(7042)

<220>

<221>STS

<222>(7838)..(7967)

<220>

<221>polyA_site

<222>(8025)..(8025)

<400>1

cgg?cgc?tgc?tgg?aag?atg?gcg?agc?ggc?cgg?gac?gag?cgg?ccg?cct?tgg 48

Arg?Arg?Cys?Trp?Lys?Met?Ala?Ser?Gly?Arg?Asp?Glu?Arg?Pro?Pro?Trp

1 5 10 15

cgg?cta?ggg?cgg?ctc?ctg?ttg?ctc?atg?tgc?ctg?ctg?ctg?ctg?ggg?agc 96

Arg?Leu?Gly?Arg?Leu?Leu?Leu?Leu?Met?Cys?Leu?Leu?Leu?Leu?Gly?Ser

20 25 30

tcg?gcc?cgg?gcg?gct?cac?atc?aag?aag?gcg?gag?gcg?act?acc?aca?act 144

Ser?Ala?Arg?Ala?Ala?His?Ile?Lys?Lys?Ala?Glu?Ala?Thr?Thr?Thr?Thr

35 40 45

acg?agc?gcg?ggc?gcc?gag?gcg?gcc?gag?ggc?cag?ttc?gac?cgc?tac?tac 192

Thr?Ser?Ala?Gly?Ala?Glu?Ala?Ala?Glu?Gly?Gln?Phe?Asp?Arg?Tyr?Tyr

50 55 60

cac?gaa?gag?gag?ttg?gag?tcg?gcg?ctg?agg?gag?gcg?gcg?gcc?gcg?ggc 240

His?Glu?Glu?Glu?Leu?Glu?Ser?Ala?Leu?Arg?Glu?Ala?Ala?Ala?Ala?Gly

65 70 75 80

ctc?ccc?ggc?ctg?gcc?cgc?ctc?ttt?agc?atc?ggc?cgc?tcg?gtg?gaa?ggc 288

Leu?Pro?Gly?Leu?Ala?Arg?Leu?Phe?Ser?Ile?Gly?Arg?Ser?Val?Glu?Gly

85 90 95

cgg?ccg?ctg?tgg?gtg?ctt?cgc?ctc?acc?gcc?ggc?ctg?ggg?tcg?cta?atc 336

Arg?Pro?Leu?Trp?Val?Leu?Arg?Leu?Thr?Ala?Gly?Leu?Gly?Ser?Leu?Ile

100 105 110

cct?gag?ggc?gac?gcg?ggg?cct?gac?gct?gcc?ggg?ccc?gac?gct?gcg?ggg 384

Pro?Glu?Gly?Asp?Ala?Gly?Pro?Asp?Ala?Ala?Gly?Pro?Asp?Ala?Ala?Gly

115 120 125

ccg?ctg?ctg?ccc?ggc?cgg?ccc?cag?gtg?aag?ctg?gtg?ggc?aac?atg?cat 432

Pro?Leu?Leu?Pro?Gly?Arg?Pro?Gln?Val?Lys?Leu?Val?Gly?Asn?Met?His

130 135 140

ggc?gac?gag?acc?gtg?tcg?cgc?cag?gtg?ttg?atc?tac?ttg?gcc?cgc?gag 480

Gly?Asp?Glu?Thr?Val?Ser?Arg?Gln?Val?Leu?Ile?Tyr?Leu?Ala?Arg?Glu

145 150 155 160

ctg?gcg?gcc?ggc?tac?cgc?cgc?ggg?gac?ccg?cgc?ctg?gtc?cgc?ctg?ctc 528

Leu?Ala?Ala?Gly?Tyr?Arg?Arg?Gly?Asp?Pro?Arg?Leu?Val?Arg?Leu?Leu

165 170 175

aac?acc?acc?gac?gtg?tac?ctg?ctg?ccc?agc?ctc?aac?ccc?gat?ggc?ttc 576

Asn?Thr?Thr?Asp?Val?Tyr?Leu?Leu?Pro?Ser?Leu?Asn?Pro?Asp?Gly?Phe

180 185 190

gag?cgt?gcc?cgc?gag?ggc?gac?tgt?ggc?ttc?ggc?gac?ggc?ggc?ccg?tcc 624

Glu?Arg?Ala?Arg?Glu?Gly?Asp?Cys?Gly?Phe?Gly?Asp?Gly?Gly?Pro?Ser

195 200 205

ggg?gcc?agc?ggc?cgc?gac?aat?agt?cgc?ggc?cgc?gac?ctc?aac?cga?agc 672

Gly?Ala?Ser?Gly?Arg?Asp?Asn?Ser?Arg?Gly?Arg?Asp?Leu?Asn?Arg?Ser

210 215 220

ttt?ccc?gac?cag?ttt?agc?acc?ggc?gaa?ccc?ccc?gcc?ctg?gac?gag?gtg 720

Phe?Pro?Asp?Gln?Phe?Ser?Thr?Gly?Glu?Pro?Pro?Ala?Leu?Asp?Glu?Val

225 230 235 240

ccc?gag?gtg?cgc?gcc?ctc?atc?gag?tgg?atc?cgc?agg?aac?aa g?ttt?gtg 768

ProGlu?Val?Arg?Ala?Leu?Ile?Glu?Trp?Ile?Arg?Arg?Asn?Lys Phe?Val

245 250 255

ctt?tct?gga?aat?ctg?cat?ggt?ggc?tca?gtg?gta?gca?agc?tat?cct?ttt 816

Leu?Ser?Gly?Asn?Leu?His?Gly?Gly?Ser?Val?Val?Ala?Ser?Tyr?Pro?Phe

260 265 270

gat?gat?tct?cca?gaa?cat?aag?gcc?act?gga?atc?tat?agc?aaa?acc?tca 864

Asp?Asp?Ser?Pro?Glu?His?Lys?Ala?Thr?Gly?Ile?Tyr?Ser?Lys?Thr?Ser

275 280 285

gat?gat?gaa?gta?ttt?aaa?tac?ttg?gca?aaa?gct?tat?gct?tca?aac?cac 912

Asp?Asp?Glu?Val?Phe?Lys?Tyr?Leu?Ala?Lys?Ala?Tyr?Ala?Ser?Asn?His

290 295 300

ccc?ata?atg?aaa?act?ggt?gag?cct?cat?tgt?cca?gga?gat?gaa?gac?gag 960

Pro?Ile?Met?Lys?Thr?Gly?Glu?Pro?His?Cys?Pro?Gly?Asp?Glu?Asp?Glu

305 310 315 320

act?ttc?aaa?gat?gga?atc?aca?aac?ggc?gca?cat?tgg?tat?gat?gtg?gaa?g 1009

Thr?Phe?Lys?Asp?Gly?Ile?Thr?Asn?Gly?Ala?His?Trp?Tyr?Asp?Val?Glu

325 330 335

gt ggt?atg?caa?gat?tac?aat?tat?gtg?tgg?gcc?aac?tgt?ttt?gag?atc 1056

Gly?Gly?Met?Gln?Asp?Tyr?Asn?Tyr?Val?Trp?Ala?Asn?Cys?Phe?Glu?Ile

340 345 350

aca?tta?gaa?ctg?tct?tgt?tgc?aag?tac?cca?cct?gct?tca?cag?ctt?cga 1104

Thr?Leu?Glu?Leu?Ser?Cys?Cys?Lys?Tyr?Pro?Pro?Ala?Ser?Gln?Leu?Arg

355 360 365

cag?gaa?tgg?gag?aac?aat?cgt?gag?tct?ttg?atc?aca?ttg?att?gaa?aag 1152

Gln?Glu?Trp?Glu?Asn?Asn?Arg?Glu?Ser?Leu?Ile?Thr?Leu?Ile?Glu?Lys

370 375 380

gtt?cac?att?gga?gtg?aaa?gga?ttt?gtt?aaa?gat?tcc?ata?aca?gga?tct 1200

Val?His?Ile?Gly?Val?Lys?Gly?Phe?Val?Lys?Asp?Ser?Ile?Thr?Gly?Ser

385 390 395 400

ggg?tta?gag?aat?gca?acc?atc?tca?gtg?gct?ggt?att?aat?cat?aat?atc 1248

Gly?Leu?Glu?Asn?Ala?Thr?Ile?Ser?Val?Ala?Gly?Ile?Asn?His?Asn?Ile

405 410 415

aca?aca?ggc?aga?ttt?ggt?gat?ttc?tac?cga?tta?ctt?gtt?cct?gga?act 1296

Thr?Thr?Gly?Arg?Phe?Gly?Asp?Phe?Tyr?Arg?Leu?Leu?Val?Pro?Gly?Thr

420 425 430

tac?aac?ctt?aca?gta?gtt?tta?act?gg g?tat?atg?cca?ttg?act?gtt?act 1344

Tyr?Asn?Leu?Thr?Val?Val?Leu?Thr?Gly Tyr?Met?Pro?Leu?Thr?Val?Thr

435 440 445

aat?gta?gtg?gtg?aaa?gaa?gga?cca?gcc?aca?gag?gtg?gat?ttt?tct?ctt 1392

Asn?Val?Val?Val?Lys?Glu?Gly?Pro?Ala?Thr?Glu?Val?Asp?Phe?Ser?Leu

450 455 460

agg?cca?act?gta?act?tca?gta?atc?cct?gac?acg?aca?gag?gct?gta?tca 1440

Arg?Pro?Thr?Val?Thr?Ser?Val?Ile?Pro?Asp?Thr?Thr?Glu?Ala?Val?Ser

465 470 475 480

act?gct?agc?aca?gtt?gct?ata?cct?aat?att?ctt?tct?gga?aca?tca?tcc 1488

Thr?Ala?Ser?Thr?Val?Ala?Ile?Pro?Asn?Ile?Leu?Ser?Gly?Thr?Ser?Ser

485 490 495

tcc?tac?cag?cca?att?cag?cca?aag?gac?ttt?cac?cac?cac?cat?ttc?cct 1536

Ser?Tyr?Gln?Pro?Ile?Gln?Pro?Lys?Asp?Phe?His?His?His?His?Phe?Pro

500 505 510

gat?atg?gaa?atc?ttc?ttg?aga?agg?ttt?gcc?aat?gaa?tat?cct?aac?att 1584

Asp?Met?Glu?Ile?Phe?Leu?Arg?Arg?Phe?Ala?Asn?Glu?Tyr?Pro?Asn?Ile

515 520 525

acc?cgg?ctt?tat?tcc?ttg?gga?aaa?tca?gta?gag?tca?aga?gaa?ctt?tat 1632

Thr?Arg?Leu?Tyr?Ser?Leu?Gly?Lys?Ser?Val?Glu?Ser?Arg?Glu?Leu?Tyr

530 535 540

gtg?atg?gag?ata?tct?gat?aat?ccg?ggt?gtc?cat?gaa?cca?g?gt gaa?cca 1680

Val?Met?Glu?Ile?Ser?Asp?Asn?Pro?Gly?Val?His?Glu?Pro Gly?Glu?Pro

545 550 555 560

gaa?ttt?aag?tac?att?gga?aat?atg?cat?gga?aat?gaa?gtg?gtt?gga?aga 1728

Glu?Phe?Lys?Tyr?Ile?Gly?Asn?Met?His?Gly?Asn?Glu?Val?Val?Gly?Arg

565 570 575

gaa?ctg?ctg?ttg?aac?ctc?ata?gaa?tac?ctt?tgt?aag?aac?ttt?gga?aca 1776

Glu?Leu?Leu?Leu?Asn?Leu?Ile?Glu?Tyr?Leu?Cys?Lys?Asn?Phe?Gly?Thr

580 585 590

gac?cct?gaa?gtc?aca?gat?ttg?gtt?cat?aac?act?aga?att?cac?ctt?atg 1824

Asp?Pro?Glu?Val?Thr?Asp?Leu?Val?His?Asn?Thr?Arg?Ile?His?Leu?Met

595 600 605

cca?tcc?atg?aat?cct?gat?ggg?tat?gaa?aag?tcc?cag?gaa?g?ga gat?tca 1872

Pro?Ser?Met?Asn?Pro?Asp?Gly?Tyr?Glu?Lys?Ser?Gln?Glu Gly?Asp?Ser

610 615 620

ata?agt?gta?att?ggc?aga?aac?aac?agc?aac?aac?ttt?gac?ctg?aac?cga 1920

Ile?Ser?Val?Ile?Gly?Arg?Asn?Asn?Ser?Asn?Asn?Phe?Asp?Leu?Asn?Arg

625 630 635 640

aat?ttc?cca?gac?cag?ttt?gtt?cag?atc?aca?gat?cct?acg?caa?cca?gaa 1968

Asn?Phe?Pro?Asp?Gln?Phe?Val?Gln?Ile?Thr?Asp?Pro?Thr?Gln?Pro?Glu

645 650 655

act?att?gct?gta?atg?agc?tgg?atg?aag?tcc?tat?cca?ttt?gta?ctt?tca 2016

Thr?Ile?Ala?Val?Met?Ser?Trp?Met?Lys?Ser?Tyr?Pro?Phe?Val?Leu?Ser

660 665 670

gca?aac?ctg?cat?gga?g?gt tct?ttg?gtg?gtt?aac?tac?cct?ttt?gat?gat 2064

Ala?Asn?Leu?His?Gly Gly?Ser?Leu?Val?Val?Asn?Tyr?Pro?Phe?Asp?Asp

675 680 685

gat?gaa?caa?gga?ctt?gcc?aca?tat?agt?aaa?tca?cca?gat?gat?gct?gtg 2112

Asp?Glu?Gln?Gly?Leu?Ala?Thr?Tyr?Ser?Lys?Ser?Pro?Asp?Asp?Ala?Val

690 695 700

ttc?caa?caa?ata?gca?ctt?tct?tat?tcc?aag?gaa?aat?tcc?cag?atg?ttt 2160

Phe?Gln?Gln?Ile?Ala?Leu?Ser?Tyr?Ser?Lys?Glu?Asn?Ser?Gln?Met?Phe

705 710 715 720

caa?ggt?aga?cct?tgc?aag?aat?atg?tat?cct?aat?gaa?tat?ttt?cct?cat 2208

Gln?Gly?Arg?Pro?Cys?Lys?Asn?Met?Tyr?Pro?Asn?Glu?Tyr?Phe?Pro?His

725 730 735

gga?ata?aca?aat?gga?gct?agt?tgg?tat?aat?gtg?cca?g?ga gga?atg?cag 2256

Gly?Ile?Thr?Asn?Gly?Ala?Ser?Trp?Tyr?Asn?Val?Pro Gly?Gly?Met?Gln

740 745 750

gac?tgg?aac?tat?tta?caa?aca?aat?tgc?ttt?gaa?gtg?act?att?gaa?cta 2304

Asp?Trp?Asn?Tyr?Leu?Gln?Thr?Asn?Cys?Phe?Glu?Val?Thr?Ile?Glu?Leu

755 760 765

ggt?tgt?gtg?aaa?tat?cca?ctt?gag?aaa?gag?ctg?cca?aac?ttt?tgg?gaa 2352

Gly?Cys?Val?Lys?Tyr?Pro?Leu?Glu?Lys?Glu?Leu?Pro?Asn?Phe?Trp?Glu

770 775 780

cag?aat?cga?aga?tca?cta?atc?cag?ttt?atg?aaa?cag?gtt?cat?cag?ggc 2400

Gln?Asn?Arg?Arg?Ser?Leu?Ile?Gln?Phe?Met?Lys?Gln?Val?His?Gln?Gly

785 790 795 800

gtc?aga?gga?ttt?gtt?cta?gat?gcc?aca?gat?ggc?agg?ggt?ata?tta?aat 2448

Val?Arg?Gly?Phe?Val?Leu?Asp?Ala?Thr?Asp?Gly?Arg?Gly?Ile?Leu?Asn

805 810 815

gcc?acc?att?agt?gtt?gct?gag?att?aat?cac?cca?gtg?act?act?tac?aaa 2496

Ala?Thr?Ile?Ser?Val?Ala?Glu?Ile?Asn?His?Pro?Val?Thr?Thr?Tyr?Lys

820 825 830

act?gga?gat?tac?tgg?cgt?ctc?ttg?gtt?cca?gga?act?tat?aaa?atc?aca 2544

Thr?Gly?Asp?Tyr?Trp?Arg?Leu?Leu?Val?Pro?Gly?Thr?Tyr?Lys?Ile?Thr

835 840 845

gca?tct?gct?cga?gg g?tat?aat?cca?gtt?acc?aag?aat?gtg?act?gtc?aag 2592

Ala?Ser?Ala?Arg?Gly Tyr?Asn?Pro?Val?Thr?Lys?Asn?Val?Thr?Val?Lys

850 855 860

agt?gaa?ggc?gct?att?cag?gtc?aac?ttc?aca?ctt?gtt?cga?tcc?tca?aca 2640

Ser?Glu?Gly?Ala?Ile?Gln?Val?Asn?Phe?Thr?Leu?Val?Arg?Ser?Ser?Thr

865 870 875 880

gat?tca?aac?aat?gaa?tca?aag?aaa?gga?aaa?ggg?gct?agc?agc?agc?acc 2688

Asp?Ser?Asn?Asn?Glu?Ser?Lys?Lys?Gly?Lys?Gly?Ala?Ser?Ser?Ser?Thr

885 890 895

aat?gat?gcc?agt?gat?cca?act?act?aaa?gag?ttt?gaa?act?tta?att?aaa 2736

Asn?Asp?Ala?Ser?Asp?Pro?Thr?Thr?Lys?Glu?Phe?Glu?Thr?Leu?Ile?Lys

900 905 910

gac?ctt?tca?gcg?gag?aat?ggt?ttg?gaa?agc?ctc?atg?tta?cgc?tcc?tcc 2784

Asp?Leu?Ser?Ala?Glu?Asn?Gly?Leu?Glu?Ser?Leu?Met?Leu?Arg?Ser?Ser

915 920 925

tca?aat?ctg?gct?ctg?gct?ctt?tat?cga?tac?cat?tcc?tac?aaa?gac?tta 2832

Ser?Asn?Leu?Ala?Leu?Ala?Leu?Tyr?Arg?Tyr?His?Ser?Tyr?Lys?Asp?Leu

930 935 940

tca?gag?ttt?ctg?aga?gga?ctt?gta?atg?aac?tat?cca?cat?att?aca?aat 2880

Ser?Glu?Phe?Leu?Arg?Gly?Leu?Val?Met?Asn?Tyr?Pro?His?Ile?Thr?Asn

945 950 955 960

ctt?acc?aa?t?ttg?gga?cag?agc?act?gaa?tat?cgt?cac?att?tgg?tcc?ctt 2928

Leu?Thr?Asn Leu?Gly?Gln?Ser?Thr?Glu?Tyr?Arg?His?Ile?Trp?Ser?Leu

965 970 975

gaa?atc?tcc?aat?aag?ccc?aat?gta?tct?gag?cct?gaa?gaa?cca?aag?att 2976

Glu?Ile?Ser?Asn?Lys?Pro?Asn?Val?Ser?Glu?Pro?Glu?Glu?Pro?Lys?Ile

980 985 990

cgt?ttt?gtt?gct?ggt?atc?cat?gga aat?gcg?cca?gtt?gga act?gaa?ctg 3024

Arg?Phe?Val?Ala?Gly?Ile?His?Gly Asn?Ala?Pro?Val?Gly Thr?Glu?Leu

995 1000 1005

ctt?ttg gct?ctg?gca?gaa?ttt ctc?tgc?ctg?aac?tac aaa?aag?aac 3069

Leu?Leu Ala?Leu?Ala?Glu?Phe Leu?Cys?Leu?Asn?Tyr Lys?Lys?Asn

1010 1015 1020

cca?gct gtt?acc?caa?ttg?gtt gac?agg?act?agg?att gtg?att?gtc 3114

Pro?Ala Val?Thr?Gln?Leu?Val Asp?Arg?Thr?Arg?Ile Val?Ile?Val

1025 1030 1035

cct?tct cta?aat?cca?gat?ggg cga?gag?aga?gct?caa gag?aaa?gac 3159

Pro?Ser Leu?Asn?Pro?Asp?Gly Arg?Glu?Arg?Ala?Gln Glu?Lys?Asp

1040 1045 1050

tgt?act tca?aaa?ata?gga?caa aca?aat?gct?cgt?ggc aaa?gat?ttg 3204

Cys?Thr Ser?Lys?Ile?Gly?Gln Thr?Asn?Ala?Arg?Gly Lys?Asp?Leu

1055 1060 1065

gat?aca gac?ttc?aca?a?at aat gcc?tcc?caa?cct?gag acc?aaa?gcc 3249

Asp?Thr Asp?Phe?Thr Asn?Asn Ala?Ser?Gln?Pro?Glu Thr?Lys?Ala

1070 1075 1080

atc?att gaa?aat?ttg?att?caa aaa?cag?gac?ttt?agt ctt?tct?gtt 3294

Ile?Ile Glu?Asn?Leu?Ile?Gln Lys?Gln?Asp?Phe?Ser Leu?Ser?Val

1085 1090 1095

gcc?tta gat?ggt?ggt?tcc?atg ctg?gtc?aca?tat?cct tat?gac?aag 3339

Ala?Leu Asp?Gly?Gly?Ser?Met Leu?Val?Thr?Tyr?Pro Tyr?Asp?Lys

1100 1105 1110

cca?gta cag?aca?g?tg gaa?aat aaa?gag?act?ctg?aag cat?ttg?gca 3384

Pro?Val Gln?Thr Val?Glu?Asn Lys?Glu?Thr?Leu?Lys His?Leu?Ala

1115 1120 1125

tct?ctt tat?gca?aat?aat?cat cca?tcc?atg?cac?atg ggt?cag?ccc 3429

Ser?Leu Tyr?Ala?Asn?Asn?His Pro?Ser?Met?His?Met Gly?Gln?Pro

1130 1135 1140

agt?tgc cca?aat?aaa?tca?g?at gag?aat?att?cca?gga gga?gta?atg 3474

Ser?Cys Pro?Asn?Lys?Ser Asp?Glu?Asn?Ile?Pro?Gly Gly?Val?Met

1145 1155

cgt?gga gca?gaa?tgg?cat?agt cac?ctg?ggc?agc?atg aag?gattatagtg?3523

Arg?Gly Ala?Glu?Trp?His?Ser His?Leu?Gly?Ser?Met Lys

1160 1165 1170

tca?cct?atg?gcc att?gtc?cgg?aaa?tca cag?tat?aca?caa?gct gct 3568

Ser?Pro?Met?Ala Ile?Val?Arg?Lys?Ser Gln?Tyr?Thr?Gln?Ala Ala

1175 1180 1185

gtt?act?ttc?cta gtg?ctg?cac?gac?tcc ctt?cct?tgt?ggg?cag aca 3613

Val?Thr?Phe?Leu Val?Leu?His?Asp?Ser Leu?Pro?Cys?Gly?Gln Thr

1190 1195 1200

ata?aga?gat?ctc ttc?tta?gta?tgt?tag?tgg ag g?ttc?aca?agg?gag 3658

Ile?Arg?Asp?Leu Phe?Leu?Val?Cys Trp Arg Phe?Thr?Arg?Glu

1205 1210 1215

ttc?atg?gat?ttg?tta aag?ata?aga?ctg?gaa agc?caa?tct?cta?aag 3703

Phe?Met?Asp?Leu?Leu Lys?Ile?Arg?Leu?Glu Ser?Gln?Ser?Leu?Lys

1220 1225 1230

cag?tca?ttg?tac?tta atg?aag?gaa?taa?agg?tac aaa?caa?aag?agg 3748

Gln?Ser?Leu?Tyr?Leu Met?Lys?Glu Arg?Tyr Lys?Gln?Lys?Arg

1235 1240

gag gtt?att?tcc?atg?tac tct?tag?cgc?cag?gtg?tcc ata?aca?tta 3793

Glu Val?Ile?Ser?Met?Tyr Ser Arg?Gln?Val?Ser Ile?Thr?Leu

1245 1250 1255

ttg?cca tcg?ctg?atg?ggt?acc agc?aac?aac?att?cac ag g?tct?ttg 3838

Leu?Pro Ser?Leu?Met?Gly?Thr Ser?Asn?Asn?Ile?His Arg Ser?Leu

1260 1265 1270

tgc?atc atg?atg?cag?cta?gtt ctg?tgg?tga?tag?tct?ttg?aca cag 3883

Cys?Ile Met?Met?Gln?Leu?Val Leu?Trp Ser?Leu?Thr Gln

1275 1280 1285

ata?acc?gga?tat ttg?gtt?tgc?caa?ggg agc?ttg?tgg?taa?ctg?tat 3928

Ile?Thr?Gly?Tyr Leu?Val?Cys?Gln?Gly Ser?Leu?Trp Leu?Tyr

1290 1295 1300

cag?gtg?cta?cta?tgt cgg?cat?tga?tcc?taa?cag?ctt gca?tta?ttt?ggt?3976

Gln?Val?Leu?Leu?Cys Arg?His Ser Gln?Leu Ala?Leu?Phe?Gly

1305 1310

gca tct?gct?caa?tca?agt cta?ata?gac?aca?agg atg?gct?ttc?atc 4021

Ala Ser?Ala?Gln?Ser?Ser Leu?Ile?Asp?Thr?Arg Met?Ala?Phe?Ile

1315 1320 1325

ggc tca?ggc?agc?atc?atg atg?agt?atg?aag?atg aaa?ttc?gca?tga 4066

Gly Ser?Gly?Ser?Ile?Met Met?Ser?Met?Lys?Met Lys?Phe?Ala

1330 1335 1340

tgt?cta ccg?gct?cca?aga?agt ccc?tcc?taa?gcc?atg?agt tcc?agg 4111

Cys?Leu Pro?Ala?Pro?Arg?Ser Pro?Ser Ala?Met?Ser Ser?Arg

1345 1350 1355

atg?aaa?cag aca?ctg?aag?agg?aaa cat?tat?att?cta?gca aac?att 4156

Met?Lys?Gln Thr?Leu?Lys?Arg?Lys His?Tyr?Ile?Leu?Ala Asn?Ile

1360 1365 1370

gaa?aaa?cac att?ttg?cat?atc?tcc cag?cat?aag?tac?caa gca?aaa 4201

Glu?Lys?His Ile?Leu?His?Ile?Ser Gln?His?Lys?Tyr?Gln Ala?Lys

1375 1380 1385

ttacag?ttc ctc?ttg?gga?gaa?cac tgc?att?aag?aag?aga gac?tct 4246

Leu?Gln?Phe?Leu?Leu?Gly?Glu?His Cys?Ile?Lys?Lys?Arg Asp?Ser

1390 1395 1400

ctt?gct?tct tca?aag?agc?ttt?ggg?aaa?tta?aat?tgc?taa?att tgt 4291

Leu?Ala?Ser Ser?Lys?Ser?Phe?Gly Lys?Leu?Asn?Cys Ile Cys

1405 1410 1415

att?ctc?tgt?gaa ttt?cac?tgg?cag?ttt tga?act?tcc?ctt?cct?taa 4336

Ile?Leu?Cys?Glu Phe?His?Trp?Gln?Phe Thr?Ser?Leu?Pro

1420 1425

agt act?cta?aac?ctt?taa?aaa aaa?atc?tga?ttt?atg?cag cag?aga 4381

Ser Thr?Leu?Asn?Leu Lys LysIle Phe?Met?Gln Gln?Arg

1430 1435 1440

tgg?gac?agc cac?ttt?ttc?ttt?tta att?taa?gat?gag?cta?ttt gga 4426

Trp?Asp?Ser His?Phe?Phe?Phe?Leu Ile Asp?Glu?Leu?Phe Gly

1445 1450 1455

gct?tat?gta?ata atg?gca?taa?agc?caa?cta gag?gat?gtt?gta?ttt 4471

Ala?Tyr?Val?Ile Met?Ala Ser?Gln?Leu Glu?Asp?Val?Val?Phe

1460 1465 1470

tgc?aca?tca?gat?gtt tac?tag?tgg?ctt?tag?tat?ttt tct?ttg?ttt?taa?4519

Cys?Thr?Ser?Asp?Val Tyr Trp?Leu Tyr?Phe Ser?Leu?Phe

1475 1480

atg?gcc aaa?aga?atc?cag?aaa cat?taa?ggc?agg?gac?agc agt?cag 4564

Met?Ala Lys?Arg?Ile?Gln?Lys His Gly?Arg?Asp?Ser Ser?Gln

1485 1490 1495

aat cga?cat?aaa?gct?tta?aaa?act caa?ggt?ttt?ttc?aac cta?ctg 4609

Asn?Arg?His Lys?Ala?Leu?Lys?Thr Gln?Gly?Phe?Phe?Asn Leu?Leu

1500 1505 1510

agg?agt?act ttt?ctc?tag?ttg?tta?aat agc?tgg?agt?ttt?tct tat 4654

Arg?Ser?Thr Phe?Leu Leu?Leu?Asn Ser?Trp?Ser?Phe?Ser Tyr

1515 1520 1525

tca?ggt?tta?atg gag?gtt?gaa?ttg?att ttt?aaa?cac?ata?taa?cag 4699

Ser?Gly?Leu?Met Glu?Val?Glu?Leu?Ile Phe?Lys?His?Ile Gln

1530 1535 1540

tag?gaa?atg?aat?aaa?tgg gct?tct?gca?ttt?ggc ttt?cta?cct?gtt 4744

Glu?Met?Asn?Lys?Trp Ala?Ser?Ala?Phe?Gly Phe?Leu?Pro?Val

1545 1550

cca agg?cta?gat?cgg?aac tgg?tag?act?acg?ctg?taa?gca gga?ttt 4789

Pro Arg?Leu?Asp?Arg?Asn Trp Thr?Thr?Leu Ala Gly?Phe

1555 1560 1565

cac?tac?ctc tct?taa?ggt?tta?gca?aac ttc?taa?ata?gcc?cat?ttt 4834

His?Tyr?Leu Ser Gly?Leu?Ala?Asn Phe Ile?Ala?His?Phe

1570 1575 1580

aag?gga?gaa?ctt?act aac?ttt?att?gtg?aaa ggt?cta?aat?gcc?cac 4879

Lys?Gly?Glu?Leu?Thr Asn?Phe?Ile?Val?Lys Gly?Leu?Asn?Ala?His

1585 1590 1595

ttg?aat?gaa?gct?gag aga?gag?atc?tag?caa?aag cta?aaa?ctc?atg 4924

Leu?Asn?Glu?Ala?Glu Arg?Glu?Ile Gln?Lys Leu?Lys?Leu?Met

1600 1605

ttg tct?atc?ttt?gaa?ctt ggt?aaa?aac?cca?cag gtg?ctg?ctg?ctt 4969

Leu Ser?Ile?Phe?Glu?Leu Gly?Lys?Asn?Pro?Gln Val?Leu?Leu?Leu

1610 1615 1620

ata tct?gtg?aag?cac?tag?ctt att?cta?gga?atg?cct gat?tct?tta 5014

Ile Ser?Val?Lys?His Leu Ile?Leu?Gly?Met?Pro Asp?Ser?Leu

1625 1630 1635

ata?ttg cct?aaa?tcg?gaa?cct ttt?tct?atg?ttg?cac aca?tgg?ttt 5059

Ile?Leu Pro?Lys?Ser?Glu?Pro Phe?Ser?Met?Leu?His Thr?Trp?Phe

1640 1645 1650

tca?gat gac?cca?gcc?atc?tac aag?atc?tga?att?cta?ctg aaa?ata 5104

Ser?Asp Asp?Pro?Ala?Ile?Tyr Lys?Ile Ile?Leu?Leu Lys?Ile

1655 1660 1665

tct?aga?aat gtg?gaa?gag?acc?tac ttg?cac?att?ctt?aac ctg?tat 5149

Ser?Arg?Asn Val?Glu?Glu?Thr?Tyr Leu?His?Ile?Leu?Asn Leu?Tyr

1670 1675 1680

ttg?aac?aca aaa?tat?cta?tac?ttc atg?ctc?cag?ccc?aag cct?ata 5194

Leu?Asn?Thr Lys?Tyr?Leu?Tyr?Phe Met?Leu?Gln?Pro?Lys Pro?Ile

1685 1690 1695

ccc?tgt?aat agc?ata?cta?tta?ttg?aaa?tcg?ctt?gac?cgg tct tgt 5239

Pro?Cys?Asn Ser?Ile?Leu?Leu?Leu Lys?Ser?Leu?Asp?Arg Ser?Cys

1700 1705 1710

tca?cat?agg cct?ctg?gga?gtg?att tgg?ttc?ttt?gcc?cta atg?ttt 5284

Ser?His?Arg Pro?Leu?Gly?Val?Ile Trp?Phe?Phe?Ala?Leu Met?Phe

1715 1720 1725

cat?ttg?acg gtc?tct?ttt?tga?tca?acc aat?ttt?tct?aaa?agt tca 5329

His?Leu?Thr Val?Ser?Phe Ser?Thr Asn?Phe?Ser?Lys?Ser Ser

1730 1735 1740

gtc?gaa?agc?ttt taa?gta?tag?ctt?cct?ccc?ttg aaa?aaa?aat?gta 5374

Val?Glu?Ser?Phe Val Leu?Pro?Pro?Leu Lys?Lys?Asn?Val

1745 1750

aac tat?gac?tgc?tga?gtg?ata aaa?cac?tgt?ggt?gtg aaa?gtg?tca 5419

Asn Tyr?Asp?Cys Val?Ile Lys?His?Cys?Gly?Val Lys?Val?Ser

1755 1760 1765

tct?tca ctg?cca?atc?agg?caa aga?ccg?gaa?aga?ttt gca?ttt?tat 5464

Ser?Ser Leu?Pro?Ile?Arg?Gln Arg?Pro?Glu?Arg?Phe Ala?Phe?Tyr

1770 1775 1780

tat?gtc tgt?ctt?atc?atg?caa tgg?aaa?tga?tgc?ttt?ttg taa?gta 5509

Tyr?Val Cys?Leu?Ile?Met?Gln Trp?Lys Cys?Phe?Leu Val

1785 1790 1795

tgc?atc?tta?cca atg?atg?taa?cgg?ttt?aat acc?ttt?gaa?tgt?ttt 5554

Cys?Ile?Leu?Pro Met?Met Arg?Phe?Asn Thr?Phe?Glu?Cys?Phe

1800 1805 1810

aat?aac?caa?gtt?gct gct?gaa?ctt?ata?cta aat?cag?ggg?acc?aaa 5599

Asn?Asn?Gln?Val?Ala Ala?Glu?Leu?Ile?Leu Asn?Gln?Gly?Thr?Lys

1815 1820 1825

aaa?ctt?gct?ctt?atc ttc?tca?aat?tgt?att cta?tat?cca?tta?atg 5644

Lys?Leu?Ala?Leu?Ile Phe?Ser?Asn?Cys?Ile Leu?Tyr?Pro?Leu?Met

1830 1835 1840

tat?cag?tta?tcc?caa agc?ctt?cag?gtg?gag ggg?ttt?acc?acc?ttc 5689

Tyr?Gln?Leu?Ser?Gln Ser?Leu?Gln?Val?Glu Gly?Phe?Thr?Thr?Phe

1845 1850 1855

cta?ggt?cgt?tca?acc agg?ttt?tgt?gag?gaa tgc?att?caa?agt?ggc 5734

Leu?Gly?Arg?Ser?Thr Arg?Phe?Cys?Glu?Glu Cys?Ile?Gln?Ser?Gly

1860 1865 1870

ttt?ata?aaa?gaa?gat?ttt?ctt?tag?caa?gaa?taa?tga?ggt cat?gtc?att 5782

Phe?Ile?Lys?Glu?Asp Phe?Leu Gln?Glu Gly His?Val?Ile

1875 1880

tgt?taa?taa?gta tct?gtg?ata?aat?ccg tgg?ttc?aag?gtt?aag cca 5827

Cys Val Ser?Val?Ile?Asn?Pro Trp?Phe?Lys?Val?Lys Pro

1885 1890 1895

ttc?tgg?tat?tct ggt?att?agc?aac?tgt aaa?ttc?tgc?cac?ctc ata 5872

Phe?Trp?Tyr?Ser Gly?Ile?Ser?Asn?Cys Lys?Phe?Cys?His?Leu Ile

1900 1905 1910

cat?gga?aca?gag ctt?gtg?gga?tgc?taa?tag?tta gtg?aag?tat?aca?tga 5920

His?Gly?Thr?Glu Leu?Val?Gly?Cys Leu Val?Lys?Tyr?Thr

1915 1920

ttt aat?ttc?taa?taa?tct?tta?tgt ttt?ctt?taa?gga?tgg?tgg tgt 5965

Phe Asn?Phe Ser?Leu?Cys Phe?Leu Gly?Trp?Trp Cys

1925 1930 1935

att?gct?ctt?ttt cag?ctt?tat?ttt?taa?gag tac?agt?cag?gaa?acc 6010

Ile?Ala?Leu?Phe Gln?Leu?Tyr?Phe Glu Tyr?Ser?Gln?Glu?Thr

1940 1945 1950

aac?aag?ggg?cct?aag agt?ggc?tgc?ccc?tgc ttg?gga?cat?tac?agc 6055

Asn?Lys?Gly?Pro?Lys Ser?Gly?Cys?Pro?Cys Leu?Gly?His?Tyr?Ser

1955 1960 1965

aag?tga?aac?aaa?gtt?aat gtg?aca?agc?ttt?gct ttg?tta?tca?ttg 6100

Lys Asn?Lys?Val?Asn Val?Thr?Ser?Phe?Ala Leu?Leu?Ser?Leu

1970 1975

gtc ttc?act?aga?gga?tac ctt?tta?cat?gta?ctt ctc?tct?tgg?atc 6145

Val Phe?Thr?Arg?Gly?Tyr Leu?Leu?His?Val?Leu Leu?Ser?Trp?Ile

1980 1985 1990

aaa tat?gtc?ttt?aac?tgt aca?tct?cag?tgg?ctg gag?gcc?atg?cct 6190

Lys Tyr?Val?Phe?Asn?Cys Thr?Ser?Gln?Trp?Leu Glu?Ala?Met?Pro

1995 2000 2005

ttt aag?cat?gtg?taa?aat?ttt taa?aga?aat?gaa?cat?aca cat?agt 6235

Phe Lys?His?Val Asn?Phe Arg?Asn?Glu?His?Thr His?Ser

2010 2015 2020

tat?ttt?agt aat?att?tcc?tga?aag?aaa aac?caa?att?ctg?cta taa 6280

Tyr?Phe?Ser Asn?Ile?Ser Lys?Lys Asn?Gln?Ile?Leu?Leu

2025 2030 2035

gtc?ttg?atc?ttc?aat gaa?ctt?tta?aat?aat gca?ttt?agc?tgg?aaa 6325

Val?Leu?Ile?Phe?Asn Glu?Leu?Leu?Asn?Asn Ala?Phe?Ser?Trp?Lys

2040 2045 2050

aca?aga?ctt?tcc?cag ctt?gta?tta?cct?aga agc?gtg?aat?gta?tag 6370

Thr?Arg?Leu?Ser?Gln Leu?Val?Leu?Pro?Arg Ser?Val?Asn?Val

2055 2060

gat acc?tga?cta?cta?aga?cta tat?tct?cag?ccc?tgc cct?gtc?ttt 6415

Asp Thr Leu?Leu?Arg?Leu Tyr?Ser?Gln?Pro?Cys Pro?Val?Phe

2065 2070 2075

tat?ttg cgg?gtc?taa?tct?aat?att aga?ata?tat?taa?ccg?ctt aag 6460

Tyr?Leu Arg?Val Ser?Asn?Ile Arg?Ile?Tyr Pro?Leu Lys

2080 2085 2090

gca?ttg?aag?cca tat?ggg?atg?ggg?aat gca?ttt?ctt?cag?tgt ttc 6505

Ala?Leu?Lys?Pro Tyr?Gly?Met?Gly?Asn Ala?Phe?Leu?Gln?Cys Phe

2095 2100 2105

tcc?gag?aga?ctt tcc?att?tcc?ttg?gag tta?tgg?cgg?caa?gta agt 6550

Ser?Glu?Arg?Leu Ser?Ile?Ser?Leu?Glu Leu?Trp?Arg?Gln?Val Ser

2110 2115 2120

atc?ata?gta?tta aga?aat?ttg?cct?aaa tct?gag?ttg?tgc?ctt tct 6595

Ile?Ile?Val?Leu Arg?Asn?Leu?Pro?Lys Ser?Glu?Leu?Cys?Leu Ser

2125 2130 2135

tta?ctc?aca?agg cat?ggg?ctt?tgt?cct ggt?gat?cag?ttt?gta agc 6640

Leu?Leu?Thr?Arg His?Gly?Leu?Cys?Pro Gly?Asp?Gln?Phe?Val Ser

2140 2145 2150

ctt?ctt?cct?tcc cag?ctc?ctt?aat?aaa agc?aaa?gtg?att?gag tag 6685

Leu?Leu?Pro?Ser Gln?Leu?Leu?Asn?Lys Ser?Lys?Val?Ile?Glu

2155 2160 2165

gta?atg?ttc?aaa?gtg tct?gcc?tgt?gta?cat gta?ctt?gta?ttg?att 6730

Val?Met?Phe?Lys?Val Ser?Ala?Cys?Val?His Val?Leu?Val?Leu?Ile

2170 2175 2180

atg?tag?ttc?agt?aag?atg tgc?cca?agt?cat?ttc aga?aag?aaa?gac 6775

Met Phe?Ser?Lys?Met Cys?Pro?Ser?His?Phe Arg?Lys?Lys?Asp

2185 2190

cct tca?gtt?ttg?atg?cat ttt?gct?gaa?cac?ttg ggt?agt?gag?tgg 6820

Pro Ser?Val?Leu?Met?His Phe?Ala?Glu?His?Leu Gly?Ser?Glu?Trp

2195 2200 2205

gat cct?atc?cag?ttg?agg?aat?gct?tgc?aat?gct cat?tga?agg?gat 6865

Asp Pro?Ile?Gln?Leu?Arg Asn?Ala?Cys?Asn?Ala His Arg?Asp

2210 2215 2220

ttg?ctt tgg?gac?ttt?gtc?atc ttc?cag?aaa?gga?aac ata?ttg?tat 6910

Leu?Leu Trp?Asp?Phe?Val?Ile Phe?Gln?Lys?Gly?Asn Ile?Leu?Tyr

2225 2230 2235

att?tgg ccc?agt?gtg?att?gat tgc?ttt?atc?ttt?ggt aac?ttt?tac 6955

Ile?Trp Pro?Ser?Val?Ile?Asp Cys?Phe?Ile?Phe?Gly Asn?Phe?Tyr

2240 2245 2250

ttg?aat ggg?att?tgc?tga?att?aat gac?tat?tga?att?taa?aac?taa 7000

Leu?Asn Gly?Ile?Cys Ile?Asn Asp?Tyr Ile Asn

2255 2260

tta tga?gtt?gac?aaa?taa?ata?aaa ggt?agt?gtt?tat?gtc tga?gct 7045

Leu Val?Asp?Lys Ile?Lys Gly?Ser?Val?Tyr?Val Ala

2265 2270 2275

tat?tgt?gtt?tga?gct aac?acc?agg?tta?ctc agt?aac?cat?gac?ctg 7090

Tyr?Cys?Val Ala Asn?Thr?Arg?Leu?Leu Ser?Asn?His?Asp?Leu

2280 2285 2290

ctc?ctc?cat?ttc?cat tta?ttc?tca?aca?tta aat?agt?ttt?atc?ttg 7135

Leu?Leu?His?Phe?His Leu?Phe?Ser?Thr?Leu Asn?Ser?Phe?Ile?Leu

2295 2300 2305

ttg?ttg?cca?gaa?atg cac?ttg?tgc?cag?gta ttg?tcc?ctg?ctg?tat 7180

Leu?Leu?Pro?Glu?Met His?Leu?Cys?Gln?Val Leu?Ser?Leu?Leu?Tyr

2310 2315 2320

gaa?aag?ctt?ctt?ggc aat?gaa?ttc?tgt?aat agt?gcc?cta?cat?tat 7225

Glu?Lys?Leu?Leu?Gly Asn?Glu?Phe?Cys?Asn Ser?Ala?Leu?His?Tyr

2325 2330 2335

ggt?ttt?ctg?gtg?gaa ttg?ttt?taa?cag?tga?caa?ccc agg?att?tcc?aat 7273

Gly?Phe?Leu?Val?Glu Leu?Phe Gln Gln Pro Arg?Ile?Ser?Asn

2340 2345

ata ttt?ttg?ttt?tat?tgt tat?tac?caa?aaa?ttc cac?tat?gat?tga 7318

Ile Phe?Leu?Phe?Tyr?Cys Tyr?Tyr?Gln?Lys?Phe His?Tyr?Asp

2350 2355 2360

tgt?tca gtg?att?ttc?tat?agc aac?ttt?ttt?ggt?aac tct?ttg?ggt 7363

Cys?Ser Val?Ile?Phe?Tyr?Ser Asn?Phe?Phe?Gly?Asn Ser?Leu?Gly

2365 2370 2375

ttc?tga?ttt gtt?tta?gct?aaa?att ttg?ggg?ata?tga?ttt?ggg tct 7408

Phe Phe Val?Leu?Ala?Lys?Ile Leu?Gly?Ile Phe?Gly Ser

2380 2385 2390

ttg?att?aat?gtc agc?tga?act?tgg?att?tct agt?tca?tga?aga?aat 7453

Leu?Ile?Asn?Val Ser Thr?Trp?Ile?Ser Ser?Ser Arg?Asn

2395 2400

ctc tcc?caa?tac?cca?ttt atc?cta?ttt?tta?gca?ata?att?cgt?taa 7498

Leu Ser?Gln?Tyr?Pro?Phe Ile?Leu?Phe?Leu?Ala Ile?Ile?Arg

2405 2410 2415

tga?ttc?cac ttg?att?ttc?aga?ata ttg?tcc?tgg?ttg?att ttg?att 7543

Phe?His Leu?Ile?Phe?Arg?Ile Leu?Ser?Trp?Leu?Ile Leu?Ile

2420 2425 2430

tga?cag?cat?aca tta?tga?aat?ttg?aaa?gta ggt?tac?cat?ttt?gag 7588

Gln?His?Thr Leu Asn?Leu?Lys?Val Gly?Tyr?His?Phe?Glu

2435 2440 2445

gca?gtt?gga?tat?aaa tta?tgt?aaa?tat?gta tga?tta?tga?ttt?tta?taa 7636

Ala?Val?Gly?Tyr?Lys Leu?Cys?Lys?Tyr?Val Leu Phe?Leu

2450 2455

atg?gca taa?cat?gag?tgt?act?aac tac?ctt?cta?tgc?tgg cca?tgc 7681

Met?Ala His?Glu?Cys?Thr?Asn Tyr?Leu?Leu?Cys?Trp Pro?Cys

2460 2465 2470

tac?aga?ttt tct?gga?ggt?atg?aca ata?gta?ttt?ttt?tat gct?cag 7726

Tyr?Arg?Phe Ser?Gly?Gly?Met?Thr Ile?Val?Phe?Phe?Tyr Ala?Gln

2475 2480 2485

att?aaa?aat cag?ctt?ttc?acc?tct cca?gtt?ttt?cca?agt gat?act 7771

Ile?Lys?Asn Gln?Leu?Phe?Thr?Ser Pro?Val?Phe?Pro?Ser Asp?Thr

2490 2495 2500

ccc?agt?tct aga?gca?atc?tac?agc tgt?tta?tgt?gag?gtg ccc?aac 7816

Pro?Ser?Ser Arg?Ala?Ile?Tyr?Ser Cys?Leu?Cys?Glu?Val Pro?Asn

2505 2510 2515

acc?cat?tca?tct?caa?gtg?ctt?cag?tct?ttg?gtt?tat?ttc?atg?cac 7861

Thr?His?Ser?Ser?Gln?Val?Leu?Gln?Ser?Leu?Val?Tyr?Phe?Met?His

2520 2525 2530

tgt?gcc?ttc?aaa?atg?aaa?ttt?tta?aaa?ggg?act?tta?aat gaa?gtt 7906

Cys?Ala?Phe?Lys?Met?Lys?Phe?Leu?Lys?Gly?Thr?Leu?Asn Glu?Val

2535 2540 2545

gaa?tag?tag?ttt?tta?aaa?gtc?aat?ttg?taa?ttt?atg?tga?aat?cta?act 7954

Glu Phe?Leu?Lys?Val?Asn?Leu Phe?Met Asn?Leu?Thr

2550 2555

gta atg?agg?tcc?ttt?ctg ttt?ttt?ata?tgt?aaa cag?atc?tac?taa 7999

Val Met?Arg?Ser?Phe?Leu Phe?Phe?Ile?Cys?Lys Gln?Ile?Tyr

2560 2565 2570

tcc?tgt ata?aaa?gtt?att?tta cga?tg?8025

Ser?Cys Ile?Lys?Val?Ile?Leu?Arg

2575 2580

SEQUENCE?LISTING5

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_144782

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2558

<212>DNA

<213>Homo?sapiens

<220>

<221>STS

<222>(80)..(312)

<220>

<221>transit_peptide

<222>(296)..(328)

<220>

<221>misc_feature

<222>(1139)..(1140)

<220>

<221>STS

<222>(1688)..(2398)

<220>

<221>STS

<222>(1921)..(2176)

<220>

<221>STS

<222>(2156)..(2430)

<220>

<221>STS

<222>(2348)..(2493)

<220>

<221>polyA_signal

<222>(2509)..(2514)

<220>

<221>polyA_site

<222>(2533)..(2533)

<400>1

atcgatgccc?cgcccccgcc?ccacagccaa?cctcccgggc?accgttgccc?gcccggggcc 60

cgctaccggc?ccaggccccg?cctcgcgagt?cctcctcccc?gggtgcctgc?ccgcagcccg 120

ctcggcccag?agggtgggcg?cggggctgcc?tctaccggct?ggcggctgta?actcagcgac 180

cttggcccga?aggctctagc?aaggacccac?cgaccccagc?cgcggcggcg?gcggcgcgga 240

ctttgcccgg?tgtgtggggc?ggagcggact?gcgtgtccgc?ggacgggcag?cgaagatgtt 300

agccttcgct?gccaggaccg?tggtgaagcc?tctgggcttc?ctgaagccct?tctccttgat 360

gaaggcttcc?agccgcttca?aggcacacca?ggatgcactg?ccacggctgc?ccgtgccccc 420

tctccagcag?tccctggacc?actacctgaa?ggcgctgcag?cccatcgtga?gtgaggagga 480

gtgggcccac?accaagcagc?tggtggatga?gtttcaggcc?tcaggaggtg?taggggagcg 540

cctgcagaag?gggctggagc?gtcgggccag?gaagacggag?aactggctgt?ctgagtggtg 600

gctcaagacc?gcctacctcc?agtaccgcca?gcctgtggtc?atctactcga?gcccaggcgt 660

gatgctaccc?aagcaggact?tcgtggacct?gcagggtcag?ctccgatttg?ctgccaaact 720

cattgagggt?gtgttggatt?tcaaggtcat?gattgacaac?gagaccctgc?ccgtggagta 780

cctggggggg?aagccactgt?gcatgaacca?gtactatcag?atcttgtcct?cctgccgagt 840

gccgggcccc?aagcaggaca?cagtcagcaa?cttcagcaag?accaagaagc?ctcccacgca 900

catcaccgtg?gtacacaact?accagttttt?tgagctggat?gtgtaccaca?gtgacgggac 960

acccctcact?gcggatcaga?tctttgtgca?gctggagaag?atctggaact?catccctaca 1020

gaccaacaag?gagcctgtgg?gcatcctcac?ctccaaccac?cgcaactcct?gggccaaggc 1080

atacaacacc?ctcatcaaag?acaaggtgaa?ccgggattcc?gtgcgctcca?tccagaagaa 1140

acccgagctt?gtgcggtctc?ccatggtgcc?cctgcccatg?cccaagaagc?tgcggttcaa 1200

catcaccccc?gagatcaaga?gcgacatcga?gaaggccaag?cagaacctca?gcatcatgat 1260

ccaggacctg?gatatcaccg?tgatggtgtt?ccaccatttt?ggaaaagact?tccccaagtc 1320

ggagaagcta?agcccagatg?ccttcatcca?gatggctttg?cagctggcct?actacaggat 1380

ctacggacag?gcatgtgcca?cctatgaaag?tgcctccctg?cgcatgtttc?acctgggccg 1440

caccgacacc?atccgctcgg?cttccatgga?ctcactcacc?tttgtcaagg?ccatggatga 1500

ctccagcgtc?acggagcacc?agaaggtgga?gctgctgcgg?aaggccgtgc?aggcccaccg 1560

aggctacacc?gaccgggcca?tccgcgggga?ggcctttgat?cgacacctgc?tgggcctgaa 1620

gctgcaggcc?atcgaggacc?tggtgagcat?gcccgacatc?ttcatggaca?cctcctacgc 1680

catcgccatg?cacttccacc?tctccaccag?ccaggtccct?gccaagacag?actgtgtcat 1740

gttcttcggg?cccgtggtcc?ccgacggcta?cggtgtctgc?tataacccca?tggaggccca 1800

catcaacttc?tccctgtcgg?cctacaacag?ctgcgcggag?accaacgccg?cccgcctggc 1860

gcattacctg?gagaaggcgc?tcctggacat?gcgtgccctg?ctgcagagcc?acccccgggc 1920

caagctctga?gcccctagga?ctcaggcctg?ccaatgccac?agccaagccc?accctgggat 1980

gggccaccca?ccagggctca?gctccttggt?tccctcttcc?ttggttccct?cttccctggt 2040

ccccccaaat?ctactgagcc?acggaccgca?tcctccaggg?ggcctgcagg?ccccagccaa 2100

gtgccttccg?tgggtcatcc?cagcacctgc?cagggcccga?cctggggctg?agtgcagagg 2160

ctgagcagga?cgttaggccc?gggcccctgg?cacgtcctcc?accggtgcct?cctctgggga 2220

agggaaccag?ccctccagag?caggagactg?gcaagagctc?tttgtctcac?cagctcagcc 2280

ccggccactc?cctgccaact?ccatgaccag?gccaccatct?gtaccctgct?tcccaaactc 2340

ccaggacctg?gagacaggat?tgtctggggc?cgaggggcca?gggtgtgagg?tttcacctcc 2400

gttgcggctg?tgctcctgtg?gataacattg?ctagcgagcc?gcctctggtt?ccactcagct 2460

tggttcctgc?ccccgccctg?ctgtatgata?ttaatgtgga?aggtcatcaa?taaaggggaa 2520

ttgtgttggt?gaaaaaaaaa?aaaaaaaaaa?aaaaaaaa 2558

SEQUENCE?LISTING6

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_001896

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1674

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(246)

<220>

<221>exon

<222>(247)..(358)

<220>

<221>exon

<222>(359)..(460)

<220>

<221>exon

<222>(461)..(511)

<220>

<221>exon

<222>(512)..(571)

<220>

<221>exon

<222>(572)..(655)

<220>

<221>exon

<222>(656)..(766)

<220>

<221>exon

<222>(767)..(868)

<220>

<221>STS

<222>(783)..(987)

<220>

<221>exon

<222>(869)..(969)

<220>

<221>exon

<222>(970)..(1118)

<220>

<221>exon

<222>(1119)..(1212)

<220>

<221>exon

<222>(1213)..(1659)

<220>

<221>STS

<222>(1293)..(1569)

<220>

<221>STS

<222>(1376)..(1558)

<400>1

gcg?gcc?gcc?cgc?cgc?cgc?gct?cct?cct?cct?cct?cct?cca?gcg?ccc?ggc 48

Ala?Ala?Ala?Arg?Arg?Arg?Ala?Pro?Pro?Pro?Pro?Pro?Pro?Ala?Pro?Gly

1 5 10 15

ggc?ccg?ctg?cct?cct?ccg?ccc?gac?gcc?ccg?cgt?ccc?ccg?ccg?cgc?cgc 96

Gly?Pro?Leu?Pro?Pro?Pro?Pro?Asp?Ala?Pro?Arg?Pro?Pro?Pro?Arg?Arg

20 25 30

cgc?cgc?cac?cct?ctg?cgc?ccc?gcg?ccg?ccc?ccc?ggt?ccc?gcc?cgc?cat 144

Arg?Arg?His?Pro?Leu?Arg?Pro?Ala?Pro?Pro?Pro?Gly?Pro?Ala?Arg?His

35 40 45

gcc?cgg?ccc?ggc?cgc?ggg?cag?cag?ggc?ccg?ggt?cta?cgc?cga?ggt?gaa 192

Ala?Arg?Pro?Gly?Arg?Gly?Gln?Gln?Gly?Pro?Gly?Leu?Arg?Arg?Gly?Glu

50 55 60

cag?tct?gag?gag?ccg?cga?gta?ctg?gga?cta?cga?ggc?tca?cgt?ccc?gag 240

Gln?Ser?Glu?Glu?Pro?Arg?Val?Leu?Gly?Leu?Arg?Gly?Ser?Arg?Pro?Glu

65 70 75 80

ctg?ggg?taa?tca?aga?tga?tta?cca?act?ggt?tcg?aaa?act?tgg?tcg?ggg 288

Leu?Gly Ser?Arg Leu?Pro?Thr?Gly?Ser?Lys?Thr?Trp?Ser?Gly

85 90

aaa?ata?tag?tga?agt?att?tga?ggc?cat?taa?tat?cac?caa?caa?tga?gag 336

Lys?Ile Ser?Ile Gly?His Tyr?His?Gln?Gln Glu

95 100 105

agt?ggt?tgt?aaa?aat?cct?gaa?g?cc agt?gaa?gaa?aaa?gaa?gat?aaa?acg 384

Ser?Gly?Cys?Lys?Asn?Pro?Glu Ala?Ser?Glu?Glu?Lys?Glu?Asp?Lys?Thr

110 115 120

aga?ggt?taa?gat?tct?gga?gaa?cct?tcg?tgg?tgg?aac?aaa?tat?cat?taa 432

Arg?Gly Asp?Ser?Gly?Glu?Pro?Ser?Trp?Trp?Asn?Lys?Tyr?His

125 130 135

gct?gat?tga?cac?tgt?aaa?gga?ccc?cgt?g?tc?aaa gac?acc?agc?ttt?ggt 480

Ala?Asp His?Cys?Lys?Gly?Pro?Arg Val?Lys?Asp?Thr?Ser?Phe?Gly

140 145 150

att?tga?ata?tat?caa?taa?tac?aga?ttt?taa?g?ca act?cta?cca?gat?cct 528

Ile Ile?Tyr?Gln Tyr?Arg?Phe Ala?Thr?Leu?Pro?Asp?Pro

155 160

gac?aga?ctt?tga?tat?ccg?gtt?tta?tat?gta?tga?act?act?taa?a?gc tct 576

Asp?Arg?Leu Tyr?Pro?Val?Leu?Tyr?Val Thr?Thr Ser?Ser

165 170

gga?tta?ctg?cca?cag?caa?ggg?aat?cat?gca?cag?gga?tgt?gaa?acc?tca 624

Gly?Leu?Leu?Pro?Gln?Gln?Gly?Asn?His?Ala?Gln?Gly?Cys?Glu?Thr?Ser

180 185 190

caa?tgt?cat?gat?aga?tca?cca?aca?gaa?aaa?g?ct gcg?act?gat?aga?ttg 672

Gln?Cys?His?Asp?Arg?Ser?Pro?Thr?Glu?Lys Ala?Ala?Thr?Asp?Arg?Leu

195 200 205

ggg?tct?ggc?aga?att?cta?tca?tcc?tgc?tca?gga?gta?caa?tgt?tcg?tgt 720

Gly?Ser?Gly?Arg?Ile?Leu?Ser?Ser?Cys?Ser?Gly?Val?Gln?Cys?Ser?Cys

210 215 220

agc?ctc?aag?gta?ctt?caa?ggg?acc?aga?gct?cct?cgt?gga?cta?tca?g?at 768

Ser?Leu?Lys?Val?Leu?Gln?Gly?Thr?Arg?Ala?Pro?Arg?Gly?Leu?Ser Asp

225 230 235

gta?tga?tta?tag?ctt?gga?cat?gtg?gag?ttt?ggg?ctg?tat?gtt?agc?aag 816

Val Leu Leu?Gly?His?Val?Glu?Phe?Gly?Leu?Tyr?Val?Ser?Lys

245 250

cat?gat?ctt?tcg?aag?gga?acc?att?ctt?cca?tgg?aca?gga?caa?cta?tga 864

His?Asp?Leu?Ser?Lys?Gly?Thr?Ile?Leu?Pro?Trp?Thr?Gly?Gln?Leu

255 260 265

cca?g?ct tgt?tcg?cat?tgc?caa?ggt?tct?ggg?tac?aga?aga?act?gta?tgg 912

Pro Ala?Cys?Ser?His?Cys?Gln?Gly?Ser?Gly?Tyr?Arg?Arg?Thr?Val?Trp

270 275 280 285

gta?tct?gaa?gaa?gta?tca?cat?aga?cct?aga?tcc?aca?ctt?caa?cga?tat 960

Val?Ser?Glu?Glu?Val?Ser?His?Arg?Pro?Arg?Ser?Thr?Leu?Gln?Arg?Tyr

290 295 300

cct?ggg?aca?aca?ttc?acg?gaa?acg?ctg?gga?aaa?ctt?tat?cca?tag?tga 1008

Pro?Gly?Thr?Thr?Phe?Thr?Glu?Thr?Leu?Gly?Lys?Leu?Tyr?Pro

305 310 315

gaa?cag?aca?cct?tgt?cag?ccc?tga?ggc?cct?aga?tct?tct?gga?caa?act 1056

Glu?Gln?Thr?Pro?Cys?Gln?Pro Gly?Pro?Arg?Ser?Ser?Gly?Gln?Thr

320 325 330

tct?gcg?ata?cga?cca?tca?aca?gag?act?gac?tgc?caa?aga?ggc?cat?gga 1104

Ser?Ala?Ile?Arg?Pro?Ser?Thr?Glu?Thr?Asp?Cys?Gln?Arg?Gly?His?Gly

335 340 345

gca?ccc?ata?ctt?ct?a ccc?tgt?ggt?gaa?gga?gca?gtc?cca?gcc?ttg?tgc 1152

Ala?Pro?Ile?Leu?Leu Pro?Cys?Gly?Glu?Gly?Ala?Val?Pro?Ala?Leu?Cys

350 355 360

aga?caa?tgc?tgt?gct?ttc?cag?tgg?tct?cac?ggc?agc?acg?atg?aag?act 1200

Arg?Gln?Cys?Cys?Ala?Phe?Gln?Trp?Ser?His?Gly?Ser?Thr?Met?Lys?Thr

365 370 375

gga?aag?cga?cgg?gtc?tgt?tgc?ggt?tct?ccc?act?ttt?cca?taa?gca?gaa 1248

Gly?Lys?Arg?Arg?Val?Cys?Cys?Gly?Ser?Pro?Thr?Phe?Pro Ala?Glu

380 385 390

caa?gaa?cca?aat?caa?acg?tct?taa?cgc?gta?tag?aga?gat?cac?gtt?ccg 1296

Glu?Glu?Pro?Asn?Gln?Thr?Ser Arg?Val Arg?Asp?His?Val?Pro

395 400 405

tga?gca?gac?aca?aaa?cgg?tgg?cag?gtt?tgg?cga?gca?cga?act?aga?cca 1344

Ala?Asp?Thr?Lys?Arg?Trp?Gln?Val?Trp?Arg?Ala?Arg?Thr?Arg?Pro

410 415 420

agc?gaa?ggg?cag?ccc?acc?acc?gta?tat?caa?acc?tca?ctt?ccg?aat?gta 1392

Ser?Glu?Gly?Gln?Pro?Thr?Thr?Val?Tyr?Gln?Thr?Ser?Leu?Pro?Asn?Val

425 430 435

aaa?ggc?tca?ctt?gcc?ttt?ggc?ttc?ctg?ttg?act?tct?tcc?cga?ccc?aga 1440

Lys?Gly?Ser?Leu?Ala?Phe?Gly?Phe?Leu?Leu?Thr?Ser?Ser?Arg?Pro?Arg

440 445 450

aag?cat?ggg?gaa?tgt?gaa?ggg?tat?gca?gaa?tgt?tgt?tgg?tta?ctg?ttg 1488

Lys?His?Gly?Glu?Cys?Glu?Gly?Tyr?Ala?Glu?Cys?Cys?Trp?Leu?Leu?Leu

455 460 465 470

ctc?ccc?gag?ccc?ctc?aac?tcg?tcc?cgt?ggc?cgc?ctg?ttt?ttc?cag?caa 1536

Leu?Pro?Glu?Pro?Leu?Asn?Ser?Ser?Arg?Gly?Arg?Leu?Phe?Phe?Gln?Gln

475 480 485

acc?acg?cta?act?agc?tga?cca?cag?act?cca?cag?tgg?ggg?gac?ggg?cgc 1584

Thr?Thr?Leu?Thr?Ser Pro?Gln?Thr?Pro?Gln?Trp?Gly?Asp?Gly?Arg

490 495 500

agt?atg?tgg?cat?ggc?ggc?agt?tac?ata?tta?tta?ttt?taa?aag?tat?ata 1632

Ser?Met?Trp?His?Gly?Gly?Ser?Tyr?Ile?Leu?Leu?Phe Lys?Tyr?Ile

505 510 515

tta?ttg?aat?aaa?agg?ttt?taa?aag?aaa?aaaaaaaaaaa?aaaaa 1674

Leu?Leu?Asn?Lys?Arg?Phe Lys?Lys

520

SEQUENCE?LISTING7

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_003462

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2663

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(157)

<220>

<221>exon

<222>(158)..(303)

<220>

<221>exon

<222>(304)..(473)

<220>

<221>exon

<222>(474)..(652)

<220>

<221>exon

<222>(653)..(817)

<220>

<221>STS

<222>(653)..(817)

<220>

<221>exon

<222>(818)..(2649)

<220>

<221>STS

<222>(1639)..(1769)

<220>

<221>STS

<222>(2489)..(2621)

<220>

<221>polyA_signal

<222>(2628)..(2633)

<220>

<221>polyA_site

<222>(2649)..(2649)

<400>1

ggc?ggt?ttc?cat?ggt?gac?ggc?aaa?caa?ggc?cca?cac?tgg?aca?ggg?cag 48

Gly?Gly?Phe?His?Gly?Asp?Gly?Lys?Gln?Gly?Pro?His?Trp?Thr?Gly?Gln

1 5 10 15

ctg?ctg?ggt?tgc?tac?tct?cgc?ctc?cgc?cat?gat?tcc?gcc?cgc?aga?ctc 96

Leu?Leu?Gly?Cys?Tyr?Ser?Arg?Leu?Arg?His?Asp?Ser?Ala?Arg?Arg?Leu

20 25 30

ttt?gct?caa?gta?cga?cac?ccc?agt?gct?ggt?gag?ccg?gaa?cac?gga?gaa 144

Phe?Ala?Gln?Val?Arg?His?Pro?Ser?Ala?Gly?Glu?Pro?Glu?His?Gly?Glu

35 40 45

acg?gag?ccc?caa?g?gc tcg?gct?act?gaa?agt?cag?ccc?cca?gca?gcc?tgg 192

Thr?Glu?Pro?Gln Gly?Ser?Ala?Thr?Glu?Ser?Gln?Pro?Pro?Ala?Ala?Trp

50 55 60

acc?ttc?agg?ttc?agc?ccc?aca?gcc?acc?caa?gac?caa?gct?ccc?ctc?aac 240

Thr?Phe?Arg?Phe?Ser?Pro?Thr?Ala?Thr?Gln?Asp?Gln?Ala?Pro?Leu?Asn

65 70 75 80

tcc?ctg?tgt?ccc?aga?tcc?tac?aaa?gca?ggc?aga?aga?aat?ctt?gaa?tgc 288

Ser?Leu?Cys?Pro?Arg?Ser?Tyr?Lys?Ala?Gly?Arg?Arg?Asn?Leu?Glu?Cys

85 90 95

cat?act?acc?ccc?aag?gga?gtg?ggt?gga?aga?cac?gca?gct?atg?gat?cca 336

His?Thr?Thr?Pro?Lys?Gly?Val?Gly?Gly?Arg?His?Ala?Ala?Met?Asp?Pro

100 105 110

gca?ggt?gtc?cag?cac?ccc?tag?cac?cag?gat?gga?cgt?ggt?gca?cct?cca 384

Ala?Gly?Val?Gln?His?Pro His?Gln?Asp?Gly?Arg?Gly?Ala?Pro?Pro

115 120 125

gga?gca?gtt?aga?ctt?aaa?gct?gca?gca?gcg?gca?ggc?cag?gga?aac?agg 432

Gly?Ala?Val?Arg?Leu?Lys?Ala?Ala?Ala?Ala?Ala?Gly?Gln?Gly?Asn?Arg

130 135 140

cat?ctg?ccc?tgt?ccg?cag?gga?act?cta?ctc?aca?gtg?ttt?tg a?tga?gtt 480

His?Leu?Pro?Cys?Pro?Gln?Gly?Thr?Leu?Leu?Thr?Val?Phe Val

145 150 155

gat?ccg?gga?ggt?cac?cat?caa?ctg?tgc?gga?gag?ggg?gct?gct?gct?gct 528

Asp?Pro?Gly?Gly?His?His?Gln?Leu?Cys?Gly?Glu?Gly?Ala?Ala?Ala?Ala

160 165 170

gcg?agt?ccg?gga?cga?gat?ccg?cat?gac?cat?cgc?tgc?cta?cca?gac?cct 576

Ala?Ser?Pro?Gly?Arg?Asp?Pro?His?Asp?His?Arg?Cys?Leu?Pro?Asp?Pro

175 180 185 190

gta?cga?gag?cag?cgt?ggc?gtt?tgg?cat?gag?gaa?ggc?act?gca?ggc?tga 624

Val?Arg?Glu?Gln?Arg?Gly?Val?Trp?His?Glu?Glu?Gly?Thr?Ala?Gly

195 200 205

gca?ggg?gaa?gtc?aga?cat?gga?gag?gaa?a?at cgc?aga?att?gga?gac?gga 672

Ala?Gly?Glu?Val?Arg?His?Gly?Glu?Glu Asn?Arg?Arg?Ile?Gly?Asp?Gly

210 220

aaa?gag?aga?cct?gga?gag?gca?agt?gaa?cga?gca?gaa?ggc?aaa?atg?tga 720

Lys?Glu?Arg?Pro?Gly?Glu?Ala?Ser?Glu?Arg?Ala?Glu?Gly?Lys?Met

225 230 235

agc?cac?tga?gaa?gcg?gga?gag?cga?gag?gcg?gca?ggt?gga?gga?gaa?gaa 768

Ser?His Glu?Ala?Gly?Glu?Arg?Glu?Ala?Ala?Gly?Gly?Gly?Glu?Glu

240 245 250

gca?caa?tga?gga?gat?tca?gtt?cct?gaa?gcg?aac?aaa?tca?gca?gct?gaa?g 817

Ala?Gln Gly?Asp?Ser?Val?Pro?Glu?Ala?Asn?Lys?Ser?Ala?Ala?Glu

255 260 265

gc cca?act?gga?agg?cat?tat?tgc?acc?aaa?gaa?gtg?ata?att?tcc?aca 864

Gly?Pro?Thr?Gly?Arg?His?Tyr?Cys?Thr?Lys?Glu?Val?Ile?Ile?Ser?Thr

270 275 280

tga?tta?att?tcc?aac?aag?aca?ctt?ggg?agt?tat?tta?ctg?tgt?tcc?tct 912

Leu?Ile?Ser?Asn?Lys?Thr?Leu?Gly?Ser?Tyr?Leu?Leu?Cys?Ser?Ser

285 290 295

ggc?agc?caa?taa?aat?cat?cat?aag?ccc?ttt?gta?ata?aaa?agc?tag?ttt 960

Gly?Ser?Gln Asn?His?His?Lys?Pro?Phe?Val?Ile?Lys?Ser Phe

300 305 310

cct?gag?tga?aca?agc?cat?aac?ctc?ccc?taa?aca?cca?cct?agg?tat?ttg 1008

Pro?Glu Thr?Ser?His?Asn?Leu?Pro Thr?Pro?Pro?Arg?Tyr?Leu

315 320 325

tta?gaa?gtc?aca?cta?tta?ctc?caa?tgt?cat?cag?aca?cct?aag?gtc?tgc 1056

Leu?Glu?Val?Thr?Leu?Leu?Leu?Gln?Cys?His?Gln?Thr?Pro?Lys?Val?Cys

330 335 340

cag?cca?ggc?tcc?tgg?ctg?ggc?aat?gga?aga?tgg?tgt?ggc?cct?gtt?agt 1104

Gln?Pro?Gly?Ser?Trp?Leu?Gly?Asn?Gly?Arg?Trp?Cys?Gly?Pro?Val?Ser

345 350 355

ctc?cgt?gtg?tgg?ctt?act?agc?cag?cct?tgg?gaa?ctg?cca?act?caa?att 1152

Leu?Arg?Val?Trp?Leu?Thr?Ser?Gln?Pro?Trp?Glu?Leu?Pro?Thr?Gln?Ile

360 365 370

cta?aga?aag?cca?ctg?ctt?tct?cat?cat?cac?tct?ata?cca?ata?ctt?att 1200

Leu?Arg?Lys?Pro?Leu?Leu?Ser?His?His?His?Ser?Ile?Pro?Ile?Leu?Ile

375 380 385

tct?ggc?caa?atg?aat?ctg?ctt?ctc?tgc?ccc?tca?aac?ttt?tag?ttc?aca 1248

Ser?Gly?Gln?Met?Asn?Leu?Leu?Leu?Cys?Pro?Ser?Asn?Phe Phe?Thr

390 395 400

att?cat?ctt?cta?cct?taa?ctt?ggg?ctt?ctt?ggg?cct?ctg?gcc?ttc?ctt 1296

Ile?His?Leu?Leu?Pro Leu?Gly?Leu?Leu?Gly?Pro?Leu?Ala?Phe?Leu

405 410 415

act?taa?tgt?ctt?ctt?ttc?cct?act?cta?atg?cat?ttc?taa?ctc?act?ttg 1344

Thr Cys?Leu?Leu?Phe?Pro?Thr?Leu?Met?His?Phe Leu?Thr?Leu

420 425 430

gag?ctt?tgg?ttt?tct?aat?gta?tta?tcc?cca?ctt?gcc?agt?caa?ctg?gac 1392

Glu?Leu?Trp?Phe?Ser?Asn?Val?Leu?Ser?Pro?Leu?Ala?Ser?Gln?Leu?Asp

435 440 445

ccc?ttc?ctc?ctc?ggt?ttc?aga?ctg?cct?aca?tta?gga?aac?aat?ggc?agt 1440

Pro?Phe?Leu?Leu?Gly?Phe?Arg?Leu?Pro?Thr?Leu?Gly?Asn?Asn?Gly?Ser

450 455 460 465

caa?acc?cat?ggc?ttt?gga?gaa?agt?aaa?tgt?ttg?cca?gaa?agg?aat?act 1488

Gln?Thr?His?Gly?Phe?Gly?Glu?Ser?Lys?Cys?Leu?Pro?Glu?Arg?Asn?Thr

470 475 480

agt?cac?agt?ggc?ctt?tgt?gag?ttg?tct?gca?act?cag?ctc?ttc?ccc?cag 1536

Ser?His?Ser?Gly?Leu?Cys?Glu?Leu?Ser?Ala?Thr?Gln?Leu?Phe?Pro?Gln

485 490 495

cac?aga?tct?gtt?ccc?ctt?atc?ctg?cag?aaa?atc?aag?ccc?tga?ctc?tgc 1584

His?Arg?Ser?Val?Pro?Leu?Ile?Leu?Gln?Lys?Ile?Lys?Pro Leu?Cys

500 505 5l0

act?ccc?cga?agt?agt?gat?gtt?aat?taa?caa?ctg?aag?agg?taa?cta?aat 1632

Thr?Pro?Arg?Ser?Ser?Asp?Val?Asn Gln?Leu?Lys?Arg Leu?Asn

515 520 525

ctc?aca?tgc?agg?tct?aat?gac?taa?taa?ttg?gag?tac?ggc?tgc?tag?aca 1680

Leu?Thr?Cys?Arg?Ser?Asn?Asp Leu?Glu?Tyr?Gly?Cys Thr

530 535

act?gca?ttt?tag?tat?ttc?tct?tcc?att?ctc?ctg?gtt?ttg?tag?acc?cag 1728

Thr?Ala?Phe Tyr?Phe?Ser?Ser?Ile?Leu?Leu?Val?Leu Thr?Gln

540 545 550

aag?att?gaa?tga?gtg?aca?taa?atc?ttt?agt?tcg?ggg?caa?gcc?agg?gtg 1776

Lys?Ile?Glu Val?Thr Ile?Phe?Ser?Ser?Gly?Gln?Ala?Arg?Val

555 560 565

ggc?tag?ggt?ggt?aag?ctg?gag?gac?ttc?atc?ctt?cag?tta?ggc?tgc?aca 1824

Gly Gly?Gly?Lys?Leu?Glu?Asp?Phe?Ile?Leu?Gln?Leu?Gly?Cys?Thr

570 575 580

agt?aac?att?acc?taa?aag?gca?cta?aca?tgc?tca?ggt?tcc?cca?gaa?aga 1872

Ser?Asn?Ile?Thr Lys?Ala?Leu?Thr?Cys?Ser?Gly?Ser?Pro?Glu?Arg

585 590 595

ggc?gta?aga?agg?gcc?tct?cct?tag?cag?agc?ttc?cac?ctg?cca?tcc?gtc 1920

Gly?Val?Arg?Arg?Ala?Ser?Pro Gln?Ser?Phe?His?Leu?Pro?Ser?Val

600 605 610

ttg?ggt?tca?gtg?agc?ttc?aag?gct?cac?aat?gga?agc?act?gtc?att?tcc 1968

Leu?Gly?Ser?Val?Ser?Phe?Lys?Ala?His?Asn?Gly?Ser?Thr?Val?Ile?Ser

615 620 625

cca?gaa?aag?ctg?tgt?tcc?cta?tgc?tga?aca?cac?cat?aca?cat?tct?cat 2016

Pro?Glu?Lys?Leu?Cys?Ser?Leu?Cys Thr?His?His?Thr?His?Ser?His

630 635 640

ctg?gaa?tct?aag?gag?cag?ctt?tta?ccc?tga?tcc?agt?atc?ctg?agg?aat 2064

Leu?Glu?Ser?Lys?Glu?Gln?Leu?Leu?Pro Ser?Ser?Ile?Leu?Arg?Asn

645 650 655

ttt?aag?cct?cca?ctc?aaa?tga?cct?gcc?tgt?gtt?gtc?att?tcc?atg?gga 2112

Phe?Lys?Pro?Pro?Leu?Lys Pro?Ala?Cys?Val?Val?Ile?Ser?Met?Gly

660 665 670

aag?aac?tct?ttc?cac?gag?atc?tgc?tag?ttc?cag?gcc?tct?aag?aca?gga 2160

Lys?Asn?Ser?Phe?His?Glu?Ile?Cys Phe?Gln?Ala?Ser?Lys?Thr?Gly

675 680 685

acg?tat?gtg?cca?taa?gtg?ggt?cta?ctt?cac?aga?ctc?aat?gag?gca?gaa 2208

Thr?Tyr?Val?Pro Val?Gly?Leu?Leu?His?Arg?Leu?Asn?Glu?Ala?Glu

690 695 700

att?att?gta?gtt?ttc?tcc?tat?ttc?ttc?tgc?acc?caa?ctt?tct?cct?tgt 2256

Ile?Ile?Val?Val?Phe?Ser?Tyr?Phe?Phe?Cys?Thr?Gln?Leu?Ser?Pro?Cys

705 710 715

att?tca?aag?gcc?agg?cca?tgt?aca?cta?acg?tcc?ttg?aaa?ttt?gca?gtt 2304

Ile?Ser?Lys?Ala?Arg?Pro?Cys?Thr?Leu?Thr?Ser?Leu?Lys?Phe?Ala?Val

720 725 730 735

ctg?tat?gct?tct?att?cca?aat?cat?tca?tta?cca?ata?aaa?acg?aaa?tac 2352

Leu?Tyr?Ala?Ser?Ile?Pro?Asn?His?Ser?Leu?Pro?Ile?Lys?Thr?Lys?Tyr

740 745 750

cac?cct?ttc?cat?ttt?ata?gac?ctc?atc?ccc?tat?ttc?tgt?cag?aca?gtt 2400

His?Pro?Phe?His?Phe?Ile?Asp?Leu?Ile?Pro?Tyr?Phe?Cys?Gln?Thr?Val

755 760 765

ata?tga?cag?ggt?gac?tgt?gga?acc?tct?tag?ttc?atc?caa?agt?cta?cct 2448

Ile Gln?Gly?Asp?Cys?Gly?Thr?Ser Phe?Ile?Gln?Ser?Leu?Pro

770 775 780

gaa?gtg?cta?gac?ttt?cag?act?ctt?atc?act?gaa?atc?ctt?aag?gtt?gag 2496

Glu?Val?Leu?Asp?Phe?Gln?Thr?Leu?Ile?Thr?Glu?Ile?Leu?Lys?Val?Glu

785 790 795

gag?gct?tta?ttt?ccc?tag?cac?tgg?tga?agg?gct?tca?act?gtc?aaa?cct 2544

Glu?Ala?Leu?Phe?Pro His?Trp Arg?Ala?Ser?Thr?Val?Lys?Pro

800 805 810

cag?aac?aaa?tgc?att?agg?gcc?tta?gaa?atg?tca?atg?ggg?cag?gaa?gaa 2592

Gln?Asn?Lys?Cys?Ile?Arg?Ala?Leu?Glu?Met?Ser?Met?Gly?Gln?Glu?Glu

815 820 825

aac?aca?att?tct?aac?tgc?ctg?ttt?ttg?tat?aat?tta?ata?aaa?acc?ttt 2640

Asn?Thr?Ile?Ser?Asn?Cys?Leu?Phe?Leu?Tyr?Asn?Leu?Ile?Lys?Thr?Phe

830 835 840

taa?aca?tta?aaaaaaaaaa?aaaa 2663

Thr?Leu

845

SEQUENCE?LISTING8

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_033214

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1899

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(1866)

<220>

<221>CDS

<222>(19)..(1680)

<220>

<221>STS

<222>(943)..(1214)

<220>

<221>STS

<222>(1362)..(1690)

<220>

<221>STS

<222>(1686)..(1872)

<400>1

agc?cga?cct?act?ggt?gtc?atg?gca?gcc?cca?aag?aca?gca?gct?gtg?ggg 48

Ser?Arg?Pro?Thr?Gly?Val?Met?Ala?Ala?Pro?Lys?Thr?Ala?Ala?Val?Gly

1 5 10 15

ccg?ttg?gtg?gga?gcg?gtg?gtc?cag?ggc?acc?aac?tcc?act?cgc?ttt?ctg 96

Pro?Leu?Val?Gly?Ala?Val?Val?Gln?Gly?Thr?Asn?Ser?Thr?Arg?Phe?Leu

20 25 30

gtt?ttc?aat?tca?aaa?aca?gcg?gaa?cta?ctt?agt?cat?cac?aaa?gtg?gaa 144

Val?Phe?Asn?Ser?Lys?Thr?Ala?Glu?Leu?Leu?Ser?His?His?Lys?Val?Glu

35 40 45

tta?aca?caa?gag?ttc?cca?aaa?gaa?gga?tgg?gtg?gaa?caa?gac?cct?aaa 192

Leu?Thr?Gln?Glu?Phe?Pro?Lys?Glu?Gly?Trp?Val?Glu?Gln?Asp?Pro?Lys

50 55 60

gaa?att?ctt?cag?tct?gtc?tac?gag?tgt?ata?gcg?aga?acg?tgt?gag?aaa 240

Glu?Ile?Leu?Gln?Ser?Val?Tyr?Glu?Cys?Ile?Ala?Arg?Thr?Cys?Glu?Lys

65 70 75 80

ctt?gac?gaa?ctg?aat?att?gat?ata?tcc?aac?ata?aaa?gct?gtt?ggt?gtc 288

Leu?Asp?Glu?Leu?Asn?Ile?Asp?Ile?Ser?Asn?Ile?Lys?Ala?Val?Gly?Val

85 90 95

agc?aat?cag?agg?gaa?acc?act?gta?atc?tgg?gac?aag?tta?aca?gga?gag 336

Ser?Asn?Gln?Arg?Glu?Thr?Thr?Val?Ile?Trp?Asp?Lys?Leu?Thr?Gly?Glu

100 105 110

cct?ctc?tac?aat?gct?gtg?gtg?tgg?ctt?gat?cta?aga?acc?cag?act?act 384

Pro?Leu?Tyr?Asn?Ala?Val?Val?Trp?Leu?Asp?Leu?Arg?Thr?Gln?Thr?Thr

115 120 125

gtt?gag?gat?ctt?agt?aaa?aaa?att?cca?gga?aat?agt?aac?ttc?gtc?aag 432

Val?Glu?Asp?Leu?Ser?Lys?Lys?Ile?Pro?Gly?Asn?Ser?Asn?Phe?Val?Lys

130 135 140

tct?aag?aca?ggc?ctt?cca?ctc?agc?act?tac?ttc?agt?gca?gta?aaa?ctt 480

Ser?Lys?Thr?Gly?Leu?Pro?Leu?Ser?Thr?Tyr?Phe?Ser?Ala?Val?Lys?Leu

145 150 155 160

cgt?tgg?atg?ctt?gac?aat?gtg?aga?aac?gtc?caa?aag?gct?gtt?gaa?gaa 528

Arg?Trp?Met?Leu?Asp?Asn?Val?Arg?Asn?Val?Gln?Lys?Ala?Val?Glu?Glu

165 170 175

ggt?aga?gct?ctt?ttt?ggt?acc?att?gat?tca?tgg?ctt?atc?tgg?agt?ttg 576

Gly?Arg?Ala?Leu?Phe?Gly?Thr?Ile?Asp?Ser?Trp?Leu?Ile?Trp?Ser?Leu

180 185 190

aca?gga?gga?gtt?aat?gga?ggc?gtg?cat?tgt?aca?gat?gta?aca?aat?gca 624

Thr?Gly?Gly?Val?Asn?Gly?Gly?Val?His?Cys?Thr?Asp?Val?Thr?Asn?Ala

195 200 205

agt?agg?aca?atg?ctt?ttt?aat?atc?cat?tct?ttg?gaa?tgg?gat?aaa?gag 672

Ser?Arg?Thr?Met?Leu?Phe?Asn?Ile?His?Ser?Leu?Glu?Trp?Asp?Lys?Glu

210 215 220

ctc?tgt?gac?ttt?ttt?gaa?att?cca?atg?gac?ctt?ctt?cca?aat?gtc?ttc 720

Leu?Cys?Asp?Phe?Phe?Glu?Ile?Pro?Met?Asp?Leu?Leu?Pro?Asn?Val?Phe

225 230 235 240

agt?tct?tct?gag?atc?tat?ggc?cta?att?aaa?act?gga?gcc?ctg?gaa?ggt 768

Ser?Ser?Ser?Glu?Ile?Tyr?Gly?Leu?Ile?Lys?Thr?Gly?Ala?Leu?Glu?Gly

245 250 255

gtg?cca?ata?tct?ggg?tgt?ttg?ggg?gac?caa?tgt?gct?gca?tta?gta?gga 816

Val?Pro?Ile?Ser?Gly?Cys?Leu?Gly?Asp?Gln?Cys?Ala?Ala?Leu?Val?Gly

260 265 270

caa?atg?tgc?ttc?cag?gag?gga?caa?gcc?aaa?aac?acc?tat?gga?aca?ggt 864

Gln?Met?Cys?Phe?Gln?Glu?Gly?Gln?Ala?Lys?Asn?Thr?Tyr?Gly?Thr?Gly

275 280 285

tgc?ttc?tta?ctg?tgt?aat?acg?ggt?cgt?aaa?tgt?gtg?ttt?tct?gaa?cat 912

Cys?Phe?Leu?Leu?Cys?Asn?Thr?Gly?Arg?Lys?Cys?Val?Phe?Ser?Glu?His

290 295 300

ggc?ctt?ttg?acc?aca?gta?gct?tac?aaa?cta?ggc?aga?gag?aag?cca?gca 960

Gly?Leu?Leu?Thr?Thr?Val?Ala?Tyr?Lys?Leu?Gly?Arg?Glu?Lys?Pro?Ala

305 310 315 320

tat?tat?gca?ctg?gaa?ggt?tct?gtt?gct?ata?gca?ggt?gct?gtt?att?cgt 1008

Tyr?Tyr?Ala?Leu?Glu?Gly?Ser?Val?Ala?Ile?Ala?Gly?Ala?Val?Ile?Arg

325 330 335

tgg?cta?aga?gac?aat?ctt?gga?att?ata?gag?acc?tca?gga?gac?att?gaa 1056

Trp?Leu?Arg?Asp?Asn?Leu?Gly?Ile?Ile?Glu?Thr?Ser?Gly?Asp?Ile?Glu

340 345 350

aga?ctt?gct?aaa?gaa?gta?gga?act?tct?tat?ggc?tgt?tac?ttt?gtc?cca 1104

Arg?Leu?Ala?Lys?Glu?Val?Gly?Thr?Ser?Tyr?Gly?Cys?Tyr?Phe?Val?Pro

355 360 365

gcc?ttt?tca?ggg?tta?tat?gca?cct?tat?tgg?gag?ccc?agt?gca?aga?ggg 1152

Ala?Phe?Ser?Gly?Leu?Tyr?Ala?Pro?Tyr?Trp?Glu?Pro?Ser?Ala?Arg?Gly

370 375 380

ata?ctc?tgt?ggc?ctc?act?cag?ttt?acc?aat?aaa?tgt?cat?att?gct?ttt 1200

Ile?Leu?Cys?Gly?Leu?Thr?Gln?Phe?Thr?Asn?Lys?Cys?His?Ile?Ala?Phe

385 390 395 400

gct?gca?tta?gaa?gct?gtt?tgt?ttc?caa?acc?cga?gag?att?ttg?gaa?gcc 1248

Ala?Ala?Leu?Glu?Ala?Val?Cys?Phe?Gln?Thr?Arg?Glu?Ile?Leu?Glu?Ala

405 410 415

atg?aac?cgt?gac?tgt?gga?att?cca?ctt?cgt?cat?ttg?cag?gta?gat?gga 1296

Met?Asn?Arg?Asp?Cys?Gly?Ile?Pro?Leu?Arg?His?Leu?Gln?Val?Asp?Gly

420 425 430

gga?atg?acc?aac?aac?aaa?gtt?ctt?atg?cag?cta?caa?gca?gat?att?ctt 1344

Gly?Met?Thr?Asn?Asn?Lys?Val?Leu?Met?Gln?Leu?Gln?Ala?Asp?Ile?Leu

435 440 445

cat?att?cca?gta?ata?aaa?ccc?ttt?atg?cct?gaa?aca?act?gca?cta?gga 1392

His?Ile?Pro?Val?Ile?Lys?Pro?Phe?Met?Pro?Glu?Thr?Thr?Ala?Leu?Gly

450 455 460

gct?gcc?atg?gca?gca?ggg?gct?gca?gag?gga?gta?agc?gtt?tgg?agc?ctt 1440

Ala?Ala?Met?Ala?Ala?Gly?Ala?Ala?Glu?Gly?Val?Ser?Val?Trp?Ser?Leu

465 470 475 480

gaa?ccc?cag?gct?ttg?tca?gtt?ctc?agg?atg?gaa?cga?ttt?gaa?cca?cag 1488

Glu?Pro?Gln?Ala?Leu?Ser?Val?Leu?Arg?Met?Glu?Arg?Phe?Glu?Pro?Gln

485 490 495

atc?cag?gcc?aca?gaa?agt?gaa?att?cgt?tat?gcc?aca?tgg?aag?aaa?gcc 1536

Ile?Gln?Ala?Thr?Glu?Ser?Glu?Ile?Arg?Tyr?Ala?Thr?Trp?Lys?Lys?Ala

500 505 510

gta?atg?aag?tca?atg?ggt?tgg?gtt?acc?agt?cag?tct?cct?gaa?ggt?ggt 1584

Val?Met?Lys?Ser?Met?Gly?Trp?Val?Thr?Ser?Gln?Ser?Pro?Glu?Gly?Gly

515 520 525

gat?cct?tct?atc?ttc?tct?agt?ctg?cct?ttg?gga?ttt?ttt?ata?gtg?agt 1632

Asp?Pro?Ser?Ile?Phe?Ser?Ser?Leu?Pro?Leu?Gly?Phe?Phe?Ile?Val?Ser

530 535 540

agc?atg?gta?atg?cta?att?gga?gca?aga?tat?atc?tcg?ggt?gtg?cca?taa 1680

Ser?Met?Val?Met?Leu?Ile?Gly?Ala?Arg?Tyr?Ile?Ser?Gly?Val?Pro

545 550 555

taa?tac?cag?cta?tgg?agt?ccc?aag?atg?taa?aca?ttt?tac?ata?atg?aaa 1728

Tyr?Gln?Leu?Trp?Ser?Pro?Lys?Met Thr?Phe?Tyr?Ile?Met?Lys

560 565 570

gca?tat?agc?agt?tct?gcc?tct?taa?tat?aat?gac?act?att?ata?gac?tct 1776

Ala?Tyr?Ser?Ser?Ser?Ala?Ser Tyr?Asn?Asp?Thr?Ile?Ile?Asp?Ser

575 580 585

gat?ttt?gtt?tat?aaa?cca?ctt?gct?aca?tga?ccc?atg?aaa?acc?cta?gac 1824

Asp?Phe?Val?Tyr?Lys?Pro?Leu?Ala?Thr Pro?Met?Lys?Thr?Leu?Asp

590 595 600

ttg?tga?cct?gaa?ata?aag?aaa?ata?cgt?tag?aag?agc?act?gta 1866

Leu Pro?Glu?Ile?Lys?Lys?Ile?Arg Lys?Ser?Thr?Val

605 610 615

aaaaaaaaaa?aaaaaaaaaa?aaaaaaaaaa?aaa 1899

SEQUENCE?LISTING9

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_153823

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1942

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(177)

<220>

<221>exon

<222>(178)..(493)

<220>

<221>exon

<222>(494)..(541)

<220>

<221>exon

<222>(542)..(694)

<220>

<221>exon

<222>(695)..(806)

<220>

<221>exon

<222>(807)..(1942)

<220>

<221>STS

<222>(884)..(1736)

<220>

<221>polyA_site

<222>(1225)..(1225)

<400>1

agc?att?taa?tca?tga?ggc?act?cca?aag?aat?atg?aga?tag?aag?ggg?agg 48

Ser?Ile Ser Gly?Thr?Pro?Lys?Asn?Met?Arg Lys?Gly?Arg

1 5 10

ggt?agg?agg?aga?ggg?agg?agg?gta?gga?aga?cag?ttt?gca?ttc?ttg?caa 96

Gly?Arg?Arg?Arg?Gly?Arg?Arg?Val?Gly?Arg?Gln?Phe?Ala?Phe?Leu?Gln

15 20 25

cat?taa?acc?aaa?ggg?act?tgg?agt?gca?gat?ggc?atc?ctt?cgg?ttc?ttc 144

His Thr?Lys?Gly?Thr?Trp?Ser?Ala?Asp?Gly?Ile?Leu?Arg?Phe?Phe

30 35 40

cag?aca?agc?tgc?aag?acg?ctg?acc?atg?gcc?aag?atg?gag?ctc?tcg?aag 192

Gln?Thr?Ser?Cys?Lys?Thr?Leu?Thr?Met?Ala?Lys?Met?Glu?Leu?Ser?Lys

45 50 55 60

gcc?ttc?tct?ggc?cag?cgg?aca?ctc?cta?tct?gcc?atc?ctc?agc?atg?cta 240

Ala?Phe?Ser?Gly?Gln?Arg?Thr?Leu?Leu?Ser?Ala?Ile?Leu?Ser?Met?Leu

65 70 75

tca?ctc?agc?ttc?tcc?aca?aca?tcc?ctg?ctc?agc?aac?tac?tgg?ttt?gtg 288

Ser?Leu?Ser?Phe?Ser?Thr?Thr?Ser?Leu?Leu?Ser?Asn?Tyr?Trp?Phe?Val

80 85 90

ggc?aca?cag?aag?gtg?ccc?aag?ccc?ctg?tgc?gag?aaa?ggt?ctg?gca?gcc 336

Gly?Thr?Gln?Lys?Val?Pro?Lys?Pro?Leu?Cys?Glu?Lys?Gly?Leu?Ala?Ala

95 100 105

aag?tgc?ttt?gac?atg?cca?gtg?tcc?ctg?gat?gga?gat?acc?aac?aca?tcc 384

Lys?Cys?Phe?Asp?Met?Pro?Val?Ser?Leu?Asp?Gly?Asp?Thr?Asn?Thr?Ser

110 115 120

acc?cag?gag?gtg?gta?caa?tac?aac?tgg?gag?act?ggg?gat?gac?cgg?ttc 432

Thr?Gln?Glu?Val?Val?Gln?Tyr?Asn?Trp?Glu?Thr?Gly?Asp?Asp?Arg?Phe

125 130 135 140

tcc?ttc?cgg?agc?ttc?cgg?agt?ggc?atg?tgg?cta?tcc?tgt?gag?gaa?act 480

Ser?Phe?Arg?Ser?Phe?Arg?Ser?Gly?Met?Trp?Leu?Ser?Cys?Glu?Glu?Thr

145 150 155

gtg?gaa?gaa?cca?g?gg gag?agg?tgc?cga?agt?ttc?att?gaa?ctt?aca?cca 528

Val?Glu?Glu?Pro Gly?Glu?Arg?Cys?Arg?Ser?Phe?Ile?Glu?Leu?Thr?Pro

160 165 170

cca?gcc?aag?aga?g?aa atc?cta?tgg?tta?tcc?ctg?gga?acg?cag?atc?acc 576

Pro?Ala?Lys?Arg Glu?Ile?Leu?Trp?Leu?Ser?Leu?Gly?Thr?Gln?Ile?Thr

175 180 185

tac?atc?gga?ctt?caa?ttc?atc?agc?ttc?ctc?ctg?cta?cta?aca?gac?ttg 624

Tyr?Ile?Gly?Leu?Gln?Phe?Ile?Ser?Phe?Leu?Leu?Leu?Leu?Thr?Asp?Leu

190 195 200

cta?ctc?act?ggg?aac?cct?gcc?tgt?ggg?ctc?aaa?ctg?agc?gcc?ttt?gct 672

Leu?Leu?Thr?Gly?Asn?Pro?Ala?Cys?Gly?Leu?Lys?Leu?Ser?Ala?Phe?Ala

205 210 215 220

gct?gtt?tcc?tct?gtc?ctg?tca?g?gt ctc?ctg?ggg?atg?gtg?gcc?cac?atg 720

Ala?Val?Ser?Ser?Val?Leu?Ser Gly?Leu?Leu?Gly?Met?Val?Ala?His?Met

225 230 235

atg?tat?tca?caa?gtc?ttc?caa?gcg?act?gtc?aac?ttg?ggt?cca?gaa?gac 768

Met?Tyr?Ser?Gln?Val?Phe?Gln?Ala?Thr?Val?Asn?Leu?Gly?Pro?Glu?Asp

240 245 250

tgg?aga?cca?cat?gtt?tgg?aat?tat?ggc?tgg?gcc?ttc?ta c?atg?gcc?tgg 816

Trp?Arg?Pro?His?Val?Trp?Asn?Tyr?Gly?Trp?Ala?Phe?Tyr Met?Ala?Trp

255 260

ctc?tcc?ttc?acc?tgc?tgc?atg?gcg?tcg?gct?gtc?acc?acc?ttc?aac?acg 864

Leu?Ser?Phe?Thr?Cys?Cys?Met?Ala?Ser?Ala?Val?Thr?Thr?Phe?Asn?Thr

270 275 280

tac?acc?agg?atg?gtg?ctg?gag?ttc?aag?tgc?aag?cat?agt?aag?agc?ttc 912

Tyr?Thr?Arg?Met?Val?Leu?Glu?Phe?Lys?Cys?Lys?His?Ser?Lys?Ser?Phe

285 290 295 300

aag?gaa?aac?ccg?aac?tgc?cta?cca?cat?cac?cat?cag?tgt?ttc?cct?cgg 960

Lys?Glu?Asn?Pro?Asn?Cys?Leu?Pro?His?His?His?Gln?Cys?Phe?Pro?Arg

305 310 315

cgg?ctg?tca?agt?gca?gcc?ccc?accgtg?ggt cct?ttg?acc?agc?tac?cac 1008

Arg?Leu?Ser?Ser?Ala?Ala?Pro?Thr?Val?Gly?Pro?Leu?Thr?Ser?Tyr?His

320 325 330

cag?tat?cat?aat?cag?ccc?atc?cac?tct?gtc?tct?gag?gga?gtc?gac?ttc 1056

Gln?Tyr?His?Asn?Gln?Pro?Ile?His?Ser?Val?Ser?Glu?Gly?Val?Asp?Phe

335 340 345

tac?tcc?gag?ctg?cgg?aac?aag?gga?ttt?caa?aga?ggg?gcc?agc?cag?gag 1104

Tyr?Ser?Glu?Leu?Arg?Asn?Lys?Gly?Phe?Gln?Arg?Gly?Ala?Ser?Gln?Glu

350 355 360

ctg?aaa?gaa?gca?gtt?agg?tca?tct?gta?gag?gaa?gag?cag?tgt?tag?gag 1152

Leu?Lys?Glu?Ala?Val?Arg?Ser?Ser?Val?Glu?Glu?Glu?Gln?Cys Glu

365 370 375

tta?agc?ggg?ttt?ggg?gag?tag?gct?tga?gcc?cta?cct?tac?acg?tct?gct 1200

Leu?Ser?Gly?Phe?Gly?Glu Ala Ala?Leu?Pro?Tyr?Thr?Ser?Ala

380 385 390

gat?tat?caa?cat?gtg?ctt?aag?cca?aca?tcc?gtc?tct?tga?gca?tgg?ttt 1248

Asp?Tyr?Gln?His?Val?Leu?Lys?Pro?Thr?Ser?Val?Ser Ala?Trp?Phe

395 400 405

tta?gag?gct?acg?aat?aag?gct?atg?aat?aag?ggt?tat?ctt?taa?gtc?cta 1296

Leu?Glu?Ala?Thr?Asn?Lys?Ala?Met?Asn?Lys?Gly?Tyr?Leu Val?Leu

410 415 420

agg?gat?tcc?tgg?gtg?cca?ctg?ctc?tct?ttt?cct?cta?cag?ctc?cat?ctt 1344

Arg?Asp?Ser?Trp?Val?Pro?Leu?Leu?Ser?Phe?Pro?Leu?Gln?Leu?His?Leu

425 430 435

gtt?tca?ccc?acc?cca?cat?ctc?aca?cat?cca?gaa?ttc?cct?tct?tta?ctg 1392

Val?Ser?Pro?Thr?Pro?His?Leu?Thr?His?Pro?Glu?Phe?Pro?Ser?Leu?Leu

440 445 450 455

ata?gtt?tct?gtg?cca?ggt?tct?ggg?cta?aac?cat?gga?gat?aaa?aag?aag 1440

Ile?Val?Ser?Val?Pro?Gly?Ser?Gly?Leu?Asn?His?Gly?Asp?Lys?Lys?Lys

460 465 470

agt?aaa?ata?cac?ttc?ccg?acc?tta?agg?atc?tga?tac?atc?tag?tta?ttg 1488

Ser?Lys?Ile?His?Phe?Pro?Thr?Leu?Arg?Ile Tyr?Ile Leu?Leu

475 480 485

gtc?tgg?aaa?ttg?gag?aaa?tgg?agg?tga?gca?aat?taa?cgg?tag?tgt?gac 1536

Val?Trp?Lys?Leu?Glu?Lys?Trp?Arg Ala?Asn Arg Cys?Asp

490 495

tgt?ggc?tca?act?ttc?cat?ggt?acg?cgc?gaa?ttg?ttc?tgg?aag?tca?cag 1584

Cys?Gly?Ser?Thr?Phe?His?Gly?Thr?Arg?Glu?Leu?Phe?Trp?Lys?Ser?Gln

500 505 510

atg?gga?aga?cag?aag?cgc?ccc?tga?gtg?ctt?tgt?cat?ata?gca?cag?aag 1632

Met?Gly?Arg?Gln?Lys?Arg?Pro Val?Leu?Cys?His?Ile?Ala?Gln?Lys

515 520 525

tcc?tcc?aca?ctg?cct?ggg?aca?gtg?tcc?tgc?atc?cac?aca?gta?ggt?acc 1680

Ser?Ser?Thr?Leu?Pro?Gly?Thr?Val?Ser?Cys?Ile?His?Thr?Val?Gly?Thr

530 535 540 545

cag?taa?aag?tgt?tat?taa?ata?ttg?tcc?cag?gag?ccc?tta?gga?gag?tgg 1728

Gln?Lys?Cys?Tyr Ile?Leu?Ser?Gln?Glu?Pro?Leu?Gly?Glu?Trp

550 555

ttt?aac?atg?aga?agg?cgc?caa?cag?cac?aca?ggg?tca?ggg?tca?ctt?cta 1776

Phe?Asn?Met?Arg?Arg?Arg?Gln?Gln?His?Thr?Gly?Ser?Gly?Ser?Leu?Leu

560 565 570 575

gaa?ata?gcc?cac?caa?ggc?tat?tca?gat?tgg?act?gtg?gtt?ccc?ttc?tgg 1824

Glu?Ile?Ala?His?Gln?Gly?Tyr?Ser?Asp?Trp?Thr?Val?Val?Pro?Phe?Trp

580 585 590

aca?gtc?aca?cca?ggg?act?tcc?cag?tga?aca?agg?ggg?cat?agg?ctc?ctc 1872

Thr?Val?Thr?Pro?Gly?Thr?Ser?Gln Thr?Arg?Gly?His?Arg?Leu?Leu

595 600 605

tct?gga?tcc?cac?ctt?ttc?atc?cct?tct?gag?aaa?tgt?acc?cta?tta?ttt 1920

Ser?Gly?Ser?His?Leu?Phe?Ile?Pro?Ser?Glu?Lys?Cys?Thr?Leu?Leu?Phe

610 615 620

cct?tca?taa?aga?atg?ccaccc?a 1942

Pro?Ser Arg?Met?Pro?Pro

625

SEQUENCE?LISTING10

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_000849

<160>1

<170>PatentIn?version?3.5

<210>1

<211>4144

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(86)

<220>

<221>exon

<222>(87)..(358)

<220>

<221>exon

<222>(359)..(434)

<220>

<221>exon

<222>(435)..(499)

<220>

<221>exon

<222>(500)..(581)

<220>

<221>exon

<222>(582)..(682)

<220>

<221>exon

<222>(683)..(778)

<220>

<221>exon

<222>(779)..(889)

<220>

<221>STS

<222>(826)..(1064)

<220>

<221>exon

<222>(890)..(4127)

<220>

<221>polyA_site

<222>(1084)..(1084)

<220>

<221>STS

<222>(1092)..(1277)

<220>

<221>polyA_site

<222>(1133)..(1133)

<220>

<221>polyA_signal

<222>(1532)..(1537)

<220>

<221>polyA_site

<222>(1557)..(1557)

<220>

<221>polyA_signal

<222>(4098)..(4103)

<220>

<221>polyA_site

<222>(4127)..(4127)

<400>1

ggt?tgg?ttc?tga?gaa?ggc?ttc?aag?gaa?tag?gca?gac?att?tca?gca?agg 48

Gly?Trp?Phe Glu?Gly?Phe?Lys?Glu Ala?Asp?Ile?Ser?Ala?Arg

1 5 10

ctg?ctg?agg?aag?gat?agg?ctg?tgg?aaa?tta?gga?tgc?ag c?act?cct?gcc 96

Leu?Leu?Arg?Lys?Asp?Arg?Leu?Trp?Lys?Leu?Gly?Cys?Ser Thr?Pro?Ala

15 20 25 30

cgg?gtc?ccg?cct?cgg?ggt?cgc?cag?gcc?ctg?aac?ccc?aac?gcc?ggc?att 144

Arg?Val?Pro?Pro?Arg?Gly?Arg?Gln?Ala?Leu?Asn?Pro?Asn?Ala?Gly?Ile

35 40 45

agt?cgc?gcc?tgc?gca?cgg?ccc?tgt?gga?gcc?gcg?gag?gca?agg?gac?gga 192

Ser?Arg?Ala?Cys?Ala?Arg?Pro?Cys?Gly?Ala?Ala?Glu?Ala?Arg?Asp?Gly

50 55 60

gaa?cgg?ggc?gga?ggc?gga?gtc?agg?gcg?ccc?gcg?cgt?ggg?ccc?cgc?ccc 240

Glu?Arg?Gly?Gly?Gly?Gly?Val?Arg?Ala?Pro?Ala?Arg?Gly?Pro?Arg?Pro

65 70 75

ctt?atg?tcg?ggt?ata?aag?ccc?ctc?ccg?ctc?aca?gtt?tcc?cta?gtc?ctc 288

Leu?Met?Ser?Gly?Ile?Lys?Pro?Leu?Pro?Leu?Thr?Val?Ser?Leu?Val?Leu

80 85 90

gaa?ggc?tcg?gaa?gcc?cgt?cac?cat?gtc?gtg?cga?gtc?gtc?tat?ggt?tct 336

Glu?Gly?Ser?Glu?Ala?Arg?His?His?Val?Val?Arg?Val?Val?Tyr?Gly?Ser

95 100 105 110

cgg?gta?ctg?gga?tat?tcg?tgg?g?ct ggc?gca?cgc?cat?ccg?cct?gct?cct 384

Arg?Val?Leu?Gly?Tyr?Ser?Trp Ala?Gly?Ala?Arg?His?Pro?Pro?Ala?Pro

115 120 125

gga?gtt?cac?gga?tac?ctc?tta?tga?gga?gaa?acg?gta?cac?gtg?cgg?gga 432

Gly?Val?His?Gly?Tyr?Leu?Leu Gly?Glu?Thr?Val?His?Val?Arg?Gly

130 135 140

ag?c?tcc?tga?cta?tga?tcg?aag?cca?atg?gct?gga?tgt?gaa?att?caa?gct 480

Ser Ser Leu Ser?Lys?Pro?Met?Ala?Gly?Cys?Glu?Ile?Gln?Ala

145 150 155

aga?cct?gga?ctt?tcc?taa?t?ct gcc?cta?cct?cct?gga?tgg?gaa?gaa?caa 528

Arg?Pro?Gly?Leu?Ser Ser?Ala?Leu?Pro?Pro?Gly?Trp?Glu?Glu?Gln

160 165 170

gat?cac?cca?gag?caa?tgc?cat?ctt?gcg?cta?cat?cgc?tcg?caa?gca?caa 576

Asp?His?Pro?Glu?Gln?Cys?His?Leu?Ala?Leu?His?Arg?Ser?Gln?Ala?Gln

175 180 185

cat?gt?g?tgg?tga?gac?tga?aga?aga?aaa?gat?tcg?agt?gga?cat?cat?aga 624

His?Val Trp Asp Arg?Arg?Lys?Asp?Ser?Ser?Gly?His?His?Arg

190 195 200

gaa?cca?agt?aat?gga?ttt?ccg?cac?aca?act?gat?aag?gct?ctg?tta?cag 672

Glu?Pro?Ser?Asn?Gly?Phe?Pro?His?Thr?Thr?Asp?Lys?Ala?Leu?Leu?Gln

205 210 215

ctc?tga?cca?c?ga aaa?act?gaa?gcc?tca?gta?ctt?gga?aga?gct?acc?tgg 720

Leu Pro Arg?Lys?Thr?Glu?Ala?Ser?Val?Leu?Gly?Arg?Ala?Thr?Trp

220 225 230

aca?act?gaa?aca?att?ctc?cat?gtt?tct?ggg?gaa?att?ctc?atg?gtt?tgc 768

Thr?Thr?Glu?Thr?Ile?Leu?His?Val?Ser?Gly?Glu?Ile?Leu?Met?Val?Cys

235 240 245

cgg?gga?aaa?g?ct cac?ctt?tgt?gga?ttt?tct?cac?cta?tga?tat?ctt?gga 816

Arg?Gly?Lys Ala?His?Leu?Cys?Gly?Phe?Ser?His?Leu Tyr?Leu?Gly

250 255 260

tca?gaa?ccg?tat?att?tga?ccc?caa?gtg?cct?gga?tga?gtt?ccc?aaa?cct 864

Ser?Glu?Pro?TyrIle Pro?Gln?Val?Pro?Gly Val?Pro?Lys?Pro

265 270 275

gaa?ggc?ttt?cat?gtg?ccg?ttt?tga?g?gc ttt?gga?gaa?aat?cgc?tgc?cta 912

Glu?Gly?Phe?His?Val?Pro?Phe Gly?Phe?Gly?Glu?Asn?Arg?Cys?Leu

280 285 290

ctt?aca?gtc?tga?tca?gtt?ctg?caa?gat?gcc?cat?caa?caa?caa?gat?ggc 960

Leu?Thr?Val Ser?Val?Leu?Gln?Asp?Ala?His?Gln?Gln?Gln?Asp?Gly

295 300 305

cca?gtg?ggg?caa?caa?gcc?tgt?atg?ctg?agc?agg?agg?cag?act?tgc?aga 1008

Pro?Val?Gly?Gln?Gln?Ala?Cys?Met?Leu?Ser?Arg?Arg?Gln?Thr?Cys?Arg

310 315 320

gct?tgt?ttt?gtt?tca?tcc?tgt?ccg?taa?ggg?gtc?agc?gct?ctt?gct?ttg 1056

Ala?Cys?Phe?Val?Ser?Ser?Cys?Pro Gly?Val?Ser?Ala?Leu?Ala?Leu

325 330 335

ctc?ttt?tca?atg?aat?agc?act?tat?gtt?act?ggt?gtc?cag?ctg?agt?ttc 1104

Leu?Phe?Ser?Met?Asn?Ser?Thr?Tyr?Val?Thr?Gly?Val?Gln?Leu?Ser?Phe

340 345 350

tct?tgg?gta?taa?agg?cta?aaa?ggg?aaa?aag?gat?atg?tgg?aga?atc?atc 1152

Ser?Trp?Val Arg?Leu?Lys?Gly?Lys?Lys?Asp?Met?Trp?Arg?Ile?Ile

355 360 365

aag?ata?tga?att?gaa?tcg?ctg?cga?tac?tgg?cat?ttc?cct?act?ccc?caa 1200

Lys?Ile Ile?Glu?Ser?Leu?Arg?Tyr?Trp?His?Phe?Pro?Thr?Pro?Gln

370 375 380

ctg?agt?tca?agg?gct?gta?ggt?tca?tgc?cca?agc?cct?gag?agt?ggg?tac 1248

Leu?Ser?Ser?Arg?Ala?Val?Gly?Ser?Cys?Pro?Ser?Pro?Glu?Ser?Gly?Tyr

385 390 395

tag?aaa?aaa?cga?gat?tgc?aca?gtt?gga?gag?agc?agg?tgt?gtt?aaa?tgg 1296

Lys?Lys?Arg?Asp?Cys?Thr?Val?Gly?Glu?Ser?Arg?Cys?Val?Lys?Trp

400 405 410

gac?tgg?agt?ccc?tgt?gaa?gac?tgg?gtg?agg?ata?aca?caa?gta?aaa?ctg 1344

Asp?Trp?Ser?Pro?Cys?Glu?Asp?Trp?Val?Arg?Ile?Thr?Gln?Val?Lys?Leu

415 420 425 430

tgg?tac?tga?tgg?act?taa?ccg?gag?ttc?gga?aac?cgt?cct?gtg?tac?aca 1392

Trp?Tyr Trp?Thr Pro?Glu?Phe?Gly?Asn?Arg?Pro?Val?Tyr?Thr

435 440

tgg?gag?ttt?agt?gtg?ata?aag?gca?gta?ttt?cag?act?ggt?ggg?cta?gcc 1440

Trp?Glu?Phe?Ser?Val?Ile?Lys?Ala?Val?Phe?Gln?Thr?Gly?Gly?Leu?Ala

445 450 455 460

aat?aga?gtt?ggg?aca?att?gct?tac?tca?tta?aaa?ata?ata?gag?ccc?cac 1488

Asn?Arg?Val?Gly?Thr?Ile?Ala?Tyr?Ser?Leu?Lys?Ile?Ile?Glu?Pro?His

465 470 475

ttg?aca?cta?ttc?act?aaa?att?aat?ctg?gaa?ttt?aag?gcc?caa?cat?taa 1536

Leu?Thr?Leu?Phe?Thr?Lys?Ile?Asn?Leu?Glu?Phe?Lys?Ala?Gln?His

480 485 490

aca?caa?agc?tgt?tga?aat?att?gat?gaa?aat?gta?aga?att?ttt?gtg?acc 1584

Thr?Gln?Ser?Cys Asn?Ile?Asp?Glu?Asn?Val?Arg?Ile?Phe?Val?Thr

495 500 505

acg?ggg?tag?gag?aag?ttt?ctt?taa?aga?cgt?aaa?aag?aaa?aaa?acc?ata 1632

Thr?Gly Glu?Lys?Phe?Leu Arg?Arg?Lys?Lys?Lys?Lys?Thr?Ile

510 515 520

ggc?tgc?tct?gcc?tgt?gga?gta?gcc?att?ctt?tat?tct?ttt?act?ttt?taa 1680

Gly?Cys?Ser?Ala?Cys?Gly?Val?Ala?Ile?Leu?Tyr?Ser?Phe?Thr?Phe

525 530 535

aat?aat?aac?aat?cac?aaa?gga?aag?att?tgc?caa?ttg?aat?agg?atc?aaa 1728

Asn?Asn?Asn?Asn?His?Lys?Gly?Lys?Ile?Cys?Gln?Leu?Asn?Arg?Ile?Lys

540 545 550

ttc?tac?aac?ttt?tcc?taa?ggc?acc?cac?aaa?taa?atg?aca?agt?gag?aca 1776

Phe?Tyr?Asn?Phe?Ser Gly?Thr?His?Lys Met?Thr?Ser?Glu?Thr

555 560 565

aaa?agc?act?agt?ata?aag?att?ata?taa?aga?cct?ata?aat?cat?taa?gac 1824

Lys?Ser?Thr?Ser?Ile?Lys?Ile?Ile Arg?Pro?Ile?Asn?His Asp

570 575

aac?tga?gtt?ttt?aaa?aat?gga?caa?aat?cca?tga?aca?att?tat?aaa?ata 1872

Asn Val?Phe?Lys?Asn?Gly?Gln?Asn?Pro Thr?Ile?Tyr?Lys?Ile

580 585 590

gaa?ata?tag?cca?aaa?atg?tct?aaa?aga?tgt?tta?tga?tgt?aag?gaa?tta 1920

Glu?Ile Pro?Lys?Met?Ser?Lys?Arg?Cys?Leu Cys?Lys?Glu?Leu

595 600 605

tca?att?aca?aca?gtg?aga?aac?cat?att?tcc?ttc?tat?ccg?atg?agt?aaa 1968

Ser?Ile?Thr?Thr?Val?Arg?Asn?His?Ile?Ser?Phe?Tyr?Pro?Met?Ser?Lys

610 615 620

aag?ttt?cta?aag?tgt?tgg?caa?ggc?tta?gga?aag?tga?tat?gca?ttt?cct 2016

Lys?Phe?Leu?Lys?Cys?Trp?Gln?Gly?Leu?Gly?Lys Tyr?Ala?Phe?Pro

625 630 635

gct?ggt?caa?gtt?gta?aat?tag?tat?agc?tac?ttt?gga?gga?caa?ttg?taa 2064

Ala?Gly?Gln?Val?Val?Asn Tyr?Ser?Tyr?Phe?Gly?Gly?Gln?Leu

640 645 650

aat?tta?aat?cat?atc?cta?tga?ccc?agc?aat?tcc?atg?cta?taa?aaa?ctc 2112

Asn?Leu?Asn?His?Ile?Leu Pro?Ser?Asn?Ser?Met?Leu Lys?Leu

655 660 665

atc?cat?ggc?cgg?gct?tgg?tgg?ctc?acg?cct?gta?atc?cca?gca?ctt?tgg 2160

Ile?His?Gly?Arg?Ala?Trp?Trp?Leu?Thr?Pro?Val?Ile?Pro?Ala?Leu?Trp

670 675 680

gag?gct?gag?gtg?ggc?aga?tca?cga?ggt?caa?gag?atc?gag?acc?atc?ctg 2208

Glu?Ala?Glu?Val?Gly?Arg?Ser?Arg?Gly?Gln?Glu?Ile?Glu?Thr?Ile?Leu

685 690 695

gcc?aac?atg?atg?aaa?ccc?cgt?ttc?tac?taa?aaa?tac?aaa?aat?tag?ctg 2256

Ala?Asn?Met?Met?Lys?Pro?Arg?Phe?Tyr Lys?Tyr?Lys?Asn Leu

700 705 710

ggc?atg?gtg?gca?tgt?gcc?tat?agt?ccc?agc?tac?tca?gga?ggc?tga?ggc 2304

Gly?Met?Val?Ala?Cys?Ala?Tyr?Ser?Pro?Ser?Tyr?Ser?Gly?Gly Gly

715 720 725

agg?aga?att?gct?tga?acc?tgg?gag?gca?gag?gtt?gca?gtg?agc?cga?gat 2352

Arg?Arg?Ile?Ala Thr?Trp?Glu?Ala?Glu?Val?Ala?Val?Ser?Arg?Asp

730 735 740

cac?gcc?act?gca?ctc?cag?cct?ggc?tac?agg?gcg?aga?ctc?tgt?ctc?aaa 2400

His?Ala?Thr?Ala?Leu?Gln?Pro?Gly?Tyr?Arg?Ala?Arg?Leu?Cys?Leu?Lys

745 750 755

aaa?aaa?aaa?aaa?aaa?aaa?aaa?aaa?aca?ttc?aaa?gag?aca?tat?act?aag 2448

Lys?Lys?Lys?Lys?Lys?Lys?Lys?Lys?Thr?Phe?Lys?Glu?Thr?Tyr?Thr?Lys

760 765 770

atg?ttc?act?gtg?gca?ttg?tct?gta?atg?aca?aat?aag?tgg?aaa?ccg?tgt 2496

Met?Phe?Thr?Val?Ala?Leu?Ser?Val?Met?Thr?Asn?Lys?Trp?Lys?Pro?Cys

775 780 785 790

aaa?tac?ctg?tca?ata?cta?tgg?agt?acc?atg?tgg?caa?cgg?aag?aat?gag 2544

Lys?Tyr?Leu?Ser?Ile?Leu?Trp?Ser?Thr?Met?Trp?Gln?Arg?Lys?Asn?Glu

795 800 805

act?gaa?ctg?tgt?gaa?cta?aca?tgc?aaa?gat?ccc?caa?aac?agg?cca?ggt 2592

Thr?Glu?Leu?Cys?Glu?Leu?Thr?Cys?Lys?Asp?Pro?Gln?Asn?Arg?Pro?Gly

810 815 820

gtg?gtt?gct?cac?agc?tgt?aat?aac?aac?acc?ttc?aga?ggc?tga?ggt?gag 2640

Val?Val?Ala?His?Ser?Cys?Asn?Asn?Asn?Thr?Phe?Arg?Gly Gly?Glu

825 830 835

agg?atc?agt?tga?ggc?cag?gag?ttt?aag?acc?agc?ctg?ggc?aac?ata?gtg 2688

ArgIle?Ser Gly?Gln?Glu?Phe?Lys?Thr?Ser?Leu?Gly?Asn?Ile?Val

840 845 850

aga?ccc?ctg?tct?ccc?aaa?aat?ttt?ttt?taa?tta?gct?gtg?cgc?aat?tgc 2736

Arg?Pro?Leu?Ser?Pro?Lys?Asn?Phe?Phe Leu?Ala?Val?Arg?Asn?Cys

855 860 865

tca?tgc?ata?gtc?cca?gct?acc?cag?gag?gct?gag?gtg?gga?gga?tca?ctt 2784

Ser?Cys?Ile?Val?Pro?Ala?Thr?Gln?Glu?Ala?Glu?Val?Gly?Gly?Ser?Leu

870 875 880

gag?ccc?agg?aat?ttg?aag?ctg?cag?tga?gct?gtg?ttc?ttg?cca?ctg?cac 2832

Glu?Pro?Arg?Asn?Leu?Lys?Leu?Gln Ala?Val?Phe?Leu?Pro?Leu?His

885 890 895

tcc?aat?ctg?ggt?gac?tga?gca?aga?ccc?tgt?ctc?tta?aaa?aaa?taa?aaa 2880

Ser?Asn?Leu?Gly?Asp Ala?Arg?Pro?Cys?Leu?Leu?Lys?Lys Lys

900 905 910

aga?tct?cca?agc?ata?gag?aag?agt?ctg?gag?gga?aac?acc?aaa?ctc?ata 2928

Arg?Ser?Pro?Ser?Ile?Glu?Lys?Ser?Leu?Glu?Gly?Asn?Thr?Lys?Leu?Ile

915 920 925

aca?gtc?tta?ctg?cag?gca?agt?ggg?ata?aag?gcc?cag?act?cca?tgg?tgg 2976

Thr?Val?Leu?Leu?Gln?Ala?Ser?Gly?Ile?Lys?Ala?Gln?Thr?Pro?Trp?Trp

930 935 940

aag?tta?aag?ggc?att?tcc?aag?tta?agg?cta?aga?ctt?gct?ttt?cta?act 3024

Lys?Leu?Lys?Gly?Ile?Ser?Lys?Leu?Arg?Leu?Arg?Leu?Ala?Phe?Leu?Thr

945 950 955 960

aag?aga?atg?tgc?tca?tgc?att?gct?tgt?gta?gta?gaa?act?agt?ttt?tag 3072

Lys?Arg?Met?Cys?Ser?Cys?Ile?Ala?Cys?Val?Val?Glu?Thr?Ser?Phe

965 970 975

aaa?aga?aag?caa?act?taa?gaa?aca?ctg?act?cct?gtg?gag?atg?act?tgg 3120

Lys?Arg?Lys?Gln?Thr Glu?Thr?Leu?Thr?Pro?Val?Glu?Met?Thr?Trp

980 985 990

cac?cac?tct?cct?ttc?aca?gag?cag?agt?ctg?aat?agt?ctt?cag?aga?tag 3168

His?His?Ser?Pro?Phe?Thr?Glu?Gln?Ser?Leu Asn?Ser?Leu?Gln?Arg

995 1000 1005

gcc?tgt?ggg?cca?gat tgc?cat?ccc?cta?tgg acc?aga?agc?caa?gga 3213

Ala?Cys?Gly?Pro?Asp Cys?His?Pro?Leu?Trp Thr?Arg?Ser?Gln?Gly

1010 1015 1020

tct?ctc?tag?tga?tgg?tca?gag ggc?cca?aat?ggc?agg gat?acc?cag?tga 3261

Ser?Leu Trp?Ser?Glu Gly?Pro?Asn?Gly?Arg Asp?Thr?Gln

1025 1030

tgt?cag gag?gaa?tag?tac?aga?cag aag?gtg?cta?agc?aga caa?ttc 3306

Cys?Gln Glu?Glu Tyr?Arg?Gln Lys?Val?Leu?Ser?Arg Gln?Phe

1035 1040 1045

aac?tgc?cat gtt?ttg?cca?ccc?cct gtg?agc?agg?gat?tag?gtg ttc 3351

Asn?Cys?His Val?Leu?Pro?Pro?Pro Val?Ser?Arg?Asp Val Phe

1050 1055 1060

agg?cca?gta?tct tgg?gca?tgg?ggg?agc ctt?tgg?cca?gaa?gag gta 3396

Arg?Pro?Val?Ser Trp?Ala?Trp?Gly?Ser Leu?Trp?Pro?Glu?Glu Val

1065 1070 1075

taa?agc?tca?gaa?gtt ttt?cag?tct?gat?aac tat?tga?tat?aat?ttc 3441

Ser?Ser?Glu?Val Phe?Gln?Ser?Asp?Asn Tyr Tyr?Asn?Phe

1080 1085

cat agt?gtg?agg?gag?cgg tat?gct?cta?ccc?ttg tgt?att?taa?ggc 3486

His Ser?Val?Arg?Glu?Arg Tyr?Ala?Leu?Pro?Leu Cys?Ile Gly

1090 1095 1100

agg?aca gag?aaa?ttg?agg?atg ccc?ctg?ggg?cta?gat cga?tga?tat 3531

Arg?Thr Glu?Lys?Leu?Arg?Met Pro?Leu?Gly?Leu?Asp Arg Tyr

1105 1110 1115

gac?cag?aaa tca?aaa?agg?gaa?tgc att?att?tat?tgc?tgt gta?aca 3576

Asp?Gln?Lys Ser?Lys?Arg?Glu?Cys Ile?Ile?Tyr?Cys?Cys Val?Thr

1120 1125 1130

ctg?tta?aga gag?gag?gta?gtt?aag gga?tgg?ata?ggc?aca tag?aga 3621

Leu?Leu?Arg Glu?Glu?Val?Val?Lys Gly?Trp?Ile?Gly?Thr Arg

1135 1140 1145

ggg?aag?gtc?tca gga?gaa?ggg?ata?gaa agg?aac?tat?gtt?cac aag 3666

Gly?Lys?Val?Ser Gly?Glu?Gly?Ile?Glu Arg?Asn?Tyr?Val?His Lys

1150 1155 1160

aac?aac?ggc?aag aca?gtg?cct?ata?ctg cct?cta?cag?tta?ata gga 3711

Asn?Asn?Gly?Lys Thr?Val?Pro?Ile?Leu Pro?Leu?Gln?Leu?Ile Gly

1165 1170 1175

aaa?acg?gaa?gaa gtt?acc?ctt?aag?cta gga?tgt?tgc?tca?gaa gtg 3756

Lys?Thr?Glu?Glu Val?Thr?Leu?Lys?Leu Gly?Cys?Cys?Ser?Glu Val

1180 1185 1190

acc?atc?cca?act ttg?gtg?cgg?gca?caa taa?atc?agc?cta?aat?gtc 3801

Thr?Ile?Pro?Thr Leu?Val?Arg?Ala?Gln Ile?Ser?Leu?Asn?Val

1195 1200 1205

cct?aat?tta?acc?cag ctc?att?ata?atg?tca tta?aac?atg?aca?tta 3846

Pro?Asn?Leu?Thr?Gln Leu?Ile?Ile?Met?Ser Leu?Asn?Met?Thr?Leu

1210 1215 1220

gca?ttg?tgg?ttt?tag?cac ccc?cat?ggg?ttt?tgc tta?ggc?act?cat 3891

Ala?Leu?Trp?Phe His Pro?His?Gly?Phe?Cys Leu?Gly?Thr?His

1225 1230

ggg taa?taa?cca?aga?tgg?agt?ccc ttt?ggc?aaa?act?tag?gca tgc 3936

Gly Pro?Arg?Trp?Ser?Pro Phe?Gly?Lys?Thr Ala Cys

1235 1240 1245

aca?gct?gta?gta ccc?caa?gaa?gaa?aat gtt?act?tct?ctc?atc tgg 3981

Thr?Ala?Val?Val Pro?Gln?Glu?Glu?Asn Val?Thr?Ser?Leu?Ile Trp

1250 1255 1260

gca?aaa?ccc?aca?gaa?gac?ttc?cca?gct tct?gcc?aca?taa?aag?aca 4026

Ala?Lys?Pro?Thr?Glu?Asp?Phe?Pro?Ala Ser?Ala?Thr Lys?Thr

1265 1270 1275

cag?aac?aca?gac?gcc?tta?ctg?gca?acc?tgc ttt?caa?gac?ccc?tgt 4071

Gln?Asn?Thr?Asp?Ala?Leu?Leu?Ala?Thr?Cys Phe?Gln?Asp?Pro?Cys

1280 1285 1290

ctt?tgc?tga?gag?ctt?tcc ttt?ttc?cca?ata?aat?tct?act?ctg?ccc 4116

Leu?Cys Glu?Leu?Ser Phe?Phe?Pro?Ile?Asn?Ser?Thr?Leu?Pro

1295 1300

tac?tca?ctc?tc?aaaaaaaaaa?aaaaaaa 4144

Tyr?Ser?Leu

1305

SEQUENCE?LISTING11

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_000640

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1376

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(92)

<220>

<221>exon

<222>(93)..(219)

<220>

<221>sig_peptide

<222>(126)..(203)

<220>

<221>exon

<222>(220)..(371)

<220>

<221>exon

<222>(372)..(525)

<220>

<221>exon

<222>(526)..(646)

<220>

<221>exon

<222>(647)..(831)

<220>

<221>exon

<222>(832)..(977)

<220>

<221>exon

<222>(978)..(1122)

<220>

<221>exon

<222>(1123)..(1241)

<220>

<221>exon

<222>(1242)..(1373)

<220>

<221>polyA_signal

<222>(1343)..(1348)

<220>

<221>polyA_site

<222>(1366)..(1366)

<220>

<221>polyA_site

<222>(1373)..(1373)

<400>1

gta?aga?aca?ctc?tcg?tga?gtc?taa?cgg?tct?tcc?gga?tga?agg?cta?ttt 48

Val?Arg?Thr?Leu?Ser Val Arg?Ser?Ser?Gly Arg?Leu?Phe

1 5 10

gaa?gtc?gcc?ata?acc?tgg?tca?gaa?gtg?tgc?ctg?tcg?gcg?ggg?ag a?gag 96

Glu?Val?Ala?Ile?Thr?Trp?Ser?Glu?Val?Cys?Leu?Ser?Ala?Gly?Arg Glu

15 20 25

gca?ata?tca?agg?ttt?taa?atc?tcg?gag?aaa?tgg?ctt?tcg?ttt?gct?tgg 144

Ala?Ile?Ser?Arg?Phe Ile?Ser?Glu?Lys?Trp?Leu?Ser?Phe?Ala?Trp

30 35 40

cta?tcg?gat?gct?tat?ata?cct?ttc?tga?taa?gca?caa?cat?ttg?gct?gta 192

Leu?Ser?Asp?Ala?Tyr?Ile?Pro?Phe Ala?Gln?His?Leu?Ala?Val

45 50 55

ctt?cat?ctt?cag?aca?ccg?aga?taa?aag?tta?acc?ctc?ctc?agg?att?ttg 240

Leu?His?Leu?Gln?Thr?Pro?Arg Lys?Leu?Thr?Leu?Leu?Arg?Ile?Leu

60 65 70

aga?tag?tgg?atc?ccg?gat?act?tag?gtt?atc?tct?att?tgc?aat?ggc?aac 288

Arg Trp?Ile?Pro?Asp?Thr Val?Ile?Ser?Ile?Cys?Asn?Gly?Asn

75 80 85

ccc?cac?tgt?ctc?tgg?atc?att?tta?agg?aat?gca?cag?tgg?aat?atg?aac 336

Pro?His?Cys?Leu?Trp?Ile?Ile?Leu?Arg?Asn?Ala?Gln?Trp?Asn?Met?Asn

90 95 100

taa?aat?acc?gaa?aca?ttg?gta?gtg?aaa?cat?gga?ag a?cca?tca?tta?cta 384

Asn?Thr?Glu?Thr?Leu?Val?Val?Lys?His?Gly?Arg Pro?Ser?Leu?Leu

105 110 115

aga?atc?tac?att?aca?aag?atg?ggt?ttg?atc?tta?aca?agg?gca?ttg?aag 432

Arg?Ile?Tyr?Ile?Thr?Lys?Met?Gly?Leu?Ile?Leu?Thr?Arg?Ala?Leu?Lys

120 125 130

cga?aga?tac?aca?cgc?ttt?tac?cat?ggc?aat?gca?caa?atg?gat?cag?aag 480

Arg?Arg?Tyr?Thr?Arg?Phe?Tyr?His?Gly?Asn?Ala?Gln?Met?Asp?Gln?Lys

135 140 145 150

ttc?aaa?gtt?cct?ggg?cag?aaa?cta?ctt?att?gga?tat?cac?cac?aag?gaa 528

Phe?Lys?Val?Pro?Gly?Gln?Lys?Leu?Leu?Ile?Gly?Tyr?His?His?Lys?Glu

155 160 165

ttc?cag?aaa?cta?aag?ttc?agg?ata?tgg?att?gcg?tat?att?aca?att?ggc 576

Phe?Gln?Lys?Leu?Lys?Phe?Arg?Ile?Trp?Ile?Ala?Tyr?Ile?Thr?Ile?Gly

170 175 180

aat?att?tac?tct?gtt?ctt?gga?aac?ctg?gca?tag?gtg?tac?ttc?ttg?ata 624

Asn?Ile?Tyr?Ser?Val?Leu?Gly?Asn?Leu?Ala Val?Tyr?Phe?Leu?Ile

185 190 195

cca?att?aca?act?tgt?ttt?act?g?gt atg?agg?gct?tgg?atc?atg?cat?tac 672

Pro?Ile?Thr?Thr?Cys?Phe?Thr Gly?Met?Arg?Ala?Trp?Ile?Met?His?Tyr

200 210

agt?gtg?ttg?att?aca?tca?agg?ctg?atg?gac?aaa?ata?tag?gat?gca?gat 720

Ser?Val?Leu?Ile?Thr?Ser?Arg?Leu?Met?Asp?Lys?Ile Asp?Ala?Asp

215 220 225

ttc?cct?att?tgg?agg?cat?cag?act?ata?aag?att?tct?ata?ttt?gtg?tta 768

Phe?Pro?Ile?Trp?Arg?His?Gln?Thr?Ile?Lys?Ile?Ser?Ile?Phe?Val?Leu

230 235 240

atg?gat?cat?cag?aga?aca?agc?cta?tca?gat?cca?gtt?att?tca?ctt?ttc 816

Met?Asp?His?Gln?Arg?Thr?Ser?Leu?Ser?Asp?Pro?Val?Ile?Ser?Leu?Phe

245 250 255 260

agc?ttc?aaa?ata?tag?tta?aac?ctt?tgc?cgc?cag?tct?atc?tta?ctt?tta 864

Ser?Phe?Lys?Ile Leu?Asn?Leu?Cys?Arg?Gln?Ser?Ile?Leu?Leu?Leu

265 270 275

ctc?ggg?aga?gtt?cat?gtg?aaa?tta?agc?tga?aat?gga?gca?tac?ctt?tgg 912

Leu?Gly?Arg?Val?His?Val?Lys?Leu?Ser Asn?Gly?Ala?Tyr?Leu?Trp

280 285 290

gac?cta?ttc?cag?caa?ggt?gtt?ttg?att?atg?aaa?ttg?aga?tca?gag?aag 960

Asp?Leu?Phe?Gln?Gln?Gly?Val?Leu?Ile?Met?Lys?Leu?Arg?Ser?Glu?Lys

295 300 305

atg?ata?cta?cct?tgg?tg?a?ctg?cta?cag?ttg?aaa?atg?aaa?cat?aca?cct 1008

Met?Ile?Leu?Pro?Trp Leu?Leu?Gln?Leu?Lys?Met?Lys?His?Thr?Pro

310 315 320

tga?aaa?caa?caa?atg?aaa?ccc?gac?aat?tat?gct?ttg?tag?taa?gaa?gca 1056

Lys?Gln?Gln?MetLys?Pro?Asp?Asn?Tyr?Ala?Leu Glu?Ala

325 330 335

aag?tga?ata?ttt?att?gct?cag?atg?acg?gaa?ttt?gga?gtg?agt?gga?gtg 1104

Lys Ile?Phe?Ile?Ala?Gln?Met?Thr?Glu?Phe?Gly?Val?Ser?Gly?Val

340 345 350

ata?aac?aat?gct?ggg?aag?gtg?aag?acc?tat?cga?aga?aaa?ctt?tgc?tac 1152

Ile?Asn?Asn?Ala?Gly?Lys?Val?Lys?Thr?Tyr?Arg?Arg?Lys?Leu?Cys?Tyr

355 360 365

gtt?tct?ggc?tac?cat?ttg?gtt?tca?tct?taa?tat?tag?tta?tat?ttg?taa 1200

Val?Ser?Gly?Tyr?His?Leu?Val?Ser?Ser Tyr Leu?Tyr?Leu

370 375

ccg?gtc?tgc?ttt?tgc?gta?agc?caa?aca?cct?acc?caa?aaa?tg?a?ttc?cag 1248

Pro?Val?Cys?Phe?Cys?Val?Ser?Gln?Thr?Pro?Thr?Gln?Lys Phe?Gln

380 385 390 395

aat?ttt?tct?gtg?ata?cat?gaa?gac?ttt?cca?tat?caa?gag?aca?tgg?tat 1296

Asn?Phe?Ser?Val?Ile?His?Glu?Asp?Phe?Pro?Tyr?Gln?Glu?Thr?Trp?Tyr

400 405 410

tga?ctc?aac?agt?ttc?cag?tca?tgg?cca?aat?gtt?caa?tat?gag?tct?caa 1344

Leu?Asn?Ser?Phe?Gln?Ser?Trp?Pro?Asn?Val?Gln?Tyr?Glu?Ser?Gln

415 420 425

taa?act?gaa?ttt?ttc?ttg?cga?atg?ttg?aa?aaa 1376

Thr?Glu?Phe?Phe?Leu?Arg?Met?Leu

430

SEQUENCE?LISTING12

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_016368

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1852

<212>DNA

<213>Homo?sapiens<220>

<221>exon

<222>(1)..(41)

<220>

<221>exon

<222>(42)..(170)

<220>

<221>exon

<222>(171)..(332)

<220>

<221>exon

<222>(333)..(465)

<220>

<221>exon

<222>(466)..(659)

<220>

<221>exon

<222>(660)..(809)

<220>

<221>STS

<222>(715)..(970)

<220>

<221>exon

<222>(810)..(1025)

<220>

<221>exon

<222>(1026)..(1190)

<220>

<221>exon

<222>(1191)..(1304)

<220>

<221>exon

<222>(1305)..(1522)

<220>

<221>exon

<222>(1523)..(1825)

<220>

<221>STS

<222>(1559)..(1791)

<400>1

ccg?cgc?tgt?ccg?ccg?ccg?ctg?cct?gag?tcg?act?ctg?cgc?cg c?ccg?ccg 48

Pro?Arg?Cys?Pro?Pro?Pro?Leu?Pro?Glu?Ser?Thr?Leu?Arg?Arg Pro?Pro

1 5 10 15

cga?tgg?agg?ccg?ccg?ccc?agt?tct?tcg?tcg?aga?gcc?cgg?acg?tgg?tct 96

Arg?Trp?Arg?Pro?Pro?Pro?Ser?Ser?Ser?Ser?Arg?Ala?Arg?Thr?Trp?Ser

20 25 30

acg?gcc?ccg?agg?cca?tcg?agg?cgc?aat?acg?agt?acc?gga?cga?cgc?gcg 144

Thr?Ala?Pro?Arg?Pro?Ser?Arg?Arg?Asn?Thr?Ser?Thr?Gly?Arg?Arg?Ala

35 40 45

tca?gcc?gcg?agg?gtg?gcg?ttc?tca?ag g?tgc?acc?cca?cgt?cca?cgc?gct 192

Ser?Ala?Ala?Arg?Val?Ala?Phe?Ser?Arg Cys?Thr?Pro?Arg?Pro?Arg?Ala

50 55 60

tca?cct?tcc?gga?ccg?ccc?ggc?agg?tgc?ccc?ggc?tcg?ggg?tca?tgc?ttg 240

Ser?Pro?Ser?Gly?Pro?Pro?Gly?Arg?Cys?Pro?Gly?Ser?Gly?Ser?Cys?Leu

65 70 75 80

tcg?gct?ggg?gcg?gga?aca?acg?gct?cca?cac?tca?ccg?ccg?cgg?tgc?tgg 288

Ser?Ala?Gly?Ala?Gly?Thr?Thr?Ala?Pro?His?Ser?Pro?Pro?Arg?Cys?Trp

85 90 95

cca?atc?gac?tgc?gtt?tgt?cct?ggc?cca?cgc?gca?gcg?gcc?gca?ag g?agg 336

Pro?Ile?Asp?Cys?Val?Cys?Pro?Gly?Pro?Arg?Ala?Ala?Ala?Ala?Arg Arg

100 105 110

cca?act?act?acg?gct?cgc tga?ctc?agg?cgg?gca?ccg?tga?gcc?tgg?gcc 384

Pro?Thr?Thr?Thr?Ala?Arg Leu?Arg?Arg?Ala?Pro Ala?Trp?Ala

115 120 125

tgg?acg?ccg?agg?gcc?agg?agg?tgt?tcg?tac?cct?tca?gcg?cgg?tgc?tgc 432

Trp?Thr?Pro?Arg?Ala?Arg?Arg?Cys?Ser?Tyr?Pro?Ser?Ala?Arg?Cys?Cys

130 135 140

cca?tgg?tgg?cgc?cca?acg?acc?tcg?tgt?tcg?atg?gct?ggg?aca?tct?cgt 480

Pro?Trp?Trp?Arg?Pro?Thr?Thr?Ser?Cys?Ser?Met?Ala?Gly?Thr?Ser?Arg

145 150 155

cgc?tga?acc?tgg?ccg?agg?cga?tgc?ggc?gcg?cga?agg?tgc?tgg?act?ggg 528

Arg Thr?Trp?Pro?Arg?Arg?Cys?Gly?Ala?Arg?Arg?Cys?Trp?Thr?Gly

160 165 170

ggc?tgc?agg?agc?aac?tgt?ggc?cgc?aca?tgg?agg?ccc?tgc?ggc?ccc?ggc 576

Gly?Cys?Arg?Ser?Asn?Cys?Gly?Arg?Thr?Trp?Arg?Pro?Cys?Gly?Pro?Gly

175 180 185

ctt?ctg?ttt?aca?tcc?ccg?aat?tca?tcg?cgg?cca?acc?aga?gcg?cgc?gcg 624

Leu?Leu?Phe?Thr?Ser?Pro?Asn?Ser?Ser?Arg?Pro?Thr?Arg?Ala?Arg?Ala

190 195 200 205

cgg?aca?acc?tca?tcc?cag?gct?cgc?gtg?cgc?agc?ag c?tgg?agc?aga?tcc 672

Arg?Thr?Thr?Ser?Ser?Gln?Ala?Arg?Val?Arg?Ser?Ser Trp?Ser?Arg?Ser

210 215 220

gca?ggg?aca?tcc?gag?act?tcc?ggt?cta?gcg?cgg?ggc?tgg?aca?aag?tca 720

Ala?Gly?Thr?Ser?Glu?Thr?Ser?Gly?Leu?Ala?Arg?Gly?Trp?Thr?Lys?Ser

225 230 235

tag?tgc?tgt?gga?cgg?cga?aca?cgg?agc?gct tct?gtg?agg?tga?ttc?cag 768

Cys?Cys?Gly?Arg?Arg?Thr?Arg?Ser?Ala?Ser?Val?Arg Phe?Gln

240 245 250

gcc?tca?acg?aca?cag?ccg?aga?acc?tgc?tgc?gca?cca?ttg?ag c?tcg?gtc 816

Ala?Ser?Thr?Thr?Gln?Pro?Arg?Thr?Cys?Cys?Ala?Pro?Leu?Ser Ser?Val

255 260

tgg?agg?tgt?cgc?cct?cca?cgc?tct?tcg?ccg?tgg?cca?gca?tcc?tgg?agg 864

Trp?Arg?Cys?Arg?Pro?Pro?Arg?Ser?Ser?Pro?Trp?Pro?Ala?Ser?Trp?Arg

270 275 280

gct?gtg?cct?tcc?tca?atg?ggt?ctc?cgc?aga?aca?ccc?tgg?tgc?ccg?gag 912

Ala?Val?Pro?Ser?Ser?Met?Gly?Leu?Arg?Arg?Thr?Pro?Trp?Cys?Pro?Glu

285 290 295

ctc?ttg?agc?tcg?cgt?ggc?agc?acc?ggg?ttt?ttg?tgg?gcg?gag?atg?act 960

Leu?Leu?Ser?Ser?Arg?Gly?Ser?Thr?Gly?Phe?Leu?Trp?Ala?Glu?Met?Thr

300 305 310 315

tca?agt?cag?gcc?aga?cca?aag?tca?agt?ccg?tgc?ttg?tgg?act?tcc?tca 1008

Ser?Ser?Gln?Ala?Arg?Pro?Lys?Ser?Ser?Pro?Cys?Leu?Trp?Thr?Ser?Ser

320 325 330

ttg?gct?ccg?gcc?tca?ag a?cca?tgt?cca?tcgtga?gtt?aca?acc?acc?tgg 1056

Leu?Ala?Pro?Ala?Ser?Arg Pro?Cys?Pro?Ser Val?Thr?Thr?Thr?Trp

335 340 345

gca?aca?acg?atg?ggg?aga?acc?tat?cgg?cgc?cat?tgc?agt?tcc?gct?cta 1104

Ala?Thr?Thr?Met?Gly?Arg?Thr?Tyr?Arg?Arg?His?Cys?Ser?Ser?Ala?Leu

350 355 360

agg?agg?tgt?cca?aga?gca?acg?tgg?tgg?acg?aca?tgg?tgc?aga?gca?acc 1152

Arg?Arg?Cys?Pro?Arg?Ala?Thr?Trp?Trp?Thr?Thr?Trp?Cys?Arg?Ala?Thr

365 370 375

cag?tgc?tct?ata?cgc?ccg?gcg?aag?agc?ctg?acc?act?gc g?tgg?tca?tca 1200

Gln?Cys?Ser?Ile?Arg?Pro?Ala?Lys?Ser?Leu?Thr?Thr?Ala Trp?Ser?Ser

380 385 390

agt?atg?tgc?cgt?acg?tgg?gtg?aca?gca?agc?gcg?cgc?tgg?atg?agt?ata 1248

Ser?Met?Cys?Arg?Thr?Trp?Val?Thr?Ala?Ser?Ala?Arg?Trp?Met?Ser?Ile

395 400 405 410

cct?cgg?agc?tga?tgc?tgg?gcg?gaa?cca?aca?cac?tgg?tgc?tgc?aca?aca 1296

Pro?Arg?Ser Cys?Trp?Ala?Glu?Pro?Thr?His?Trp?Cys?Cys?Thr?Thr

415 420 425

cgt?gtg?ag g?act?cgc?tgc?tgg?ccg?cac?cca?tca?tgc?tgg?acc?tag?cgc 1344

Arg?Val?Arg Thr?Arg?Cys?Trp?Pro?His?Pro?Ser?Cys?Trp?Thr Arg

430 435 440

tgc?tga?ccg?agc?tgt?gcc?agc?gcg?tga?gct?tct?gca?ctg?aca?tgg?acc 1392

Cys Pro?Ser?Cys?Ala?Ser?Ala Ala?Ser?Ala?Leu?Thr?Trp?Thr

445 450

ccg?agc?cgc?aga?cct?tcc?acc?ccg?tgc?tgt?ccc?tgc?tca?gct?tcc?tct 1440

Pro?Ser?Arg?Arg?Pro?Ser?Thr?Pro?Cys?Cys?Pro?Cys?Ser?Ala?Ser?Ser

455 460 465 470

tca?agg?cgc?cac?tag?tgc?cgc?ccg?gca?gcc?cgg?tgg?tca?atg?cgc?ttt 1488

Ser?Arg?Arg?His Cys?Arg?Pro?Ala?Ala?Arg?Trp?Ser?Met?Arg?Phe

475 480 485

tcc?gcc?agc?gca?gct?gca?tcg?aga?aca?tcc?tca?g?gg cct?gcg?tgg?ggc 1536

Ser?Ala?Ser?Ala?Ala?Ala?Ser?Arg?Thr?Ser?Ser Gly?Pro?Ala?Trp?Gly

490 495 500

tcc?cgc?cac?aga?acc?aca?tgc?tcc?tgg?aac?aca?aaa?tgg?agc?gcc?cag 1584

Ser?Arg?His?Arg?Thr?Thr?Cys?Ser?Trp?Asn?Thr?Lys?Trp?Ser?Ala?Gln

505 510 515

ggc?cca?gcc?tca?agc?gag?ttg?gac?ccg?tgg?ctg?cca?cct?acc?cta?tgt 1632

Gly?Pro?Ala?Ser?Ser?Glu?Leu?Asp?Pro?Trp?Leu?Pro?Pro?Thr?Leu?Cys

520 525 530

tga?aca?aga?aag?gac?cgg?tac?ccg?ctg?cca?cca?atg?gct?gca?ccg?gtg 1680

Thr?Arg?Lys?Asp?Arg?Tyr?Pro?Leu?Pro?Pro?Met?Ala?Ala?Pro?Val

535 540 545

atg?cca?atg?ggc?atc?tgc?aag?agg?agc?ccc?caa?tgc?cca?cca?cct?gag 1728

Met?Pro?Met?Gly?Ile?Cys?Lys?Arg?Ser?Pro?Gln?Cys?Pro?Pro?Pro?Glu

550 555 560

gcc?ccg?gtc?aca?cag?ttt?ctc?ggc?tct?tcc?tcc?ccg?ctg?ccc?ccc?acg 1776

Ala?Pro?Val?Thr?Gln?Phe?Leu?Gly?Ser?Ser?Ser?Pro?Leu?Pro?Pro?Thr

565 570 575 580

acc?cta?cct?tga?agg?ccc?cca?caa?ata?aag?gcg?ctg?cca?ctc?agc?cct?c 1825

Thr?Leu?Pro Arg?Pro?Pro?Gln?Ile?Lys?Ala?Leu?Pro?Leu?Ser?Pro

585 590 595

aaaaaaaaaa?aaaaaaaaaa?aaaaaaa 1852

SEQUENCE?LISTING13

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_004923

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2535

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(101)

<220>

<221>exon

<222>(102)..(611)

<220>

<221>exon

<222>(612)..(770)

<220>

<221>exon

<222>(771)..(891)

<220>

<221>exon

<222>(892)..(968)

<220>

<221>exon

<222>(969)..(1057)

<220>

<221>exon

<222>(1058)..(1160)

<220>

<221>exon

<222>(1161)..(1298)

<220>

<221>exon

<222>(1299)..(1474)

<220>

<221>exon

<222>(1475)..(2535)

<220>

<221>STS

<222>(2123)..(2304)

<220>

<221>polyA_signal

<222>(2512)..(2517)

<220>

<221>polyA_site

<222>(2535)..(2535)

<400>1

acc?ctt?ccc?cct?tct?cca?acc?gcc?aac?ggc?cgc?ctg?cgc?ctg?agg?ccc 48

Thr?Leu?Pro?Pro?Ser?Pro?Thr?Ala?Asn?Gly?Arg?Leu?Arg?Leu?Arg?Pro

1 5 10 15

ggc?cca?cgc?ccc?atc?ccg?ctc?gct?cca?cgc?tgc?ggc?agc?ccc?ggc?ggc 96

Gly?Pro?Arg?Pro?Ile?Pro?Leu?Ala?Pro?Arg?Cys?Gly?Ser?Pro?Gly?Gly

20 25 30

ccc?ag g?tgc?gcg?gcc?ccc?gcc?atc?ccg?ccc?cgc?cgc?cct?gcg?cca?tgg 144

Pro?Arg Cys?Ala?Ala?Pro?Ala?Ile?Pro?Pro?Arg?Arg?Pro?Ala?Pro?Trp

35 40 45

agg?agg?gcc?ctc?tgc?cgg?gcg?ggc?tgc?cca?gcc?ccg?agg?atg?cga?tgg 192

Arg?Arg?Ala?Leu?Cys?Arg?Ala?Gly?Cys?Pro?Ala?Pro?Arg?Met?Arg?Trp

50 55 60

tga?cgg?agc?tct?taa?gcc?ccg?agg?gtc?cgt?tcg?ctt?cgg?aga?aca?tcg 240

Arg?Ser?Ser Ala?Pro?Arg?Val?Arg?Ser?Leu?Arg?Arg?Thr?Ser

65 70 75

gcc?tga?agg?ccc?ccg?tga?agt?acg?agg?agg?acg?agt?tcc?acg?tct?tca 288

Ala Arg?Pro?Pro Ser?Thr?Arg?Arg?Thr?Ser?Ser?Thr?Ser?Ser

80 85 90

aag?aag?cgt?acc?tgg?gcc?cgg?cgg?acc?cca?agg?aac?ccg?tcc?tgc?acg 336

Lys?Lys?Arg?Thr?Trp?Ala?Arg?Arg?Thr?Pro?Arg?Asn?Pro?Ser?Cys?Thr

95 100 105

cgt?tca?acc?ccg?cgc?tgg?gcg?ccg?act?gca?agg?gcc?agg?tca?agg?cga 384

Arg?Ser?Thr?Pro?Arg?Trp?Ala?Pro?Thr?Ala?Arg?Ala?Arg?Ser?Arg?Arg

110 115 120

agc?tcg?cgg?ggg?gcg?aca?gcg?acg?gcg?ggg?agc?tcc?tcg?ggg?agt?acc 432

Ser?Ser?Arg?Gly?Ala?Thr?Ala?Thr?Ala?Gly?Ser?Ser?Ser?Gly?Ser?Thr

125 130 135 140

ccg?gga?tcc?cag?agc?tca?gcg?cgc?tgg?agg?acg?tcg?cgc?tcc?tgc?agg 480

Pro?Gly?Ser?Gln?Ser?Ser?Ala?Arg?Trp?Arg?Thr?Ser?Arg?Ser?Cys?Arg

145 150 155

ccc?cgc?agc?cgc?ccg?cct?gca?acg?tgc?act?tcc?tgt?cct?cgc?tgc?tac 528

Pro?Arg?Ser?Arg?Pro?Pro?Ala?Thr?Cys?Thr?Ser?Cys?Pro?Arg?Cys?Tyr

160 165 170

ccg?cgc?acc?gca?gcc?cgg?cgg?tgt?tgc?ccc?tgg?gcg?cct?ggg?tcc?tgg 576

Pro?Arg?Thr?Ala?Ala?Arg?Arg?Cys?Cys?Pro?Trp?Ala?Pro?Gly?Ser?Trp

175 180 185

aag?gag?cct?ccc?acc?cgg?gcg?tcc?gca?tga?tcc?ca g?ttg?aaa?tca?agg 624

Lys?Glu?Pro?Pro?Thr?Arg?Ala?Ser?Ala Ser?Gln Leu?Lys?Ser?Arg

190 195 200

aag?cag?gtg?gta?cta?cta?caa?gta?ata?atc?cgg?aag?aag?caa?ctt?tgc 672

Lys?Gln?Val?Val?Leu?Leu?Gln?Val?Ile?Ile?Arg?Lys?Lys?Gln?Leu?Cys

205 210 215

aga?atc?ttc?ttg?ctc?agg?aat?cct?gtt?gca?agt?tcc?cat?cgt?ccc?agg 720

Arg?Ile?Phe?Leu?Leu?Arg?Asn?Pro?Val?Ala?Ser?Ser?His?Arg?Pro?Arg

220 225 230 235

aac?tag?agg?atg?cct?cct?gct?gtt?ctc?tta?aga?aag?att?cca?acc?caa 768

Asn Arg?Met?Pro?Pro?Ala?Val?Leu?Leu?Arg?Lys?Ile?Pro?Thr?Gln

240 245 250

tg g?tga?tat?gcc?aat?tga?aag?ggg?gca?cac?aaa?tgc?tat?gta?tag?aca 816

Trp Tyr?Ala?Asn Lys?Gly?Ala?His?Lys?Cys?Tyr?Val Thr

255 260

att?cta?gaa?caa?gag?aac?taa?aag?cac?tcc?att?tgg?ttc?ctc?agt?atc 864

Ile?Leu?Glu?Gln?Glu?Asn Lys?His?Ser?Ile?Trp?Phe?Leu?Ser?Ile

265 270 275

aag?atc?aaa?ata?att?atc?tac?agt?cag?atg?tcc?cta?aac?caa?tga?ctg 912

Lys?Ile?Lys?Ile?IleIle?Tyr?Ser?Gln?Met?Ser?Leu?Asn?Gln Leu

280 285 290

ctt?tag?tag?gga?gat?ttt?tgc?cag?cat?caa?caa?aat?taa?atc?tca?tta 960

Leu Gly?Asp?Phe?Cys?Gln?His?Gln?Gln?Asn Ile?Ser?Leu

295 300 305

cac?aac?aa c?ttg?agg?gag?cct?tac?cat?cgg?tag?tca?acg?ggt?ctg?ctt 1008

His?Asn?Asn Leu?Arg?Glu?Pro?Tyr?His?Arg Ser?Thr?Gly?Leu?Leu

310 315 320

tcc?cct?cgg?gat?caa?ctc?ttc?cag?gac?cac?caa?aaa?taa?ctt?tgg?ctg?g 1057

Ser?Pro?Arg?Asp?Gln?Leu?Phe?Gln?Asp?His?Gln?Lys Leu?Trp?Leu

325 330 335

gt act?gtg?act?gct?ttg?cca?gtg?ggg?act?ttt?gca?aca?act?gca?att 1104

Gly?Thr?Val?Thr?Ala?Leu?Pro?Val?Gly?Thr?Phe?Ala?Thr?Thr?Ala?Ile

340 345 350

gta?ata?att?gtt?gca?aca?act?tgc?atc?atg?ata?ttg?aac?ggt?tta?aag 1152

Val?Ile?Ile?Val?Ala?Thr?Thr?Cys?Ile?Met?Ile?Leu?Asn?Gly?Leu?Lys

355 360 365

cca?tta?ag g?cat?gtc?ttg?gta?gaa?atc?cag?aag?ctt?tcc?agc?caa?aaa 1200

Pro?Leu?Arg His?Val?Leu?Val?Glu?Ile?Gln?Lys?Leu?Ser?Ser?Gln?Lys

370 375 380

ttg?gga?agg?gcc?aat?tgg?gca?atg?tca?agc?ccc?agc?aca?aca?aag?ggt 1248

Leu?Gly?Arg?Ala?Asn?Trp?Ala?Met?Ser?Ser?Pro?Ser?Thr?Thr?Lys?Gly

385 390 395 400

gca?act?gca?gga?ggt?cag?gct?gcc?tga?aga?att?act?gcg?agt?gct?atg 1296

Ala?Thr?Ala?Gly?Gly?Gln?Ala?Ala Arg?Ile?Thr?Ala?Ser?Ala?Met

405 410 415

ag g?ccc?aaa?tta?tgt?gtt?ctt?cta?ttt?gca?aat?gca?ttg?gtt?gca?aaa 1344

Arg Pro?Lys?Leu?Cys?Val?Leu?Leu?Phe?Ala?Asn?Ala?Leu?Val?Ala?Lys

420 425 430

att?atg?aag?aaa?gcc?cag?aac?gaa?aga?cac?taa?tga?gca?tgc?caa?act 1392

Ile?Met?Lys?Lys?Ala?Gln?Asn?Glu?Arg?His Ala?Cys?Gln?Thr

435 440 445

aca?tgc?aga?ctg?gag?gtt?tgg?aag?gca?gcc?att?acc?tgc?cac?caa?cga 1440

Thr?Cys?Arg?Leu?Glu?Val?Trp?Lys?Ala?Ala?Ile?Thr?Cys?His?Gln?Arg

450 455 460

aat?ttt?cag?gac?ttc?caa?gat?tca?gtc?acg?ata?g?gc ggc?ctt?cct?cat 1488

Asn?Phe?Gln?Asp?Phe?Gln?Asp?Ser?Val?Thr?Ile Gly?Gly?Leu?Pro?His

465 470 475

gca?tct?cct?ggg?agg?tgg?tgg?agg?cca?cat?gcg?cct?gcc?tgc?ttg?ctc 1536

Ala?Ser?Pro?Gly?Arg?Trp?Trp?Arg?Pro?His?Ala?Pro?Ala?Cys?Leu?Leu

480 485 490

agg?gag?aag?agg?ccg?aga?aag?aac?act?gct?cca?agt?gcc?tgg?cag?agc 1584

Arg?Glu?Lys?Arg?Pro?Arg?Lys?Asn?Thr?Ala?Pro?Ser?Ala?Trp?Gln?Ser

495 500 505

aga?tga?tcc?tgg?agg?aat?ttg?gaa?ggt?gct?tat?cac?aga?ttc?tcc?aca 1632

Arg Ser?Trp?Arg?Asn?Leu?Glu?Gly?Ala?Tyr?His?Arg?Phe?Ser?Thr

510 515 520

ctg?agt?tta?aat?cta?agg?gat?tga?aaa?tgg?agt?aga?gta?taa?agt?gtg 1680

Leu?Ser?Leu?Asn?Leu?Arg?Asp Lys?Trp?Ser?Arg?Val Ser?Val

525 530 535

aat?gca?tgt?tga?ttt?tgt?ctt?agt?cta?gaa?atc?tct?agt?tta?gaa?agg 1728

Asn?Ala?Cys Phe?Cys?Leu?Ser?Leu?Glu?Ile?Ser?Ser?Leu?Glu?Arg

540 545 550

atg?ttt?agg?gga?aca?tga?ggc?tgg?ctc?tgc?agc?aac?aac?cag?gct?ccc 1776

Met?Phe?Arg?Gly?Thr Gly?Trp?Leu?Cys?Ser?Asn?Asn?Gln?Ala?Pro

555 560 565

ctg?cat?ccc?tgg?gcc?cag?gga?gtt?tac?tca?gag?ctc?tct?gaa?gat?gtg 1824

Leu?His?Pro?Trp?Ala?Gln?Gly?Val?Tyr?Ser?Glu?Leu?Ser?Glu?Asp?Val

570 575 580

gca?acc?cat?gcc?ccc?ttt?tct?gag?gag?gtg?cat?ggc?ctg?agc?att?gtt 1872

Ala?Thr?His?Ala?Pro?Phe?Ser?Glu?Glu?Val?His?Gly?Leu?Ser?Ile?Val

585 590 595 600

tgt?ctg?gcc?cag?agg?aga?gag?ctt?ggg?ttc?cca?tag?tcc?tgg?gag?agt 1920

Cys?Leu?Ala?Gln?Arg?Arg?Glu?Leu?Gly?Phe?Pro Ser?Trp?Glu?Ser

605 610 615

gtc?tgc?agg?gcg?gcg?gag?ggc?aga?gca?ggg?cag?ggg?agg?gca?cag?cag 1968

Val?Cys?Arg?Ala?Ala?Glu?Gly?Arg?Ala?Gly?Gln?Gly?Arg?Ala?Gln?Gln

620 625 630

gcc?ctg?cga?agg?gca?gag?cgg?ggc?agg?gga?ggg?cag?agc?agg?ccc?tgc 2016

Ala?Leu?Arg?Arg?Ala?Glu?Arg?Gly?Arg?Gly?Gly?Gln?Ser?Arg?Pro?Cys

635 640 645

gga?gag?ctc?act?ctg?gtc?gac?tct?tcc?tct?cag?aga?atg?ttg?ctc?tgg 2064

Gly?Glu?Leu?Thr?Leu?Val?Asp?Ser?Ser?Ser?Gln?Arg?Met?Leu?Leu?Trp

650 655 660

agg?ctg?ctc?tgc?atg?aaa?acc?cta?atg?gtt?tct?tgt?ttg?ttt?ttc?aaa 2112

Arg?Leu?Leu?Cys?Met?Lys?Thr?Leu?Met?Val?Ser?Cys?Leu?Phe?Phe?Lys

665 670 675

tta?ttt?aga?aat?aag?ttc?tcc?gga?tgg?gct?gtt?gtg?ata?cca?ctt?aaa 2160

Leu?Phe?Arg?Asn?Lys?Phe?Ser?Gly?Trp?Ala?Val?Val?Ile?Pro?Leu?Lys

680 685 690 695

atc?tct?aga?gaa?cta?ctg?aac?acc?taa?aga?ttt?tct?gta?gcg?tag?ata 2208

Ile?Ser?Arg?Glu?Leu?Leu?Asn?Thr Arg?Phe?Ser?Val?Ala Ile

700 705

ttt?ccc?cag?agg?cac?gcg?aac?tgt?cag?tct?ttc?cta?agg?ccc?ccg?gga 2256

Phe?Pro?Gln?Arg?His?Ala?Asn?Cys?Gln?Ser?Phe?Leu?Arg?Pro?Pro?Gly

710 715 720 725

gac?gca?ggc?aat?ggg?gcc?tcg?cag?gcc?agg?ctt?gca?cca?gca?tgt?ctt 2304

Asp?Ala?Gly?Ash?Gly?Ala?Ser?Gln?Ala?Arg?Leu?Ala?Pro?Ala?Cys?Leu

730 735 740

gag?tta?gag?gac?tta?aaa?tta?tcc?agt?ttc?ttc?tgt?gtt?tct?act?tga 2352

Glu?Leu?Glu?Asp?Leu?Lys?Leu?Ser?Ser?Phe?Phe?Cys?Val?Ser?Thr

745 750 755

att?gtg?gaa?aag?ctc?tat?tat?cca?att?aac?ttc?tcc?ata?att?att?gtt 2400

Ile?Val?Glu?Lys?Leu?Tyr?Tyr?Pro?Ile?Asn?Phe?Ser?Ile?Ile?Ile?Val

760 765 770

gta?ata?tta?tta?ttg?ttt?gta?aaa?cat?ggt?tca?cat?aac?tag?ctt?gtg 2448

Val?Ile?Leu?Leu?Leu?Phe?Val?Lys?His?Gly?Ser?His?Asn Leu?Val

775 780 785

gaa?acc?agc?agg?taa?aat?gaa?ttc?tta?agt?tga?cgc?ttt?tgg?ttc?tgt 2496

Glu?Thr?Ser?Arg Asn?Glu?Phe?Leu?Ser Arg?Phe?Trp?Phe?Cys

790 795 800

tgt?aaa?gca?aag?atg?aat?aaa?aat?ttc?caa?tgt?ctt?caa 2535

Cys?Lys?Ala?Lys?Met?Asn?Lys?Asn?Phe?Gln?Cys?Leu?Gln

805 810

SEQUENCE?LISTING14

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_153485

<160>1

<170>PatentIn?vetsion?3.5

<210>1

<211>4355

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(275)

<220>

<221>exon

<222>(276)..(413)

<220>

<221>exon

<222>(414)..(510)

<220>

<221>exon

<222>(511)..(581)

<220>

<221>exon

<222>(582)..(674)

<220>

<221>exon

<222>(675)..(841)

<220>

<221>exon

<222>(842)..(947)

<220>

<221>exon

<222>(948)..(1021)

<220>

<221>exon

<222>(1022)..(1113)

<220>

<221>exon

<222>(1114)..(1211)

<220>

<221>exon

<222>(1212)..(1364)

<220>

<221>exon

<222>(1365)..(1465)

<220>

<221>exon

<222>(1466)..(1636)

<220>

<221>exon

<222>(1637)..(1747)

<220>

<221>exon

<222>(1748)..(1842)

<220>

<221>exon

<222>(1843)..(1931)

<220>

<221>exon

<222>(1932)..(1994)

<220>

<221>exon

<222>(1995)..(2142)

<220>

<221>exon

<222>(2143)..(2209)

<220>

<221>exon

<222>(2210)..(2325)

<220>

<221>exon

<222>(2326)..(2423)

<220>

<221>exon

<222>(2424)..(2554)

<220>

<221>exon

<222>(2555)..(2746)

<220>

<221>exon

<222>(2747)..(2885)

<220>

<221>exon

<222>(2886)..(3021)

<220>

<221>exon

<222>(3022)..(3175)

<220>

<221>exon

<222>(3176)..(3280)

<220>

<221>exon

<222>(3281)..(3435)

<220>

<221>exon

<222>(3436)..(3565)

<220>

<221>STS

<222>(3492)..(3653)

<220>

<221>exon

<222>(3566)..(3679)

<220>

<221>exon

<222>(3680)..(3800)

<220>

<221>exon

<222>(3801)..(3911)

<220>

<221>exon

<222>(3912)..(4048)

<220>

<221>exon

<222>(4049)..(4155)

<220>

<221>exon

<222>(4156)..(4355)

<220>

<221>polyA_signal

<222>(4333)..(4338)

<220>

<221>polyA_site

<222>(4355)..(4355)

<400>1

aag?gcg?ctc?gtt?tgg?cgc?gcg?cgc?cct?agg?cgg?cgg?atc?taa?gct?aac 48

Lys?Ala?Leu?Val?Trp?Arg?Ala?Arg?Pro?Arg?Arg?Arg?Ile Ala?Asn

1 5 10 15

ttc?ttg?gat?ctt?ttc?ttg?ttt?ctc?ctt?ggt?ttt?tga?ctt?ttt?ctg?gac 96

Phe?Leu?Asp?Leu?Phe?Leu?Phe?Leu?Leu?Gly?Phe Leu?Phe?Leu?Asp

20 25 30

cct?ggt?gtc?tac?gat?ttc?cga?gat?gcc?gtc?ttc?ttt?gtt?ggg?cgc?ggc 144

Pro?Gly?Val?Tyr?Asp?Phe?Arg?Asp?Ala?Val?Phe?Phe?Val?Gly?Arg?Gly

35 40 45

gat?gcc?ggc?ctc?tac?atc?tgc?cgc?agc?cct?gca?gga?agc?tct?gga?aaa 192

Asp?Ala?Gly?Leu?Tyr?Ile?Cys?Arg?Ser?Pro?Ala?Gly?Ser?Ser?Gly?Lys

50 55 60

tgc?tgg?acg?gct?cat?cga?ccg?tca?gtt?gca?aga?gga?ccg?cat?gta?ccc 240

Cys?Trp?Thr?Ala?His?Arg?Pro?Ser?Val?Ala?Arg?Gly?Pro?His?Val?Pro

65 70 75

gga?cct?ttc?cga?gct?gct?tat?ggt?gtc?tgc?ccc?aa a?taa?tcc?cac?cgt 288

Gly?Pro?Phe?Arg?Ala?Ala?Tyr?Gly?Val?Cys?Pro?Lys Ser?His?Arg

80 85

ttc?tgg?cat?gtc?aga?tat?gga?tta?tcc?ttt?aca?agg?acc?tgg?ttt?gct 336

Phe?Trp?His?Val?Arg?Tyr?Gly?Leu?Ser?Phe?Thr?Arg?Thr?Trp?Phe?Ala

95 100 105

gtc?cgt?acc?caa?cct?tcc?aga?gat?cag?ttc?cat?ccg?aag?agt?tcc?tct 384

Val?Arg?Thr?Gln?Pro?Ser?Arg?Asp?Gln?Phe?His?Pro?Lys?Ser?Ser?Ser

110 115 120 125

ccc?acc?tga?act?tgt?tga?gca?gtt?tgg?ac a?tat?gca?gtg?taa?ttg?cat 432

Pro?Thr Thr?Cys Ala?Val?Trp?Thr Tyr?Ala?Val Leu?His

130 135

gat?ggg?tgt?gtt?ccc?tcc?tat?cag?cag?agc?ttg?gct?cac?aat?tga?cag 480

Asp?Gly?Cys?Val?Pro?Ser?Tyr?Gln?Gln?Ser?Leu?Ala?His?Asn Gln

140 145 150

tga?tat?att?cat?gtg?gaa?cta?tga?gga?tgg?agg?aga?cct?tgc?cta?ttt 528

Tyr?Ile?His?Val?Glu?Leu Gly?Trp?Arg?Arg?Pro?Cys?Leu?Phe

155 160 165

tga?tgg?act?tag?tga?gac?tat?tct?tgc?tgt?ggg?gct?tgt?gaa?gcc?aaa 576

Trp?Thr Asp?Tyr?Ser?Cys?Cys?Gly?Ala?Cys?Glu?Ala?Lys

170 175 180

agc?ag g?cat?ctt?tca?acc?tca?tgt?gcg?aca?cct?cct?ggt?ttt?ggc?gac 624

Ser?Arg His?Leu?Ser?Thr?Ser?Cys?Ala?Thr?Pro?Pro?Gly?Phe?Gly?Asp

185 190 195

ccc?tgt?aga?cat?agt?aat?tct?tgg?act?cag?cta?tgc?taa?ttt?gca?aac 672

Pro?Cys?Arg?His?Ser?Asn?Ser?Trp?Thr?Gln?Leu?Cys Phe?Ala?Asn

200 205 210

ag g?ttc?tgg?agt?tct?taa?tga?tag?ttt?gtc?tgg?tgg?aat?gca?gtt?gct 720

Arg Phe?Trp?Ser?Ser Phe?Val?Trp?Trp?Asn?Ala?Val?Ala

215 220

tcc?aga?tcc?ttt?ata?ttc?tct?tcc?tac?tga?taa?tac?tta?cct?ttt?aac 768

Ser?Arg?Ser?Phe?Ile?Phe?Ser?Ser?Tyr Tyr?Leu?Pro?Phe?Asn

225 230 235

aat?aac?ttc?cac?tga?taa?tgg?cag?aat?ttt?ctt?ggc?tgg?aaa?gga?tgg 816

Asn?Asn?Phe?His Trp?Gln?Asn?Phe?Leu?Gly?Trp?Lys?Gly?Trp

240 245 250

ctg?ttt?ata?tga?agt?agc?cta?cca?g?gc tga?agc?agg?gtg?gtt?tag?cca 864

Leu?Phe?Ile Ser?Ser?Leu?Pro Gly Ser?Arg?Val?Val Pro

255 265

aag?atg?tag?gaa?aat?aaa?cca?ctc?aaa?gag?ctc?act?ttc?ttt?cct?tgt 912

Lys?Met Glu?Asn?Lys?Pro?Leu?Lys?Glu?Leu?Thr?Phe?Phe?Pro?Cys

270 275 280

tcc?ttc?ctt?gct?aca?att?cac?gtt?ctc?aga?aga?tg a?tcc?tat?tct?tca 960

Ser?Phe?Leu?Ala?Thr?Ile?His?Val?Leu?Arg?Arg Ser?Tyr?Ser?Ser

285 290 295

aat?tgc?aat?tga?taa?ttc?tag?aaa?tat?ttt?ata?tac?acg?atc?tga?gaa 1008

Asn?Cys?Asn Phe Lys?Tyr?Phe?Ile?Tyr?Thr?Ile Glu

300 305

agg?agt?aat?aca?g?gt gta?tga?ttt?ggg?aca?aga?tgg?aca?agg?aat?gag 1056

Arg?Ser?Asn?Thr Gly?Val Phe?Gly?Thr?Arg?Trp?Thr?Arg?Asn?Glu

310 315 320

cag?agt?tgc?ctc?tgt?gtc?aca?gaa?tgc?cat?tgt?ctc?tgc?tgc?tgg?taa 1104

Gln?Ser?Cys?Leu?Cys?Val?Thr?Glu?Cys?His?Cys?Leu?Cys?Cys?Trp

325 330 335

cat?tgc?tag?gac?cat?cga?tcg?ttc?tgt?ttt?taa?acc?aat?tgt?cca?aat 1152

His?Cys Asp?His?Arg?Ser?Phe?Cys?Phe Thr?Asn?Cys?Pro?Asn

340 345 350

agc?agt?gat?tga?aaa?ttc?tga?atc?act?gga?ctg?tca?gtt?att?ggc?tgt 1200

Ser?Ser?Asp Lys?Phe Ile?Thr?Gly?Leu?Ser?Val?Ile?Gly?Cys

355 360 365

cac?aca?tgc?ag g?tgt?tag?gtt?ata?ttt?tag?cac?ttg?tcc?att?cag?aca 1248

His?Thr?Cys?Arg Cys Val?Ile?Phe His?Leu?Ser?Ile?Gln?Thr

375 380

gcc?att?agc?acg?gcc?taa?tac?act?gac?gct?ggt?tca?tgt?ccg?ctt?acc 1296

Ala?Ile?Ser?Thr?Ala Tyr?Thr?Asp?Ala?Gly?Ser?Cys?Pro?Leu?Thr

385 390 395

tcc?tgg?att?ctc?agc?atc?ttc?aac?cgt?gga?aaa?gcc?ttc?aaa?agt?aca 1344

Ser?Trp?Ile?Leu?Ser?Ile?Phe?Asn?Arg?Gly?Lys?Ala?Phe?Lys?Ser?Thr

400 405 410

tag?agc?tct?tta?tag?taa?ag g?tat?tct?att?gat?ggc?agc?ctc?aga?aaa 1392

Ser?Ser?Leu Arg Tyr?Ser?Ile?Asp?Gly?Ser?Leu?Arg?Lys

420

tga?gga?taa?tga?tat?ttt?atg?gtg?tgt?caa?cca?tga?tac?ttt?tcc?ttt 1440

Gly Tyr?Phe?Met?Val?Cys?Gln?Pro Tyr?Phe?Ser?Phe

425 430 435

cca?aaa?gcc?aat?gat?gga?aac?cca?g?at gac?agc?tgg?tgt?tga?tgg?tca 1488

Pro?Lys?Ala?Asn?Asp?Gly?Asn?Pro Asp?Asp?Ser?Trp?Cys Trp?Ser

440 450

ttc?ctg?ggc?tct?ttc?tgc?gat?aga?tga?att?gaa?agt?aga?taa?aat?aat 1536

Phe?Leu?Gly?Ser?Phe?Cys?Asp?Arg Ile?Glu?Ser?Arg Asn?Asn

455 460 465

tac?acc?ttt?aaa?caa?gga?tca?tat?tcc?aat?aac?tga?ttc?acc?agt?tgt 1584

Tyr?Thr?Phe?Lys?Gln?Gly?Ser?Tyr?Ser?Asn?Asn Phe?Thr?Ser?Cys

470 475 480

tgt?aca?gca?gca?cat?gtt?acc?tcc?gaa?gaa?att?tgt?tct?cct?ctc?ag c 1632

Cys?Thr?Ala?Ala?His?Val?Thr?Ser?Glu?Glu?Ile?Cys?Ser?Pro?Leu?Ser

485 490 495

aca?g?gg gag?cct?tat?gtt?tca?taa?act?tag?acc?tgt?aga?tca?act?gag 1680

Thr Gly?Glu?Pro?Tyr?Val?Ser Thr Thr?Cys?Arg?Ser?Thr?Glu

500 505 510

gca?tct?act?tgt?gag?taa?tgt?ggg?agg?aga?tgg?aga?aga?gat?tga?aag 1728

Ala?Ser?Thr?Cys?Glu Cys?Gly?Arg?Arg?Trp?Arg?Arg?Asp Lys

515 520

att?ctt?taa?att?aca?tca?g?ga aga?cca?ggc?ttg?tgc?aac?ttg?cct?tat 1776

Ile?Leu Ile?Thr?Ser Gly?Arg?Pro?Gly?Leu?Cys?Asn?Leu?Pro?Tyr

525 535

tct tgc?ttg?ctc?cac?tgc?tgc?ctg?tga?tag?aga?agt?atc?tgc?ctg?ggc 1824

Ser Cys?Leu?Leu?His?Cys?Cys?Leu Arg?Ser?Ile?Cys?Leu?Gly

540 545 550

tac?tcg?ggc?ttt?ctt?tag?gta?tgg?tgg?tga?agc?aca?gat?gag?att?tcc 1872

Tyr?Ser?Gly?Phe?Leu Val?Trp?Trp Ser?Thr?Asp?Glu?Ile?Ser

555 560 565

aac?cac?tct?tcc?gcc?tcc?aag?taa?tgt?tgg?tcc?cat?ctt?ggg?gtc?tcc 1920

Asn?His?Ser?Ser?Ala?Ser?Lys Cys?Trp?Ser?His?Leu?Gly?Val?Ser

570 575 580

tgt?cta?ttc?ta g?ttc?tcc?tgt?tcc?tag?tgg?tag?tcc?cta?tcc?aaa?tcc 1968

Cys?Leu?Phe Phe?Ser?Cys?Ser Trp Ser?Leu?Ser?Lys?Ser

585 590 595

atc?ctt?ttt?ggg?aac?acc?gtc?tca?tg g?tat?aca?gcc?tcc?tgc?cat?gtc 2016

Ile?Leu?Phe?Gly?Asn?Thr?Val?Ser?Trp Tyr?Thr?Ala?Ser?Cys?His?Val

600 610

aac?tcc?agt?gtg?tgc?tct?ggg?aaaccc?agc?aac?tca?ggc?cac?aaa?tat 2064

Asn?Ser?Ser?Val?Cys?Ser?Gly?Lys?Pro?Ser?Asn?Ser?Gly?His?Lys?Tyr

615 620 625

gag?ttg?tgt?gac?tgg?acc?aga?gat?tgt?gta?ctc?tgg?aaa?aca?caa?tgg 2112

Glu?Leu?Cys?Asp?Trp?Thr?Arg?Asp?Cys?Val?Leu?Trp?Lys?Thr?Gln?Trp

630 635 640

tat?ttg?cat?tta?ctt?ttc?tcg?gat?cat?ggg?aaa?cat?ttg?gga?tgc?aag 2160

Tyr?Leu?His?Leu?Leu?Phe?Ser?Asp?His?Gly?Lys?His?Leu?Gly?Cys?Lys

645 650 655 660

ctt?agt?tgt?gga?gag?aat?att?caa?gag?tgg?caa?cag?aga?gat?cac?tgc?a 2209

Leu?Ser?Cys?Gly?Glu?Asn?Ile?Gln?Glu?Trp?Gln?Gln?Arg?Asp?His?Cys

665 670 675

at tga?aag?tag?tgt?tcc?ctg?cca?act?gct?aga?gtc?agt?gct?aca?aga 2256

Asn Lys Cys?Ser?Leu?Pro?Thr?Ala?Arg?Val?Ser?Ala?Thr?Arg

680 685 690

act aaa?ggg?ttt?gca?gga?att?tct?aga?cag?aaa?ctc?cca?gtt?tgc?agg 2304

Thr Lys?Gly?Phe?Ala?Gly?Ile?Ser?Arg?Gln?Lys?Leu?Pro?Val?Cys?Arg

695 700 705

agg?acc?att?agg?aaa?tcc?aaa?tac?tac?tgc?taa?agt?gca?gca?gag?gct 2352

Arg?Thr?Ile?Arg?Lys?Ser?Lys?Tyr?Tyr?Cys Ser?Ala?Ala?Glu?Ala

710 715 720

gat?agg?att?cat?gcg?tcc?tga?aaa?cgg?aaa?tcc?cca?gca?aat?gca?aca 2400

Asp?Arg?Ile?His?Ala?Ser Lys?Arg?Lys?Ser?Pro?Ala?Asn?Ala?Thr

725 730 735

gga?act?gca?gag?gaa?gtt?tca?tg a?ggc?tca?act?aag?tga?aaa?gat?ttc 2448

Gly?Thr?Ala?Glu?Glu?Val?Ser Gly?Ser?Thr?Lys Lys?Asp?Phe

740 745 750

act?tca?ggc?aat?tca?gca?gtt?ggt?tcg?aaa?atc?ata?tca?ggc?tct?ggc 2496

Thr?Ser?Gly?Asn?Ser?Ala?Val?Gly?Ser?Lys?Ile?Ile?Ser?Gly?Ser?Gly

755 760 765

ttt?atg?gaa?act?tct?ttg?tga?aca?tca?att?cac?tat?cat?tgt?ggc?aga 2544

Phe?Met?Glu?Thr?Ser?Leu Thr?Ser?Ile?His?Tyr?His?Cys?Gly?Arg

770 775 780

act?tca?gaa?g?ga act?tca?aga?gcagct?gaa?gat?cac?cac?ctt?taa?aga 2592

Thr?Ser?Glu Gly?Thr?Ser?Arg?Ala?Ala?Glu?Asp?His?His?Leu Arg

785 790 795

tct?tgt?aat?cag?gga?caa?aga?act?cac?agg?ggc?att?aat?tgc?ttc?tct 2640

Ser?Cys?Asn?Gln?Gly?Gln?Arg?Thr?His?Arg?Gly?Ile?Asn?Cys?Phe?Ser

800 805 810

tat?caa?ctg?cta?cat?cag?aga?taa?tgc?cgc?tgt?tga?tgg?cat?tag?ttt 2688

Tyr?Gln?Leu?Leu?His?Gln?Arg Cys?Arg?Cys Trp?His Phe

815 820 825

aca?ttt?aca?gga?tat?ctg?ccc?act?tct?ata?tag?cac?tga?tga?tgc?aat 2736

Thr?Phe?Thr?Gly?Tyr?Leu?Pro?Thr?Ser?Ile His Cys?Asn

830 835

ttg?ttc?taa?g?gc?aaa?tga?gct?tct?cca?gcg?ttc?ccg?aca?agt?tca?aaa 2784

Leu?Phe Gly?Lys Ala?Ser?Pro?Ala?Phe?Pro?Thr?Ser?Ser?Lys

840 845 850

taa?gac?tga?aaa?aga?aag?aat?gtt?aag?gga?atc?att?aaa?gga?ata?tca 2832

Asp Lys?Arg?Lys?Asn?Val?Lys?Gly?Ile?Ile?Lys?Gly?Ile?Ser

855 860 865

aaa?aat?tag?caa?tca?agt?gga?cct?ttc?caa?tgt?ttg?tgc?tca?gta?tag 2880

Lys?Asn Gln?Ser?Ser?Gly?Pro?Phe?Gln?Cys?Leu?Cys?Ser?Val

870 875 880

aca?ag t?gag?att?tta?tga?ggg?tgt?ggt?gga?act?ttc?tct?tac?ggc?tgc 2928

Thr?Ser Glu?Ile?Leu Gly?Cys?Gly?Gly?Thr?Phe?Ser?Tyr?Gly?Cys

885 890 895

aga?gaa?aaa?aga?tcc?tca?agg?tct?tgg?gct?tca?ttt?cta?taa?aca?tgg 2976

Arg?Glu?Lys?Arg?Ser?Ser?Arg?Ser?Trp?Ala?Ser?Phe?Leu Thr?Trp

900 905 910

aga?acc?aga?aga?aga?cat?agt?tgg?act?tca?ggc?ctt?cca?aga?aag?att 3024

Arg?Thr?Arg?Arg?Arg?His?Ser?Trp?Thr?Ser?Gly?Leu?Pro?Arg?Lys?Ile

915 920 925

aaa?cag?tta?caa?atg?cat?tac?aga?cac?act?tca?aga?act?ggt?aaa?tca 3072

Lys?Gln?Leu?Gln?Met?His?Tyr?Arg?His?Thr?Ser?Arg?Thr?Gly?Lys?Ser

930 935 940

aag?taa?ggc?cgc?tcc?tca?gtc?tcc?cag?tgt?acc?caa?aaa?acc?tgg?tcc 3120

Lys Gly?Arg?Ser?Ser?Val?Ser?Gln?Cys?Thr?Gln?Lys?Thr?Trp?Ser

945 950 955

tcc?agt?gtt?gtc?atc?tga?tcc?aaa?tat?gct?gag?taa?tga?aga?agc?agg 3168

Ser?Ser?Val?Val?Ile Ser?Lys?Tyr?Ala?Glu Arg?Ser?Arg

960 965 970

aca?tca?t?tt tga?aca?aat?gct?taa?att?gtc?aca?gcg?atc?caa?gga?tga 3216

Thr?Ser Phe Thr?Asn?Ala Ile?Val?Thr?Ala?Ile?Gln?Gly

975 980

gct?ctt?tag?tat?tgc?cct?tta?taa?ttg?gct?aat?aca?agt?cga?cct?tgc 3264

Ala?Leu Tyr?Cys?Pro?Leu Leu?Ala?Asn?Thr?Ser?Arg?Pro?Cys

985 990 995

aga?taa?gct gct?aca?g?gt tgc?ttc tcc?att?tct?gga?gcc aca?tct 3309

Arg Ala Ala?Thr Gly?Cys?Phe Ser?Ile?Ser?Gly?Ala Thr?Ser

1000 1005 1010

agt?ccg?aat ggc?caa?agt?tga?tca?aaa cag?agt?tcg?tta?tat gga 3354

Ser?Pro?Asn Gly?Gln?Ser Ser?Lys Gln?Ser?Ser?Leu?Tyr Gly

1015 1020 1025

ttt?act?ctg?gcg gta?tta?cga?gaa?gaa cag?aag?ttt?cag?taa?tgc 3399

Phe?Thr?Leu?Ala Val?Leu?Arg?Glu?Glu Gln?Lys?Phe?Gln Cys

1030 1035 1040

tgc?tcg?tgt?act?gtc cag?act?ggc?tga?cat?gca tag?cac?aga?aat?ttc 3447

Cys?Ser?Cys?Thr?Val Gln?Thr?Gly His?Ala His?Arg?Asn?Phe

1045 1050

act tca?gca?gcg?act?aga gta?cat?tgc?tcg?agc cat?tct?tag?tgc 3492

Thr Ser?Ala?Ala?Thr?Arg Val?His?Cys?Ser?Ser His?Ser Cys

1055 1060 1065

caa?aag ttc?cac?tgc?cat?ttc atc?aat?agc?tgc?cga tgg?tga?att 3537

Gln?Lys Phe?His?Cys?His?Phe Ile?Asn?Ser?Cys?Arg Trp Ile

1070 1075 1080

tct?tca?tga?att aga?aga?aaa?aat?gga g?gt tgc?tag?gat?cca?act 3582

Ser?Ser Ile Arg?Arg?Lys?Asn?Gly Gly?Cys Asp?Pro?Thr

1085 1090 1095

tca?gat?aca?gga?gac act?aca?aag?gca?gta ttc?cca?tca?ttc?tt 3627

Ser?Asp?Thr?Gly?Asp Thr?Thr?Lys?Ala?Val Phe?Pro?Ser?Phe?Phe

1100 1105 1110

tgt?aca?gga?tgc?agt ttc?tca?gct?gga?ttc tga?gct?gat?gga?cat 3672

Cys?Thr?Gly?Cys?Ser Phe?Ser?Ala?Gly?Phe Ala?Asp?Gly?His

1115 1120

aac taa?g?ct tta?tgg?gga?att tgc?tga?ccc?att?taa?act?tgc aga 3717

Asn Ala?Leu?Trp?Gly?Ile Cys Pro?Ile Thr?Cys Arg

1125 1130 1135

gtg?caa?act?tgc aat?aat?tca?ttg?tgc cgg?tta?ttc?aga?ccc tat 3762

Val?Gln?Thr?Cys Asn?Asn?Ser?Leu?Cys Arg?Leu?Phe?Arg?Pro Tyr

1140 1145 1150

att?ggt?gca?gac act?ttg?gca?aga?tat cat?aga?gaa?ag a?att gag 3807

Ile?Gly?Ala?Asp Thr?Leu?Ala?Arg?Tyr His?Arg?Glu?Arg Ile Glu

1155 1160 1165

tga?cag?tgt?gac?att gag?ctc?ctc?gga?tag?aat gca?tgc?tct?tag?tct 3855

Gln?Cys?Asp?Ile Glu?Leu?Leu?Gly Asn?Ala?Cys?Ser Ser

1170 1175

caa gat?tgt?tct?cct?tgg caa?aat?tta?tgc?tgg cac?acc?acg?ctt 3900

Gln Asp?Cys?Ser?Pro?Trp Gln?Asn?Leu?Cys?Trp His?Thr?Thr?Leu

1180 1185 1190

ctt tcc?ttt?ag a?ttt?tat?tgt?aca?gtt?ttt?aga aca?gca?ggt?ttg 3945

Leu Ser?Phe?Arg Phe?Tyr?Cys?Thr?Val?Phe?Arg Thr?Ala?Gly?Leu

1195 1200 1205

tac ttt?gaa?ctg?gga?tgt ggg?ctt?cgt?aat?aca gac?aat?gaa?tga 3990

Tyr Phe?Glu?Leu?Gly?Cys Gly?Leu?Arg?Asn?Thr Asp?Asn?Glu

1210 1215 1220

aat?tgg agt?acc?att?acc?tag?act?act?aga?agt?tta?tga?tca?gtt 4035

Asn?Trp Ser?Thr?Ile?Thr Thr?Thr?Arg?Ser?Leu Ser?Val

1225 1230 1235

gtt?caa?atc?acg?g?ga?tcc?att?ctg?gaa?cag?aat?gaa?gaa?gcc act 4080

Val?Gln?Ile?Thr Gly?Ser?Ile?Leu?Glu?Gln?Asn?Glu?Glu?Ala?Thr

1240 1245 1250

gca?cct?ttt?gga ttg?tat?aca?tgt?att att?gat?aag?ata?tgt tga 4125

Ala?Pro?Phe?Gly Leu?Tyr?Thr?Cys?Ile Ile?Asp?Lys?Ile?Cys

1255 1260 1265

gaa?tcc?cag?cca?agt?ttt?aaa?ttg?tga?aag?gag?aag?att?tac?aaa 4170

Glu?Ser?Gln?Pro?Ser?Phe?Lys?Leu Lys?Glu?Lys?Ile?Tyr?Lys

1270 1275

tct ctg?cct?gga?tgc tgt?ttg?tgg?tta?cct?tgt?tga?gct?cca?gtc 4215

Ser Leu?Pro?Gly?Cys Cys?Leu?Trp?Leu?Pro?Cys Ala?Pro?Val

1280 1285 1290

tat?gag ctc?gtc?agt?agc agt?aca?agc?cat?cac?tgg gaa?ttt?taa 4260

Tyr?Glu Leu?Val?Ser?Ser Ser?Thr?Ser?His?His?Trp Glu?Phe

1295 1300 1305

atc?tct?tca?agc?taa?att?aga?acg?gct?tca?tta?att?act?gtg?ata 4305

Ile?Ser?Ser?Ser Ile?Arg?Thr?Ala?Ser?Leu?Ile?Thr?Val?Ile

1310 1315 1320

tac?ttt?cat?ccg?ttt?tat?gat?ctg?taa?aat?aaa?aac?tca?gct?ggg 4350

Tyr?Phe?His?Pro?Phe?Tyr?Asp?Leu Asn?Lys?Asn?Ser?Ala?Gly

1325 1330 1335

tcc?ag 4355

Ser

SEQUENCE?LISTING15

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_015589

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2356

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(194)

<220>

<221>exon

<222>(195)..(713)

<220>

<221>exon

<222>(714)..(977)

<220>

<221>exon

<222>(978)..(1087)

<220>

<221>exon

<222>(1088)..(1174)

<220>

<221>exon

<222>(1175)..(1508)

<220>

<221>exon

<222>(1509)..(1594)

<220>

<221>exon

<222>(1595)..(1713)

<220>

<221>exon

<222>(1714)..(1915)

<220>

<221>exon

<222>(1916)..(2042)

<220>

<221>exon

<222>(2043)..(2126)

<220>

<221>exon

<222>(2127)..(2338)

<400>1

gat?gtt?tcg?cga?cca?ggt?cgg?ggt?gct?ggc?ggg?ctg?gtt?taa?ggg?ctg 48

Asp?Val?Ser?Arg?Pro?Gly?Arg?Gly?Ala?Gly?Gly?Leu?Val Gly?Leu

1 5 10 15

gaa?cga?gtg?cga?gca?gac?tgt?tgc?gct?gct?gtc?gct?gct?caa?gcg?cgt 96

Glu?Arg?Val?Arg?Ala?Asp?Cys?Cys?Ala?Ala?Val?Ala?Ala?Gln?Ala?Arg

20 25 30

gag?cca?gac?cca?ggc?ccg?ctt?cct?cca?gct?ctg?cct?gga?gca?ctc?gct 144

Glu?Pro?Asp?Pro?Gly?Pro?Leu?Pro?Pro?Ala?Leu?Pro?Gly?Ala?Leu?Ala

35 40 45

ggc?cga?ctg?cgc?cga?gct?gca?cgt?cct?cga?acg?cga?ggc?caa?cag?ccc 192

Gly?Arg?Leu?Arg?Arg?Ala?Ala?Arg?Pro?Arg?Thr?Arg?Gly?Gln?Gln?Pro

50 55 60

cg g?aat?cat?taa?cca?atg?gca?aca?gga?atc?caa?gga?taa?agt?gat?ttc 240

Arg Asn?His Pro?Met?Ala?Thr?Gly?Ile?Gln?Gly Ser?Asp?Phe

65 70 75

cct?cct?gtt?aac?tca?tct?gcc?ttt?gct?gaa?gcc?agg?aaa?cct?cga?cgc 288

Pro?Pro?Val?Asn?Ser?Ser?Ala?Phe?Ala?Glu?Ala?Arg?Lys?Pro?Arg?Arg

80 85 90

gaa?agt?aga?ata?tat?gaa?act?gct?gcc?caa?aat?cct?ggc?tca?ctc?tat 336

Glu?Ser?Arg?Ile?Tyr?Glu?Thr?Ala?Ala?Gln?Asn?Pro?Gly?Ser?Leu?Tyr

95 100 105

tga?aca?caa?cca?gca?cat?tga?gga?gag?cag?gca?gct?gct?gtc?cta?tgc 384

Thr?Gln?Pro?Ala?His Gly?Glu?Gln?Ala?Ala?Ala?Val?Leu?Cys

110 115 120

ttt?gat?aca?tcc?agc?cac?ttc?gtt?aaa?aga?ccg?tag?tgc?ttt?agc?cat 432

Phe?Asp?Thr?Ser?Ser?His?Phe?Val?Lys?Arg?Pro Cys?Phe?Ser?His

125 130 135

gtg?gct?gaa?tca?ctt?gga?gga?ccg?cac?gtc?gac?cag?ctt?tgg?tgg?cca 480

Val?Ala?Glu?Ser?Leu?Gly?Gly?Pro?His?Val?Asp?Gln?Leu?Trp?Trp?Pro

140 145 150

gaa?ccg?agg?ccg?ctc?aga?ctc?tgt?gga?tta?tgg?aca?gac?aca?cta?cta 528

Glu?Pro?Arg?Pro?Leu?Arg?Leu?Cys?Gly?Leu?Trp?Thr?Asp?Thr?Leu?Leu

155 160 165 170

tca?cca?aag?aca?gaa?ctc?tga?tga?caa?gct?caa?tgg?gtg?gca?gaa?ctc 576

Ser?Pro?Lys?Thr?Glu?Leu Gln?Ala?Gln?Trp?Val?Ala?Glu?Leu

175 180

tcg?gga?ttc?tgg?gat?ttg?cat?caa?tgc?ctc?caa?ctg?gca?gga?caa?aag 624

Ser?Gly?Phe?Trp?Asp?Leu?His?Gln?Cys?Leu?Gln?Leu?Ala?Gly?Gln?Lys

185 190 195 200

cat?ggg?gtg?tga?gaa?tgg?cca?tgt?gcc?cct?cta?ctc?ctc?ctc?atc?tgt 672

His?Gly?Val Glu?Trp?Pro?Cys?Ala?Pro?Leu?Leu?Leu?Leu?Ile?Cys

205 210 215

ccc?cac?cac?aat?caa?tac?gat?tgg?aac?cag?cac?aag?tac?aa t?tct?ctc 720

Pro?His?His?Asn?Gln?Tyr?Asp?Trp?Asn?Gln?His?Lys?Tyr?Asn Ser?Leu

220 225 230

agg?cca?ggc?aca?cca?cag?ccc?ttt?gaa?acg?atc?tgt?gtc?cct?tac?ccc 768

Arg?Pro?Gly?Thr?Pro?Gln?Pro?Phe?Glu?Thr?Ile?Cys?Val?Pro?Tyr?Pro

235 240 245

acc?cat?gaa?tgt?gcc?aaa?cca?gcc?tct?agg?aca?tgg?atg?gat?gtc?tca 816

Thr?His?Glu?Cys?Ala?Lys?Pro?Ala?Ser?Arg?Thr?Trp?Met?Asp?Val?Ser

250 255 260

tga?gga?ctt?acg?agc?tag?agg?acc?cca?gtg?cct?ccc?atc?cga?tca?tgc 864

Gly?Leu?Thr?Ser Arg?Thr?Pro?Val?Pro?Pro?Ile?Arg?Ser?Cys

265 270 275

ccc?cct?gtc?tcc?aca?aag?cag?tgt?agc?ctc?ttc?agg?aag?tgg?tgg?gag 912

Pro?Pro?Val?Ser?Thr?Lys?Gln?Cys?Ser?Leu?Phe?Arg?Lys?Trp?Trp?Glu

280 285 290

tga?aca?ctt?aga?aga?tca?gac?cac?tgc?tcg?taa?cac?att?cca?aga?aga 960

Thr?Leu?Arg?Arg?Ser?Asp?His?Cys?Ser His?Ile?Pro?Arg?Arg

295 300 305

agg?tag?tgg?gat?gaa?ag a?tgt?tcc?agc?ctg?gct?gaa?aag?cct?ccg?cct 1008

Arg Trp?Asp?Glu?Arg Cys?Ser?Ser?Leu?Ala?Glu?Lys?Pro?Pro?Pro

310 315 320

gca?caa?ata?tgc?cgc?gct?ttt?ctc?cca?gat?gac?cta?tga?gga?gat?gat 1056

Ala?Gln?Ile?Cys?Arg?Ala?Phe?Leu?Pro?Asp?Asp?Leu Gly?Asp?Asp

325 330 335

ggc?cct?cac?cga?gtg?cca?gct?gga?ggc?gca?g?aa tgt?tac?caa?agg?tgc 1104

Gly?Pro?His?Arg?Val?Pro?Ala?Gly?Gly?Ala Glu?Cys?Tyr?Gln?Arg?Cys

340 345 350

aag?aca?caa?aat?tgt?cat?cag?tat?tca?gaa?gct?caa?aga?aag?aca?aaa 1152

Lys?Thr?Gln?Asn?Cys?His?Gln?Tyr?Ser?Glu?Ala?Gln?Arg?Lys?Thr?Lys

355 360 365

tct?cct?gaa?gtc?ttt?gga?aag?g?ga cat?cat?cga?ggg?ggg?cag?cct?gcg 1200

Ser?Pro?Glu?Val?Phe?Gly?Lys Gly?His?His?Arg?Gly?Gly?Gln?Pro?Ala

370 375 380 385

cat?ccc?gct?cca?gga?act?gca?cca?gat?gat?cct?gac?tcc?gat?caa?ggc 1248

His?Pro?Ala?Pro?Gly?Thr?Ala?Pro?Asp?Asp?Pro?Asp?Ser?Asp?Gln?Gly

390 395 400

cta?cag?ctc?ccc?gag?cac?cac?ccc?cga?ggc?tcg?ccg?ccg?gga?gcc?cca 1296

Leu?Gln?Leu?Pro?Glu?His?His?Pro?Arg?Gly?Ser?Pro?Pro?Gly?Ala?Pro

405 410 415

ggc?ccc?gcg?tca?gcc?ctc?act?gat?ggg?ccc?cga?gag?cca?gag?ccc?cga 1344

Gly?Pro?Ala?Ser?Ala?Leu?Thr?Asp?Gly?Pro?Arg?Glu?Pro?Glu?Pro?Arg

420 425 430

ctg?caa?aga?tgg?ggc?cgc?agc?cac?tgg?cgc?cac?ggc?cac?ccc?ctc?ggc 1392

Leu?Gln?Arg?Trp?Gly?Arg?Ser?His?Trp?Arg?His?Gly?His?Pro?Leu?Gly

435 440 445

cgg?ggc?cag?cgg?ggg?gct?cca?gcc?gca?cca?gct?gag?cag?ctg?cga?tgg 1440

Arg?Gly?Gln?Arg?Gly?Ala?Pro?Ala?Ala?Pro?Ala?Glu?Gln?Leu?Arg?Trp

450 455 460 465

gga?gct?ggc?cgt?cgc?ccc?cct?gcc?aga?ggg?gga?cct?ccc?cgg?gca?gtt 1488

Gly?Ala?Gly?Arg?Arg?Pro?Pro?Ala?Arg?Gly?Gly?Pro?Pro?Arg?Ala?Val

470 475 480

cac?acg?cgt?cat?ggg?gaa?ag t?gtg?cac?aca?gct?ctt?ggt?ctc?cag?acc 1536

His?Thr?Arg?His?Gly?Glu?Ser Val?His?Thr?Ala?Leu?Gly?Leu?Gln?Thr

485 490 495

tga?tga?gga?aaa?tat?aag?ttc?cta?ttt?aca?gct?cat?aga?caa?gtg?tct 1584

Gly?Lys?Tyr?Lys?Phe?Leu?Phe?Thr?Ala?His?Arg?Gln?Val?Ser

500 505 510

aat?tca?tga?g?gc att?tac?aga?gac?aca?gaa?aaa?aag?att?gtt?gtc?atg 1632

Asn?Ser Gly?Ile?Tyr?Arg?Asp?Thr?Glu?Lys?Lys?Ile?Val?Val?Met

515 520 525

gaa?aca?gca?ggt?gca?gaa?gct?ctt?tcg?gtc?ttt?ccc?tcg?gaa?aac?cct 1680

Glu?Thr?Ala?Gly?Ala?Glu?Ala?Leu?Ser?Val?Phe?Pro?Ser?Glu?Asn?Pro

530 535 540

tct?aga?cat?atc?agg?ata?tcg?aca?gca?aag?aaa?tcg?agg?ctt?tgg?gca 1728

Ser?Arg?His?Ile?Arg?Ile?Ser?Thr?Ala?Lys?Lys?Ser?Arg?Leu?Trp?Ala

545 550 555

atc?caa?ctc?cct?ccc?gac?ggc?tgg?ctc?tgt?ggg?cgg?tgg?cat?ggg?cag 1776

Ile?Gln?Leu?Pro?Pro?Asp?Gly?Trp?Leu?Cys?Gly?Arg?Trp?His?Gly?Gln

560 565 570

acg?gaa?ccc?gcg?cca?gta?cca?gat?ccc?ctc?tcg?gaa?cgt?ccc?ttc?cgc 1824

Thr?Glu?Pro?Ala?Pro?Val?Pro?Asp?Pro?Leu?Ser?Glu?Arg?Pro?Phe?Arg

575 580 585 590

ccg?cct?ggg?cct?ctt?ggg?cac?cag?tgg?att?cgt?cag?ctc?caa?cca?gcg 1872

Pro?Pro?Gly?Pro?Leu?Gly?His?Gln?Trp?Ile?Arg?Gln?Leu?Gln?Pro?Ala

595 600 605

caa?cac?cac?agc?tac?ccc?cac?cat?cat?gaa?aca?agg?aag?aca?g?aa cct 1920

Gln?His?His?Ser?Tyr?Pro?His?His?His?Glu?Thr?Arg?Lys?Thr Glu?Pro

610 615 620

gtg?gtt?tgc?caa?ccc?cgg?ggg?cag?caa?tag?cat?gcc?aag?ccg?cac?cca 1968

Val?Val?Cys?Gln?Pro?Arg?Gly?Gln?Gln His?Ala?Lys?Pro?His?Pro

625 630 635

cag?ctc?agt?cca?gag?gac?ccg?ctc?gct?gcc?cgt?gca?cac?ttc?ccc?aca 2016

Gln?Leu?Ser?Pro?Glu?Asp?Pro?Leu?Ala?Ala?Arg?Ala?His?Phe?Pro?Thr

640 645 650

gaa?cat?gct?gat?gtt?cca?gca?gcc?ag a?att?cca?gct?tcc?cgt?gac?cga 2064

Glu?His?Ala?Asp?Val?Pro?Ala?Ala?Arg Ile?Pro?Ala?Ser?Arg?Asp?Arg

655 660 665

acc?tga?cat?caa?caa?cag?gct?gga?gtc?gtt?gtg?cct?cag?tat?gac?cga 2112

Thr His?Gln?Gln?Gln?Ala?Gly?Val?Val?Val?Pro?Gln?Tyr?Asp?Arg

670 675 680

aca?cgc?cct?ggg?ag a?cgg?ggt?tga?ccg?gac?ctc?cac?cat?cta?gaa?gct 2160

Thr?Arg?Pro?Gly?Arg Arg?Gly Pro?Asp?Leu?His?His?Leu?Glu?Ala

685 690 695

gaa?gat?gag?agt?gac?cgc?gct?ggc?cgt?gaa?atc?gac?tgc?tgc?ggg?tcc 2208

Glu?Asp?Glu?Ser?Asp?Arg?Ala?Gly?Arg?Glu?Ile?Asp?Cys?Cys?Gly?Ser

700 705 710 715

agt?gtc?cgc?cat?ctt?cag?ggt?tgc?aca?gaa?tcc?tcc?aag?ata?ctt?tgc 2256

Ser?Val?Arg?His?Leu?Gln?Gly?Cys?Thr?Glu?Ser?Ser?Lys?Ile?Leu?Cys

720 725 730

agc?ctt?ttt?tcc?ccc?tgg?tcc?ctc?tcc?cgt?ttt?gat?ttt?gtg?aga?gcg 2304

Ser?Leu?Phe?Ser?Pro?Trp?Ser?Leu?Ser?Arg?Phe?Asp?Phe?Val?Arg?Ala

735 740 745

tag?gtc?atc?ctc?gta?aac?ata?tca?gta?gac?ctg?g?aaaaaaaaaa?aaaaaaaa 2356

Val?Ile?Leu?Val?Asn?Ile?Ser?Val?Asp?Leu

750 755

SEQUENCE?LISTING16

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_016002

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2482

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(537)

<220>

<221>exon

<222>(538)..(650)

<220>

<221>exon

<222>(651)..(731)

<220>

<221>exon

<222>(732)..(861)

<220>

<221>exon

<222>(862)..(911)

<220>

<221>exon

<222>(912)..(1042)

<220>

<221>exon

<222>(1043)..(1160)

<220>

<221>exon

<222>(1161)..(1280)

<220>

<221>exon

<222>(1281)..(1337)

<220>

<221>exon

<222>(1338)..(1449)

<220>

<221>exon

<222>(1450)..(1531)

<220>

<221>exon

<222>(1532)..(2474)

<220>

<221>STS

<222>(1577)..(1739)

<220>

<221>STS

<222>(1901)..(2027)

<220>

<221>STS

<222>(2019)..(2168)

<220>

<221>STS

<222>(2020)..(2144)

<220>

<221>STS

<222>(2020)..(2144)

<220>

<221>STS

<222>(2184)..(2428)

<220>

<221>STS

<222>(2247)..(2421)

<400>1

tgc?gct?gcc?cgg?ggc?ggc?cag?agc?cct?gca?gaa?caa?acc?gcc?gca?cgg 48

Cys?Ala?Ala?Arg?Gly?Gly?Gln?Ser?Pro?Ala?Glu?Gln?Thr?Ala?Ala?Arg

1 5 10 15

aat?tag?ggg?ccg?ccg?tcc?gcg?cct?gcc?agg?ctt?gga?agc?gga?ctc?gcc 96

Asn Gly?Pro?Pro?Ser?Ala?Pro?Ala?Arg?Leu?Gly?Ser?Gly?Leu?Ala

20 25 30

ccc?agg?gcc?acc?gcc?cta?gga?aac?ctc?ccg?tcg?gaa?gcc?tcc?caa?gca 144

Pro?Arg?Ala?Thr?Ala?Leu?Gly?Asn?Leu?Pro?Ser?Glu?Ala?Ser?Gln?Ala

35 40 45

agc?cgc?tca?ccc?gcg?gct?ccc?gcg?cga?ggc?ggc?gtg?ggc?gtg?ggc?gcg 192

Ser?Arg?Ser?Pro?Ala?Ala?Pro?Ala?Arg?Gly?Gly?Val?Gly?Val?Gly?Ala

50 55 60

gcc?ctg?gcg?cgg?cgg?cgc?gcg?cgg?ggt?gaa?ggg?agc?ccg?gcg?cgc?tgg 240

Ala?Leu?Ala?Arg?Arg?Arg?Ala?Arg?Gly?Glu?Gly?Ser?Pro?Ala?Arg?Trp

65 70 75

ctg?cgg?cga?cgg?cgg?ccg?ttg?ctg?cgc?cgg?gta?ctg?ggg?tcg?ctg?cct 288

Leu?Arg?Arg?Arg?Arg?Pro?Leu?Leu?Arg?Arg?Val?Leu?Gly?Ser?Leu?Pro

80 85 90 95

gag?gcg?cag?gcg?ccg?tgg?act?cca?ccc?gcc?ccg?ggg?cct?ggg?ctc?gct 336

Glu?Ala?Gln?Ala?Pro?Trp?Thr?Pro?Pro?Ala?Pro?Gly?Pro?Gly?Leu?Ala

100 105 110

gtg?gac?tcg?tca?tgg?cga?ccg?agc?aga?ggc?ctt?tcc?acc?tgg?tgg?tgt 384

Val?Asp?Ser?Ser?Trp?Arg?Pro?Ser?Arg?Gly?Leu?Ser?Thr?Trp?Trp?Cys

115 120 125

tcg?gcg?cgt?ctg?gct?tca?ccg?gcc?agt?tcg?tga?ccg?agg?agg?tgg?ccc 432

Ser?Ala?Arg?Leu?Ala?Ser?Pro?Ala?Ser?Ser Pro?Arg?Arg?Trp?Pro

130 135 140

ggg?agc?agg?tgg?acc?cgg?agc?gga?gct?ccc?gcc?tgc?cct?ggg?ccg?tgg 480

Gly?Ser?Arg?Trp?Thr?Arg?Ser?Gly?Ala?Pro?Ala?Cys?Pro?Gly?Pro?Trp

145 150 155

cgg?gcc?gct?ccc?ggg?aga?agc?tgc?agc?ggg?tgc?tgg?aga?agg?cgg?ccc 528

Arg?Ala?Ala?Pro?Gly?Arg?Ser?Cys?Ser?Gly?Cys?Trp?Arg?Arg?Arg?Pro

160 165 170

tga?agc?tgg?gaa?gac?caa?cac?tgt?cat?ctg?aag?ttg?gaa?tca?tca?tct 576

Ser?Trp?Glu?Asp?Gln?His?Cys?His?Leu?Lys?Leu?Glu?Ser?Ser?Ser

175 180 185

gtg?ata?ttg?cta?atc?cag?cct?cgc?ttg?atg?aaa?tgg?cta?aac?agg?caa 624

Val?Ile?Leu?Leu?Ile?Gln?Pro?Arg?Leu?Met?Lys?Trp?Leu?Asn?Arg?Gln

190 195 200 205

cag?ttg?tcc?tca?att?gcg?tag?gac?ca t?atc?ggt?ttt?atg?gag?aac?ctg 672

Gln?Leu?Ser?Ser?Ile?Ala Asp?His Ile?Gly?Phe?Met?Glu?Asn?Leu

210 215 220

taa?taa?aag?cat?gta?ttg?aaa?atg?gag?cca?gtt?gta?tcg?aca?tca?gtg 720

Lys?His?Val?Leu?Lys?Met?Glu?Pro?Val?Val?Ser?Thr?Ser?Val

225 230

gag?aac?ctc?ag t?ttc?tgg?aac?taa?tgc?aac?tga?agt?atc?atg?aga?aag 768

Glu?Asn?Leu?Ser Phe?Trp?Asn Cys?Asn Ser?Ile?Met?Arg?Lys

235 240 245

ctg?cag?aca?aag?ggg?ttt?ata?tca?ttg?gaa?gca?gcg?gct?ttg?act?cca 816

Leu?Gln?Thr?Lys?Gly?Phe?Ile?Ser?Leu?Glu?Ala?Ala?Ala?Leu?Thr?Pro

250 255 260

ttc?cag?cag?atc?tgg?gag?taa?tat?ata?cca?gaa?ata?aaa?tga?atg?gta 864

Phe?Gln?Gln?Ile?Trp?Glu Tyr?Ile?Pro?Glu?Ile?Lys Met?Val

265 270 275

ctt?tga?ctg?ctg?tgg?aaa?gtt?tcc?tga?cta?tac?att?cag?gac?ctg?ag g 912

Leu Leu?Leu?Trp?Lys?Val?Ser Leu?Tyr?Ile?Gln?Asp?Leu?Arg

280 285 290

ggt?tga?gca?ttc?atg?atg?gta?cct?gga?agt?cag?caa?ttt?atg?gtt?ttg 960

Gly Ala?Phe?Met?Met?Val?Pro?Gly?Ser?Gln?Gln?Phe?Met?Val?Leu

295 300 305

gag?atc?aga?gta?att?tga?gaa?aac?taa?gaa?atg?tat?caa?atc?tga?aac 1008

Glu?Ile?Arg?Val?Ile Glu?Asn Glu?Met?Tyr?Gln?Ile Asn

310 315 320

ctg?tcc?cgc?tca?ttg?gtc?caa?aat?tga?aga?gaa?g?gt ggc?caa?ttt?ctt 1056

Leu?Ser?Arg?Ser?Leu?Val?Gln?Asn Arg?Glu Gly?Gly?Gln?Phe?Leu

325 330 335

att?gtc?ggg?aac?tca?aag?gtt?att?cca?ttc?ctt?tta?tgg?gat?ctg?atg 1104

Ile?Val?Gly?Asn?Ser?Lys?Val?Ile?Pro?Phe?Leu?Leu?Trp?Asp?Leu?Met

340 345 350

tgt?ctg?ttg?taa?gga?gga?ctc?aac?gtt?act?tgt?atg?aaa?att?tag?agg 1152

Cys?Leu?Leu Gly?Gly?Leu?Asn?Val?Thr?Cys?Met?Lys?Ile Arg

355 360 365

aat?cac?ca g?ttc?agt?atg?ctg?cgt?atg?taa?ctg?tgg?gag?gca?tca?cct 1200

Asn?His?Gln Phe?Ser?Met?Leu?Arg?Met Leu?Trp?Glu?Ala?Ser?Pro

370 375 380

ctg?tta?tta?agc?tga?tgt?ttg?cag?gac?ttt?tct?ttt?tgt?tct?ttg?tga 1248

Leu?Leu?Leu?Ser Cys?Leu?Gln?Asp?Phe?Ser?Phe?Cys?Ser?Leu

385 390

ggt?ttg?gaa?ttg?gaa?ggc?aac?ttc?tca?taa?aa t?tcc?cat?ggt?tct?tct 1296

Gly?Leu?Glu?Leu?Glu?Gly?Asn?Phe?Ser Asn Ser?His?Gly?Ser?Ser

395 400 405

cct?ttg?gct?att?ttt?caa?aac?aag?gcc?caa?cac?aaa?aac?ag a?ttg?atg 1344

Pro?Leu?Ala?Ile?Phe?Gln?Asn?Lys?Ala?Gln?His?Lys?Asn?Arg Leu?Met

410 415 420 425

ctg?cct?cat?tca?cgc?tga?cat?tct?ttg?gtc?aag?gat?aca?gcc?aag?gca 1392

Leu?Pro?His?Ser?Arg His?Ser?Leu?Val?Lys?Asp?Thr?Ala?Lys?Ala

430 435 440

ctg?gta?cag?ata?aga?aca?aac?caa?ata?tca?aaa?ttt?gta?ctc?agg?tga 1440

Leu?Val?Gln?Ile?Arg?Thr?Asn?Gln?Ile?Ser?Lys?Phe?Val?Leu?Arg

445 450 455

aag?gac?cag?agg?ctg?gct?atg?tgg?cta?ccc?cca?tag?cta?tgg?ttc?agg 1488

Lys?Asp?Gln?Arg?Leu?Ala?Met?Trp?Leu?Pro?Pro Leu?Trp?Phe?Arg

460 465 470

cag?cca?tga?ctc?ttc?taa?gtg?atg?ctt?ctc?atc?tgc?cta?agg?c?gg gcg 1536

Gln?Pro Leu?Phe Val?Met?Leu?Leu?Ile?Cys?Leu?Arg Arg?Ala

475 480

ggg?tct?tca?cac?ctg?gag?cag?ctt?ttt?cca?aaa?caa?agt?tga?ttg?aca 1584

Gly?Ser?Ser?His?Leu?Glu?Gln?Leu?Phe?Pro?Lys?Gln?Ser Leu?Thr

485 490 495

gac?tca?aca?aac?acg?gta?ttg?agt?tta?gtg?tta?tta?gca?gct?ctg?aag 1632

Asp?Ser?Thr?Asn?Thr?Val?Leu?Ser?Leu?Val?Leu?Leu?Ala?Ala?Leu?Lys

500 505 510 515

tct?aaa?cac?tgg?aag?aat?taa?ctg?aag?tca?taa?cgt?gcg?tga?att?aac 1680

Ser?Lys?His?Trp?Lys?Asn Leu?Lys?Ser Arg?Ala Ile?Asn

520 525

agc?ttc?tct?att?tga?tat?ttg?aaa?ttc?ttc?tgt?aag?cct?gtc?tga?gtg 1728

Ser?Phe?Ser?Ile Tyr?Leu?Lys?Phe?Phe?Cys?Lys?Pro?Val Val

530 535 540

tat?gtg?gaa?acg?att?gtc?aaa?tct?aaa?ata?tct?ata?tat?taa?aaa?gta 1776

Tyr?Val?Glu?Thr?Ile?Val?Lys?Ser?Lys?Ile?Ser?Ile?Tyr Lys?Val

545 550 555

gga?aat?tgt?cct?agc?tta?ccc?taa?att?tca?aat?ctg?agt?tga?ttt?tgt 1824

Gly?Asn?Cys?Pro?Ser?Leu?Pro Ile?Ser?Asn?Leu?Ser Phe?Cys

560 565 570

gat?ttt?att?gct?tat?aac?aga?gaa?ctc?ata?ttt?gac?ata?ttt?ttt?tca 1872

Asp?Phe?Ile?Ala?Tyr?Asn?Arg?Glu?Leu?Ile?Phe?Asp?Ile?Phe?Phe?Ser

575 580 585

ttg?atg?tgt?tcc?tgg?tag?att?ttc?acg?aat?gag?ctg?gca?ggt?cta?atg 1920

Leu?Met?Cys?Ser?Trp Ile?Phe?Thr?Asn?Glu?Leu?Ala?Gly?Leu?Met

590 595 600

ggg?gag?gcg?gcg?tcc?cag?tct?gtg?ttg?cag?cag?cat?tct?cat?cgg?ggg 1968

Gly?Glu?Ala?Ala?Ser?Gln?Ser?Val?Leu?Gln?Gln?His?Ser?His?Arg?Gly

605 610 615

tgc?gca?cac?cat?cgt?tac?tgt?cgg?gca?gta?act?gcc?gct?tgc?ctt?gcc 2016

Cys?Ala?His?His?Arg?Tyr?Cys?Arg?Ala?Val?Thr?Ala?Ala?Cys?Leu?Ala

620 625 630

gca?gta?gga?ggg?aaa?tct?cac?ctt?cct?tcc?aca?tac?tgt?ctt?gag?cct 2064

Ala?Val?Gly?Gly?Lys?Ser?His?Leu?Pro?Ser?Thr?Tyr?Cys?Leu?Glu?Pro

635 640 645 650

ttg?cta?aat?taa?act?gca?ctt?ttt?gct?att?ttt?gcc?tag?ttt?ttc?gcc 2112

Leu?Leu?Asn Thr?Ala?Leu?Phe?Ala?Ile?Phe Ala?Phe?Phe?Ala

655 660

aat?cta?cac?tga?ttt?tgg?act?gtt?acc?taa?gtt?gaa?aaa?taa?aag?gtt 2160

Asn?Leu?His Phe?Trp?Thr?Val?Thr Val?Glu?Lys Lys?Val

665 670 675

gt?c?aat?cga?atg?gtg?gtt?taa?tgt?ttg?gac?ctg?ccg?atg?tat?ttg?tat 2208

Val?Asn?Arg?Met?Val?Val Cys?Leu?Asp?Leu?Pro?Met?Tyr?Leu?Tyr

680 685 690

agt?ggt?aga?aac?atg?ctg?ctt?aag?tgg?cct?aac?ctg?ttt?ctt?gcc?aat 2256

Ser?Gly?Arg?Asn?Met?Leu?Leu?Lys?Trp?Pro?Asn?Leu?Phe?Leu?Ala?Asn

695 700 705

aag?tag?gct?tat?cat?ttt?atc?ttt?acg?taa?ttc?tat?atc?tgt?gac?tag 2304

Lys Ala?Tyr?His?Phe?Ile?Phe?Thr Phe?Tyr?Ile?Cys?Asp

710 715 720

gtt?ttt?aag?gat?aca?gct?tat?aag?ttg?cta?tca?att?ttc?act?acc?taa 2352

Val?Phe?Lys?Asp?Thr?Ala?Tyr?Lys?Leu?Leu?Ser?Ile?Phe?Thr?Thr

725 730 735

gca?gaa?ttt?ttc?tct?aat?tta?ctt?ttt?gta?ttt?taa?cta?ggt?ttt?aca 2400

Ala?Glu?Phe?Phe?Ser?Asn?Leu?Leu?Phe?Val?Phe Leu?Gly?Phe?Thr

740 745 750

tgg?aag?ccc?taa?aat?aag?gca?aaa?gac?ttt?ttc?ttt?tgt?aat?aag?cat 2448

Trp?Lys?Pro Asn?Lys?Ala?Lys?Asp?Phe?Phe?Phe?Cys?Asn?Lys?His

755 760 765

ata?ata?aac?acg?tat?ata?cat?agc?aa?aaaaaaaa 2482

Ile?Ile?Asn?Thr?Tyr?Ile?His?Ser

770

SEQUENCE?LISTING?17

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_019073

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1739

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(216)

<220>

<221>exon

<222>(217)..(354)

<220>

<221>exon

<222>(355)..(403)

<220>

<221>exon

<222>(404)..(445)

<220>

<221>exon

<222>(446)..(570)

<220>

<221>exon

<222>(571)..(651)

<220>

<221>exon

<222>(652)..(945)

<220>

<221>exon

<222>(946)..(1033)

<220>

<221>exon

<222>(1034)..(1074)

<220>

<221>exon

<222>(1075)..(1259)

<220>

<221>exon

<222>(1260)..(1359)

<220>

<221>exon

<222>(1360)..(1451)

<220>

<221>exon

<222>(1452)..(1739)

<400>1

gct?tct?ccg?gcg?gaa?ccc?agg?ctg?gac?cgc?ggg?ccc?cgg?cct?ggg?ggc 48

Ala?Ser?Pro?Ala?Glu?Pro?Arg?Leu?Asp?Arg?Gly?Pro?Arg?Pro?Gly?Gly

1 5 10 15

cac?tgc?tgc?cac?cgc?cgc?cgc?cac?ctc?gtc?tcc?tcc?ccg?tcc?ccg?ccc 96

His?Cys?Cys?His?Arg?Arg?Arg?His?Leu?Val?Ser?Ser?Pro?Ser?Pro?Pro

20 25 30

agc?ccc?agg?tct?ccc?cgc?ctc?act?cgg?gcc?cgt?ggc?cgg?ggt?cac?tcc 144

Ser?Pro?Arg?Ser?Pro?Arg?Leu?Thr?Arg?Ala?Arg?Gly?Arg?Gly?His?Ser

35 40 45

ccg?ccg?ccc?ctc?ccc?gca?cgg?atg?ccg?aag?gtg?aag?gcg?ctg?cag?tgc 192

Pro?Pro?Pro?Leu?Pro?Ala?Arg?Met?Pro?Lys?Val?Lys?Ala?Leu?Gln?Cys

50 55 60

gcc?ctg?gcg?ctg?gag?atc?agc?tca?gta?act?tgc?cca?gga?gtc?gtg?ctt 240

Ala?Leu?Ala?Leu?Glu?Ile?Ser?Ser?Val?Thr?Cys?Pro?Gly?Val?Val?Leu

65 70 75 80

aaa?gac?aaa?gag?gac?atc?tat?ctt?agc?atc?tgt?gtg?ttt?ggc?caa?tac 288

Lys?Asp?Lys?Glu?Asp?Ile?Tyr?Leu?Ser?Ile?Cys?Val?Phe?Gly?Gln?Tyr

85 90 95

aaa?aag?aca?caa?tgt?gtc?cca?gcc?act?ttt?ccc?ctg?gtc?ttc?aat?gcc 336

Lys?Lys?Thr?Gln?Cys?Val?Pro?Ala?Thr?Phe?Pro?Leu?Val?Phe?Asn?Ala

100 105 110

aga?atg?gtg?ttt?gaa?aag?gtg?ttc?ccg?gac?gca?gta?gat?cct?gga?gat 384

Arg?Met?Val?Phe?Glu?Lys?Val?Phe?Pro?Asp?Ala?Val?Asp?Pro?Gly?Asp

115 120 125

gtg?gtt?aca?cag?ctt?gaa?t?at gat?aca?gca?gtg?ttc?gag?ttg?ata?cag 432

Val?Val?Thr?Gln?Leu?Glu Tyr?Asp?Thr?Ala?Val?Phe?Glu?Leu?Ile?Gln

130 140

cta?gtt?cca?cca?g?tg ggt?gaa?aca?ctg?tct?acg?tat?gac?gaa?aat?aca 480

Leu?Val?Pro?Pro Val?Gly?Glu?Thr?Leu?Ser?Thr?Tyr?Asp?Glu?Asn?Thr

145 150 155 160

cga?gat?ttc?atg?ttt?ccg?ggt?cca?aac?caa?atg?tct?gga?cac?cat?gat 528

Arg?Asp?Phe?Met?Phe?Pro?Gly?Pro?Asn?Gln?Met?Ser?Gly?His?His?Asp

165 170 175

tca?aac?cgc?cag?gtt?acc?atg?agg?agg?att?tct?ggc?ctt?cga?gga?aat 576

Ser?Asn?Arg?Gln?Val?Thr?Met?Arg?Arg?Ile?Ser?Gly?Leu?Arg?Gly?Asn

180 185 190

gct?cca?agg?ctg?gaa?ttt?tct?acg?act?tca?gtg?att?act?gaa?tgt?ctg 624

Ala?Pro?Arg?Leu?Glu?PheSer?Thr?Thr?Ser?Val?Ile?Thr?Glu?Cys?Leu

195 200 205

ata?agt?tca?agg?aaa?tgc?cac?act?cag?gat?aaa?ttt?att?tac?cat?ttg 672

Ile?Ser?Ser?Arg?Lys?Cys?His?Thr?Gln?Asp?Lys?Phe?Ile?Tyr?His?Leu

210 215 220

gct?cca?gtt?gaa?aaa?tca?cat?ggc?aga?ctg?caa?aac?aga?aca?tca?aga 720

Ala?Pro?Val?Glu?Lys?Ser?His?Gly?Arg?Leu?Gln?Asn?Arg?Thr?Ser?Arg

225 230 235 240

tca?caa?aag?aaa?aaa?tcc?aag?tca?cct?gag?aga?agt?aaa?tac?tgt?ata 768

Ser?Gln?Lys?Lys?Lys?Ser?Lys?Ser?Pro?Glu?Arg?Ser?Lys?Tyr?Cys?Ile

245 250 255

aat?gca?aaa?aac?tac?gaa?cag?cct?aca?att?tct?tca?aaa?tca?cac?tct 816

Asn?Ala?Lys?Asn?Tyr?Glu?Gln?Pro?Thr?Ile?Ser?Ser?Lys?Ser?His?Ser

260 265 270

cca?tct?ccc?tac?aca?aaa?aga?cgc?atg?tgt?gag?cta?tct?gaa?gac?acc 864

Pro?Ser?Pro?Tyr?Thr?Lys?Arg?Arg?Met?Cys?Glu?Leu?Ser?Glu?Asp?Thr

275 280 285

agg?cgg?cgg?ctg?gcc?cat?tta?aat?ctg?gga?ccc?tat?gag?ttc?aaa?aaa 912

Arg?Arg?Arg?Leu?Ala?His?Leu?Asn?Leu?Gly?Pro?Tyr?Glu?Phe?Lys?Lys

290 295 300

gaa?aca?gat?aaa?cct?cca?ttt?gtg?att?aga?cat?gtt?gat?ccc?cca?agt 960

Glu?Thr?Asp?Lys?Pro?Pro?Phe?Val?Ile?Arg?His?Val?Asp?Pro?Pro?Ser

305 310 315 320

ccc?agg?gct?gat?act?tta?ttg?gga?tct?tct?gga?aga?gac?tgt?gaa?aga 1008

Pro?Arg?Ala?Asp?Thr?Leu?Leu?Gly?Ser?Ser?Gly?Arg?Asp?Cys?Glu?Arg

325 330 335

gat?gga?tgg?tca?agg?gtg?cac?aat?g?at cat?tct?cat?ctt?ggc?tgc?tgc 1056

AspGly?Trp?Ser?Arg?Val?His?Asn Asp?His?Ser?His?Leu?Gly?Cys?Cys

340 350

cga?ccc?aag?gat?tat?aag?gtt?atc?agg?aca?ccc?cat?ggg?aga?gac?ttc 1104

Arg?Pro?Lys?Asp?Tyr?Lys?Val?Ile?Arg?Thr?Pro?His?Gly?Arg?Asp?Phe

355 360 365

gat?gac?tct?tta?gaa?aaa?tgt?gaa?gag?tat?ttg?agc?cca?agg?tcg?tgt 1152

Asp?Asp?Ser?Leu?Glu?Lys?Cys?Glu?Glu?Tyr?Leu?Ser?Pro?Arg?Ser?Cys

370 375 380

agt?aag?ccc?cgg?cat?tca?gcg?agg?acc?ttg?cta?gtc?cat?tca?gca?ccc 1200

Ser?Lys?Pro?Arg?His?Ser?Ala?Arg?Thr?Leu?Leu?Val?His?Ser?Ala?Pro

385 390 395 400

tca?aca?atg?cca?aag?cat?tct?cca?agc?cct?gtg?tta?aat?aga?gct?tct 1248

Ser?Thr?Met?Pro?Lys?His?Ser?Pro?Ser?Pro?Val?Leu?Asn?Arg?Ala?Ser

405 410 415

ctc?agg?gaa?ag?a?ttt?cat?tct?gat?tgg?tgt?tca?cct?tca?aac?tgc?gat 1296

Leu?Arg?Glu?Arg Phe?His?Ser?Asp?Trp?Cys?Ser?Pro?Ser?Asn?Cys?Asp

425 430

gag?atc?cat?gac?cgg?gta?aaa?aat?gtc?ttg?aaa?tca?cat?cag?gct?cat 1344

Glu?Ile?His?Asp?Arg?Val?Lys?Asn?Val?Leu?Lys?Ser?His?Gln?Ala?His

435 440 445

caa?aga?cat?tta?tat?gat?gag?aga?gac?cta?gag?aaa?gat?gat?gaa?ctg 1392

Gln?Arg?His?Leu?Tyr?Asp?Glu?Arg?Asp?Leu?Glu?Lys?Asp?Asp?Glu?Leu

450 455 460

gaa?ctg?aaa?aga?agt?ctt?tta?tgt?aga?gac?tct?gcc?tat?gac?agt?gac 1440

Glu?Leu?Lys?Arg?Ser?Leu?Leu?Cys?Arg?Asp?Ser?Ala?Tyr?Asp?Ser?Asp

465 470 475 480

ccc?gag?tat?ag?c?tca?tgt?cag?cag?cca?cgt?ggc?act?ttc?cat?ttg?gat 1488

Pro?Glu?Tyr?Ser Ser?Cys?Gln?Gln?Pro?Arg?Gly?Thr?Phe?His?Leu?Asp

485 490 495

gac?ggt?gaa?tac?tgg?tcc?aac?agg?gca?gcc?tct?tat?aag?gga?aaa?tcc 1536

Asp?Gly?Glu?Tyr?Trp?Ser?Asn?Arg?Ala?Ala?Ser?Tyr?Lys?Gly?Lys?Ser

500 505 510

cac?cga?ccc?atc?ttt?gag?aac?agc?atg?gac?aag?atg?tac?agg?aac?tta 1584

His?Arg?Pro?Ile?Phe?Glu?Asn?Ser?Met?Asp?Lys?Met?Tyr?Arg?Asn?Leu

515 520 525

tac?aaa?aag?gcc?tgt?agt?tct?gct?tca?cat?aca?cag?gaa?agc?ttc?tga 1632

Tyr?Lys?Lys?Ala?Cys?Ser?Ser?Ala?Ser?His?Thr?Gln?Glu?Ser?Phe

530 535 540

gac?cat?cca?tga?taa?acc?tca?tta?gtg?tcc?gtg?tca?att?tct?caa?tga 1680

Asp?His?Pro Thr?Ser?Leu?Val?Ser?Val?Ser?Ile?Ser?Gln

545 550 555

aaa?tgt?ttg?atg?tga?tca?ata?tct?gta?ttc?ctt?ttt?tta?aaa?aaa?atg 1728

Lys?Cys?Leu?Met Ser?Ile?Ser?Val?Phe?Leu?Phe?Leu?Lys?Lys?Met

560 565 570

gga?tta?taa?ct 1739

Gly?Leu

SEQUENCE?LISTING18

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_003284

<160>1

<170>PatentIn?version?3.5

<210>1

<211>415

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(164)

<220>

<221>exon

<222>(165)..(402)

<220>

<221>STS

<222>(213)..(393)

<400>1

gcc?cct?cat?ttt?ggc?aga?act?tac?cat?gtc?gac?cag?ccg?caa?att?aaa 48

Ala?Pro?His?Phe?Gly?Arg?Thr?Tyr?His?Val?Asp?Gln?Pro?Gln?Ile?Lys

1 5 10 15

gag?tca?tgg?cat?gag?gag?gag?caa?gag?ccg?atc?tcc?tca?caa?ggg?agt 96

Glu?Ser?Trp?His?Glu?Glu?Glu?Gln?Glu?Pro?Ile?Ser?Ser?Gln?Gly?Ser

20 25 30

caa?gag?agg?tgg?cag?caa?aag?aaa?ata?ccg?taa?ggg?caa?cct?gaa?aag 144

Gln?Glu?Arg?Trp?Gln?Gln?Lys?Lys?Ile?Pro Gly?Gln?Pro?Glu?Lys

35 40 45

tag?gaa?acg?ggg?cga?tga?cg c?caa?tcg?caa?tta?ccg?ctc?cca?ctt?gtg 192

Glu?Thr?Gly?Arg Arg Gln?Ser?Gln?Leu?Pro?Leu?Pro?Leu?Val

50 55 60

agc?ccc?cag?cgg?gct?ctg?ccc?tgg?tgc?gct?tca?cac?agc?acc?aag?cag 240

Ser?Pro?Gln?Arg?Ala?Leu?Pro?Trp?Cys?Ala?Ser?His?Ser?Thr?Lys?Gln

65 70 75

caa?caa?gaa?cag?cag?aag?ggg?aac?tgc?caa?gga?gac?ctg?atg?tta?gat 288

Gln?Gln?Glu?Gln?Gln?Lys?Gly?Asn?Cys?Gln?Gly?Asp?Leu?Met?Leu?Asp

80 85 90

caa?agc?cag?aga?gga?gcc?tat?gga?atg?tgg?atc?aaa?tgc?cag?ttg?tga 336

Gln?Ser?Gln?Arg?Gly?Ala?Tyr?Gly?Met?Trp?Ile?Lys?Cys?Gln?Leu

95 100 105

cga?aat?gag?gaa?tgt?ata?tgt?tgg?ctg?ttt?ttc?ccc?aac?atc?tca?ata 384

Arg?Asn?Glu?Glu?Cys?Ile?Cys?Trp?Leu?Phe?Phe?Pro?Asn?Ile?Ser?Ile

110 115 120

aaa?ctt?tga?aag?cag?aaa?aaaaaaaaaa?aaa 415

Lys?Leu Lys?Gln?Lys

125

SEQUENCE?LISTING19

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_021733

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1812

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(181)

<220>

<221>exon

<222>(182)..(410)

<220>

<221>exon

<222>(411)..(506)

<220>

<221>exon

<222>(507)..(590)

<220>

<221>exon

<222>(591)..(674)

<220>

<221>exon

<222>(675)..(1003)

<220>

<221>exon

<222>(1004)..(1198)

<220>

<221>exon

<222>(1199)..(1372)

<220>

<221>exon

<222>(1373)..(1508)

<220>

<221>exon

<222>(1509)..(1633)

<220>

<221>exon

<222>(1634)..(1812)

<220>

<221>polyA_signal

<222>(1786)..(1791)

<220>

<221>polyA_site

<222>(1812)..(1812)

<400>1

acc?ccc?aca?cca?tgg?cga?gcg?tgg?tgg?tga?aga?cga?tct?ggc?agt?cca 48

Thr?Pro?Thr?Pro?Trp?Arg?Ala?Trp?Trp Arg?Arg?Ser?Gly?Ser?Pro

1 5 10 15

aag?aga?tcc?atg?agg?ccg?ggg?aca?ccc?cca?cgg?ggg?tgg?aga?gct?gct 96

Lys?Arg?Ser?Met?Arg?Pro?Gly?Thr?Pro?Pro?Arg?Gly?Trp?Arg?Ala?Ala

20 25 30

ccc?agc?tag?tcc?cag?agg?ctc?ccc?gga?ggg?tga?cca?gcc?ggg?cca?agg 144

Pro?Ser Ser?Gln?Arg?Leu?Pro?Gly?Gly Pro?Ala?Gly?Pro?Arg

35 40 45

gga?tcc?cga?aga?aaa?aga?agg?ccg?tgt?cgt?tcc?acg?g?gg tgg?agc?ccc 192

Gly?Ser?Arg?Arg?Lys?Arg?Arg?Pro?Cys?Arg?Ser?Thr Gly?Trp?Ser?Pro

50 55 60

aga?tgt?ccc?atc?agc?cca?tgc?act?ggt?gcc?tga?acc?tca?aac?ggt?cct 240

Arg?Cys?Pro?Ile?Ser?Pro?Cys?Thr?Gly?Ala Thr?Ser?Asn?Gly?Pro

65 70 75

cgg?cct?gca?cca?acg?tgt?cac?tgc?tca?acc?tgg?ccg?cca?tgg?agc?cca 288

Arg?Pro?Ala?Pro?Thr?Cys?His?Cys?Ser?Thr?Trp?Pro?Pro?Trp?Ser?Pro

80 85 90

ctg?act?cca?cgg?gga?cag?act?cca?cag?tgg?aag?acc?tca?gcg?gcc?aac 336

Leu?Thr?Pro?Arg?Gly?Gln?Thr?Pro?Gln?Trp?Lys?Thr?Ser?Ala?Ala?Asn

95 100 105

tca?cac?tgg?ctg?ggc?ccc?ctg?cct?ccc?cta?ccc?tac?cct?ggg?atc?cgg 384

Ser?His?Trp?Leu?Gly?Pro?Leu?Pro?Pro?Leu?Pro?Tyr?Pro?Gly?Ile?Arg

110 115 120

atg?acg?cag?aca?tca?cgg?aaa?tcc?tg a?gtg?ggg?tca?aca?gtg?gat?tgg 432

Met?Thr?Gln?Thr?Ser?Arg?Lys?Ser Val?Gly?Ser?Thr?Val?Asp?Trp

125 130 135 140

tcc?gcg?cca?aag?act?cca?tca?cca?gct?tga?agg?aaa?aga?cca?acc?ggg 480

Ser?Ala?Pro?Lys?Thr?Pro?Ser?Pro?Ala Arg?Lys?Arg?Pro?Thr?Gly

145 150 155

tta?acc?agc?acg?tgc?agt?ctc?tgc?ag a?gcg?agt?gtt?ctg?tgc?tga?gcg 528

Leu?Thr?Ser?Thr?Cys?Ser?Leu?Cys?Arg Ala?Ser?Val?Leu?Cys Ala

160 165 170

aga?atc?tgg?aga?gaa?ggc?ggc?aag?agg?cag?aag?agt?tgg?agg?ggt?act 576

Arg?Ile?Trp?Arg?Glu?Gly?Gly?Lys?Arg?Gln?Lys?Ser?Trp?Arg?Gly?Thr

175 180 185

gca?ttc?aac?tca?ag g?aga?act?gct?gga?agg?tga?ccc?ggt?ctg?tgg?aag 624

Ala?Phe?Asn?Ser?Arg Arg?Thr?Ala?Gly?Arg Pro?Gly?Leu?Trp?Lys

190 195 200

atg?ctg?aaa?tca?aaa?cca?acg?tct?tga?agc?aga?att?ctg?ccc?tgc?tgg 672

Met Leu?Lys?Ser?Lys?Pro?Thr?Ser Ser?Arg?Ile?Leu?Pro?Cys?Trp

205 210 215

ag g?aga?agc?tgc?gct?acc?tcc?agc?agc?agc?tgc?agg?atg?aga?cgc?cgc 720

Arg Arg?Ser?Cys?Ala?Thr?Ser?Ser?Ser?Ser?Cys?Arg?Met?Arg?Arg?Arg

220 225 230

gac?ggc?agg?agg?ccg?agc?tgc?agg?agc?cgg?agg?aga?agc?agg?agc?cgg 768

Asp?Gly?Arg?Arg?Pro?Ser?Cys?Arg?Ser?Arg?Arg?Arg?Ser?Arg?Ser?Arg

235 240 245

agg?aga?agc?agg?agc?cgg?agg?aga?agc?aga?agc?cgg?agg?ctg?gcc?tct 816

Arg?Arg?Ser?Arg?Ser?Arg?Arg?Arg?Ser?Arg?Ser?Arg?Arg?Leu?Ala?Ser

250 255 260

cct?gga?aca?gcc?tgg?gcc?ccg?ccg?cca?cgt?ccc?agg?gct?gcc?ccg?gcc 864

Pro?Gly?Thr?Ala?Trp?Ala?Pro?Pro?Pro?Arg?Pro?Arg?Ala?Ala?Pro?Ala

265 270 275 280

cgc?cag?gga?gtc?ccg?aca?aac?cct?cgc?ggc?cac?acg?gcc?tgg?tcc?ccg 912

Arg?Gln?Gly?Val?Pro?Thr?Asn?Pro?Arg?Gly?His?Thr?Ala?Trp?Ser?Pro

285 290 295

cag?gct?ggg?gaa?tgg?ggc?ctc?ggg?ctg?gcg?agg?gcc?cct?acg?tga?gcg 960

Gln?Ala?Gly?Glu?Trp?Gly?Leu?Gly?Leu?Ala?Arg?Ala?Pro?Thr Ala

300 305 310

agc?agg?aat?tgc?aga?agc?tgt?tca?ccg?gca?tcg?aag?agc?tga?g?ga gag 1008

Ser?Arg?Asn?Cys?Arg?Ser?Cys?Ser?Pro?Ala?Ser?Lys?Ser Gly?Glu

315 320

agg?tgt?cct?cac?tga?ccg?ccc?ggt?ggc?atc?agg?agg?agg?ggg?cgg?tgc 1056

Arg?Cys?Pro?His Pro?Pro?Gly?Gly?Ile?Arg?Arg?Arg?Gly?Arg?Cys

330 335 340

agg?aag?ccc?tgc?ggc?tgc?tcg?ggg?gcc?tgg?gcg?gca?ggg?tcg?acg?gct 1104

Arg?Lys?Pro?Cys?Gly?Cys?Ser?Gly?Ala?Trp?Ala?Ala?Gly?Ser?Thr?Ala

345 350 355

tcc?tag?gcc?agt?ggg?agc?ggg?cac?agc?gcg?aac?agg?cac?aga?cgg?cgc 1152

Ser Ala?Ser?Gly?Ser?Gly?His?Ser?Ala?Asn?Arg?His?Arg?Arg?Arg

360 365 370

ggg?act?tgc?agg?agc?tgc?gag?gtc?ggg?cgg?atg?agc?tgt?gca?cca?t?gg 1200

Gly?Thr?Cys?Arg?Ser?Cys?Glu?Val?Gly?Arg?Met?Ser?Cys?Ala?Pro Trp

375 380 385

tgg?agc?ggt?cag?cag?tgt?ctg?tgg?ctt?cac?tga?gga?gcg?aac?tgg?agg 1248

Trp?Ser?Gly?Gln?Gln?Cys?Leu?Trp?Leu?His Gly?Ala?Asn?Trp?Arg

390 395 400

ggc?tgg?gcc?cac?tga?aac?cca?ttc?tgg?agg?agt?tcg?ggc?ggc?aat?ttc 1296

Gly?Trp?Ala?His Asn?Pro?Phe?Trp?Arg?Ser?Ser?Gly?Gly?Asn?Phe

405 410 415

aga?act?ctc?gaa?gag?ggc?ctg?acc?tct?cca?tga?acc?tgg?atc?ggt?ccc 1344

Arg?Thr?Leu?Glu?Glu?Gly?Leu?Thr?Ser?Pro Thr?Trp?Ile?Gly?Pro

420 425 430

acc?aag?gca?act?gtg?ccc?gct?gtg?cca?g?cc agg?ggt?cgc?agt?tgt?cta 1392

Thr?Lys?Ala?Thr?Val?Pro?Ala?Val?Pro Ala?Arg?Gly?Arg?Ser?Cys?Leu

435 440 445

cgg?agt?ccc?tgc?agc?agc?tgc?tgg?acc?gag?cac?tga?cct?cac?tag?tgg 1440

Arg?Ser?Pro?Cys?Ser?Ser?Cys?Trp?Thr?Glu?His Pro?His Trp

450 455 460

acg?agg?tga?agc?aga?ggg?gcc?tga?ctc?ctg?cct?gtc?cca?gct?gtc?aga 1488

Thr?Arg Ser?Arg?Gly?Ala Leu?Leu?Pro?Val?Pro?Ala?Val?Arg

465 470 475

ggc?tac?aca?aga?aga?ttc?tg g?agc?tgg?agc?gcc?agg?cct?tag?cca?aac 1536

Gly?Tyr?Thr?Arg?Arg?Phe?Trp Ser?Trp?Ser?Ala?Arg?Pro Pro?Asn

480 485 490

acg?tca?ggg?cag?agg?ccc?tga?gct?cca?ccc?ttc?ggc?tgg?ccc?aag?acg 1584

Thr?Ser?Gly?Gln?Arg?Pro Ala?Pro?Pro?Phe?Gly?Trp?Pro?Lys?Thr

495 500 505

agg?ccc?tgc?ggg?cca?aga?acc?tac?tgc?tga?cag?aca?aga?tga?agc?cag?a 1633

Arg?Pro?Cys?Gly?Pro?Arg?Thr?Tyr?Cys Gln?Thr?Arg Ser?Gln

510 515 520

gg?aga?aga?tgg?cca?ctc?tgg?acc?atc?tac?act?tga?aga?tgt?gct?ccc 1680

Arg?Arg?Arg?Trp?Pro?Leu?Trp?Thr?Ile?Tyr?Thr Arg?Cys?Ala?Pro

525 530 535

tcc?acg?atc?atc?tca?gca?acc?tgc?cac?ttg?agg?ggt?cca?cgg?gaa?caa 1728

Ser?Thr?Ile?Ile?Ser?Ala?Thr?Cys?His?Leu?Arg?Gly?Pro?Arg?Glu?Gln

540 545 550

tgg?ggg?gag?gca?gca?gtg?cag?gaa?ccc?ccc?caa?aac?agg?ggg?gct?cag 1776

Trp?Gly?Glu?Ala?Ala?Val?Gln?Glu?Pro?Pro?Gln?Asn?Arg?Gly?Ala?Gln

555 560 565

ccc?ctg?aac?aat?aaa?tgg?cct?ctc?atg?cta?gca?tga 1812

Pro?Leu?Asn?Asn?Lys?Trp?Pro?Leu?Met?Leu?Ala

570 575

SEQUENCE?LISTING20

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NM_017481

<160>1

<170>PatentIn?version?3.5

<210>1

<211>2347

<212>DNA

<213>Homo?sapiens

<220>

<221>exon

<222>(1)..(50)

<220>

<221>exon

<222>(51)..(2345)

<220>

<221>CDS

<222>(87)..(2054)

<220>

<221>STS

<222>(197)..(443)

<220>

<221>STS

<222>(257)..(1042)

<220>

<221>STS

<222>(422)..(665)

<220>

<221>STS

<222>(642)..(889)

<220>

<221>STS

<222>(783)..(1984)

<220>

<221>STS

<222>(860)..(1110)

<220>

<221>STS

<222>(1056)..(1303)

<220>

<221>STS

<222>(1131)..(1949)

<220>

<221>STS

<222>(1282)..(1549)

<220>

<221>STS

<222>(1520)..(1748)

<220>

<221>STS

<222>(1707)..(1947)

<220>

<221>STS

<222>(1919)..(2178)

<400>1

ggg?agg?ttt?gga?gcc?ctg?cat?aaa?gag?aag?gac?ggg?acc?aca?gct?gac 48

Gly?Arg?Phe?Gly?Ala?Leu?His?Lys?Glu?Lys?Asp?Gly?Thr?Thr?Ala?Asp

1 5 10 15

tg c?tgt?gtc?ccc?aca?gat?ctg?ggc?ctc?ctg?ctg?cca?cca?tgg?cca?aag 96

Cys Cys?Val?Pro?Thr?Asp?Leu?Gly?Leu?Leu?Leu?Pro?Pro?Trp?Pro?Lys

20 25 30

gtg?gag?aag?ccc?tgc?cac?agg?gca?gcc?cag?cac?cag?tcc?agg?atc?ccc 144

Val?Glu?Lys?Pro?Cys?His?Arg?Ala?Ala?Gln?His?Gln?Ser?Arg?Ile?Pro

35 40 45

acc?tca?tca?agg?tga?cag?tga?aga?cgc?cca?aag?aca?agg?agg?att?tct 192

Thr?Ser?Ser?Arg Gln Arg?Arg?Pro?Lys?Thr?Arg?Arg?Ile?Ser

50 55 60

cag?tta?cag?aca?cat?gca?cta?tcc?agc?agc?tga?agg?aag?aga?tat?ctc 240

Gln?Leu?Gln?Thr?His?Ala?Leu?Ser?Ser?Ser Arg?Lys?Arg?Tyr?Leu

65 70 75

agc?gct?tta?agg?ccc?acc?ccg?atc?agc?ttg?ttc?taa?tct?ttg?ctg?gca 288

Ser?Ala?Leu?Arg?Pro?Thr?Pro?Ile?Ser?Leu?Phe Ser?Leu?Leu?Ala

80 85 90

aaa?tcc?tca?agg?atc?ctg?act?cac?tgg?cac?agt?gtg?gag?tgc?gag?atg 336

Lys?Ser?Ser?Arg?Ile?Leu?Thr?His?Trp?His?Ser?Val?Glu?Cys?Glu?Met

95 100 105

gcc?tca?ctg?tcc?acc?tgg?tca?tca?aga?ggc?agc?acc?gtg?cca?tgg?gca 384

Ala?Ser?Leu?Ser?Thr?Trp?Ser?Ser?Arg?Gly?Ser?Thr?Val?Pro?Trp?Ala

110 115 120

atg?agt?gcc?cag?ctg?cct?ctg?tcc?cta?ccc?agg?gcc?caa?gtc?ctg?gat 432

Met?Ser?Ala?Gln?Leu?Pro?Leu?Ser?Leu?Pro?Arg?Ala?Gln?Val?Leu?Asp

125 130 135 140

cac?tcc?ctc?agc?caa?gct?cca?ttt?acc?cag?cag?atg?ggc?ccc?ctg?cct 480

His?Ser?Leu?Ser?Gln?Ala?Pro?Phe?Thr?Gln?Gln?Met?Gly?Pro?Leu?Pro

145 150 155

tta?gct?tag?gtc?tcc?tca?cag?gcc?tca?gta?ggc?tgg?gct?tgg?cct?atc 528

Leu?Ala Val?Ser?Ser?Gln?Ala?Ser?Val?Gly?Trp?Ala?Trp?Pro?Ile

160 165 170

gtg?gct?tcc?ctg?acc?agc?caa?gct?ccc?tga?tgc?ggc?agc?atg?tgt?ctg 576

Val?Ala?Ser?Leu?Thr?Ser?Gln?Ala?Pro Cys?Gly?Ser?Met?Cys?Leu

175 180 185

tgc?ctg?agt?ttg?tga?ctc?agc?tca?ttg?atg?acc?cct?tca?tcc?cgg?gtc 624

Cys?Leu?Ser?Leu Leu?Ser?Ser?Leu?Met?Thr?Pro?Ser?Ser?Arg?Val

190 195 200

tgc?tgt?cca?aca?cag?gcc?tag?tac?gcc?agc?tgg?ttc?ttg?aca?acc?ccc 672

Cys?Cys?Pro?Thr?Gln?Ala Tyr?Ala?Ser?Trp?Phe?Leu?Thr?Thr?Pro

205 210 215

ata?tgc?agc?agc?tga?tcc?agc?aca?acc?ctg?aga?ttg?ggc?ata?ttc?tta 720

Ile?Cys?Ser?Ser Ser?Ser?Thr?Thr?Leu?Arg?Leu?Gly?Ile?Phe?Leu

220 225 230

aca?acc?cgg?aaa?tta?tgc?ggc?aga?cac?tgg?agt?ttt?tac?gta?acc?ctg 768

Thr?Thr?Arg?Lys?Leu?Cys?Gly?Arg?His?Trp?Ser?Phe?Tyr?Val?Thr?Leu

235 240 245

cca?tga?tgc?agg?aga?tga?tac?gta?gcc?agg?acc?ggg?tgc?tca?gta?act 816

Pro Cys?Arg?Arg Tyr?Val?Ala?Arg?Thr?Gly?Cys?Ser?Val?Thr

250 255 260

tgg?aga?gca?ttc?ctg?gtg?gct?aca?atg?tgc?ttt?gca?cta?tgt?aca?cag 864

Trp?Arg?Ala?Phe?Leu?Val?Ala?Thr?Met?Cys?Phe?Ala?Leu?Cys?Thr?Gln

265 270 275

ata?tta?tgg?acc?caa?tgc?tta?acg?cag?tcc?agg?agc?agt?ttg?gcg?gca 912

Ile?Leu?Trp?Thr?Gln?Cys?Leu?Thr?Gln?Ser?Arg?Ser?Ser?Leu?Ala?Ala

280 285 290

atc?cct?ttg?cca?ctg?cca?cta?ctg?ata?atg?cca?cca?cca?cca?cca?gcc 960

Ile?Pro?Leu?Pro?Leu?Pro?Leu?Leu?Ile?Met?Pro?Pro?Pro?Pro?Pro?Ala

295 300 305

aac?ctt?caa?gga?tgg?aga?att?gtg?acc?ctc?tcc?cca?acc?cct?gga?ctt 1008

Asn?Leu?Gln?Gly?Trp?Arg?Ile?Val?Thr?Leu?Ser?Pro?Thr?Pro?Gly?Leu

310 315 320 325

cca?cac?atg?gag?gct?cag?gta?gca?ggc?aag?gaa?ggc?agg?atg?ggg?atc 1056

Pro?His?Met?Glu?Ala?Gln?Val?Ala?Gly?Lys?Glu?Gly?Arg?Met?Gly?Ile

330 335 340

agg?atg?cac?ctg?aca?tta?gaa?ata?ggt?ttc?caa?act?ttc?tgg?gta?tta 1104

Arg?Met?His?Leu?Thr?Leu?Glu?Ile?Gly?Phe?Gln?Thr?Phe?Trp?Val?Leu

345 350 355

taa?ggc?tct?atg?act?atc?tcc?agc?aat?tac?acg?aga?acc?ccc?agt?ccc 1152

Gly?Ser?Met?Thr?Ile?Ser?Ser?Asn?Tyr?Thr?Arg?Thr?Pro?Ser?Pro

360 365 370

tag?gaa?ctt?atc?tac?agg?gga?ctg?cat?ctg?ccc?tca?gcc?aaa?gcc?agg 1200

Glu?Leu?Ile?Tyr?Arg?Gly?Leu?His?Leu?Pro?Ser?Ala?Lys?Ala?Arg

375 380 385

aac?cac?cac?cat?cag?taa?aca?gag?ttc?ccc?cat?cgt?cac?cct?cat?ctc 1248

Asn?His?His?His?Gln Thr?Glu?Phe?Pro?His?Arg?His?Pro?His?Leu

390 395 400

agg?agc?ctg?ggt?cag?gcc?agc?ctc?tcc?ccg?agg?agt?cag?tag?caa?tca 1296

Arg?Ser?Leu?Gly?Gln?Ala?Ser?Leu?Ser?Pro?Arg?Ser?Gln Gln?Ser

405 410 415

agg?gaa?ggt?cct?cct?gcc?cag?ctt?tcc?tga?gat?acc?cca?cag?aga?aca 1344

Arg?Glu?Gly?Pro?Pro?Ala?Gln?Leu?Ser Asp?Thr?Pro?Gln?Arg?Thr

420 425 430

gta?ctg?gac?aag?gtg?gag?acc?aag?atg?gtg?cag?gga?aaa?gct?cta?ctg 1392

Val?Leu?Asp?Lys?Val?Glu?Thr?Lys?Met?Val?Gln?Gly?Lys?Ala?Leu?Leu

435 440 445

gac?ata?gca?caa?act?tgc?ctg?atc?ttg?tct?cgg?ggc?tgg?gag?att?ctg 1440

Asp?Ile?Ala?Gln?Thr?Cys?Leu?Ile?Leu?Ser?Arg?Gly?Trp?Glu?Ile?Leu

450 455 460

cca?aca?ggg?ttc?cat?ttg?ctc?cct?tat?ctt?ttt?ccc?cca?cgg?cag?cca 1488

Pro?Thr?Gly?Phe?His?Leu?Leu?Pro?Tyr?Leu?Phe?Pro?Pro?Arg?Gln?Pro

465 470 475 480

ttc?ctg?gaa?tcc?ctg?agc?ctc?cct?ggc?tgc?cat?ccc?cgg?ctt?atc?caa 1536

Phe?Leu?Glu?Ser?Leu?Ser?Leu?Pro?Gly?Cys?His?Pro?Arg?Leu?Ile?Gln

485 490 495

gat?ctc?tga?ggc?cag?atg?gca?tga?atc?cag?ctc?cac?agt?tac?agg?atg 1584

AspLeu Gly?Gln?Met?Ala Ile?Gln?Leu?His?Ser?Tyr?Arg?Met

500 505 510

aga?tac?aac?cac?agc?tgc?cac?tgc?tga?tgc?acc?ttc?agg?cag?cca?tgg 1632

Arg?Tyr?Asn?His?Ser?Cys?His?Cys Cys?Thr?Phe?Arg?Gln?Pro?Trp

515 520 525

caa?acc?ccc?gtg?ccc?tgc?aag?ccc?tgc?ggc?aga?ttg?agc?agg?gtc?tac 1680

Gln?Thr?Pro?Val?Pro?Cys?Lys?Pro?Cys?Gly?Arg?Leu?Ser?Arg?Val?Tyr

530 535 540

agg?tcc?tag?cta?ctg?aag?cac?ctc?gcc?tcc?tac?tct?ggt?tca?tgc?ctt 1728

Arg?Ser Leu?Leu?Lys?His?Leu?Ala?Ser?Tyr?Ser?Gly?Ser?Cys?Leu

545 550 555

gcc?tag?cag?gga?cgg?gta?gtg?tgg?cag?gag?gta?tag?agt?cta?gag?aag 1776

Ala Gln?Gly?Arg?Val?Val?Trp?Gln?Glu?Val Ser?Leu?Glu?Lys

560 565 570

atc?ccc?tta?tgt?ctg?agg?atc?ctc?tcc?caa?atc?cac?ctc?ctg?agg?tgt 1824

lle?Pro?Leu?Cys?Leu?Arg?Ile?Leu?Ser?Gln?Ile?His?Leu?Leu?Arg?Cys

575 580 585

tcc?cag?cac?tgg?act?ctg?cag?agc?tgg?gct?tcc?ttt?ccc?ctc?cct?ttc 1872

Ser?Gln?His?Trp?Thr?Leu?Gln?Ser?Trp?Ala?Ser?Phe?Pro?Leu?Pro?Phe

590 595 600

tcc?ata?tgc?tgc?aag?att?tag?tta?gta?caa?atc?ccc?agc?agc?tgc?agc 1920

Ser?Ile?Cys?Cys?Lys?Ile Leu?Val?Gln?Ile?Pro?Ser?Ser?Cys?Ser

605 610 615

ctg?agg?ctc?act?ttc?agg?tgc?agc?tgg?agc?aac?tgc?ggt?cca?tgg?gct 1968

Leu?Arg?Leu?Thr?Phe?Arg?Cys?Ser?Trp?Ser?Asn?Cys?Gly?Pro?Trp?Ala

620 625 630

ttc?tga?atc?gtg?aag?cca?atc?ttc?agg?ccc?tca?ttg?cta?cgg?ggg?gcg 2016

Phe Ile?Val?Lys?Pro?Ile?Phe?Arg?Pro?Ser?Leu?Leu?Arg?Gly?Ala

635 640 645

acg?tgg?atg?ctg?ctg?tgg?aga?agc?tga?gac?agt?cgt?agg?agc?ctt?att 2064

Thr?Trp?Met?Leu?Leu?Trp?Arg?Ser Asp?Ser?Arg?Arg?Ser?Leu?Ile

650 655 660

cat?tca?aac?cat?acg?ttt?tcc?tct?gtg?cct?ttt?tcc?cat?atc?cta?gtt 2112

His?Ser?Asn?His?Thr?Phe?Ser?Ser?Val?Pro?Phe?Ser?His?Ile?Leu?Val

665 670 675

ccc?tag?ctc?tcc?cat?ttt?tga?ata?cag?ctg?cat?tat?aaa?cca?aat?tta 2160

Pro Leu?Ser?His?Phe Ile?Gln?Leu?His?Tyr?Lys?Pro?Asn?Leu

680 685 690

cta?tga?agt?cct?ttg?ctg?tgg?agg?caatgt?tgt?tcc?aga?gtc?aac?gag 2208

Leu Ser?Pro?Leu?Leu?Trp?Arg?Gln?Cys?Cys?Ser?Arg?Val?Asn?Glu

695 700 705

gaa?gac?taa?tgg?cca?aaa?cat?agt?gga?ggt?gct?gtg?tgt?gag?tca?acc 2256

Glu?Asp Trp?Pro?Lys?His?Ser?Gly?Gly?Ala?Val?Cys?Glu?Ser?Thr

710 715 720

act?tgt?acc?act?ata?cca?ctg?ggg?ggc?ccc?agt?cta?agc?tct?gct?tat 2304

Thr?Cys?Thr?Thr?Ile?Pro?Leu?Gly?Gly?Pro?Ser?Leu?Ser?Ser?Ala?Tyr

725 730 735

gcc?tat?ctt?gag?atg?caa?tta?cac?ccaatt?tcc?aat?gtg?aa?aa 2347

Ala?Tyr?Leu?Glu?Met?Gln?Leu?His?Pro?Ile?Ser?Asn?Val

740 745 750

SEQUENCE?LISTING21

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_001455

<160>1

<170>PatentIn?version?3.5

<210>1

<211>735

<212>PRT

<213>Homo?sapiens

<220>

<221>SITE

<222>(313)..(314)

<220>

<221>SITE

<222>(317)..(317)

<220>

<221>SITE

<222>(323)..(323)

<400>1

Met?Trp?Arg?Val?Leu?Phe?Leu?Leu?Ser?Gly?Leu?Gly?Gly?Leu?Arg?Met

1 5 10 15

Asp?Ser?Asn?Phe?Asp?Ser?Leu?Pro?Val?Gln?Ile?Thr?Val?Pro?Glu?Lys

20 25 30

Ile?Arg?Ser?Ile?Ile?Lys?Glu?Gly?Ile?Glu?Ser?Gln?Ala?Ser?Tyr?Lys

35 40 45

Ile?Val?Ile?Glu?Gly?Lys?Pro?Tyr?Thr?Val?Asn?Leu?Met?Gln?Lys?Asn

50 55 60

Phe?Leu?Pro?His?Asn?Phe?Arg?Val?Tyr?Ser?Tyr?Ser?Gly?Thr?Gly?Ile

65 70 75 80

Met?Lys?Pro?Leu?Asp?Gln?Asp?Phe?Gln?Asn?Phe?Cys?His?Tyr?Gln?Gly

85 90 95

Tyr?Ile?Glu?Gly?Tyr?Pro?Lys?Ser?Val?Val?Met?Val?Ser?Thr?Cys?Thr

100 105 110

Gly?Leu?Arg?Gly?Val?Leu?Gln?Phe?Glu?Asn?Val?Ser?Tyr?Gly?Ile?Glu

115 120 125

Pro?Leu?Glu?Ser?Ser?Val?Gly?Phe?Glu?His?Val?Ile?Tyr?Gln?Val?Lys

130 135 140

His?Lys?Lys?Ala?Asp?Val?Ser?Leu?Tyr?Asn?Glu?Lys?Asp?Ile?Glu?Ser

145 150 155 160

Arg?Asp?Leu?Ser?Phe?Lys?Leu?Gln?Ser?Val?Glu?Pro?Gln?Gln?Asp?Phe

165 170 175

Ala?Lys?Tyr?Ile?Glu?Met?His?Val?Ile?Val?Glu?Lys?Gln?Leu?Tyr?Asn

180 185 190

His?Met?Gly?Ser?Asp?Thr?Thr?Val?Val?Ala?Gln?Lys?Val?Phe?Gln?Leu

195 200 205

Ile?Gly?Leu?Thr?Asn?Ala?Ile?Phe?Val?Ser?Phe?Asn?Ile?Thr?Ile?Ile

210 215 220

Leu?Ser?Ser?Leu?Glu?Leu?Trp?Ile?Asp?Glu?Asn?Lys?Ile?Ala?Thr?Thr

225 230 235 240

Gly?Glu?Ala?Asn?Glu?Leu?Leu?His?Thr?Phe?Leu?Arg?Trp?Lys?Thr?Ser

245 250 255

Tyr?Leu?Val?Leu?Arg?Pro?His?Asp?Val?Ala?Phe?Leu?Leu?Val?Tyr?Arg

260 265 270

Glu?Lys?Ser?Asn?Tyr?Val?Gly?Ala?Thr?Phe?Gln?Gly?Lys?Met?Cys?Asp

275 280 285

Ala?Asn?Tyr?Ala?Gly?Gly?Val?Val?Leu?His?Pro?Arg?Thr?Ile?Ser?Leu

290 295 300

Glu?Ser?Leu?Ala?Val?Ile?Leu?Ala?Gln?Leu?Leu?Ser?Leu?Ser?Met?Gly

305 310 315 320

Ile?Thr?Tyr?Asp?Asp?Ile?Asn?Lys?Cys?Gln?Cys?Ser?Gly?Ala?Val?Cys

325 330 335

Ile?Met?Asn?Pro?Glu?Ala?Ile?His?Phe?Ser?Gly?Val?Lys?Ile?Phe?Ser

340 345 350

Asn?Cys?Ser?Phe?Glu?Asp?Phe?Ala?His?Phe?Ile?Ser?Lys?Gln?Lys?Ser

355 360 365

Gln?Cys?Leu?His?Asn?Gln?Pro?Arg?Leu?Asp?Pro?Phe?Phe?Lys?Gln?Gln

370 375 380

Ala?Val?Cys?Gly?Asn?Ala?Lys?Leu?Glu?Ala?Gly?Glu?Glu?Cys?Asp?Cys

385 390 395 400

Gly?Thr?Glu?Gln?Asp?Cys?Ala?Leu?Ile?Gly?Glu?Thr?Cys?Cys?Asp?Ile

405 410 415

Ala?Thr?Cys?Arg?Phe?Lys?Ala?Gly?Ser?Asn?Cys?Ala?Glu?Gly?Pro?Cys

420 425 430

Cys?Glu?Asn?Cys?Leu?Phe?Met?Ser?Lys?Glu?Arg?Met?Cys?Arg?Pro?Ser

435 440 445

Phe?Glu?Glu?Cys?Asp?Leu?Pro?Glu?Tyr?Cys?Asn?Gly?Ser?Ser?Ala?Ser

450 455 460

Cys?Pro?Glu?Asn?His?Tyr?Val?Gln?Thr?Gly?His?Pro?Cys?Gly?Leu?Asn

465 470 475 480

Gln?Trp?Ile?Cys?Ile?Asp?Gly?Val?Cys?Met?Ser?Gly?Asp?Lys?Gln?Cys

485 490 495

Thr?Asp?Thr?Phe?Gly?Lys?Glu?Val?Glu?Phe?Gly?Pro?Ser?Glu?Cys?Tyr

500 505 510

Ser?His?Leu?Asn?Ser?Lys?Thr?Asp?Val?Ser?Gly?Asn?Cys?Gly?Ile?Ser

515 520 525

Asp?Ser?Gly?Tyr?Thr?Gln?Cys?Glu?Ala?Asp?Asn?Leu?Gln?Cys?Gly?Lys

530 535 540

Leu?Ile?Cys?Lys?Tyr?Val?Gly?Lys?Phe?Leu?Leu?Gln?Ile?Pro?Arg?Ala

545 550 555 560

Thr?Ile?Ile?Tyr?Ala?Asn?Ile?Ser?Gly?His?Leu?Cys?Ile?Ala?Val?Glu

565 570 575

Phe?Ala?Ser?Asp?His?Ala?Asp?Ser?Gln?Lys?Met?Trp?Ile?Lys?Asp?Gly

580 585 590

Thr?Ser?Cys?Gly?Ser?Asn?Lys?Val?Cys?Arg?Asn?Gln?Arg?Cys?Val?Ser

595 600 605

Ser?Ser?Tyr?Leu?Gly?Tyr?Asp?Cys?Thr?Thr?Asp?Lys?Cys?Asn?Asp?Arg

610 615 620

Gly?Val?Cys?Asn?Asn?Lys?Lys?His?Cys?His?Cys?Ser?Ala?Ser?Tyr?Leu

625 630 635 640

Pro?Pro?Asp?Cys?Ser?Val?Gln?Ser?Asp?Leu?Trp?Pro?Gly?Gly?Ser?Ile

645 650 655

Asp?Ser?Gly?Asn?Phe?Pro?Pro?Val?Ala?Ile?Pro?Ala?Arg?Leu?Pro?Glu

660 665 670

Arg?Arg?Tyr?Ile?Glu?Asn?Ile?Tyr?His?Ser?Lys?Pro?Met?Arg?Trp?Pro

675 680 685

Phe?Phe?Leu?Phe?Ile?Pro?Phe?Phe?Ile?Ile?Phe?Cys?Val?Leu?Ile?Ala

690 695 700

Ile?Met?Val?Lys?Val?Asn?Phe?Gln?Arg?Lys?Lys?Trp?Arg?Thr?Glu?Asp

705 710 715 720

Tyr?Ser?Ser?Asp?Glu?Gln?Pro?Glu?Ser?Glu?Ser?Glu?Pro?Lys?Gly

725 730 735

SEQUENCE?LISTING22

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_076957

<160>1

<170>PatentIn?version?3.5

<210>1

<211>300

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(300)

<400>1

Met?Cys?Ala?Arg?Gly?Gln?Val?Gly?Arg?Gly?Thr?Gln?Leu?Arg?Thr?Gly

1 5 10 15

Arg?Pro?Cys?Ser?Gln?Val?Pro?Gly?Ser?Arg?Trp?Arg?Pro?Glu?Arg?Leu

20 25 30

Leu?Arg?Arg?Gln?Arg?Ala?Gly?Gly?Arg?Pro?Ser?Arg?Pro?His?Pro?Ala

35 40 45

Arg?Ala?Arg?Pro?Gly?Leu?Ser?Leu?Pro?Ala?Thr?Leu?Leu?Gly?Ser?Arg

50 55 60

Ala?Ala?Ala?Ala?Val?Pro?Leu?Pro?Leu?Pro?Pro?Ala?Leu?Ala?Pro?Gly

65 70 75 80

Asp?Pro?Ala?Met?Pro?Val?Arg?Thr?Glu?Cys?Pro?Pro?Pro?Ala?Gly?Ala

85 90 95

Ser?Ala?Ala?Ser?Ala?Ala?Ser?Leu?Ile?Pro?Pro?Pro?Pro?Ile?Asn?Thr

100 105 110

Gln?Gln?Pro?Gly?Val?Ala?Thr?Ser?Leu?Leu?Tyr?Ser?Gly?Ser?Lys?Phe

115 120 125

Arg?Gly?His?Gln?Lys?Ser?Lys?Gly?Asn?Ser?Tyr?Asp?Val?Glu?Val?Val

130 135 140

Leu?Gln?His?Val?Asp?Thr?Gly?Asn?Ser?Tyr?Leu?Cys?Gly?Tyr?Leu?Lys

145 150 155 160

Ile?Lys?Gly?Leu?Thr?Glu?Glu?Tyr?Pro?Thr?Leu?Thr?Thr?Phe?Phe?Glu

165 170 175

Gly?Glu?Ile?Ile?Ser?Lys?Lys?His?Pro?Phe?Leu?Thr?Arg?Lys?Trp?Asp

180 185 190

Ala?Asp?Glu?Asp?Val?Asp?Arg?Lys?His?Trp?Gly?Lys?Phe?Leu?Ala?Phe

195 200 205

Tyr?Gln?Tyr?Ala?Lys?Ser?Phe?Asn?Ser?Asp?Asp?Phe?Asp?Tyr?Glu?Glu

210 215 220

Leu?Lys?Asn?Gly?Asp?Tyr?Val?Phe?Met?Arg?Trp?Lys?Glu?Gln?Phe?Leu

225 230 235 240

Val?Pro?Asp?His?Thr?Ile?Lys?Asp?Ile?Ser?Gly?Ala?Ser?Phe?Ala?Gly

245 250 255

Phe?Tyr?Tyr?Ile?Cys?Phe?Gln?Lys?Ser?Ala?Ala?Ser?Ile?Glu?Gly?Tyr

260 265 270

Tyr?Tyr?His?Arg?Ser?Ser?Glu?Trp?Tyr?Gln?Ser?Leu?Asn?Leu?Thr?His

275 280 285

Val?Pro?Glu?His?Ser?Ala?Pro?Ile?Tyr?Glu?Phe?Arg

290 295 300

SEQUENCE?LIST?ING23

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_659473

<160>1

<170>PatentIn?version?3.5

<210>1

<211>955

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(955)

<400>1

Met?Glu?Val?Gly?Ser?Glu?Glu?Glu?Lys?Trp?Glu?Lys?Leu?Asp?Ala?Glu

1 5 10 15

Phe?Asp?His?Phe?Val?Val?Asp?Met?Lys?Pro?Phe?Val?Leu?Lys?Leu?Pro

20 25 30

His?Arg?Thr?Glu?Arg?Gln?Arg?Cys?Ala?Leu?Trp?Ile?Arg?Lys?Leu?Cys

35 40 45

Glu?Pro?Ser?Gly?Thr?Gly?Ala?Gly?Ile?Met?Gly?Arg?Lys?Asn?Arg?Asn

50 55 60

Leu?Tyr?Ala?Lys?Leu?Leu?Leu?His?Met?Leu?Lys?Arg?Gly?Ala?Leu?Glu

65 70 75 80

Gly?Pro?Phe?Thr?His?Arg?Pro?Glu?Pro?Gly?Thr?Leu?Lys?Ile?Leu?Pro

85 90 95

Ser?Tyr?Met?Ser?Ile?Tyr?Phe?Asp?Glu?Pro?Asn?Pro?Ala?Arg?Ala?Lys

100 105 110

Gly?Ser?Ser?Pro?Glu?Gly?Leu?Pro?Ala?Trp?Val?Leu?Gly?Glu?Leu?Glu

115 120 125

Thr?Ser?Glu?His?Lys?Leu?Asn?Glu?Ser?Trp?Lys?Leu?Ser?Ser?Gly?Glu

130 135 140

Asp?Asn?Thr?Leu?Val?Gln?Ser?Pro?Thr?Asp?Val?Tyr?Ser?Arg?Glu?Gln

145 150 155 160

Tyr?Thr?Gly?Lys?Leu?Arg?Val?Arg?Ser?His?Ser?Leu?Ser?Pro?Thr?His

165 170 175

Arg?Glu?Asp?Gly?Gln?Asn?Ile?Thr?Pro?Lys?Ile?Cys?Glu?Val?Tyr?Ser

180 185 190

Lys?Lys?Ser?Pro?Val?Ser?Leu?Asp?Asp?Ser?Asp?Ile?Glu?Ala?Arg?Leu

195 200 205

Asn?Ser?Trp?Asn?Leu?Gly?Ile?Glu?Asn?Pro?Arg?Tyr?Leu?Arg?Gln?Lys

210 215 220

Pro?Ile?Pro?Val?Ser?Leu?Met?Thr?Pro?Lys?Phe?Ser?Leu?Arg?Lys?Ser

225 230 235 240

Ser?Ser?Phe?His?Asp?Asp?His?Phe?Leu?Ser?Arg?Ile?Arg?Glu?Lys?Glu

245 250 255

Leu?Asp?Met?Lys?Thr?Lys?Met?Met?Glu?Ala?Lys?Phe?His?Glu?Glu?Lys

260 265 270

Leu?Lys?Leu?Gln?Gln?Lys?His?Asp?Ala?Asp?Val?Gln?Lys?Ile?Leu?Glu

275 280 285

Arg?Lys?Asn?Asn?Glu?Ile?Glu?Glu?Leu?Lys?Thr?Leu?Tyr?Arg?Ser?Lys

290 295 300

Gln?His?Glu?Thr?Glu?Glu?Thr?Ile?Arg?Lys?Leu?Glu?Lys?Lys?Val?Gln

305 310 315 320

Thr?Leu?Ile?Arg?Asp?Cys?Gln?Val?Ile?Arg?Glu?Thr?Lys?Glu?Asp?Gln

325 330 335

Ile?Ala?Glu?Leu?Lys?Lys?Ile?Cys?Glu?Gln?Ser?Thr?Glu?Ser?Leu?Asn

340 345 350

Asn?Asp?Trp?Glu?Lys?Lys?Leu?His?Asn?Ala?Val?Ala?Glu?Met?Glu?Gln

355 360 365

Glu?Lys?Phe?Asp?Leu?Gln?Lys?Gln?His?Thr?Glu?Asn?Ile?Gln?Glu?Leu

370 375 380

Leu?Glu?Asp?Thr?Asn?Val?Arg?Leu?Asn?Lys?Met?Glu?Ser?Glu?Tyr?Met

385 390 395 400

Ala?Gln?Thr?Gln?Ser?Thr?Asn?His?Met?Ile?Lys?Glu?Leu?Glu?Ala?Arg

405 410 415

Val?Gln?Gln?Leu?Thr?Gly?Glu?Ala?Glu?Asn?Ser?Asn?Leu?Gln?Arg?Gln

420 425 430

Lys?Leu?Ile?Gln?Glu?Lys?Ala?Glu?Leu?Glu?Arg?Cys?Tyr?Gln?Ile?Thr

435 440 445

Cys?Ser?Glu?Leu?Gln?Glu?Val?Lys?Ala?Arg?Arg?Asn?Thr?Leu?His?Lys

450 455 460

Glu?Lys?Asp?His?Leu?Val?Asn?Asp?Tyr?Glu?Gln?Asn?Met?Lys?Leu?Leu

465 470 475 480

Gln?Thr?Lys?Tyr?Asp?Ala?Asp?Ile?Asn?Leu?Leu?Lys?Gln?Glu?His?Ala

485 490 495

Leu?Ser?Ala?Ser?Lys?Ala?Ser?Ser?Met?Ile?Glu?Glu?Leu?Glu?Gln?Asn

500 505 510

Val?Cys?Gln?Leu?Lys?Gln?Gln?Leu?Gln?Glu?Ser?Glu?Leu?Gln?Arg?Lys

515 520 525

Gln?Gln?Leu?Arg?Asp?Gln?Glu?Asn?Lys?Phe?Gln?Met?Glu?Lys?Ser?His

530 535 540

Leu?Lys?His?Ile?Tyr?Glu?Lys?Lys?Ala?His?Asp?Leu?Gln?Ser?Glu?Leu

545 550 555 560

Asp?Lys?Gly?Lys?Glu?Asp?Thr?Gln?Lys?Lys?Ile?His?Lys?Phe?Glu?Glu

565 570 575

Ala?Leu?Lys?Glu?Lys?Glu?Glu?Gln?Leu?Thr?Arg?Val?Thr?Glu?Val?Gln

580 585 590

Arg?Leu?Gln?Ala?Gln?Gln?Ala?Asp?Ala?Ala?Leu?Glu?Glu?Phe?Lys?Arg

595 600 605

Gln?Val?Glu?Leu?Asn?Ser?Glu?Lys?Val?Tyr?Ala?Glu?Met?Lys?Glu?Gln

610 615 620

Met?Glu?Lys?Val?Glu?Ala?Asp?Leu?Thr?Arg?Ser?Lys?Ser?Leu?Arg?Glu

625 630 635 640

Lys?Gln?Ser?Lys?Glu?Phe?Leu?Trp?Gln?Leu?Glu?Asp?Ile?Arg?Gln?Arg

645 650 655

Tyr?Glu?Gln?Gln?Ile?Val?Glu?Leu?Lys?Leu?Glu?His?Glu?Gln?Glu?Lys

660 665 670

Thr?His?Leu?Leu?Gln?Gln?His?Asn?Ala?Glu?Lys?Asp?Ser?Leu?Val?Arg

675 680 685

Asp?His?Glu?Arg?Glu?Ile?Glu?Asn?Leu?Glu?Lys?Gln?Leu?Arg?Ala?Ala

690 695 700

Asn?Met?Glu?His?Glu?Asn?Gln?Ile?Gln?Glu?Phe?Lys?Lys?Arg?Asp?Ala

705 710 715 720

Gln?Val?Ile?Ala?Asp?Met?Glu?Ala?Gln?Val?His?Lys?Leu?Arg?Glu?Glu

725 730 735

Leu?Ile?Asn?Val?Asn?Ser?Gln?Arg?Lys?Gln?Gln?Leu?Val?Glu?Leu?Gly

740 745 750

Leu?Leu?Arg?Glu?Glu?Glu?Lys?Gln?Arg?Ala?Thr?Arg?Glu?His?Glu?Ile

755 760 765

Val?Val?Asn?Lys?Leu?Lys?Ala?Glu?Ser?Glu?Lys?Met?Lys?Ile?Glu?Leu

770 775 780

Lys?Lys?Thr?His?Ala?Ala?Glu?Thr?Glu?Met?Thr?Leu?Glu?Lys?Ala?Asn

785 790 795 800

Ser?Lys?Leu?Lys?Gln?Ile?Glu?Lys?Glu?Tyr?Thr?Gln?Lys?Leu?Ala?Lys

805 810 815

Ser?Ser?Gln?Ile?Ile?Ala?Glu?Leu?Gln?Thr?Thr?Ile?Ser?Ser?Leu?Lys

820 825 830

Glu?Glu?Asn?Ser?Gln?Gln?Gln?Leu?Ala?Ala?Glu?Arg?Arg?Leu?Gln?Asp

835 840 845

Val?Arg?Gln?Lys?Phe?Glu?Asp?Glu?Lys?Lys?Gln?Leu?Ile?Arg?Asp?Asn

850 855 860

Asp?Gln?Ala?Ile?Lys?Val?Leu?Gln?Asp?Glu?Leu?Glu?Asn?Arg?Ser?Asn

865 870 875 880

Gln?Val?Arg?Cys?Ala?Glu?Lys?Lys?Leu?Gln?His?Lys?Glu?Leu?Glu?Ser

885 890 895

Gln?Glu?Gln?Ile?Thr?Tyr?Ile?Arg?Gln?Glu?Tyr?Glu?Thr?Lys?Leu?Lys

900 905 910

Gly?Leu?Met?Pro?Ala?Ser?Leu?Arg?Gln?Glu?Leu?Glu?Asp?Thr?Ile?Ser

915 920 925

Ser?Leu?Lys?Ser?Gln?Val?Asn?Phe?Leu?Gln?Lys?Arg?Ala?Ser?Ile?Leu

930 935 940

Gln?Glu?Glu?Leu?Thr?Thr?Tyr?Gln?Gly?Arg?Arg

945 950 955

SEQUENCE?LISTING24

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_001295

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1380

<212>PRT

<213>Homo?sapiens

<220>

<221>SITE

<222>(172)..(172)

<220>

<221>SITE

<222>(811)..(811)

<220>

<221>SITE

<222>(955)..(955)

<400>1

Met?Ala?Ser?Gly?Arg?Asp?Glu?Arg?Pro?Pro?Trp?Arg?Leu?Gly?Arg?Leu

1 5 10 15

Leu?Leu?Leu?Met?Cys?Leu?Leu?Leu?Leu?Gly?Ser?Ser?Ala?Arg?Ala?Ala

20 25 30

His?Ile?Lys?Lys?Ala?Glu?Ala?Thr?Thr?Thr?Thr?Thr?Ser?Ala?Gly?Ala

35 40 45

Glu?Ala?Ala?Glu?Gly?Gln?Phe?Asp?Arg?Tyr?Tyr?His?Glu?Glu?Glu?Leu

50 55 60

Glu?Ser?Ala?Leu?Arg?Glu?Ala?Ala?Ala?Ala?Gly?Leu?Pro?Gly?Leu?Ala

65 70 75 80

Arg?Leu?Phe?Ser?Ile?Gly?Arg?Ser?Val?Glu?Gly?Arg?Pro?Leu?Trp?Val

85 90 95

Leu?Arg?Leu?Thr?Ala?Gly?Leu?Gly?Ser?Leu?Ile?Pro?Glu?Gly?Asp?Ala

100 105 110

Gly?Pro?Asp?Ala?Ala?Gly?Pro?Asp?Ala?Ala?Gly?Pro?Leu?Leu?Pro?Gly

115 120 125

Arg?Pro?Gln?Val?Lys?Leu?Val?Gly?Asn?Met?His?Gly?Asp?Glu?Thr?Val

130 135 140

Ser?Arg?Gln?Val?Leu?Ile?Tyr?Leu?Ala?Arg?Glu?Leu?Ala?Ala?Gly?Tyr

145 150 155 160

Arg?Arg?Gly?Asp?Pro?Arg?Leu?Val?Arg?Leu?Leu?Asn?Thr?Thr?Asp?Val

165 170 175

Tyr?Leu?Leu?Pro?Ser?Leu?Asn?Pro?Asp?Gly?Phe?Glu?Arg?Ala?Arg?Glu

180 185 190

Gly?Asp?Cys?Gly?Phe?Gly?Asp?Gly?Gly?Pro?Ser?Gly?Ala?Ser?Gly?Arg

195 200 205

Asp?Asn?Ser?Arg?Gly?Arg?Asp?Leu?Asn?Arg?Ser?Phe?Pro?Asp?Gln?Phe

210 215 220

Ser?Thr?Gly?Glu?Pro?Pro?Ala?Leu?Asp?Glu?Val?Pro?Glu?Val?Arg?Ala

225 230 235 240

Leu?Ile?Glu?Trp?Ile?Arg?Arg?Asn?Lys?Phe?Val?Leu?Ser?Gly?Asn?Leu

245 250 255

His?Gly?Gly?Ser?Val?Val?Ala?Ser?Tyr?Pro?Phe?Asp?Asp?Ser?Pro?Glu

260 265 270

His?Lys?Ala?Thr?Gly?Ile?Tyr?Ser?Lys?Thr?Ser?Asp?Asp?Glu?Val?Phe

275 280 285

Lys?Tyr?Leu?Ala?Lys?Ala?Tyr?Ala?Ser?Asn?His?Pro?Ile?Met?Lys?Thr

290 295 300

Gly?Glu?Pro?His?Cys?Pro?Gly?Asp?Glu?Asp?Glu?Thr?Phe?Lys?Asp?Gly

305 310 315 320

Ile?Thr?Asn?Gly?Ala?His?Trp?Tyr?Asp?Val?Glu?Gly?Gly?Met?Gln?Asp

325 330 335

Tyr?Asn?Tyr?Val?Trp?Ala?Asn?Cys?Phe?Glu?Ile?Thr?Leu?Glu?Leu?Ser

340 345 350

Cys?Cys?Lys?Tyr?Pro?Pro?Ala?Ser?Gln?Leu?Arg?Gln?Glu?Trp?Glu?Asn

355 360 365

Asn?Arg?Glu?Ser?Leu?Ile?Thr?Leu?Ile?Glu?Lys?Val?His?Ile?Gly?Val

370 375 380

Lys?Gly?Phe?Val?Lys?Asp?Ser?Ile?Thr?Gly?Ser?Gly?Leu?Glu?Asn?Ala

385 390 395 400

Thr?Ile?Ser?Val?Ala?Gly?Ile?Asn?His?Asn?Ile?Thr?Thr?Gly?Arg?Phe

405 410 415

Gly?Asp?Phe?Tyr?Arg?Leu?Leu?Val?Pro?Gly?Thr?Tyr?Asn?Leu?Thr?Val

420 425 430

Val?Leu?Thr?Gly?Tyr?Met?Pro?Leu?Thr?Val?Thr?Asn?Val?Val?Val?Lys

435 440 445

Glu?Gly?Pro?Ala?Thr?Glu?Val?Asp?Phe?Ser?Leu?Arg?Pro?Thr?Val?Thr

450 455 460

Ser?Val?Ile?Pro?Asp?Thr?Thr?Glu?Ala?Val?Ser?Thr?Ala?Ser?Thr?Val

465 470 475 480

Ala?Ile?Pro?Asn?Ile?Leu?Ser?Gly?Thr?Ser?Ser?Ser?Tyr?Gln?Pro?Ile

485 490 495

Gln?Pro?Lys?Asp?Phe?His?His?His?His?Phe?Pro?Asp?Met?Glu?Ile?Phe

500 505 510

Leu?Arg?Arg?Phe?Ala?Asn?Glu?Tyr?Pro?Asn?Ile?Thr?Arg?Leu?Tyr?Ser

515 520 525

Leu?Gly?Lys?Ser?Val?Glu?Ser?Arg?Glu?Leu?Tyr?Val?Met?Glu?Ile?Ser

530 535 540

Asp?Asn?Pro?Gly?Val?His?Glu?Pro?Gly?Glu?Pro?Glu?Phe?Lys?Tyr?Ile

545 550 555 560

Gly?Asn?Met?His?Gly?Asn?Glu?Val?Val?Gly?Arg?Glu?Leu?Leu?Leu?Asn

565 570 575

Le?Ile?Glu?Tyr?Leu?Cys?Lys?Asn?Phe?Gly?Thr?Asp?Pro?Glu?Val?Thr

580 585 590

Asp?Leu?Val?His?Asn?Thr?Arg?Ile?His?Leu?Met?Pro?Ser?Met?Asn?Pro

595 600 605

Asp?Gly?Tyr?Glu?Lys?Ser?Gln?Glu?Gly?Asp?Ser?Ile?Ser?Val?Ile?Gly

610 615 620

Arg?Asn?Asn?Ser?Asn?Asn?Phe?Asp?Leu?Asn?Arg?Asn?Phe?Pro?Asp?Gln

625 630 635 640

Phe?Val?Gln?Ile?Thr?Asp?Pro?Thr?Gln?Pro?Glu?Thr?Ile?Ala?Val?Met

645 650 655

Ser?Trp?Met?Lys?Ser?Tyr?Pro?Phe?Val?Leu?Ser?Ala?Asn?Leu?His?Gly

660 665 670

Gly?Ser?Leu?Val?Val?Asn?Tyr?Pro?Phe?Asp?Asp?Asp?Glu?Gln?Gly?Leu

675 680 685

Ala?Thr?Tyr?Ser?Lys?Ser?Pro?Asp?Asp?Ala?Val?Phe?Gln?Gln?Ile?Ala

690 695 700

Leu?Ser?Tyr?Ser?Lys?Glu?Asn?Ser?Gln?Met?Phe?Gln?Gly?Arg?Pro?Cys

705 710 715 720

Lys?Asn?Met?Tyr?Pro?Asn?Glu?Tyr?Phe?Pro?His?Gly?Ile?Thr?Asn?Gly

725 730 735

Ala?Ser?Trp?Tyr?Asn?Val?Pro?Gly?Gly?Met?Gln?Asp?Trp?Asn?Tyr?Leu

740 745 750

Gln?Thr?Asn?Cys?Phe?Glu?Val?Thr?Ile?Glu?Leu?Gly?Cys?Val?Lys?Tyr

755 760 765

Pro?Leu?Glu?Lys?Glu?Leu?Pro?Asn?Phe?Trp?Glu?Gln?Asn?Arg?Arg?Ser

770 775 780

Leu?Ile?Gln?Phe?Met?Lys?Gln?Val?His?Gln?Gly?Val?Arg?Gly?Phe?Val

785 790 795 800

Leu?Asp?Ala?Thr?Asp?Gly?Arg?Gly?Ile?Leu?Asn?Ala?Thr?Ile?Ser?Val

805 810 815

Ala?Glu?Ile?Asn?His?Pro?Val?Thr?Thr?Tyr?Lys?Thr?Gly?Asp?Tyr?Trp

820 825 830

Arg?Leu?Leu?Val?Pro?Gly?Thr?Tyr?LysIle?Thr?Ala?Ser?Ala?Arg?Gly

835 840 845

Tyr?Asn?Pro?Val?Thr?Lys?Asn?Val?Thr?Val?Lys?Ser?Glu?Gly?Ala?Ile

850 855 860

Gln?Val?Asn?Phe?Thr?Leu?Val?Arg?Ser?Ser?Thr?Asp?Ser?Asn?Asn?Glu

865 870 875 880

Ser?Lys?Lys?Gly?Lys?Gly?Ala?Ser?Ser?Ser?Thr?Asn?Asp?Ala?Ser?Asp

885 890 895

Pro?Thr?Thr?Lys?Glu?Phe?Glu?Thr?Leu?Ile?Lys?Asp?Leu?Ser?Ala?Glu

900 905 910

Asn?Gly?Leu?Glu?Ser?Leu?Met?Leu?Arg?Ser?Ser?Ser?Asn?Leu?Ala?Leu

915 920 925

Ala?Leu?Tyr?Arg?Tyr?His?Ser?Tyr?Lys?Asp?Leu?Ser?Glu?Phe?Leu?Arg

930 935 940

Gly?Leu?Val?Met?Asn?Tyr?Pro?His?Ile?Thr?Asn?Leu?Thr?Asn?Leu?Gly

945 950 955 960

Gln?Ser?Thr?Glu?Tyr?Arg?His?Ile?Trp?Ser?Leu?Glu?Ile?Ser?Asn?Lys

965 970 975

Pro?Asn?Val?Ser?Glu?Pro?Glu?Glu?Pro?Lys?Ile?Arg?Phe?Val?Ala?Gly

980 985 990

Ile?His?Gly?Asn?Ala?Pro?Val?Gly Thr?Glu?Leu?Leu?Leu Ala?Leu?Ala

995 1000 1005

Glu?Phe Leu?Cys?Leu?Asn?Tyr Lys?Lys?Asn?Pro?Ala Val?Thr?Gln

1010 1015 1020

Leu?Val Asp?Arg?Thr?Arg?Ile Val?Ile?Val?Pro?Ser Leu?Asn?Pro

1025 1030 1035

Asp?Gly Arg?Glu?Arg?Ala?Gln Glu?Lys?Asp?Cys?Thr Ser?Lys?Ile

1040 1045 1050

Gly?Gln Thr?Asn?Ala?Arg?Gly Lys?Asp?Leu?Asp?Thr Asp?Phe?Thr

1055 1060 1065

Asn?Asn Ala?Ser?Gln?Pro?Glu Thr?Lys?Ala?Ile?Ile Glu?Asn?Leu

1070 1075 1080

Ile?Gln Lys?Gln?Asp?Phe?Ser Leu?Ser?Val?Ala?Leu Asp?Gly?Gly

1085 1090 1095

Ser?Met Leu?Val?Thr?Tyr?Pro Tyr?Asp?Lys?Pro?Val Gln?Thr?Val

1100 1105 1110

Glu?Asn Lys?Glu?Thr?Leu?Lys His?Leu?Ala?Ser?Leu Tyr?Ala?Asn

1115 1120 1125

Asn?His?Pro?Ser?Met?His?Met Gly?Gln?Pro?Ser?Cys Pro?Asn?Lys

1130 1135 1140

Ser?Asp Glu?Asn?Ile?Pro?Gly Gly?Val?Met?Arg?Gly Ala?Glu?Trp

1145 1150 1155

His?Ser His?Leu?Gly?Ser?Met Lys?Asp?Tyr?Ser?Val Thr?Tyr?Gly

1160 1165 1170

His?Cys Pro?Glu?Ile?Thr?Val Tyr?Thr?Ser?Cys?Cys Tyr?Phe?Pro

1175 1180 1185

Ser?Ala Ala?Arg?Leu?Pro?Ser Leu?Trp?Ala?Asp?Asn Lys?Arg?Ser

1190 1195 1200

Leu?Leu Ser?Met?Leu?Val?Glu Val?His?Lys?Gly?Val His?Gly?Phe

1205 1210 1215

Val?Lys Asp?Lys?Thr?Gly?Lys Pro?Ile?Ser?Lys?Ala Val?Ile?Val

1220 1225 1230

Leu?Asn Glu?Gly?Ile?Lys?Val Gln?Thr?Lys?Glu?Gly Gly?Tyr?Phe

1235 1240 1245

His?Val Leu?Leu?Ala?Pro?Gly Val?His?Asn?Ile?Ile Ala?Ile?Ala

1250 1255 1260

Asp?Gly?Tyr?Gln?Gln?Gln?His?Ser Gln?Val?Phe?Val?His?His?Asp

1265 1270 1275

Ala?Ala?Ser?Ser?Val?Val?Ile?Val Phe?Asp?Thr?Asp?Asn?Arg?Ile

1280 1285 1290

Phe?Gly?Leu?Pro?Arg?Glu?Leu?Val Val?Thr?Val?Ser?Gly?Ala?Thr

1295 1300 1305

Met?Ser?Ala?Leu?Ile?Leu?Thr?Ala Cys?Ile?Ile?Trp?Cys?Ile?Cys

1310 1315 1320

Ser?Ile?Lys?Ser?Asn?Arg?His?Lys Asp?Gly?Phe?His?Arg?Leu?Arg

1325 1330 1335

Gln?His?His?Asp?Glu?Tyr?Glu?Asp Glu?Ile?Arg?Met?Met?Ser?Thr

1340 1345 1350

Gly?Ser?Lys?Lys?Ser?Leu?Leu?Ser His?Glu?Phe?Gln?Asp?Glu?Thr

1355 1360 1365

Asp?Thr?Glu?Glu?Glu?Thr?Leu?Tyr Ser?Ser?Lys?His

1370 1375 1380

SEQUENCE?LISTING25

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_000746

<160>1

<170>PatentIn?version?3.5

<210>1

<211>626

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(626)

<400>1

Met?Leu?Ala?Phe?Ala?Ala?Arg?Thr?Val?Val?Lys?Pro?Leu?Gly?Phe?Leu

1 5 10 15

Lys?Pro?Phe?Ser?Leu?Met?Lys?Ala?Ser?Ser?Arg?Phe?Lys?Ala?His?Gln

20 25 30

Asp?Ala?Leu?Pro?Arg?Leu?Pro?Val?Pro?Pro?Leu?Gln?Gln?Ser?Leu?Asp

35 40 45

His?Tyr?Leu?Lys?Ala?Leu?Gln?Pro?Ile?Val?Ser?Glu?Glu?Glu?Trp?Ala

50 55 60

His?Thr?Lys?Gln?Leu?Val?Asp?Glu?Phe?Gln?Ala?Ser?Gly?Gly?Val?Gly

65 70 75 80

Glu?Arg?Leu?Gln?Lys?Gly?Leu?Glu?Arg?Arg?Ala?Arg?Lys?Thr?Glu?Asn

85 90 95

Trp?Leu?Ser?Glu?Trp?Trp?Leu?Lys?Thr?Ala?Tyr?Leu?Gln?Tyr?Arg?Gln

100 105 110

Pro?Val?Val?Ile?Tyr?Ser?Ser?Pro?Gly?Val?Met?Leu?Pro?Lys?Gln?Asp

115 120 125

Phe?Val?Asp?Leu?Gln?Gly?Gln?Leu?Arg?Phe?Ala?Ala?Lys?Leu?Ile?Glu

130 135 140

Gly?Val?Leu?Asp?Phe?Lys?Val?Met?Ile?Asp?Asn?Glu?Thr?Leu?Pro?Val

145 150 155 160

Glu?Tyr?Leu?Gly?Gly?Lys?Pro?Leu?Cys?Met?Asn?Gln?Tyr?Tyr?Gln?Ile

165 170 175

Leu?Ser?Ser?Cys?Arg?Val?Pro?Gly?Pro?Lys?Gln?Asp?Thr?Val?Ser?Asn

180 185 190

Phe?Ser?Lys?Thr?Lys?Lys?Pro?Pro?Thr?His?Ile?Thr?Val?Val?His?Asn

195 200 205

Tyr?Gln?Phe?Phe?Glu?Leu?Asp?Val?Tyr?His?Ser?Asp?Gly?Thr?Pro?Leu

210 215 220

Thr?Ala?Asp?Gln?Ile?Phe?Val?Gln?Leu?Glu?Lys?Ile?Trp?Asn?Ser?Ser

225 230 235 240

Leu?Gln?Thr?Asn?Lys?Glu?Pro?Val?Gly?Ile?Leu?Thr?Ser?Asn?His?Arg

245 250 255

Asn?Ser?Trp?Ala?Lys?Ala?Tyr?Asn?Thr?Leu?Ile?Lys?Asp?Lys?Val?Asn

260 265 270

Arg?Asp?Ser?Val?Arg?Ser?Ile?Gln?Lys?Ser?Ile?Phe?Thr?Val?Cys?Leu

275 280 285

Asp?Ala?Thr?Met?Pro?Arg?Val?Ser?Glu?Asp?Val?Tyr?Arg?Ser?His?Val

290 295 300

Ala?Gly?Gln?Met?Leu?His?Gly?Gly?Gly?Ser?Arg?Leu?Asn?Ser?Gly?Asn

305 310 315 320

Arg?Trp?Phe?Asp?Lys?Thr?Leu?Gln?Phe?Ile?Val?Ala?Glu?Asp?Gly?Ser

325 330 335

Cys?Gly?Leu?Val?Tyr?Glu?His?Ala?Ala?Ala?Glu?Gly?Pro?Pro?Ile?Val

340 345 350

Thr?Leu?Leu?Asp?Tyr?Val?Ile?Glu?Tyr?Thr?Lys?Lys?Pro?Glu?Leu?Val

355 360 365

Arg?Ser?Pro?Met?Val?Pro?Leu?Pro?Met?Pro?Lys?Lys?Leu?Arg?Phe?Asn

370 375 380

Ile?Thr?Pro?Glu?Ile?Lys?Ser?Asp?Ile?Glu?Lys?Ala?Lys?Gln?Asn?Leu

385 390 395 400

Ser?Ile?Met?Ile?Gln?Asp?Leu?Asp?Ile?Thr?Val?Met?Val?Phe?His?His

405 410 415

Phe?Gly?Lys?Asp?Phe?Pro?Lys?Ser?Glu?Lys?Leu?Ser?Pro?Asp?Ala?Phe

420 425 430

Ile?Gln?Met?Ala?Leu?Gln?Leu?Ala?Tyr?Tyr?Arg?Ile?Tyr?Gly?Gln?Ala

435 440 445

Cys?Ala?Thr?Tyr?Glu?Ser?Ala?Ser?Leu?Arg?Met?Phe?His?Leu?Gly?Arg

450 455 460

Thr?Asp?Thr?Ile?Arg?Ser?Ala?Ser?Met?Asp?Ser?Leu?Thr?Phe?Val?Lys

465 470 475 480

Ala?Met?Asp?Asp?Ser?Ser?Val?Thr?Glu?His?Gln?Lys?Val?Glu?Leu?Leu

485 490 495

Arg?Lys?Ala?Val?Gln?Ala?His?Arg?Gly?Tyr?Thr?Asp?Arg?Ala?Ile?Arg

500 505 510

Gly?Glu?Ala?Phe?Asp?Arg?His?Leu?Leu?Gly?Leu?Lys?Leu?Gln?Ala?Ile

515 520 525

Glu?Asp?Leu?Val?Ser?Met?Pro?Asp?Ile?Phe?Met?Asp?Thr?Ser?Tyr?Ala

530 535 540

Ile?Ala?Met?His?Phe?His?Leu?Ser?Thr?Ser?Gln?Val?Pro?Ala?Lys?Thr

545 550 555 560

Asp?Cys?Val?Met?Phe?Phe?Gly?Pro?Val?Val?Pro?Asp?Gly?Tyr?Gly?Val

565 570 575

Cys?Tyr?Asn?Pro?Met?Glu?Ala?His?Ile?Asn?Phe?Ser?Leu?Ser?Ala?Tyr

580 585 590

Asn?Ser?Cys?Ala?Glu?Thr?Asn?Ala?Ala?Arg?Leu?Ala?His?Tyr?Leu?Glu

595 600 605

Lys?Ala?Leu?Leu?Asp?Met?Arg?Ala?Leu?Leu?Gln?Ser?His?Pro?Arg?Ala

610 615 620

Lys?Leu

625

SEQUENCE?LISTING26

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_001887

<160>1

<170>PatentIn?version?3.5

<210>1

<211>350

<212>PRT

<213>Homo?sapiens

<220>

<221>SITE

<222>(46)..(47)

<220>

<221>SITE

<222>(49)..(49)

<220>

<221>SITE

<222>(52)..(52)

<220>

<221>SITE

<222>(54)..(54)

<220>

<221>SITE

<222>(67)..(67)

<220>

<221>SITE

<222>(114)..(114)

<220>

<221>SITE

<222>(119)..(119)

<220>

<221>SITE

<222>(121)..(121)

<220>

<221>SITE

<222>(155)..(164)

<220>

<221>SITE

<222>(159)..(159)

<220>

<221>SITE

<222>(162)..(162)

<220>

<221>SITE

<222>(164)..(164)

<220>

<221>SITE

<222>(175)..(177)

<220>

<221>SITE

<222>(176)..(185)

<220>

<221>SITE

<222>(189)..(202)

<220>

<221>SITE

<222>(191)..(192)

<220>

<221>SITE

<222>(194)..(194)

<220>

<221>SITE

<222>(196)..(197)

<400>1

Met?Pro?Gly?Pro?Ala?Ala?Gly?Ser?Arg?Ala?Arg?Val?Tyr?Ala?Glu?Val

1 5 10 15

Asn?Ser?Leu?Arg?Ser?Arg?Glu?Tyr?Trp?Asp?Tyr?Glu?Ala?His?Val?Pro

20 25 30

Ser?Trp?Gly?Asn?Gln?Asp?Asp?Tyr?Gln?Leu?Val?Arg?Lys?Leu?Gly?Arg

35 40 45

Gly?Lys?Tyr?Ser?Glu?Val?Phe?Glu?Ala?Ile?Asn?Ile?Thr?Asn?Asn?Glu

50 55 60

Arg?Val?Val?Val?Lys?Ile?Leu?Lys?Pro?Val?Lys?Lys?Lys?Lys?Ile?Lys

65 70 75 80

Arg?Glu?Val?Lys?Ile?Leu?Glu?Asn?Leu?Arg?Gly?Gly?Thr?Asn?Ile?Ile

85 90 95

Lys?Leu?Ile?Asp?Thr?Val?Lys?Asp?Pro?Val?Ser?Lys?Thr?Pro?Ala?Leu

100 105 110

Val?Phe?Glu?Tyr?Ile?Asn?Asn?Thr?Asp?Phe?Lys?Gln?Leu?Tyr?Gln?Ile

115 120 125

Leu?Thr?Asp?Phe?Asp?Ile?Arg?Phe?Tyr?Met?Tyr?Glu?Leu?Leu?Lys?Ala

130 135 140

Leu?Asp?Tyr?Cys?His?Ser?Lys?Gly?Ile?Met?His?Arg?Asp?Val?Lys?Pro

145 150 155 160

His?Asn?Val?Met?Ile?Asp?His?Gln?Gln?Lys?Lys?Leu?Arg?Leu?Ile?Asp

165 170 175

Trp?Gly?Leu?Ala?Glu?Phe?Tyr?His?Pro?Ala?Gln?Glu?Tyr?Asn?Val?Arg

180 185 190

Val?Ala?Ser?Arg?Tyr?Phe?Lys?Gly?Pro?Glu?Leu?Leu?Val?Asp?Tyr?Gln

195 200 205

Met?Tyr?Asp?Tyr?Ser?Leu?Asp?Met?Trp?Ser?Leu?Gly?Cys?Met?Leu?Ala

210 215 220

Ser?Met?Ile?Phe?Arg?Arg?Glu?Pro?Phe?Phe?His?Gly?Gln?Asp?Asn?Tyr

225 230 235 240

Asp?Gln?Leu?Val?Arg?Ile?Ala?Lys?Val?Leu?Gly?Thr?Glu?Glu?Leu?Tyr

245 250 255

Gly?Tyr?Leu?Lys?Lys?Tyr?His?Ile?Asp?Leu?Asp?Pro?His?Phe?Asn?Asp

260 265 270

Ile?Leu?Gly?Gln?His?Ser?Arg?Lys?Arg?Trp?Glu?Asn?Phe?Ile?His?Ser

275 280 285

Glu?Asn?Arg?His?Leu?Val?Ser?Pro?Glu?Ala?Leu?Asp?Leu?Leu?Asp?Lys

290 295 300

Leu?Leu?Arg?Tyr?Asp?His?Gln?Gln?Arg?Leu?Thr?Ala?Lys?Glu?Ala?Met

305 310 315 320

Glu?His?Pro?Tyr?Phe?Tyr?Pro?Val?Val?Lys?Glu?Gln?Ser?Gln?Pro?Cys

325 330 335

Ala?Asp?Asn?Ala?Val?Leu?Ser?Ser?Gly?Leu?Thr?Ala?Ala?Arg

340 345 350

SEQUENCE?LISTING27

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_003453

<160>1

<170>PatentIn?version?3.5

<210>1

<211>280

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(280)

<400>1

Met?Val?Thr?Ala?Asn?Lys?Ala?His?Thr?Gly?Gln?Gly?Ser?Cys?Trp?Val

1 5 10 15

Ala?Thr?Leu?Ala?Ser?Ala?Met?Ile?Pro?Pro?Ala?Asp?Ser?Leu?Leu?Lys

20 25 30

Tyr?Asp?Thr?Pro?Val?Leu?Val?Ser?Arg?Asn?Thr?Glu?Lys?Arg?Ser?Pro

35 40 45

Lys?Ala?Arg?Leu?Leu?Lys?Val?Ser?Pro?Gln?Gln?Pro?Gly?Pro?Ser?Gly

50 55 60

Ser?Ala?Pro?Gln?Pro?Pro?Lys?Thr?Lys?Leu?Pro?Ser?Thr?Pro?Cys?Val

65 70 75 80

Pro?Asp?Pro?Thr?Lys?Gln?Ala?Glu?Glu?Ile?Leu?Asn?Ala?Ile?Leu?Pro

85 90 95

Pro?Arg?Glu?Trp?Val?Glu?Asp?Thr?Gln?Leu?Trp?Ile?Gln?Gln?Val?Ser

100 105 110

Ser?Thr?Pro?Ser?Thr?Arg?Met?Asp?Val?Val?His?Leu?Gln?Glu?Gln?Leu

115 120 125

Asp?Leu?Lys?Leu?Gln?Gln?Arg?Gln?Ala?Arg?Glu?Thr?Gly?Ile?Cys?Pro

130 135 140

Val?Arg?Arg?Glu?Leu?Tyr?Ser?Gln?Cys?Phe?Asp?Glu?Leu?Ile?Arg?Glu

145 150 155 160

Val?Thr?Ile?Asn?Cys?Ala?Glu?Arg?Gly?Leu?Leu?Leu?Leu?Arg?Val?Arg

165 170 175

Asp?Glu?Ile?Arg?Met?Thr?Ile?Ala?Ala?Tyr?Gln?Thr?Leu?Tyr?Glu?Ser

180 185 190

Ser?Val?Ala?Phe?Gly?Met?Arg?Lys?Ala?Leu?Gln?Ala?Glu?Gln?Gly?Lys

195 200 205

Ser?Asp?Met?Glu?Arg?Lys?Ile?Ala?Glu?Leu?Glu?Thr?Glu?Lys?Arg?Asp

210 215 220

Leu?Glu?Arg?Gln?Val?Asn?Glu?Gln?Lys?Ala?Lys?Cys?Glu?Ala?Thr?Glu

225 230 235 240

Lys?Arg?Glu?Ser?Glu?Arg?Arg?Gln?Val?Glu?Glu?Lys?Lys?His?Asn?Glu

245 250 255

Glu?Ile?Gln?Phe?Leu?Lys?Arg?Thr?Asn?Gln?Gln?Leu?Lys?Ala?Gln?Leu

260 265 270

Glu?Gly?Ile?Ile?Ala?Pro?Lys?Lys

275 280

SEQUENCE?LISTING28

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_149991

<160>1

<170>PatentIn?version?3.5

<210>1

<211>553

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(553)

<400>1

Met?Ala?Ala?Pro?Lys?Thr?Ala?Ala?Val?Gly?Pro?Leu?Val?Gly?Ala?Val

1 5 10 15

Val?Gln?Gly?Thr?Asn?Ser?Thr?Arg?Phe?Leu?Val?Phe?Asn?Ser?Lys?Thr

20 25 30

Ala?Glu?Leu?Leu?Ser?His?His?Lys?Val?Glu?Leu?Thr?Gln?Glu?Phe?Pro

35 40 45

Lys?Glu?Gly?Trp?Val?Glu?Gln?Asp?Pro?Lys?Glu?Ile?Leu?Gln?Ser?Val

50 55 60

Tyr?Glu?Cys?Ile?Ala?Arg?Thr?Cys?Glu?Lys?Leu?Asp?Glu?Leu?Asn?Ile

65 70 75 80

Asp?Ile?Ser?Asn?Ile?Lys?Ala?Val?Gly?Val?Ser?Asn?Gln?Arg?Glu?Thr

85 90 95

Thr?Val?Ile?Trp?Asp?Lys?Leu?Thr?Gly?Glu?Pro?Leu?Tyr?Asn?Ala?Val

100 105 110

Val?Trp?Leu?Asp?Leu?Arg?Thr?Gln?Thr?Thr?Val?Glu?Asp?Leu?Ser?Lys

115 120 125

Lys?Ile?Pro?Gly?Asn?Ser?Asn?Phe?Val?Lys?Ser?Lys?Thr?Gly?Leu?Pro

130 135 140

Leu?Ser?Thr?Tyr?Phe?Ser?Ala?Val?Lys?Leu?Arg?Trp?Met?Leu?Asp?Asn

145 150 155 160

Val?Arg?Asn?Val?Gln?Lys?Ala?Val?Glu?Glu?Gly?Arg?Ala?Leu?Phe?Gly

165 170 175

Thr?Ile?Asp?Ser?Trp?Leu?Ile?Trp?Ser?Leu?Thr?Gly?Gly?Val?Asn?Gly

180 185 190

Gly?Val?His?Cys?Thr?Asp?Val?Thr?Asn?Ala?Ser?Arg?Thr?Met?Leu?Phe

195 200 205

Asn?Ile?His?Ser?Leu?Glu?Trp?Asp?Lys?Glu?Leu?Cys?Asp?Phe?Phe?Glu

210 215 220

Ile?Pro?Met?Asp?Leu?Leu?Pro?Asn?Val?Phe?Ser?Ser?Ser?Glu?Ile?Tyr

225 230 235 240

Gly?Leu?Ile?Lys?Thr?Gly?Ala?Leu?Glu?Gly?Val?Pro?Ile?Ser?Gly?Cys

245 250 255

Leu?Gly?Asp?Gln?Cys?Ala?Ala?Leu?Val?Gly?Gln?Met?Cys?Phe?Gln?Glu

260 265 270

Gly?Gln?Ala?Lys?Asn?Thr?Tyr?Gly?Thr?Gly?Cys?Phe?Leu?Leu?Cys?Asn

275 280 285

Thr?Gly?Arg?Lys?Cys?Val?Phe?Ser?Glu?His?Gly?Leu?Leu?Thr?Thr?Val

290 295 300

Ala?Tyr?Lys?Leu?Gly?Arg?Glu?Lys?Pro?Ala?Tyr?Tyr?Ala?Leu?Glu?Gly

305 310 315 320

Ser?Val?Ala?Ile?Ala?Gly?Ala?Val?Ile?Arg?Trp?Leu?Arg?Asp?Asn?Leu

325 330 335

Gly?Ile?Ile?Glu?Thr?Ser?Gly?Asp?Ile?Glu?Arg?Leu?Ala?Lys?Glu?Val

340 345 350

Gly?Thr?Ser?Tyr?Gly?Cys?Tyr?Phe?Val?Pro?Ala?Phe?Ser?Gly?Leu?Tyr

355 360 365

Ala?Pro?Tyr?Trp?Glu?Pro?Ser?Ala?Arg?Gly?Ile?Leu?Cys?Gly?Leu?Thr

370 375 380

Gln?Phe?Thr?Asn?Lys?Cys?His?Ile?Ala?Phe?Ala?Ala?Leu?Glu?Ala?Val

385 390 395 400

Cys?Phe?Gln?Thr?Arg?Glu?Ile?Leu?Glu?Ala?Met?Asn?Arg?Asp?Cys?Gly

405 410 415

Ile?Pro?Leu?Arg?His?Leu?Gln?Val?Asp?Gly?Gly?Met?Thr?Asn?Asn?Lys

420 425 430

Val?Leu?Met?Gln?Leu?Gln?Ala?Asp?Ile?Leu?His?Ile?Pro?Val?Ile?Lys

435 440 445

Pro?Phe?Met?Pro?Glu?Thr?Thr?Ala?Leu?Gly?Ala?Ala?Met?Ala?Ala?Gly

450 455 460

Ala?Ala?Glu?Gly?Val?Ser?Val?Trp?Ser?Leu?Glu?Pro?Gln?Ala?Leu?Ser

465 470 475 480

Val?Leu?Arg?Met?Glu?Arg?Phe?Glu?Pro?Gln?Ile?Gln?Ala?Thr?Glu?Ser

485 490 495

Glu?Ile?Arg?Tyr?Ala?Thr?Trp?Lys?Lys?Ala?Val?Met?Lys?Ser?Met?Gly

500 505 510

Trp?Val?Thr?Ser?Gln?Ser?Pro?Glu?Gly?Gly?Asp?Pro?Ser?Ile?Phe?Ser

515 520 525

Ser?Leu?Pro?Leu?Gly?Phe?Phe?Ile?Val?Ser?Ser?Met?Val?Met?Leu?Ile

530 535 540

Gly?Ala?Arg?Tyr?Ile?Ser?Gly?Val?Pro

545 550

SEQUENCE?LISTING29

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_722545

<160>1

<170>PatentIn?version?3.5

<210>1

<211>326

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(326)

<400>1

Met?Ala?Lys?Met?Glu?Leu?Ser?Lys?Ala?Phe?Ser?Gly?Gln?Arg?Thr?Leu

1 5 10 15

Leu?Ser?Ala?Ile?Leu?Ser?Met?Leu?Ser?Leu?Ser?Phe?Ser?Thr?Thr?Ser

20 25 30

Leu?Leu?Ser?Asn?Tyr?Trp?Phe?Val?Gly?Thr?Gln?Lys?Val?Pro?Lys?Pro

35 40 45

Leu?Cys?Glu?Lys?Gly?Leu?Ala?Ala?Lys?Cys?Phe?Asp?Met?Pro?Val?Ser

50 55 60

Leu?Asp?Gly?Asp?Thr?Asn?Thr?Ser?Thr?Gln?Glu?Val?Val?Gln?Tyr?Asn

65 70 75 80

Trp?Glu?Thr?Gly?Asp?Asp?Arg?Phe?Ser?Phe?Arg?Ser?Phe?Arg?Ser?Gly

85 90 95

Met?Trp?Leu?Ser?Cys?Glu?Glu?Thr?Val?Glu?Glu?Pro?Gly?Glu?Arg?Cys

100 105 110

Arg?Ser?Phe?Ile?Glu?Leu?Thr?Pro?Pro?Ala?Lys?Arg?Glu?Ile?Leu?Trp

115 120 125

Leu?Ser?Leu?Gly?Thr?Gln?Ile?Thr?Tyr?Ile?Gly?Leu?Gln?Phe?Ile?Ser

130 135 140

Phe?Leu?Leu?Leu?Leu?Thr?Asp?Leu?Leu?Leu?Thr?Gly?Asn?Pro?Ala?Cys

145 150 155 160

Gly?Leu?Lys?Leu?Ser?Ala?Phe?Ala?Ala?Val?Ser?Ser?Val?Leu?Ser?Gly

165 170 175

Leu?Leu?Gly?Met?Val?Ala?His?Met?Met?Tyr?Ser?Gln?Val?Phe?Gln?Ala

180 185 190

Thr?Val?Asn?Leu?Gly?Pro?Glu?Asp?Trp?Arg?Pro?His?Val?Trp?Asn?Tyr

195 200 205

Gly?Trp?Ala?Phe?Tyr?Met?Ala?Trp?Leu?Ser?Phe?Thr?Cys?Cys?Met?Ala

210 215 220

Ser?Ala?Val?Thr?Thr?Phe?Asn?Thr?Tyr?Thr?Arg?Met?Val?Leu?Glu?Phe

225 230 235 240

Lys?Cys?Lys?His?Ser?Lys?Ser?Phe?Lys?Glu?Asn?Pro?Asn?Cys?Leu?Pro

245 250 255

His?His?His?Gln?Cys?Phe?Pro?Arg?Arg?Leu?Ser?Ser?Ala?Ala?Pro?Thr

260 265 270

Val?Gly?Pro?Leu?Thr?Ser?Tyr?His?Gln?Tyr?His?Asn?Gln?Pro?Ile?His

275 280 285

Ser?Val?Ser?Glu?Gly?Val?Asp?Phe?Tyr?Ser?Glu?Leu?Arg?Asn?Lys?Gly

290 295 300

Phe?Gln?Arg?Gly?Ala?Ser?Gln?Glu?Leu?Lys?Glu?Ala?Val?Arg?Ser?Ser

305 310 315 320

Val?Glu?Glu?Glu?Gln?Cys

325

SEQUENCE?LISTING30

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_000840

<160>1

<170>PatentIn?version?3.5

<210>1

<211>225

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(225)

<400>1

Met?Ser?Cys?Glu?Ser?Ser?Met?Val?Leu?Gly?Tyr?Trp?Asp?Ile?Arg?Gly

1 5 10 15

Leu?Ala?His?Ala?Ile?Arg?Leu?Leu?Leu?Glu?Phe?Thr?Asp?Thr?Ser?Tyr

20 25 30

Glu?Glu?Lys?Arg?Tyr?Thr?Cys?Gly?Glu?Ala?Pro?Asp?Tyr?Asp?Arg?Ser

35 40 45

Gln?Trp?Leu?Asp?Val?Lys?Phe?Lys?Leu?Asp?Leu?Asp?Phe?Pro?Asn?Leu

50 55 60

Pro?Tyr?Leu?Leu?Asp?Gly?Lys?Asn?Lys?Ile?Thr?Gln?Ser?Asn?Ala?Ile

65 70 75 80

Leu?Arg?Tyr?Ile?Ala?Arg?Lys?His?Asn?Met?Cys?Gly?Glu?Thr?Glu?Glu

85 90 95

Glu?Lys?Ile?Arg?Val?Asp?Ile?Ile?Glu?Asn?Gln?Val?Met?Asp?Phe?Arg

100 105 110

Thr?Gln?Leu?Ile?Arg?Leu?Cys?Tyr?Ser?Ser?Asp?His?Glu?Lys?Leu?Lys

115 120 125

Pro?Gln?Tyr?Leu?Glu?Glu?Leu?Pro?Gly?Gln?Leu?Lys?Gln?Phe?Ser?Met

130 135 140

Phe?Leu?Gly?Lys?Phe?Ser?Trp?Phe?Ala?Gly?Glu?Lys?Leu?Thr?Phe?Val

145 150 155 160

Asp?Phe?Leu?Thr?Tyr?Asp?Ile?Leu?Asp?Gln?Asn?Arg?Ile?Phe?Asp?Pro

165 170 175

Lys?Cys?Leu?Asp?Glu?Phe?Pro?Asn?Leu?Lys?Ala?Phe?Met?Cys?Arg?Phe

180 185 190

Glu?Ala?Leu?Glu?Lys?Ile?Ala?Ala?Tyr?Leu?Gln?Ser?Asp?Gln?Phe?Cys

195 200 205

Lys?Met?Pro?Ile?Asn?Asn?Lys?Met?Ala?Gln?Trp?Gly?Asn?Lys?Pro?Val

210 215 220

Cys

225

SEQUENCE?LISTING31

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_000631

<160>1

<170>PatentIn?version?3.5

<210>1

<211>380

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(380)

<400>1

Met?Ala?Phe?Val?Cys?Leu?Ala?Ile?Gly?Cys?Leu?Tyr?Thr?Phe?Leu?Ile

1 5 10 15

Ser?Thr?Thr?Phe?Gly?Cys?Thr?Ser?Ser?Ser?Asp?Thr?Glu?Ile?Lys?Val

20 25 30

Asn?Pro?Pro?Gln?Asp?Phe?Glu?Ile?Val?Asp?Pro?Gly?Tyr?Leu?Gly?Tyr

35 40 45

Leu?Tyr?Leu?Gln?Trp?Gln?Pro?Pro?Leu?Ser?Leu?Asp?His?Phe?Lys?Glu

50 55 60

Cys?Thr?Val?Glu?Tyr?Glu?Leu?Lys?Tyr?Arg?Asn?Ile?Gly?Ser?Glu?Thr

65 70 75 80

Trp?Lys?Thr?Ile?Ile?Thr?Lys?Asn?Leu?His?Tyr?Lys?Asp?Gly?Phe?Asp

85 90 95

Leu?Asn?Lys?Gly?Ile?Glu?Ala?Lys?Ile?His?Thr?Leu?Leu?Pro?Trp?Gln

100 105 110

Cys?Thr?Asn?Gly?Ser?Glu?Val?Gln?Ser?Ser?Trp?Ala?Glu?Thr?Thr?Tyr

115 120 125

Trp?Ile?Ser?Pro?Gln?Gly?Ile?Pro?Glu?Thr?Lys?Val?Gln?Asp?Met?Asp

130 135 140

Cys?Val?Tyr?Tyr?Asn?Trp?Gln?Tyr?Leu?Leu?Cys?Ser?Trp?Lys?Pro?Gly

145 150 155 160

Ile?Gly?Val?Leu?Leu?Asp?Thr?Asn?Tyr?Asn?Leu?Phe?Tyr?Trp?Tyr?Glu

165 170 175

Gly?Leu?Asp?His?Ala?Leu?Gln?Cys?Val?Asp?Tyr?Ile?Lys?Ala?Asp?Gly

180 185 190

Gln?Asn?Ile?Gly?Cys?Arg?Phe?Pro?Tyr?Leu?Glu?Ala?Ser?Asp?Tyr?Lys

195 200 205

Asp?Phe?Tyr?Ile?Cys?Val?Asn?Gly?Ser?Ser?Glu?Asn?Lys?Pro?Ile?Arg

210 215 220

Ser?Ser?Tyr?Phe?Thr?Phe?Gln?Leu?Gln?Asn?Ile?Val?Lys?Pro?Leu?Pro

225 230 235 240

Pro?Val?Tyr?Leu?Thr?Phe?Thr?Arg?Glu?Ser?Ser?Cys?Glu?Ile?Lys?Leu

245 250 255

Lys?Trp?Ser?Ile?Pro?Leu?Gly?Pro?Ile?Pro?Ala?Arg?Cys?Phe?Asp?Tyr

260 265 270

Glu?Ile?Glu?Ile?Arg?Glu?Asp?Asp?Thr?Thr?Leu?Val?Thr?Ala?Thr?Val

275 280 285

Glu?Asn?Glu?Thr?Tyr?Thr?Leu?Lys?Thr?Thr?Asn?Glu?Thr?Arg?Gln?Leu

290 295 300

Cys?Phe?Val?Val?Arg?Ser?Lys?Val?Asn?Ile?Tyr?Cys?Ser?Asp?Asp?Gly

305 310 315 320

Ile?Trp?Ser?Glu?Trp?Ser?Asp?Lys?Gln?Cys?Trp?Glu?Gly?Glu?Asp?Leu

325 330 335

Ser?Lys?Lys?Thr?Leu?Leu?Arg?Phe?Trp?Leu?Pro?Phe?Gly?Phe?Ile?Leu

340 345 350

Ile?Leu?Val?Ile?Phe?Val?Thr?Gly?Leu?Leu?Leu?Arg?Lys?Pro?Asn?Thr

355 360 365

Tyr?Pro?Lys?Met?Ile?Pro?Glu?Phe?Phe?Cys?Asp?Thr

370 375 380

SEQUENCE?LISTING32

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_057452

<160>1

<170>PatentIn?version?3.5

<210>1

<211>558

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(558)

<400>1

Met?Glu?Ala?Ala?Ala?Gln?Phe?Phe?Val?Glu?Ser?Pro?Asp?Val?Val?Tyr

1 5 10 15

Gly?Pro?Glu?Ala?Ile?Glu?Ala?Gln?Tyr?Glu?Tyr?Arg?Thr?Thr?Arg?Val

20 25 30

Ser?Arg?Glu?Gly?Gly?Val?Leu?Lys?Val?His?Pro?Thr?Ser?Thr?Arg?Phe

35 40 45

Thr?Phe?Arg?Thr?Ala?Arg?Gln?Val?Pro?Arg?Leu?Gly?Val?Met?Leu?Val

50 55 60

Gly?Trp?Gly?Gly?Asn?Asn?Gly?Ser?Thr?Leu?Thr?Ala?Ala?Val?Leu?Ala

65 70 75 80

Asn?Arg?Leu?Arg?Leu?Ser?Trp?Pro?Thr?Arg?Ser?Gly?Arg?Lys?Glu?Ala

85 90 95

Asn?Tyr?Tyr?Gly?Ser?Leu?Thr?Gln?Ala?Gly?Thr?Val?Ser?Leu?Gly?Leu

100 105 110

Asp?Ala?Glu?Gly?Gln?Glu?Val?Phe?Val?Pro?Phe?Ser?Ala?Val?Leu?Pro

115 120 125

Met?Val?Ala?Pro?Asn?Asp?Leu?Val?Phe?Asp?Gly?Trp?Asp?Ile?Ser?Ser

130 135 140

Leu?Asn?Leu?Ala?Glu?Ala?Met?Arg?Arg?Ala?Lys?Val?Leu?Asp?Trp?Gly

145 150 155 160

Leu?Gln?Glu?Gln?Leu?Trp?Pro?His?Met?Glu?Ala?Leu?Arg?Pro?Arg?Pro

165 170 175

Ser?Val?Tyr?Ile?Pro?Glu?Phe?Ile?Ala?Ala?Asn?Gln?Ser?Ala?Arg?Ala

180 185 190

Asp?Asn?Leu?Ile?Pro?Gly?Ser?Arg?Ala?Gln?Gln?Leu?Glu?Gln?Ile?Arg

195 200 205

Arg?Asp?Ile?Arg?Asp?Phe?Arg?Ser?Ser?Ala?Gly?Leu?Asp?Lys?Val?Ile

210 215 220

Val?Leu?Trp?Thr?Ala?Asn?Thr?Glu?Arg?Phe?Cys?Glu?Val?Ile?Pro?Gly

225 230 235 240

Leu?Asn?Asp?Thr?Ala?Glu?Asn?Leu?Leu?Arg?Thr?Ile?Glu?Leu?Gly?Leu

245 250 255

Glu?Val?Ser?Pro?Ser?Thr?Leu?Phe?Ala?Val?Ala?Ser?Ile?Leu?Glu?Gly

260 265 270

Cys?Ala?Phe?Leu?Asn?Gly?Ser?Pro?Gln?Asn?Thr?Leu?Val?Pro?Gly?Ala

275 280 285

Leu?Glu?Leu?Ala?Trp?Gln?His?Arg?Val?Phe?Val?Gly?Gly?Asp?Asp?Phe

290 295 300

Lys?Ser?Gly?Gln?Thr?Lys?Val?Lys?Ser?Val?Leu?Val?Asp?Phe?Leu?Ile

305 310 315 320

Gly?Ser?Gly?Leu?Lys?Thr?Met?Ser?Ile?Val?Ser?Tyr?Asn?His?Leu?Gly

325 330 335

Asn?Asn?Asp?Gly?Glu?Asn?Leu?Ser?Ala?Pro?Leu?Gln?Phe?Arg?Ser?Lys

340 345 350

Glu?Val?Ser?Lys?Ser?Asn?Val?Val?Asp?Asp?Met?Val?Gln?Ser?Asn?Pro

355 360 365

Val?Leu?Tyr?Thr?Pro?Gly?Glu?Glu?Pro?Asp?His?Cys?Val?Val?Ile?Lys

370 375 380

Tyr?Val?Pro?Tyr?Val?Gly?Asp?Ser?Lys?Arg?Ala?Leu?Asp?Glu?Tyr?Thr

385 390 395 400

Ser?Glu?Leu?Met?Leu?Gly?Gly?Thr?Asn?Thr?Leu?Val?Leu?His?Asn?Thr

405 410 415

Cys?Glu?Asp?Ser?Leu?Leu?Ala?Ala?Pro?Ile?Met?Leu?Asp?Leu?Ala?Leu

420 425 430

Leu?Thr?Glu?Leu?Cys?Gln?Arg?Val?Ser?Phe?Cys?Thr?Asp?Met?Asp?Pro

435 440 445

Glu?Pro?Gln?Thr?Phe?His?Pro?Val?Leu?Ser?Leu?Leu?Ser?Phe?Leu?Phe

450 455 460

Lys?Ala?Pro?Leu?Val?Pro?Pro?Gly?Ser?Pro?Val?Val?Asn?Ala?Leu?Phe

465 470 475 480

Arg?Gln?Arg?Ser?Cys?Ile?Glu?Asn?Ile?Leu?Arg?Ala?Cys?Val?Gly?Leu

485 490 495

Pro?Pro?Gln?Asn?His?Met?Leu?Leu?Glu?His?Lys?Met?Glu?Arg?Pro?Gly

500 505 510

Pro?Ser?Leu?Lys?Arg?Val?Gly?Pro?Val?Ala?Ala?Thr?Tyr?Pro?Met?Leu

515 520 525

Asn?Lys?Lys?Gly?Pro?Val?Pro?Ala?Ala?Thr?Asn?Gly?Cys?Thr?Gly?Asp

530 535 540

Ala?Asn?Gly?His?Leu?Gln?Glu?Glu?Pro?Pro?Met?Pro?Thr?Thr

545 550 555

SEQUENCE?LISTING33

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_004914

<160>1

<170>PatentIn?version?3.5

<210>1

<211>508

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(508)

<400>1

Met?Glu?Glu?Gly?Pro?Leu?Pro?Gly?Gly?Leu?Pro?Ser?Pro?Glu?Asp?Ala

1 5 10 15

Met?Val?Thr?Glu?Leu?Leu?Ser?Pro?Glu?Gly?Pro?Phe?Ala?Ser?Glu?Asn

20 25 30

Ile?Gly?Leu?Lys?Ala?Pro?Val?Lys?Tyr?Glu?Glu?Asp?Glu?Phe?His?Val

35 40 45

Phe?Lys?Glu?Ala?Tyr?Leu?Gly?Pro?Ala?Asp?Pro?Lys?Glu?Pro?Val?Leu

50 55 60

His?Ala?Phe?Asn?Pro?Ala?Leu?Gly?Ala?Asp?Cys?Lys?Gly?Gln?Val?Lys

65 70 75 80

Ala?Lys?Leu?Ala?Gly?Gly?Asp?Ser?Asp?Gly?Gly?Glu?Leu?Leu?Gly?Glu

85 90 95

Tyr?Pro?Gly?Ile?Pro?Glu?Leu?Ser?Ala?Leu?Glu?Asp?Val?Ala?Leu?Leu

100 105 110

Gln?Ala?Pro?Gln?Pro?Pro?Ala?Cys?Asn?Val?His?Phe?Leu?Ser?Ser?Leu

115 120 125

Leu?Pro?Ala?His?Arg?Ser?Pro?Ala?Val?Leu?Pro?Leu?Gly?Ala?Trp?Val

130 135 140

Leu?Glu?Gly?Ala?Ser?His?Pro?Gly?Val?Arg?Met?Ile?Pro?Val?Glu?Ile

145 150 155 160

Lys?Glu?Ala?Gly?Gly?Thr?Thr?Thr?Ser?Asn?Asn?Pro?Glu?Glu?Ala?Thr

165 170 175

Leu?Gln?Asn?Leu?Leu?Ala?Gln?Glu?Ser?Cys?Cys?Lys?Phe?Pro?Ser?Ser

180 185 190

Gln?Glu?Leu?Glu?Asp?Ala?Ser?Cys?Cys?Ser?Leu?Lys?Lys?Asp?Ser?Asn

195 200 205

Pro?Met?Val?Ile?Cys?Gln?Leu?Lys?Gly?Gly?Thr?Gln?Met?Leu?Cys?Ile

210 215 220

Asp?Asn?Ser?Arg?Thr?Arg?Glu?Leu?Lys?Ala?Leu?His?Leu?Val?Pro?Gln

225 230 235 240

Tyr?Gln?Asp?Gln?Asn?Asn?Tyr?Leu?Gln?Ser?Asp?Val?Pro?Lys?Pro?Met

245 250 255

Thr?Ala?Leu?Val?Gly?Arg?Phe?Leu?Pro?Ala?Ser?Thr?Lys?Leu?Asn?Leu

260 265 270

Ile?Thr?Gln?Gln?Leu?Glu?Gly?Ala?Leu?Pro?Ser?Val?Val?Asn?Gly?Ser

275 280 285

Ala?Phe?Pro?Ser?Gly?Ser?Thr?Leu?Pro?Gly?Pro?Pro?Lys?Ile?Thr?Leu

290 295 300

Ala?Gly?Tyr?Cys?Asp?Cys?Phe?Ala?Ser?Gly?Asp?Phe?Cys?Asn?Asn?Cys

305 310 315 320

Asn?Cys?Asn?Asn?Cys?Cys?Asn?Asn?Leu?His?His?Asp?Ile?Glu?Arg?Phe

325 330 335

Lys?Ala?Ile?Lys?Ala?Cys?Leu?Gly?Arg?Asn?Pro?Glu?Ala?Phe?Gln?Pro

340 345 350

Lys?Ile?Gly?Lys?Gly?Gln?Leu?Gly?Asn?Val?Lys?Pro?Gln?His?Asn?Lys

355 360 365

Gly?Cys?Asn?Cys?Arg?Arg?Ser?Gly?Cys?Leu?Lys?Asn?Tyr?Cys?Glu?Cys

370 375 380

Tyr?Glu?Ala?Gln?Ile?Met?Cys?Ser?Ser?Ile?Cys?Lys?Cys?Ile?Gly?Cys

385 390 395 400

Lys?Asn?Tyr?Glu?Glu?Ser?Pro?Glu?Arg?Lys?Thr?Leu?Met?Ser?Met?Pro

405 410 415

Asn?Tyr?Met?Gln?Thr?Gly?Gly?Leu?Glu?Gly?Ser?His?Tyr?Leu?Pro?Pro

420 425 430

Thr?Lys?Phe?Ser?Gly?Leu?Pro?Arg?Phe?Ser?His?Asp?Arg?Arg?Pro?Ser

435 440 445

Ser?Cys?Ile?Ser?Trp?Glu?Val?Val?Glu?Ala?Thr?Cys?Ala?Cys?Leu?Leu

450 455 460

Ala?Gln?Gly?Glu?Glu?Ala?Glu?Lys?Glu?His?Cys?Ser?Lys?Cys?Leu?Ala

465 470 475 480

Glu?Gln?Met?Ile?Leu?Glu?Glu?Phe?Gly?Arg?Cys?Leu?Ser?Gln?Ile?Leu

485 490 495

His?Thr?Glu?Phe?Lys?Ser?Lys?Gly?Leu?Lys?Met?Glu

500 505

SEQUENCE?LISTING34

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_004289

<160>1

<170>PatentIn?version?3.5

<210>1

<211>1332

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(1332)

<400>1

Met?Ser?Asp?Met?Asp?Tyr?Pro?Leu?Gln?Gly?Pro?Gly?Leu?Leu?Ser?Val

1 5 10 15

Pro?Asn?Leu?Pro?Glu?Ile?Ser?Ser?Ile?Arg?Arg?Val?Pro?Leu?Pro?Pro

20 25 30

Glu?Leu?Val?Glu?Gln?Phe?Gly?His?Met?Gln?Cys?Asn?Cys?Met?Met?Gly

35 40 45

Val?Phe?Pro?Pro?Ile?Ser?Arg?Ala?Trp?Leu?Thr?Ile?Asp?Ser?Asp?Ile

50 55 60

Phe?Met?Trp?Asn?Tyr?Glu?Asp?Gly?Gly?Asp?Leu?Ala?Tyr?Phe?Asp?Gly

65 70 75 80

Leu?Ser?Glu?Thr?Ile?Leu?Ala?Val?Gly?Leu?Val?Lys?Pro?Lys?Ala?Gly

85 90 95

Ile?Phe?Gln?Pro?His?Val?Arg?His?Leu?Leu?Val?Leu?Ala?Thr?Pro?Val

100 105 110

Asp?Ile?Val?Ile?Leu?Gly?Leu?Ser?Tyr?Ala?Asn?Leu?Gln?Thr?Gly?Ser

115 120 125

Gly?Val?Leu?Asn?Asp?Ser?Leu?Ser?Gly?Gly?Met?Gln?Leu?Leu?Pro?Asp

130 135 140

Pro?Leu?Tyr?Ser?Leu?Pro?Thr?Asp?Asn?Thr?Tyr?Leu?Leu?Thr?Ile?Thr

145 150 155 160

Ser?Thr?Asp?Asn?Gly?Arg?Ile?Phe?Leu?Ala?Gly?Lys?Asp?Gly?Cys?Leu

165 170 175

Tyr?Glu?Val?Ala?Tyr?Gln?Ala?Glu?Ala?Gly?Trp?Phe?Ser?Gln?Arg?Cys

180 185 190

Arg?Lys?Ile?Asn?His?Ser?Lys?Ser?Ser?Leu?Ser?Phe?Leu?Val?Pro?Ser

195 200 205

Leu?Leu?Gln?Phe?Thr?Phe?Ser?Glu?Asp?Asp?Pro?Ile?Leu?Gln?Ile?Ala

210 215 220

Ile?Asp?Asn?Ser?Arg?Asn?Ile?Leu?Tyr?Thr?Arg?Ser?Glu?Lys?Gly?Val

225 230 235 240

Ile?Gln?Val?Tyr?Asp?Leu?Gly?Gln?Asp?Gly?Gln?Gly?Met?Ser?Arg?Val

245 250 255

Ala?Ser?Val?Ser?Gln?Asn?Ala?Ile?Val?Ser?Ala?Ala?Gly?Asn?Ile?Ala

260 265 270

Arg?Thr?Ile?Asp?Arg?Ser?Val?Phe?Lys?Pro?Ile?Val?Gln?Ile?Ala?Val

275 280 285

Ile?Glu?Asn?Ser?Glu?Ser?Leu?Asp?Cys?Gln?Leu?Leu?Ala?Val?Thr?His

290 295 300

Ala?Gly?Val?Arg?Leu?Tyr?Phe?Ser?Thr?Cys?Pro?Phe?Arg?Gln?Pro?Leu

305 310 315 320

Ala?Arg?Pro?Asn?Thr?Leu?Thr?Leu?Val?His?Val?Arg?Leu?Pro?Pro?Gly

325 330 335

Phe?Ser?Ala?Ser?Ser?Thr?Val?Glu?Lys?Pro?Ser?Lys?Val?His?Arg?Ala

340 345 350

Leu?Tyr?Ser?Lys?Gly?Ile?Leu?Leu?Met?Ala?Ala?Ser?Glu?Asn?Glu?Asp

355 360 365

Asn?Asp?Ile?Leu?Trp?Cys?Val?Asn?His?Asp?Thr?Phe?Pro?Phe?Gln?Lys

370 375 380

Pro?Met?Met?Glu?Thr?Gln?Met?Thr?Ala?Gly?Val?Asp?Gly?His?Ser?Trp

385 390 395 400

Ala?Leu?Ser?Ala?Ile?Asp?Glu?Leu?Lys?Val?Asp?Lys?Ile?Ile?Thr?Pro

405 410 415

Leu?Asn?Lys?Asp?His?Ile?Pro?Ile?Thr?Asp?Ser?Pro?Val?Val?Val?Gln

420 425 430

Gln?His?Met?Leu?Pro?Pro?Lys?Lys?Phe?Val?Leu?Leu?Ser?Ala?Gln?Gly

435 440 445

Ser?Leu?Met?Phe?His?Lys?Leu?Arg?Pro?Val?Asp?Gln?Leu?Arg?His?Leu

450 455 460

Leu?Val?Ser?Asn?Val?Gly?Gly?Asp?Gly?Glu?Glu?Ile?Glu?Arg?Phe?Phe

465 470 475 480

Lys?Leu?His?Gln?Glu?Asp?Gln?Ala?Cys?Ala?Thr?Cys?Leu?Ile?Leu?Ala

485 490 495

Cys?Ser?Thr?Ala?Ala?Cys?Asp?Arg?Glu?Val?Ser?Ala?Trp?Ala?Thr?Arg

500 505 510

Ala?Phe?Phe?Arg?Tyr?Gly?Gly?Glu?Ala?Gln?Met?Arg?Phe?Pro?Thr?Thr

515 520 525

Leu?Pro?Pro?Pro?Ser?Asn?Val?Gly?Pro?Ile?Leu?Gly?Ser?Pro?Val?Tyr

530 535 540

Ser?Ser?Ser?Pro?Val?Pro?Ser?Gly?Ser?Pro?Tyr?Pro?Asn?Pro?Ser?Phe

545 550 555 560

Leu?Gly?Thr?Pro?Ser?His?Gly?Ile?Gln?Pro?Pro?Ala?Met?Ser?Thr?Pro

565 570 575

Val?Cys?Ala?Leu?Gly?Asn?Pro?Ala?Thr?Gln?Ala?Thr?Asn?Met?Ser?Cys

580 585 590

Val?Thr?Gly?Pro?Glu?Ile?Val?Tyr?Ser?Gly?Lys?His?Asn?Gly?Ile?Cys

595 600 605

Ile?Tyr?Phe?Ser?Arg?Ile?Met?Gly?Asn?Ile?Trp?Asp?Ala?Ser?Leu?Val

610 615 620

Val?Glu?Arg?Ile?Phe?Lys?Ser?Gly?Asn?Arg?Glu?Ile?Thr?Ala?Ile?Glu

625 630 635 640

Ser?Ser?Val?Pro?Cys?Gln?Leu?Leu?Glu?Ser?Val?Leu?Gln?Glu?Leu?Lys

645 650 655

Gly?Leu?Gln?Glu?Phe?Leu?Asp?Arg?Asn?Ser?Gln?Phe?Ala?Gly?Gly?Pro

660 665 670

Leu?Gly?Asn?Pro?Asn?Thr?Thr?Ala?Lys?Val?Gln?Gln?Arg?Leu?Ile?Gly

675 680 685

Phe?Met?Arg?Pro?Glu?Asn?Gly?Asn?Pro?Gln?Gln?Met?Gln?Gln?Glu?Leu

690 695 700

Gln?Arg?Lys?Phe?His?Glu?Ala?Gln?Leu?Ser?Glu?Lys?Ile?Ser?Leu?Gln

705 710 715 720

Ala?Ile?Gln?Gln?Leu?Val?Arg?Lys?Ser?Tyr?Gln?Ala?Leu?Ala?Leu?Trp

725 730 735

Lys?Leu?Leu?Cys?Glu?His?Gln?Phe?Thr?Ile?Ile?Val?Ala?Glu?Leu?Gln

740 745 750

Lys?Glu?Leu?Gln?Glu?Gln?Leu?Lys?Ile?Thr?Thr?Phe?Lys?Asp?Leu?Val

755 760 765

Ile?Arg?Asp?Lys?Glu?Leu?Thr?Gly?Ala?Leu?Ile?Ala?Ser?Leu?Ile?Asn

770 775 780

Cys?Tyr?Ile?Arg?Asp?Asn?Ala?Ala?Val?Asp?Gly?Ile?Ser?Leu?His?Leu

785 790 795 800

Gln?Asp?Ile?Cys?Pro?Leu?Leu?Tyr?Ser?Thr?Asp?Asp?Ala?Ile?Cys?Ser

805 810 815

Lys?Ala?Asn?Glu?Leu?Leu?Gln?Arg?Ser?Arg?Gln?Val?Gln?Asn?Lys?Thr

820 825 830

Glu?Lys?Glu?Arg?Met?Leu?Arg?Glu?Ser?Leu?Lys?Glu?Tyr?Gln?Lys?Ile

835 840 845

Ser?Asn?Gln?Val?Asp?Leu?Ser?Asn?Val?Cys?Ala?Gln?Tyr?Arg?Gln?Val

850 855 860

Arg?Phe?Tyr?Glu?Gly?Val?Val?Glu?Leu?Ser?Leu?Thr?Ala?Ala?Glu?Lys

865 870 875 880

Lys?Asp?Pro?Gln?Gly?Leu?Gly?Leu?His?Phe?Tyr?Lys?His?Gly?Glu?Pro

885 890 895

Glu?Glu?Asp?Ile?Val?Gly?Leu?Gln?Ala?Phe?Gln?Glu?Arg?Leu?Asn?Ser

900 905 910

Tyr?Lys?Cys?Ile?Thr?Asp?Thr?Leu?Gln?Glu?Leu?Val?Asn?Gln?Ser?Lys

915 920 925

Ala?Ala?Pro?Gln?Ser?Pro?Ser?Val?Pro?Lys?Lys?Pro?Gly?Pro?Pro?Val

930 935 940

Leu?Ser?Ser?Asp?Pro?Asn?Met?Leu?Ser?Asn?Glu?Glu?Ala?Gly?His?His

945 950 955 960

Phe?Glu?Gln?Met?Leu?Lys?Leu?Ser?Gln?Arg?Ser?Lys?Asp?Glu?Leu?Phe

965 970 975

Ser?Ile?Ala?Leu?Tyr?Asn?Trp?Leu?Ile?Gln?Val?Asp?Leu?Ala?Asp?Lys

980 985 990

Leu?Leu?Gln?Val?Ala?Ser?Pro?Phe Leu?Glu?Pro?His?Leu?Val?Arg?Met

995 1000 1005

Ala?Lys Val?Asp?Gln?Asn?Arg Val?Arg?Tyr?Met?Asp Leu?Leu?Trp

1010 1015 1020

Arg?Tyr Tyr?Glu?Lys?Asn?Arg Ser?Phe?Ser?Asn?Ala Ala?Arg?Val

1025 1030 1035

Leu?Ser Arg?Leu?Ala?Asp?Met His?Ser?Thr?Glu?Ile Ser?Leu?Gln

1040 1045 1050

Gln?Arg Leu?Glu?Tyr?Ile?Ala Arg?Ala?Ile?Leu?Ser Ala?Lys?Ser

1055 1060 1065

Ser?Thr Ala?Ile?Ser?Ser?Ile Ala?Ala?Asp?Gly?Glu Phe?Leu?His

1070 1075 1080

Glu?Leu Glu?Glu?Lys?Met?Glu Val?Ala?Arg?Ile?Gln Leu?Gln?Ile

1085 1090 1095

Gln?Glu Thr?Leu?Gln?Arg?Gln Tyr?Ser?His?His?Ser Ser?Val?Gln

1100 1105 1110

Asp?Ala Val?Ser?Gln?Leu?Asp Ser?Glu?Leu?Met?Asp Ile?Thr?Lys

1115 1120 1125

Leu?Tyr Gly?Glu?Phe?Ala?Asp Pro?Phe?Lys?Leu?Ala Glu?Cys?Lys

1130 1135 1140

Leu?Ala Ile?Ile?His?Cys?Ala Gly?Tyr?Ser?Asp?Pro Ile?Leu?Val

1145 1150 1155

Gln?Thr Leu?Trp?Gln?Asp?Ile Ile?Glu?Lys?Glu?Leu Ser?Asp?Ser

1160 1165 1170

Val?Thr Leu?Ser?Ser?Ser?Asp Arg?Met?His?Ala?Leu Ser?Leu?Lys

1175 1180 1185

Ile?Val Leu?Leu?Gly?Lys?Ile Tyr?Ala?Gly?Thr?Pro Arg?Phe?Phe

1190 1195 1200

Pro?Leu Asp?Phe?Ile?Val?Gln Phe?Leu?Glu?Gln?Gln Val?Cys?Thr

1205 1210 1215

Leu?Asn Trp?Asp?Val?Gly?Phe Val?Ile?Gln?Thr?Met Asn?Glu?Ile

1220 1225 1230

Gly?Val?Pro?Leu?Pro?Arg?Leu Leu?Glu?Val?Tyr?Asp Gln?Leu?Phe

1235 1240 1245

Lys?Ser?Arg?Asp?Pro?Phe?Trp Asn?Arg?Met?Lys?Lys Pro?Leu?His

1250 1255 1260

Leu?Leu?Asp?Cys?Ile?His?Val Leu?Leu?Ile?Arg?Tyr Val?Glu?Asn

1265 1270 1275

Pro?Ser?Gln?Val?Leu?Asn?Cys Glu?Arg?Arg?Arg?Phe Thr?Asn?Leu

1280 1285 1290

Cys?Leu?Asp?Ala?Val?Cys?Gly Tyr?Leu?Val?Glu?Leu Gln?Ser?Met

1295 1300 1305

Ser?Ser?Ser?Val?Ala?Val?Gln Ala?Ile?Thr?Gly?Asn Phe?Lys?Ser

1310 1315 1320

Leu?Gln?Ala?Lys?Leu?Glu?Arg Leu?His

1325 1330

SEQUENCE?LISTING35

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_056404

<160>1

<170>PatentIn?version?3.5

<210>1

<211>717

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(717)

<400>1

Met?Phe?Arg?Asp?Gln?Val?Gly?Val?Leu?Ala?Gly?Trp?Phe?Lys?Gly?Trp

1 5 10 15

Ash?Glu?Cys?Glu?Gln?Thr?Val?Ala?Leu?Leu?Ser?Leu?Leu?Lys?Arg?Val

20 25 30

Ser?Gln?Thr?Gln?Ala?Arg?Phe?Leu?Gln?Leu?Cys?Leu?Glu?His?Ser?Leu

35 40 45

Ala?Asp?Cys?Ala?Glu?Leu?His?Val?Leu?Glu?Arg?Glu?Ala?Asn?Ser?Pro

50 55 60

Gly?Ile?Ile?Asn?Gln?Trp?Gln?Gln?Glu?Ser?Lys?Asp?Lys?Val?Ile?Ser

65 70 75 80

Leu?Leu?Leu?Thr?His?Leu?Pro?Leu?Leu?Lys?Pro?Gly?Asn?Leu?Asp?Ala

85 90 95

Lys?Val?Glu?Tyr?Met?Lys?Leu?Leu?Pro?Lys?Ile?Leu?Ala?His?Ser?Ile

100 105 110

Glu?His?Asn?Gln?His?Ile?Glu?Glu?Ser?Arg?Gln?Leu?Leu?Ser?Tyr?Ala

115 120 125

Leu?Ile?His?Pro?Ala?Thr?Ser?Leu?Lys?Asp?Arg?Ser?Ala?Leu?Ala?Met

130 135 140

Trp?Leu?Asn?His?Leu?Glu?Asp?Arg?Thr?Ser?Thr?Ser?Phe?Gly?Gly?Gln

145 150 155 160

Asn?Arg?Gly?Arg?Ser?Asp?Ser?Val?Asp?Tyr?Gly?Gln?Thr?His?Tyr?Tyr

165 170 175

His?Gln?Arg?Gln?Asn?Ser?Asp?Asp?Lys?Leu?Asn?Gly?Trp?Gln?Asn?Ser

180 185 190

Arg?Asp?Ser?Gly?Ile?Cys?Ile?Asn?Ala?Ser?Asn?Trp?Gln?Asp?Lys?Ser

195 200 205

Met?Gly?Cys?Glu?Asn?Gly?His?Val?Pro?Leu?Tyr?Ser?Ser?Ser?Ser?Val

210 215 220

Pro?Thr?Thr?Ile?Asn?Thr?Ile?Gly?Thr?Ser?Thr?Ser?Thr?Ile?Leu?Ser

225 230 235 240

Gly?Gln?Ala?His?His?Ser?Pro?Leu?Lys?Arg?Ser?Val?Ser?Leu?Thr?Pro

245 250 255

Pro?Met?Asn?Val?Pro?Asn?Gln?Pro?Leu?Gly?His?Gly?Trp?Met?Ser?His

260 265 270

Glu?Asp?Leu?Arg?Ala?Arg?Gly?Pro?Gln?Cys?Leu?Pro?Ser?Asp?His?Ala

275 280 285

Pro?Leu?Ser?Pro?Gln?Ser?Ser?Val?Ala?Ser?Ser?Gly?Ser?Gly?Gly?Ser

290 295 300

Glu?His?Leu?Glu?Asp?Gln?Thr?Thr?Ala?Arg?Asn?Thr?Phe?Gln?Glu?Glu

305 310 315 320

Gly?Ser?Gly?Met?Lys?Asp?Val?Pro?Ala?Trp?Leu?Lys?Ser?Leu?Arg?Leu

325 330 335

His?Lys?Tyr?Ala?Ala?Leu?Phe?Ser?Gln?Met?Thr?Tyr?Glu?Glu?Met?Met

340 345 350

Ala?Leu?Thr?Glu?Cys?Gln?Leu?Glu?Ala?Gln?Asn?Val?Thr?Lys?Gly?Ala

355 360 365

Arg?His?Lys?Ile?Val?Ile?Ser?Ile?Gln?Lys?Leu?Lys?Glu?Arg?Gln?Asn

370 375 380

Leu?Leu?Lys?Ser?Leu?Glu?Arg?Asp?Ile?Ile?Glu?Gly?Gly?Ser?Leu?Arg

385 390 395 400

Ile?Pro?Leu?Gln?Glu?Leu?His?Gln?Met?Ile?Leu?Thr?Pro?Ile?Lys?Ala

405 410 415

Tyr?Ser?Ser?Pro?Ser?Thr?Thr?Pro?Glu?Ala?Arg?Arg?Arg?Glu?Pro?Gln

420 425 430

Ala?Pro?Arg?Gln?Pro?Ser?Leu?Met?Gly?Pro?Glu?Ser?Gln?Ser?Pro?Asp

435 440 445

Cys?Lys?Asp?Gly?Ala?Ala?Ala?Thr?Gly?Ala?Thr?Ala?Thr?Pro?Ser?Ala

450 455 460

Gly?Ala?Ser?Gly?Gly?Leu?Gln?Pro?His?Gln?Leu?Ser?Ser?Cys?Asp?Gly

465 470 475 480

Glu?Leu?Ala?Val?Ala?Pro?Leu?Pro?Glu?Gly?Asp?Leu?Pro?Gly?Gln?Phe

485 490 495

Thr?Arg?Val?Met?Gly?Lys?Val?Cys?Thr?Gln?Leu?Leu?Val?Ser?Arg?Pro

500 505 510

Asp?Glu?Glu?Asn?Ile?Ser?Ser?Tyr?Leu?Gln?Leu?Ile?Asp?Lys?Cys?Leu

515 520 525

Ile?His?Glu?Ala?Phe?Thr?Glu?Thr?Gln?Lys?Lys?Arg?Leu?Leu?Ser?Trp

530 535 540

Lys?Gln?Gln?Val?Gln?Lys?Leu?Phe?Arg?Ser?Phe?Pro?Arg?Lys?Thr?Leu

545 550 555 560

Leu?Asp?Ile?Ser?Gly?Tyr?Arg?Gln?Gln?Arg?Asn?Arg?Gly?Phe?Gly?Gln

565 570 575

Ser?Asn?Ser?Leu?Pro?Thr?Ala?Gly?Ser?Val?Gly?Gly?Gly?Met?Gly?Arg

580 585 590

Arg?Asn?Pro?Arg?Gln?Tyr?Gln?Ile?Pro?Ser?Arg?Asn?Val?Pro?Ser?Ala

595 600 605

Arg?Leu?Gly?Leu?Leu?Gly?Thr?Ser?Gly?Phe?Val?Ser?Ser?Asn?Gln?Arg

610 615 620

Asn?Thr?Thr?Ala?Thr?Pro?Thr?Ile?Met?Lys?Gln?Gly?Arg?Gln?Asn?Leu

625 630 635 640

Trp?Phe?Ala?Asn?Pro?Gly?Gly?Ser?Asn?Ser?Met?Pro?Ser?Arg?Thr?His

645 650 655

Ser?Ser?Val?Gln?Arg?Thr?Arg?Ser?Leu?Pro?Val?His?Thr?Ser?Pro?Gln

660 665 670

Asn?Met?Leu?Met?Phe?Gln?Gln?Pro?Glu?Phe?Gln?Leu?Pro?Val?Thr?Glu

675 680 685

Pro?Asp?Ile?Asn?Asn?Arg?Leu?Glu?Ser?Leu?Cys?Leu?Ser?Met?Thr?Glu

690 695 700

His?Ala?Leu?Gly?Asp?Gly?Val?Asp?Arg?Thr?Ser?Thr?Ile

705 710 715

SEQUENCE?LISTING36

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_057086

<160>1

<170>PatentIn?version?3.5

<210>1

<211>429

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(429)

<400>1

Met?Ala?Thr?Glu?Gln?Arg?Pro?Phe?His?Leu?Val?Val?Phe?Gly?Ala?Ser

1 5 10 15

Gly?Phe?Thr?Gly?Gln?Phe?Val?Thr?Glu?Glu?Val?Ala?Arg?Glu?Gln?Val

20 25 30

Asp?Pro?Glu?Arg?Ser?Ser?Arg?Leu?Pro?Trp?Ala?Val?Ala?Gly?Arg?Ser

35 40 45

Arg?Glu?Lys?Leu?Gln?Arg?Val?Leu?Glu?Lys?Ala?Ala?Leu?Lys?Leu?Gly

50 55 60

Arg?Pro?Thr?Leu?Ser?Ser?Glu?Val?Gly?Ile?Ile?Ile?Cys?Asp?Ile?Ala

65 70 75 80

Asn?Pro?Ala?Ser?Leu?Asp?Glu?Met?Ala?Lys?Gln?Ala?Thr?Val?Val?Leu

85 90 95

Asn?Cys?Val?Gly?Pro?Tyr?Arg?Phe?Tyr?Gly?Glu?Pro?Val?Ile?Lys?Ala

100 105 110

Cys?Ile?Glu?Asn?Gly?Ala?Ser?Cys?Ile?Asp?Ile?Ser?Gly?Glu?Pro?Gln

115 120 125

Phe?Leu?Glu?Leu?Met?Gln?Leu?Lys?Tyr?His?Glu?Lys?Ala?Ala?Asp?Lys

130 135 140

Gly?Val?Tyr?Ile?Ile?Gly?Ser?Ser?Gly?Phe?Asp?Ser?Ile?Pro?Ala?Asp

145 150 155 160

Leu?Gly?Val?Ile?Tyr?Thr?Arg?Asn?Lys?Met?Asn?Gly?Thr?Leu?Thr?Ala

165 170 175

Val?Glu?Ser?Phe?Leu?Thr?Ile?His?Ser?Gly?Pro?Glu?Gly?Leu?Ser?Ile

180 185 190

His?Asp?Gly?Thr?Trp?Lys?Ser?Ala?Ile?Tyr?Gly?Phe?Gly?Asp?Gln?Ser

195 200 205

Asn?Leu?Arg?Lys?Leu?Arg?Asn?Val?Ser?Asn?Leu?Lys?Pro?Val?Pro?Leu

210 215 220

Ile?Gly?Pro?Lys?Leu?Lys?Arg?Arg?Trp?Pro?Ile?Ser?Tyr?Cys?Arg?Glu

225 230 235 240

Leu?Lys?Gly?Tyr?Ser?Ile?Pro?Phe?Met?Gly?Ser?Asp?Val?Ser?Val?Val

245 250 255

Arg?Arg?Thr?Gln?Arg?Tyr?Leu?Tyr?Glu?Asn?Leu?Glu?Glu?Ser?Pro?Val

260 265 270

Gln?Tyr?Ala?Ala?Tyr?Val?Thr?Val?Gly?Gly?Ile?Thr?Ser?Val?Ile?Lys

275 280 285

Leu?Met?Phe?Ala?Gly?Leu?Phe?Phe?Leu?Phe?Phe?Val?Arg?Phe?Gly?Ile

290 295 300

Gly?Arg?Gln?Leu?Leu?Ile?Lys?Phe?Pro?Trp?Phe?Phe?Ser?Phe?Gly?Tyr

305 310 315 320

Phe?Ser?Lys?Gln?Gly?Pro?Thr?Gln?Lys?Gln?Ile?Asp?Ala?Ala?Ser?Phe

325 330 335

Thr?Leu?Thr?Phe?Phe?Gly?Gln?Gly?Tyr?Ser?Gln?Gly?Thr?Gly?Thr?Asp

340 345 350

Lys?Asn?Lys?Pro?Asn?Ile?Lys?Ile?Cys?Thr?Gln?Val?Lys?Gly?Pro?Glu

355 360 365

Ala?Gly?Tyr?Val?Ala?Thr?Pro?Ile?Ala?Met?Val?Gln?Ala?Ala?Met?Thr

370 375 380

Leu?Leu?Ser?Asp?Ala?Ser?His?Leu?Pro?Lys?Ala?Gly?Gly?Val?Phe?Thr

385 390 395 400

Pro?Gly?Ala?Ala?Phe?Ser?Lys?Thr?Lys?Leu?Ile?Asp?Arg?Leu?Asn?Lys

405 410 415

His?Gly?Ile?Glu?Phe?Ser?Val?Ile?Ser?Ser?Ser?Glu?Val

420 425

SEQUENCE?LISTING37

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_061946

<160>1

<170>PatentIn?version?3.5

<210>1

<211>488

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(488)

<400>1

Met?Pro?Lys?Val?Lys?Ala?Leu?Gln?Cys?Ala?Leu?Ala?Leu?Glu?Ile?Ser

1 5 10 15

Ser?Val?Thr?Cys?Pro?Gly?Val?Val?Leu?Lys?Asp?Lys?Glu?Asp?Ile?Tyr

20 25 30

Leu?Ser?Ile?Cys?Val?Phe?Gly?Gln?Tyr?Lys?Lys?Thr?Gln?Cys?Val?Pro

35 40 45

Ala?Thr?Phe?Pro?Leu?Val?Phe?Asn?Ala?Arg?Met?Val?Phe?Glu?Lys?Val

50 55 60

Phe?Pro?Asp?Ala?Val?Asp?Pro?Gly?Asp?Val?Val?Thr?Gln?Leu?Glu?Tyr

65 70 75 80

Asp?Thr?Ala?Val?Phe?Glu?Leu?Ile?Gln?Leu?Val?Pro?Pro?Val?Gly?Glu

85 90 95

Thr?Leu?Ser?Thr?Tyr?Asp?Glu?Asn?Thr?Arg?Asp?Phe?Met?Phe?Pro?Gly

100 105 110

Pro?Asn?Gln?Met?Ser?Gly?His?His?Asp?Ser?Asn?Arg?Gln?Val?Thr?Met

115 120 125

Arg?Arg?Ile?Ser?Gly?Leu?Arg?Gly?Asn?Ala?Pro?Arg?Leu?Glu?Phe?Ser

130 135 140

Thr?Thr?Ser?Val?Ile?Thr?Glu?Cys?Leu?Ile?Ser?Ser?Arg?Lys?Cys?His

145 150 155 160

Thr?Gln?Asp?Lys?Phe?Ile?Tyr?His?Leu?Ala?Pro?Val?Glu?Lys?Ser?His

165 170 175

Gly?Arg?Leu?Gln?Asn?Arg?Thr?Ser?Arg?Ser?Gln?Lys?Lys?Lys?Ser?Lys

180 185 190

Ser?Pro?Glu?Arg?Ser?Lys?Tyr?Cys?Ile?Asn?Ala?Lys?Asn?Tyr?Glu?Gln

195 200 205

Pro?Thr?Ile?Ser?Ser?Lys?Ser?His?Ser?Pro?Ser?Pro?Tyr?Thr?Lys?Arg

210 215 220

Arg?Met?Cys?Glu?Leu?Ser?Glu?Asp?Thr?Arg?Arg?Arg?Leu?Ala?His?Leu

225 230 235 240

Asn?Leu?Gly?Pro?Tyr?Glu?Phe?Lys?Lys?Glu?Thr?Asp?Lys?Pro?Pro?Phe

245 250 255

Val?Ile?Arg?His?Val?Asp?Pro?Pro?Ser?Pro?Arg?Ala?Asp?Thr?Leu?Leu

260 265 270

Gly?Ser?Ser?Gly?Arg?Asp?Cys?Glu?Arg?Asp?Gly?Trp?Ser?Arg?Val?His

275 280 285

Asn?Asp?His?Ser?His?Leu?Gly?Cys?Cys?Arg?Pro?Lys?Asp?Tyr?Lys?Val

290 295 300

Ile?Arg?Thr?Pro?His?Gly?Arg?Asp?Phe?Asp?Asp?Ser?Leu?Glu?Lys?Cys

305 310 315 320

Glu?Glu?Tyr?Leu?Ser?Pro?Arg?Ser?Cys?Ser?Lys?Pro?Arg?His?Ser?Ala

325 330 335

Arg?Thr?Leu?Leu?Val?His?Ser?Ala?Pro?Ser?Thr?Met?Pro?Lys?His?Ser

340 345 350

Pro?Ser?Pro?Val?Leu?Asn?Arg?Ala?Ser?Leu?Arg?Glu?Arg?Phe?His?Ser

355 360 365

Asp?Trp?Cys?Ser?Pro?Ser?Asn?Cys?Asp?Glu?Ile?His?Asp?Arg?Val?Lys

370 375 380

Asn?Val?Leu?Lys?Ser?His?Gln?Ala?His?Gln?Arg?His?Leu?Tyr?Asp?Glu

385 390 395 400

Arg?Asp?Leu?Glu?Lys?Asp?Asp?Glu?Leu?Glu?Leu?Lys?Arg?Ser?Leu?Leu

405 410 415

Cys?Arg?Asp?Ser?Ala?Tyr?Asp?Ser?Asp?Pro?Glu?Tyr?Ser?Ser?Cys?Gln

420 425 430

Gln?Pro?Arg?Gly?Thr?Phe?His?Leu?Asp?Asp?Gly?Glu?Tyr?Trp?Ser?Asn

435 440 445

Arg?Ala?Ala?Ser?Tyr?Lys?Gly?Lys?Ser?His?Arg?Pro?Ile?Phe?Glu?Asn

450 455 460

Ser?Met?Asp?Lys?Met?Tyr?Arg?Asn?Leu?Tyr?Lys?Lys?Ala?Cys?Ser?Ser

465 470 475 480

Ala?Ser?His?Thr?Gln?Glu?Ser?Phe

485

SEQUENCE?LISTING38

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_003275

<160>1

<170>PatentIn?version?3.5

<210>1

<211>55

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(55)

<400>1

Met?Ser?Thr?Ser?Arg?Lys?Leu?Lys?Ser?His?Gly?Met?Arg?Arg?Ser?Lys

1 5 10 15

Ser?Arg?Ser?Pro?His?Lys?Gly?Val?Lys?Arg?Gly?Gly?Ser?Lys?Arg?Lys

20 25 30

Tyr?Arg?Lys?Gly?Asn?Leu?Lys?Ser?Arg?Lys?Arg?Gly?Asp?Asp?Ala?Asn

35 40 45

Arg?Asn?Tyr?Arg?Ser?His?Leu

50 55

SEQUENCE?LISTING39

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_068379

<160>1

<170>PatentIn?version?3.5

<210>1

<211>592

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(592)

<400>1

Met?Ala?Ser?Val?Val?Val?Lys?Thr?Ile?Trp?Gln?Ser?Lys?Glu?Ile?His

1 5 10 15

Glu?Ala?Gly?Asp?Thr?Pro?Thr?Gly?Val?Glu?Ser?Cys?Ser?Gln?Leu?Val

20 25 30

Pro?Glu?Ala?Pro?Arg?Arg?Val?Thr?Ser?Arg?Ala?Lys?Gly?Ile?Pro?Lys

35 40 45

Lys?Lys?Lys?Ala?Val?Ser?Phe?His?Gly?Val?Glu?Pro?Gln?Met?Ser?His

50 55 60

Gln?Pro?Met?His?Trp?Cys?Leu?Asn?Leu?Lys?Arg?Ser?Ser?Ala?Cys?Thr

65 70 75 80

Asn?Val?Ser?Leu?Leu?Asn?Leu?Ala?Ala?Met?Glu?Pro?Thr?Asp?Ser?Thr

85 90 95

Gly?Thr?Asp?Ser?Thr?Val?Glu?Asp?Leu?Ser?Gly?Gln?Leu?Thr?Leu?Ala

100 105 110

Gly?Pro?Pro?Ala?Ser?Pro?Thr?Leu?Pro?Trp?Asp?Pro?Asp?Asp?Ala?Asp

115 120 125

Ile?Thr?Glu?Ile?Leu?Ser?Gly?Val?Asn?Ser?Gly?Leu?Val?Arg?Ala?Lys

130 135 140

Asp?Ser?Ile?Thr?Ser?Leu?Lys?Glu?Lys?Thr?Asn?Arg?Val?Asn?Gln?His

145 150 155 160

Val?Gln?Ser?Leu?Gln?Ser?Glu?Cys?Ser?Val?Leu?Ser?Glu?Asn?Leu?Glu

165 170 175

Arg?Arg?Arg?Gln?Glu?Ala?Glu?Glu?Leu?Glu?Gly?Tyr?Cys?Ile?Gln?Leu

180 185 190

Lys?Glu?Asn?Cys?Trp?Lys?Val?Thr?Arg?Ser?Val?Glu?Asp?Ala?Glu?Ile

195 200 205

Lys?Thr?Asn?Val?Leu?Lys?Gln?Asn?Ser?Ala?Leu?Leu?Glu?Glu?Lys?Leu

210 215 220

Arg?Tyr?Leu?Gln?Gln?Gln?Leu?Gln?Asp?Glu?Thr?Pro?Arg?Arg?Gln?Glu

225 230 235 240

Ala?Glu?Leu?Gln?Glu?Pro?Glu?Glu?Lys?Gln?Glu?Pro?Glu?Glu?Lys?Gln

245 250 255

Glu?Pro?Glu?Glu?Lys?Gln?Lys?Pro?Glu?Ala?Gly?Leu?Ser?Trp?Asn?Ser

260 265 270

Leu?Gly?Pro?Ala?Ala?Thr?Ser?Gln?Gly?Cys?Pro?Gly?Pro?Pro?Gly?Ser

275 280 285

Pro?Asp?Lys?Pro?Ser?Arg?Pro?His?Gly?Leu?Val?Pro?Ala?Gly?Trp?Gly

290 295 300

Met?Gly?Pro?Arg?Ala?Gly?Glu?Gly?Pro?Tyr?Val?Ser?Glu?Gln?Glu?Leu

305 310 315 320

Gln?Lys?Leu?Phe?Thr?Gly?Ile?Glu?Glu?Leu?Arg?Arg?Glu?Val?Ser?Ser

325 330 335

Leu?Thr?Ala?Arg?Trp?His?Gln?Glu?Glu?Gly?Ala?Val?Gln?Glu?Ala?Leu

340 345 350

Arg?Leu?Leu?Gly?Gly?Leu?Gly?Gly?Arg?Val?Asp?Gly?Phe?Leu?Gly?Gln

355 360 365

Trp?Glu?Arg?Ala?Gln?Arg?Glu?Gln?Ala?Gln?Thr?Ala?Arg?Asp?Leu?Gln

370 375 380

Glu?Leu?Arg?Gly?Arg?Ala?Asp?Glu?Leu?Cys?Thr?Met?Val?Glu?Arg?Ser

385 390 395 400

Ala?Val?Ser?Val?Ala?Ser?Leu?Arg?Ser?Glu?Leu?Glu?Gly?Leu?Gly?Pro

405 410 415

Leu?Lys?Pro?Ile?Leu?Glu?Glu?Phe?Gly?Arg?Gln?Phe?Gln?Asn?Ser?Arg

420 425 430

Arg?Gly?Pro?Asp?Leu?Ser?Met?Asn?Leu?Asp?Arg?Ser?His?Gln?Gly?Asn

435 440 445

Cys?Ala?Arg?Cys?Ala?Ser?Gln?Gly?Ser?Gln?Leu?Ser?Thr?Glu?Ser?Leu

450 455 460

Gln?Gln?Leu?Leu?Asp?Arg?Ala?Leu?Thr?Ser?Leu?Val?Asp?Glu?Val?Lys

465 470 475 480

Gln?Arg?Gly?Leu?Thr?Pro?Ala?Cys?Pro?Ser?Cys?Gln?Arg?Leu?His?Lys

485 490 495

Lys?Ile?Leu?Glu?Leu?Glu?Arg?Gln?Ala?Leu?Ala?Lys?His?Val?Arg?Ala

500 505 510

Glu?Ala?Leu?Ser?Ser?Thr?Leu?Arg?Leu?Ala?Gln?Asp?Glu?Ala?Leu?Arg

515 520 525

Ala?Lys?Asn?Leu?Leu?Leu?Thr?Asp?Lys?Met?Lys?Pro?Glu?Glu?Lys?Met

530 535 540

Ala?Thr?Leu?Asp?His?Leu?His?Leu?Lys?Met?Cys?Ser?Leu?His?Asp?His

545 550 555 560

Leu?Ser?Asn?Leu?Pro?Leu?Glu?Gly?Ser?Thr?Gly?Thr?Met?Gly?Gly?Gly

565 570 575

Ser?Ser?Ala?Gly?Thr?Pro?Pro?Lys?Gln?Gly?Gly?Ser?Ala?Pro?Glu?Gln

580 585 590

SEQUENCE?LISTING40

＜110〉peace innovation Bioisystech Co., Ltd is thought in Beijing

Section, Ling Xun

＜120〉sensitive diagnosis and the associated treatment of the cancer of gene that 20 kinds of tomour specifics are relevant and product

<130>NP_059509

<160>1

<170>PatentIn?version?3.5

<210>1

<211>655

<212>PRT

<213>Homo?sapiens

<220>

<221>DOMAIN

<222>(1)..(655)

<400>1

Met?Ala?Lys?Gly?Gly?Glu?Ala?Leu?Pro?Gln?Gly?Ser?Pro?Ala?Pro?Val

1 5 10 15

Gln?Asp?Pro?His?Leu?Ile?Lys?Val?Thr?Val?Lys?Thr?Pro?Lys?Asp?Lys

20 25 30

Glu?Asp?Phe?Ser?Val?Thr?Asp?Thr?Cys?Thr?Ile?Gln?Gln?Leu?Lys?Glu

35 40 45

Glu?Ile?Ser?Gln?Arg?Phe?Lys?Ala?His?Pro?Asp?Gln?Leu?Val?Leu?Ile

50 55 60

Phe?Ala?Gly?Lys?Ile?Leu?Lys?Asp?Pro?Asp?Ser?Leu?Ala?Gln?Cys?Gly

65 70 75 80

Val?Arg?Asp?Gly?Leu?Thr?Val?His?Leu?Val?Ile?Lys?Arg?Gln?His?Arg

85 90 95

Ala?Met?Gly?Asn?Glu?Cys?Pro?Ala?Ala?Ser?Val?Pro?Thr?Gln?Gly?Pro

100 105 110

Ser?Pro?Gly?Ser?Leu?Pro?Gln?Pro?Ser?Ser?Ile?Tyr?Pro?Ala?Asp?Gly

115 120 125

Pro?Pro?Ala?Phe?Ser?Leu?Gly?Leu?Leu?Thr?Gly?Leu?Ser?Arg?Leu?Gly

130 135 140

Leu?Ala?Tyr?Arg?Gly?Phe?Pro?Asp?Gln?Pro?Ser?Ser?Leu?Met?Arg?Gln

145 150 155 160

His?Val?Ser?Val?Pro?Glu?Phe?Val?Thr?Gln?Leu?Ile?Asp?Asp?Pro?Phe

165 170 175

Ile?Pro?Gly?Leu?Leu?Ser?Asn?Thr?Gly?Leu?Val?Arg?Gln?Leu?Val?Leu

180 185 190

Asp?Asn?Pro?His?Met?Gln?Gln?Leu?Ile?Gln?His?Asn?Pro?Glu?Ile?Gly

195 200 205

His?Ile?Leu?Asn?Asn?Pro?Glu?Ile?Met?Arg?Gln?Thr?Leu?Glu?Phe?Leu

210 215 220

Arg?Asn?Pro?Ala?Met?Met?Gln?Glu?Met?Ile?Arg?Ser?Gln?Asp?Arg?Val

225 230 235 240

Leu?Ser?Asn?Leu?Glu?Ser?Ile?Pro?Gly?Gly?Tyr?Asn?Val?Leu?Cys?Thr

245 250 255

Met?Tyr?Thr?Asp?Ile?Met?Asp?Pro?Met?Leu?Asn?Ala?Val?Gln?Glu?Gln

260 265 270

Phe?Gly?Gly?Asn?Pro?Phe?Ala?Thr?Ala?Thr?Thr?Asp?Asn?Ala?Thr?Thr

275 280 285

Thr?Thr?Ser?Gln?Pro?Ser?Arg?Met?Glu?Asn?Cys?Asp?Pro?Leu?Pro?Asn

290 295 300

Pro?Trp?Thr?Ser?Thr?His?Gly?Gly?Ser?Gly?Ser?Arg?Gln?Gly?Arg?Gln

305 310 315 320

Asp?Gly?Asp?Gln?Asp?Ala?Pro?Asp?Ile?Arg?Asn?Arg?Phe?Pro?Asn?Phe

325 330 335

Leu?Gly?Ile?Ile?Arg?Leu?Tyr?Asp?Tyr?Leu?Gln?Gln?Leu?His?Glu?Asn

340 345 350

Pro?Gln?Ser?Leu?Gly?Thr?Tyr?Leu?Gln?Gly?Thr?Ala?Ser?Ala?Leu?Ser

355 360 365

Gln?Ser?Gln?Glu?Pro?Pro?Pro?Ser?Val?Asn?Arg?Val?Pro?Pro?Ser?Ser

370 375 380

Pro?Ser?Ser?Gln?Glu?Pro?Gly?Ser?Gly?Gln?Pro?Leu?Pro?Glu?Glu?Ser

385 390 395 400

Val?Ala?Ile?Lys?Gly?Arg?Ser?Ser?Cys?Pro?Ala?Phe?Leu?Arg?Tyr?Pro

405 410 415

Thr?Glu?Asn?Ser?Thr?Gly?Gln?Gly?Gly?Asp?Gln?Asp?Gly?Ala?Gly?Lys

420 425 430

Ser?Ser?Thr?Gly?His?Ser?Thr?Asn?Leu?Pro?Asp?Leu?Val?Ser?Gly?Leu

435 440 445

Gly?Asp?Ser?Ala?Asn?Arg?Val?Pro?Phe?Ala?Pro?Leu?Ser?Phe?Ser?Pro

450 455 460

Thr?Ala?Ala?Ile?Pro?Gly?Ile?Pro?Glu?Pro?Pro?Trp?Leu?Pro?Ser?Pro

465 470 475 480

Ala?Tyr?Pro?Arg?Ser?Leu?Arg?Pro?Asp?Gly?Met?Asn?Pro?Ala?Pro?Gln

485 490 495

Leu?Gln?Asp?Glu?Ile?Gln?Pro?Gln?Leu?Pro?Leu?Leu?Met?His?Leu?Gln

500 505 510

Ala?Ala?Met?Ala?Asn?Pro?Arg?Ala?Leu?Gln?Ala?Leu?Arg?Gln?Ile?Glu

515 520 525

Gln?Gly?Leu?Gln?Val?Leu?Ala?Thr?Glu?Ala?Pro?Arg?Leu?Leu?Leu?Trp

530 535 540

Phe?Met?Pro?Cys?Leu?Ala?Gly?Thr?Gly?Ser?Val?Ala?Gly?Gly?Ile?Glu

545 550 555 560

Ser?Arg?Glu?Asp?Pro?Leu?Met?Ser?Glu?Asp?Pro?Leu?Pro?Asn?Pro?Pro

565 570 575

Pro?Glu?Val?Phe?Pro?Ala?Leu?Asp?Ser?Ala?Glu?Leu?Gly?Phe?Leu?Ser

580 585 590

Pro?Pro?Phe?Leu?His?Met?Leu?Gln?Asp?Leu?Val?Ser?Thr?Asn?Pro?Gln

595 600 605

Gln?Leu?Gln?Pro?Glu?Ala?His?Phe?Gln?Val?Gln?Leu?Glu?Gln?Leu?Arg

610 615 620

Ser?Met?Gly?Phe?Leu?Asn?Arg?Glu?Ala?Asn?Leu?Gln?Ala?Leu?Ile?Ala

625 630 635 640

Thr?Gly?Gly?Asp?Val?Asp?Ala?Ala?Val?Glu?Lys?Leu?Arg?Gln?Ser

645 650 655

Claims (25)

1. isolating polynucleotide, it is selected from: (1) sequence is the polynucleotide of one of SEQ ID NO:1-20; (2) sequence is the complementary sequence of the polynucleotide of one of SEQID NO:1-20; (3) sequence is the antisense sequences of the polynucleotide of one of SEQ ID NO:1-20.

2. the polypeptide of the described polynucleotide encoding of claim 1.

3. the described polypeptide of claim 2, its aminoacid sequence is one of SEQ ID NO:21-40.

4. expression vector, it carries the described isolating polynucleotide of claim 1.

5. host cell, its conversion or transfection described isolating polynucleotide of claim 1 or the described expression vector of claim 4.

6. specificity is in conjunction with antibody or its fragment of claim 2 or 3 described polypeptide.

7. the described isolating polynucleotide of claim 1 are in the purposes of preparation in the preparation, and said preparation is used to stimulate or the T cell of the energy specific recognition oncoprotein that increase.

8. claim 2 or 3 described polypeptide are in the purposes of preparation in the preparation, and said preparation is used to stimulate or the T cell of the energy specific recognition oncoprotein that increase.

9. be used to stimulate or the preparation of the T cell that can the specific recognition oncoprotein that increases, it contains the described isolating polynucleotide of claim 1.

10. be used to stimulate or the preparation of the T cell that can the specific recognition oncoprotein that increases, it contains claim 2 or 3 described polypeptide.

11. T cell mass by claim 9 or 10 described formulation preparation.

12. the described isolating polynucleotide of claim 1 prevent and/or treat purposes in the vaccine of tumour and/or cancer in preparation.

13. claim 2 or 3 described polypeptide prevent and/or treat purposes in the vaccine of tumour and/or cancer in preparation.

14. claim 2 or 3 described polypeptide prevent and/or treat purposes in the vaccine of tumour and/or cancer in preparation.

15. the described T cell mass of claim 11 prevents and/or treats purposes in the vaccine of tumour and/or cancer in preparation.

16. prevent and/or treat the vaccine of tumour and/or cancer, it contains described isolating polynucleotide of claim 1 and pharmaceutically acceptable adjuvant.

17. prevent and/or treat the vaccine of tumour and/or cancer, it contains claim 2 or 3 described polypeptide and pharmaceutically acceptable adjuvant.

18. prevent and/or treat the vaccine of tumour and/or cancer, it contains described T cell mass of claim 11 and pharmaceutically acceptable adjuvant.

19. the purposes of the described isolating polynucleotide of claim 1 in the test kit of preparation diagnosing tumour and/or cancer.

20. claim 2 or the 3 described polypeptide purposes in the test kit of preparation diagnosing tumour and/or cancer.

21. claim 2 or the 3 described polypeptide purposes in the test kit of preparation diagnosing tumour and/or cancer.

22. the purposes of the described T cell mass of claim 11 in the test kit of preparation diagnosing tumour and/or cancer.

23. the test kit of diagnosing tumour and/or cancer, it contains the described isolating polynucleotide of claim 1.

24. the test kit of diagnosing tumour and/or cancer, it contains claim 2 or 3 described polypeptide.

25. the test kit of diagnosing tumour and/or cancer, it contains the described T cell mass of claim 11.

Images